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 Carbon–hydrogen (C–H) bonds are ubiquitous in organic compounds, and the ability 
to functionalize C–H bonds selectively is a powerful strategy for late-stage derivatizations. 
The direct C–H functionalization of electron-rich arenes with azole coupling partners was 
demonstrated using an acridinium photoredox catalyst and a nitroxyl radical cocatalyst under 
an aerobic atmosphere, occurring via the intermediacy of an arene cation radical. High levels 
of site selectivity were observed with this methodology, and it proved applicable to a wide 
variety of arene and azole coupling partners, including complex bioactive molecules. 
Anilines could be constructed using ammonium carbamate as the nucleophilic coupling 
partner. 
 The ability to predict the site of C–H functionalization on complex arenes is 
nontrivial, and for this reason, a predictive model was developed. This enabled the extension 
of our aryl amination to a wide variety of heterocyclic arenes that are common motifs in 
pharmaceuticals. Using electron density calculations, we could predict the major site of 
functionalization for over 60 arene substrates. 
 We sought to extend this arene functionalization methodology toward aliphatic amine 
coupling partners. We demonstrated this capability with a wide variety of amino acid and 
primary amine coupling partners with arene substrates. Site selectivity was dependent on 
sterics of the arene, unlike our previous work with azoles. We also disclose the 
functionalization of arenes that cannot be oxidized by the acridinium catalyst, such as 
benzene and toluene, supporting a reactive amine cation radical intermediate.  
 A modular functionalization of unactivated aliphatic C–H bonds was developed 
utilizing an acridinium photoredox catalyst, phosphate base, and several diverse radical traps. 
The development of a C–H azidation reaction highlighted good site selectivity on alkanes for 
tertiary functionalization exclusively. Through modifications of this system, a C–H 
diversification allowed for the formation of C–F, C–Br, C–Cl, C–SCF3, and C–C bonds.
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CHAPTER 1: DEVELOPMENT OF ARYL C–H  
 FUNCTIONALIZATION REACTIONS  
 
1.1 Introduction 
 Aromatic rings are ubiquitous in chemistry, present in natural products, 
pharmaceuticals, materials, and even perfumes. The ability to construct substituted arenes is 
critical to facilitate access to many valuable products within these fields. Traditional 
electrophilic aromatic substitution (EAS) reactions have allowed for the installation of aryl 
nitrates, sulfonates, halides, and ketones, among other functionality.1 However, this strategy 
exhibits limited functional group compatibility due to the necessity of strongly Brønsted or 
Lewis acidic conditions. The complementary strategy of nucleophilic aromatic substitution 
(SNAr) enables the synthesis of a variety of substituted arenes but is limited in application to 
electron-poor systems.  
More recently, the general tactic of cross-coupling reactions has been developed and 
exploited in a wide variety of contexts.2 In this mode of reactivity as originally developed, a 
prefunctionalized aryl halide or triflate undergoes a transition metal-catalyzed coupling with 
an alkene or organometallic nucleophile, which allows for the net construction of carbon-
carbon (C–C) bonds. This strategy has been extended to a variety of coupling partners, 
enabling the formation of carbon–nitrogen (C–N), carbon–oxygen (C–O), and carbon–sulfur 




1.2 Aryl Amines 
1.2.1 Importance and Traditional Synthesis 
 The development of novel methods for the synthesis of aryl amines is of significant 
interest due to the ubiquity of aryl C–N bonds in pharmaceuticals, natural products, 
pigments, agrochemicals, and optoelectronic materials.3 For instance, 84% of FDA approved 
drugs in 1994 contained at least one nitrogen atom, underscoring their importance. Several 
representative aryl amine compounds are shown in Figure 1.1. Traditionally, arene nitration 
followed by hydrogenation or other reductive conditions has been used to furnish anilines 
directly. Nitration reactions, however, require strongly oxidizing and acidic conditions, 
which can limit their applicability due to problems with functional group tolerance. 
Additionally, selective nitro group reduction in the presence of other sensitive functionality 
can be problematic.
Figure 1.1 Pharmaceuticals and natural products containing nitrogen heterocycles. 
1.2.2 Cross-Coupling Strategies for the Synthesis of Aryl Amines 
To overcome the limitations of earlier methods for synthesizing aryl amines, several 
cross-coupling reactions using transition metal catalysts have been developed, particularly 
the Buchwald-Hartwig4,5 and Chan-Lam aminations (Figure 1.2).6,7 These reactions are 
currently the most widely used strategies for the synthesis of aryl amines and generally rely 
on a palladium or copper-based catalyst system to facilitate the coupling of amines with aryl 




































Figure 1.2 General Buchwald-Hartwig amination and Chan-Lam coupling reactions. 
While many advances have been made in ligand design and expanding the amine 
nucleophile scope for Buchwald-Hartwig aminations, several limitations still exist with such 
systems. Rigorously inert, anhydrous conditions are generally required to prevent catalyst 
decomposition. Additionally, arenes used in this cross-coupling require prefunctionalization 
as the halide or triflate, lengthening the synthesis towards aryl amines. In the case of the 
Chan-Lam reaction, arylboronic acids or esters are required, which are themselves often 
prepared from the corresponding aryl halide, adding another synthetic step. Furthermore, 
cross-coupling approaches are generally limited by steric hindrance such that amination 
ortho to another functional group can be very challenging, resulting in diminished yields, as 
in the ortho-methoxy derivative (Figure 1.3).8  
 
Figure 1.3 Examples of Buchwald-Hartwig aminations with substituted arenes. 
1.2.3 Aryl Amine Construction via C–H Functionalization 
The ability to convert aryl C–H bonds into C–N bonds directly bears the prospect of 
streamlining the synthesis of valuable aryl amines. This strategy requires only one synthetic 
step instead of the minimum of two required for the analogous prefunctionalization/cross-
coupling sequence.9,10 Additionally, this benefit is magnified when applied to the context of 
late-stage functionalization of pharmaceuticals or other bioactive targets, potentially granting 















































access to libraries of compounds diversified from a single precursor. While minimizing the 
number of synthetic steps is a significant advantage of C–H amination reactions, 
regioselectivity of such transformations can be challenging to control (Figure 1.4). An 
inherent regiochemical bias is required to achieve good site selectivity due to the usual 
presence of several aryl C–H bonds in a substrate. This results in selectivities that are highly 
mechanism dependent and dictated by the electronics of a given arene.  
 
Figure 1.4 Streamlining syntheses through arene C–H functionalization compared to cross 
coupling reactions. 
 
The regiochemical outcome of transition metal-catalyzed arene C–H functionalization 
reactions is generally dictated by the presence of a preinstalled Lewis basic directing group, 
which results in predominantly ortho-selectivity with respect to that functionality. Buchwald, 
in 2005, developed an intramolecular arene C–H amination strategy to form carbazoles from 
2-acetaminobiphenyl derivatives (Figure 1.5).11 A palladium catalyst was used along with a 
stoichiometric amount of copper as a cooxidant under aerobic conditions. The amide directed 
ortho-palladation would form the metallocycle 1.1, poised to undergo reductive elimination 
to afford the desired carbazole.  


































Analogous intermolecular arene C–H amination reactions have also been developed, 
relying on Lewis basic directing groups to form ortho-substituted products selectively. In 
2010, Shen developed an aerobic copper-mediated aryl amination reaction, in which use of a 
pyridine or pyrimidine directing group facilitated the addition of a phthalimide nucleophile to 
arenes using oxygen as a terminal oxidant (Figure 1.6).12 Daugulis also reported a copper-
catalyzed ortho-selective C–H amination using an 8-aminoquinoline directing group that 
proceeded through a putative copper (III) intermediate.13 Additionally, Nakamura has 
disclosed a method for iron-catalyzed amination with N-chloroamines using the quinolin-8-yl 
moiety as the Lewis basic directing group.14 
 
Figure 1.6 Directing group-mediated aryl C–H aminations. 
While ortho selectivity is most common in directing group-mediated strategies, 
several examples of meta-selective arene amination reactions have also been reported. 
Hartwig has demonstrated a sterically controlled intermolecular arene amination using 
phthalimide as the nucleophile with diacetoxyiodobenzene as a superstoichiometric terminal 




























































ortho- reactivity, selectivity over para-functionalization was generally low. These reactions 
also required that the arene coupling partner be used as the solvent to obtain synthetically 
useful yields.  
 
Figure 1.7 Meta-selective palladium-catalyzed aryl amination.  
DeBoef reported a metal-free intermolecular oxidative dual C–H and N–H bond 
functionalization reaction (Figure 1.8).16 In the presence of diacetoxyiodobenzene and 
microwave irradiation, the authors proposed that an arene substrate could be oxidized to the 
aryl cation radical. This intermediate, most electrophilic at the ortho- and para- positions, 
was susceptible to nucleophilic addition by amide derivatives and subsequent oxidation by 
superstoichiometric diacetoxyiodobenzene to form the aminated products at the ortho- and 
para- positions in roughly 1:1 ratios. Minor amounts of meta-functionalized product were 
observed, but never as the major regioisomer. The utility of this method was limited by the 
necessity of a significant excess of the arene, in some cases even as the reaction solvent, to 
attain synthetically useful yields. DeBoef continued this work more recently, reporting that 
the use of a gold catalyst with diacetoxyiodobenzene as the oxidant could selectively form 
para-functionalized products.17 While this system improved upon previous regioselectivity, it 
required the arene to be used as the solvent, limiting potential applicability. In a related work, 










































superstoichiometric diacetoxyiodobenzene.18 Unlike the aryl cation radical postulated by 
DeBoef, however, Cho and Chang proposed that an N-(phenylacetoxyiodo)imido species 
detected by ESI-MS can undergo direct reaction with the arene, furnishing functionalization 
products as a mixture of regioisomers. 
 
Figure 1.8 Aryl amination mediated by diacetoxyiodobenzene. 
The addition of discretely formed nitrogen-centered radicals to arenes has proven to 
be an effective strategy for the synthesis of aryl amines. Baran developed N-succinimidyl 
perester 1.2 as a progenitor to the nitrogen-centered succinimidyl radical mediated by Cp2Fe 
(Figure 1.9).19 In this system, C–H imidation of arenes and heteroarenes was possible, 
generally affording the products as mixtures of regioisomers. Itami also disclosed a strategy 
for aryl and heteroaryl C–H imidation using N-fluorobenzenesulfonimide (NFSI) under 
copper catalysis via a putative imidyl radical.20 In this work, single regioisomers were 
generally formed due to the use of substrates that possessed high levels of symmetry or 
several preexisting substituents. In both of these examples, however, the addition of only one 
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Figure 1.9 Applications of nitrogen-centered radicals in aryl amination. 
Recently, Ritter explored the use of charge-transfer complexes to facilitate para 
selective functionalization of arenes using dicationic palladium catalyst 1.3 (Figure 1.10).21 
A dicationic radical generated by single electron reduction of Selectfluor could add to arenes, 
forming predominantly the para adduct 1.4 in the case of monosubstituted substrates. When 
disubstituted benzenoids or heteroarenes were used, the strongest directing substituent 
dictated regiochemistry, and deprotection afforded piperazine-functionalized arenes in good 
yields and regioselectivities. Fukui indices were used to explain the regiochemistry observed 
based on electron density. 
 
Figure 1.10 Para-selective aryl amination via a charge-transfer mechanism. 
Photoredox catalysis has also been used to generate nitrogen-centered radicals for 
arene addition. In 2014, Sanford disclosed a visible light photocatalyzed, Ir(ppy)3-mediated 
system in which N-acyloxyphthalimide 1.5 could be reduced to the radical anion with 

































































phthalimidyl radical (Figure 1.11).22 Addition of this species to arenes and heteroarenes, 
present in significant excess of 10 – 20 equivalents, followed by rearomatization produced 
aryl amine adducts. Due to the use of a prefunctionalized phthalimide derivative, no external 
oxidant was required for the system. Many of the substrates underwent functionalization at 
the ortho position, but meta selectivity was observed with pyridines. A related work was 
disclosed by Lee, in which N-chlorophthalimide served as a precursor to the phthalimidyl 
radical under photoredox catalysis with Ir(dFppy)3.23 More recently, Itami used photoredox 
catalysis to facilitate the C–H imidation of arenes and heteroarenes with diphenylsulfonimide 
as the nucleophile.24 
 
Figure 1.11 Photoredox-catalyzed generation of nitrogen-centered radicals for aryl 
amination. 
 
1.3 Photoredox Catalysis  
1.3.1 Underlying Photophysical Processes 
 Radical chemistry has garnered much attention in recent years due to the 
complementary reactivity of radical (single electron) and polar (two electron) chemistry. The 
ability to harness an open shell pathway with unpaired electrons can allow for the 
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sparked a focus on photochemical methods of radical generation and, more specifically, 
photoredox catalysis. The ability of a chromophore to absorb light and access an excited state 
can be described based on its photophysical properties.25  
A general representation of possible photophysical processes for an organic molecule 
is depicted in a Jablonski diagram (Figure 1.12). When a closed shell compound absorbs a 
photon of light of a suitable wavelength (A), it can undergo transition from the ground singlet 
state S0 to the first electronically excited singlet state S1 with no change in electron spin. By 
the Franck-Condon principle, electronic excitation is nearly instantaneous with respect to 
nuclear motion, so the geometry of the molecule in the S1 state is similar to that from which 
it originated in the S0 state. As a result, excitation tends to promote a compound to a higher 
vibrational level within the S1 state instead of to the vibrational ground state. The process of 
vibrational relaxation (B) causes rapid relaxation to the lowest vibrational state within S1. 
 
Figure 1.12 Jablonski diagram. 
 At this point, there are several possible fates of the excited state. Fluorescence (C), 
the emission of a photon with energy corresponding to a transition between the S1 and S0 
states, can occur, reverting the molecule back to the ground state. The exact energy of the 















the energy of a photon emitted via fluorescence is less than that of the photon initially 
absorbed, corresponding to a Stokes shift of the fluorescence spectrum when compared to the 
absorption spectrum. The excited state can also undergo internal conversion (D), a non-
radiative decay in which the additional energy that had been absorbed is lost to the 
surroundings in the form of heat. Additionally, intersystem crossing (E) to a triplet excited 
state T1, through which the electron changes spin multiplicity, can occur. By electronic 
selection rules, this transition is forbidden, but it can occur via spin-orbit coupling, which is 
more likely for molecules containing heavy atoms such as bromine or iodine. Once in T1, the 
molecule can undergo phosphorescence (F), the radiative process through which the 
molecule is converted to the S0 state. 
1.3.2 Excited State Electron Transfer 
 In an electronically excited singlet or triplet state, electron transfer processes can 
occur and are critical for the activity of photoredox catalysts. In a general sense, such a 
catalyst can serve as either the excited state acceptor or donor for electron transfer. 
Considering a donor D and acceptor A, electron transfer from D to A is not 
thermodynamically feasible since the LUMO of A is significantly higher than the HOMO of 
D (Figure 1.13). If A is excited with light, an electron can be promoted from the molecular 
HOMO to the LUMO, forming the excited state A*. Since there is now an electron 
deficiency in the HOMO of A and the HOMOs of D and A are close in energy, electron 
transfer can occur from the HOMO of D to A, formally oxidizing D to the cation radical and 
reducing A to the anion radical. From this point, D can undergo further reactivity with 
additional compounds in solution. Alternately, back electron transfer from the anion radical 
of A to the unfilled orbital of cation radical D can occur.		
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Figure 1.13 Electron transfer depiction. D (Donor) and A (acceptor) 
 The Gibbs energy of photoinduced electron transfer can be determined to help inform 
whether a given SET process is favorable. Assuming that the electrostatic work, related to the 
Coulombic effect of charge separation, is negligible, the Gibbs energy for a photoredox 
catalyst cat acting as an excited state reductant toward substrate sub can be formulated as: 
∆!!"# =  −ℱ(!!"#⋇ !"#⋇/!"#•! − !!" !"#•!/!"# ) 
where ℱ is the Faraday constant, !!"#⋇  is the excited state reduction potential of cat, and !!" 
is the oxidation potential of sub. !!"#⋇  is calculated by: 
!!"#⋇ !"#⋇/!"#•! = !!"# !"#/!"#•! +  !!,! 
where !!,! is the excited state energy of the catalyst.  
 Previous work in the Nicewicz lab has demonstrated the hydrofunctionalization of 
alkenes, representing a net reductive pathway (Figure 1.14).26 Through a chlorolactonization 
methodology, our lab has also demonstrated a difunctionalization reaction of alkenes in 
2016.27 The ability to functionalize an alkene or arene in a net sp2 C–H functionalization 














Figure 1.14 Nicewicz lab hydrofunctionalization methodologies. 
1.3.3 Arene C–H Functionalization via Cation Radical Intermediates 
Recently, synthetic electrochemistry has garnered increased attention as a method for 
facilitating the donation or removal of an electron from a given substrate, with commercial 
setups now readily available. Yoshida reported an electrooxidative method for aryl C–H 
amination in 2014 using anodic oxidation (Figure 1.15).28 In this transformation, single 
electron oxidation of an aromatic substrate formed an arene cation radical, which was 
susceptible to nucleophilic addition of nitrogen heterocycles, generating cationic intermediate 
1.6, for example, that was resistant to further oxidation and could be deprotected to afford a 
net amination product. The intermediacy of an arene cation radical allows for a transient 
electrophilic coupling partner to be generated in situ in a controlled manner. This 
methodology highlighted excellent site selectivity, affording single regioisomers in most 
cases. A similar approach enabled access to a variety of aniline derivatives.29 Using DFT 
calculations, Yoshida proposed that the amine nucleophile added to the carbon bearing the 
hydrogen with the largest coefficient of the LUMO of the cation radical.  
J. Am. Chem. Soc. 2012, 134, 18577
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Figure 1.15 Electrooxidative aryl and benzylic functionalization methodologies. 
Complimentary to the aryl amination methodologies, Yoshida used alkyl-substituted arenes 
and modified reaction conditions to favor benzylic amination over aryl amination.28 Upon 
formation of a similar arene cation radical via electrooxidation, deprotonation of the benzylic 
C–H bond, with a calculated pKa of –20, is thermodynamically favorable and leads to 
formation of the benzylamine.30 
The ability to generate arene cation radicals has been applied to other arene 
functionalization reactions. Fukuzumi has demonstrated the use of an acridinium photoredox 
catalyst, Mes-Acr-MeClO4, to mediate C–H bromination31 and chlorination32 reactions of 
electron-rich arenes using hydrobromic or hydrochloric acid, respectively, and dioxygen (O2) 
as a stoichiometric oxidant (Figure 1.16). Although the reactions could produce some 
haloarenes in quantitative yield, the products obtained were often those that could be 
accessed through traditional EAS methods. Mediated by visible light irradiation, it was 
proposed that catalyst Mes-Acr+ could be excited and undergo single electron transfer (SET) 




































































undergo nucleophilic halide addition to form the cyclohexadienyl radical 1.8, which could be 
rearomatized to afford the halogenated product 1.9. Based on the detection of hydrogen 
peroxide in the crude reaction mixtures, it was believed that O2 was capable of oxidizing the 
acridine radical Mes-Acr• to reenter the catalytic cycle, with the resultant hydroperoxy 
radical being involved with product rearomatization. Subsequent reports of aryl 
functionalization from Fukuzumi include C–H hydroxylation mediated by DDQ.33 
 
Figure 1.16 Acridinium-catalyzed aryl bromination. 
 











































































 Fukuzumi further examined the selectivity of the transformations by using 
computational predictions of where bromination would occur. Through DFT calculations at 
the B3LYP/6-31+G(d,p) level of theory, Fukuzumi showed that the position of the largest 
positive charge density through natural population analysis (NPA) values in the neutral 
aromatic compound was the same as in the cation radical for 1,2,3-trimethoxybenzene and 
1,2,4-trimethoxybenzene.31 It was proposed that this similarity accounts for why the 
selectivity of cation radical-based bromination is the same as that for electrophilic 
bromination. Further explanations of reactivity were highlighted by examining differences in 
energy between brominated radical 1.8 and the arene cation radical 1.7. When the brominated 
radical intermediate was more stable than the cation radical, the reaction times were 
significantly shorter, although both reactions proceeded in nearly quantitative yields if run 
for a sufficient length of time. As demonstrated with both Yoshida’s and Fukuzumi’s work, 
DFT calculations can be used to account for the regioselectivity of arene C–H 
functionalization reactions in a facile and practical manner.  
1.3.4 Considerations for Arene C–H Functionalization via Photoredox Catalysis 
 As highlighted in Fukuzumi’s aryl functionalizations, photoredox catalysts can be 
used to generate reactive intermediates efficiently, particularly arene cation radicals. 
However, for productive reactivity to ensue, careful considerations of both the catalyst and 
the substrate must be made. To remove an electron from an arene substrate, reduction 
potentials of the photoredox catalyst excited state must be understood. For this reason, redox 
potentials are critical to define the thermodynamic feasibility of SET. Common metal-based 
photoredox catalysts, including those that are ruthenium- or iridium-based, are not as 
oxidizing compared to an acridinium catalyst. Ru(bpy)3 and Ir(ppy)3 do not possess high 
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enough excited state reduction potentials to (E1/2red* = +0.77 V vs. SCE and +0.31V vs SCE) 
remove an electron from any but the most electron-rich arenes. However, acridinium 
catalysts are powerful enough oxidants to remove an electron based on redox potentials alone 
(E1/2red* = + 2.0 V vs. SCE). For this reason, using acridinium-based catalysis for arene 
functionalization can be rationalized due the thermodynamic favorability of electron transfer.  
 Work disclosed by the Nicewicz lab thoroughly examined the oxidation and reduction 
potentials of a large group of commercial reagents via cyclic voltammetry (CV), and this 
compilation is an important tool for understanding whether a given substrate can undergo 
SET with a particular catalyst.34 As shown in Figure 1.18, groupings were made based on 
functional group to highlight redox potentials. Furthermore, this study also disclosed a 
computational predictive model for calculating oxidation and reduction potentials, which is 
particularly valuable if access to a potentiostat is problematic. This model was verified by the 
correlation of over 180 experimental values with the predicted values, generally in high 
agreement. 
 
Figure 1.18 Common functional group redox potentials in V vs SCE in MeCN. 
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CHAPTER 2: ARYL C–H AMINATION VIA  
ORGANIC PHOTOREDOX CATALYSIS 
 
 Adapted from Romero, N. A.; Margrey, K. A.; Tay, N. E.; Nicewicz, D. A. Science 
2015, 349, (6254), 1326–1330. Copyright 2015 by the American Associate for the 
Advancement of Science.  
2.1 Introduction 
 This chapter will detail our efforts in developing an aryl C–H amination reaction. The 
ability to form aryl C–N bonds is important in natural product synthesis as well as 
pharmaceutical development due to the prevalence of nitrogen atoms in biologically active 
compounds. While this bond construction is often accomplished through methods such as 
cross-couplings that rely on prefunctionalized aromatic systems, the direct formation of aryl 
C–N bonds from aryl C–H bonds would streamline the preparation of valuable 
molecules.1,2,3,4 Through this work, we developed reaction conditions to facilitate the aryl C–
H amination of a wide variety of arenes with azole coupling partners. This strategy was 
applied to several complex molecules to highlight its utility in late stage functionalization, 
and an extension toward direct aniline synthesis using ammonium carbamate was also 
detailed.5 
2.2 Reaction Development 
 Based on prior knowledge of Fukuzumi’s aryl bromination work that highlighted the 
ability of an acridinium photoredox catalyst to generate arene cation radicals via single 
electron transfer (SET)6 (see Chapter 1.3.3), we wondered if other nucleophiles, such as 
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amines, could be employed (Figure 2.1). For such a transformation to be synthetically 
useful, the arene undergoing functionalization would be the limiting reagent and could react 
with a wide variety of nitrogenous coupling partners. The reaction would also need to exhibit 
high levels of site selectivity and, ideally, be easily tunable. We envisioned reactivity similar 
to that reported by Fukuzumi, in which single electron oxidation of an arene would be 
followed by nucleophilic addition and deprotonation to form a cyclohexadienyl radical. 
Under aerobic conditions, this species would undergo rearomatization to afford the C–H 
functionalization product. 
 
Figure 2.1 Reaction blueprint for site-selective C–H amination of arenes.  
 
2.2.1 Initial Optimization 
Beginning with a simple system consisting of anisole and pyrazole as the arene and 
azole coupling partners, respectively, in DCE under a balloon of oxygen with BLED 
irradiation, we observed initial reactivity of 47% yield of 2.1a and 2.1b with 6.7:1 para:ortho 
regioselectivity (Table 2.1, entry 1). As proposed by Fukuzumi, oxygen was used for 
catalyst turnover from the acridine intermediate to re-enter the catalytic cycle as well as 
product aromatization.7 The importance of oxygen was verified by the control reaction 
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amination products were observed (Table 2.1, entry 2). DCE was the superior solvent for the 
reaction (Table 2.1, entries 3 – 5), with other solvents used in prior acridinium-catalyzed 
systems affording only trace amounts of product. Dimethyl-substituted acridinium, catalyst 
B, shown to be more robust in prior work involving alkene hydrohalogenation,8 was slightly 
less effective than unsubstituted acridinium, catalyst A (Table 2.1, entry 6). Additionally, 
through the testing of other terminal oxidants such as hypervalent iodine, benzoquinone, and 
persulfates (Table 2.1, entries 7 – 9), we determined that other common oxidants were 
inferior to a simple oxygen atmosphere.  
Table 2.1 Initial optimization of aryl amination. 
 
2.2.2 Product Stability Studies and Byproduct Formation 
Since the reaction yields could not be easily improved, at this stage we decided to 
examine product stability during the course of the reaction. When products 2.2 and 2.3 were 
resubmitted to the reaction conditions, either no product was observed or only 23% yield of 

















A; R = R' = H; E*red = +2.20 V








entry additive catalyst solvent [M] yield p:o
none A DCE [0.25] 47% 6.7:1
2
none B DCE [0.25] 37% 3.6:16
PhI(OAc)2 (1.0 eq.) B DCE [0.25] 20% 4.1:17
Benzoquinone (1.0 eq.) B DCE [0.25] 18% 6.9:18
K2S2O8 (1.0 eq.) B DCE [0.25] 14% 1.8:19
33 °C, O2 (1 atm)
none A MeCN [0.25] 6% 2.0:13
none A MeOH [0.25] 4% 1:2.94
none A TFE[0.25] 9% 1:255
2.1a 2.1b
1
no O2 A DCM [0.25] 2% –
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significant problem with product degradation during the course of the reaction. Accordingly, 
we determined the oxidation potentials of the starting arene, anisole, to be +1.87 V vs SCE 
and that of product 2.3 to be +1.50V vs SCE. Because aryl amine 2.3 is more electron rich 
than anisole, its oxidation potential is lower, indicating that it is more readily oxidized by the 
acridinium than anisole is. 
 
Figure 2.2 Product stability studies and byproduct formation.  
 We also investigated the byproducts formed during the reaction via 1H NMR and GC-
MS analysis and determined that 2.4 was produced in significant amounts, presumably 
through the oxidation of the alkoxy substituent on the arene. Fukuzumi has previously 
disclosed that hydrogen peroxide can be formed using an acridinium catalyst under aerobic 
reaction conditions via a hydroperoxy radical intermediate.6 Due to this precedent, we 
believe that a hydroperoxy radical is most likely formed in situ and is responsible for the 
formation of 2.4 via C–H abstraction from the methoxy group and subsequent oxidation.  
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2.2.3 Additional Optimization 
 Knowing that product stability was problematic and that byproducts arising from 
radical side reactions were present, we screened additives that could serve to mitigate these 
processes that are detrimental to overall yield. Several additives were screened in catalytic 
amounts (Table 2.2, entries 1 – 5), including TEMPO, ABNO, and BHT. Cocatalytic 
TEMPO showed significantly increased yields and maintained the high levels of para to 
ortho selectivity. Increased amounts of TEMPO hindered the reaction, and the highest yields 
were observed with 20 mol % TEMPO (Table 2.2, entry 2). Replacing TEMPO with the 
TEMPOniumBF4 salt led to similar reaction efficiency (Table 2.2, entry 6), suggesting that 
it can produce TEMPO under the reaction conditions. Lowering the concentration of the 
reaction led to slight increases in yield (Table 2.2, entry 8). 
 Over the course of a reaction, the solution would begin yellow in color and eventually 
become a very deep red color, sometimes even brown. We wondered if catalyst degradation 
could be problematic, especially with a potent nucleophile such as the azole in solution, since 
previous work by Nathan Romero demonstrated that thiols can add to an undecorated 
acridinium at the 3-position.9 The use of 3,6-di-tert-butyl-N-phenyl-mesityl acridinium 
tetrafluoroborate C (E*1/2 = +2.15 V vs SCE),10 a small amount of which was provided by 
Merck, afforded the amination products in 88% yield with excellent para to ortho selectivity 
(Table 2.2, entry 9). It is postulated that the enhanced yield is due to improved catalyst 
stability, since the most electrophilic positions of the acridinium are shielded by the tert-butyl 





Table 2.2 Optimization with nitroxyl radicals for aryl amination.  
 
(*) Reaction run for 3 days. 
conditions, leading to higher yields. Using catalyst C under air instead of an oxygen 
atmosphere provided the final product in nearly quantitative yields (Table 2.2, entry 10), 
although longer reaction times of three days instead of 20 hours were required. Polymer-
bound TEMPO was also effective as an additive, affording the desired product in 65% yield 
(Table 2.2, entry 11). Additionally, the polymer-bound TEMPO could be recovered via 
filtration and reused in the reaction, albeit in lower yields. 
 The synthesis of catalyst C provided by Merck was then optimized so that we could 
access this catalyst on a useful scale for reaction screening and product isolation (Figure 
2.3). Previously, the Merck route took seven steps and required the use of nitromethane and 
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TEMPO (0.1 eq.) B DCM[0.25] 65% 6.7:1









TEMPO (0.5 eq.) B DCM[0.25] 45% 6.3:1
TEMPOniumBF4 (0.2 eq.) B DCM[0.25] 69% 6.5:1
TEMPO (0.2 eq.) A DCM[0.1] 61% 6.8:1
TEMPO (0.2 eq.) B DCM[0.1] 79% 6.7:1
TEMPO (0.2 eq.) C DCM[0.1] 88% 6.9:1
TEMPO (0.2 eq.) (air)* C DCM[0.1] 97% 7.5:1






polymer-TEMPO (0.2 eq.) C DCM[0.1] 65% 6.7:1
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11
ABNO (0.2 eq.) B DCM[0.25] 60% 7.7:1









butyltoluene as the starting material for the synthesis and construct the catalyst in six steps 
with only one chromatographic separation.		
	
Figure 2.3 Modified synthetic route to tert-butyl substituted acridinium catalyst (catalyst C). 
2.2.4 Arene Scope for Aryl Amination 
With the optimized conditions, we screened a diverse range of arenes to determine the 
scope of this reaction (Figure 2.4). A variety of mono-substituted phenolic ethers 
participated in the reaction, affording the amination products 2.1, 2.5 – 2.8 in modest to good 
yields, in all cases favoring formation of the para isomer over the ortho isomer. The use of 
biphenyl provided 2.9 in good yield and similar para to ortho selectivity. Arenes 
disubstituted with a methoxy group and a halogen substituent were competent in the reaction, 
delivering 2.10 and 2.11, respectively, as single regioisomers. Additionally, high levels of 
selectivity were observed with a biaryl substrate containing two electronically distinct arenes, 
affording 2.12 in good yield as a single regioisomer. 
While the ability to functionalize various benzenoid derivatives is important for 

























































substrate scope to heterocyclic compounds. Several types of heterocycles participated in the 
reaction in good yields with good regioselectivity, including a pyridine, quinoline, 
quinazolinedione, indazole, and dihydrocoumarin (2.15 – 2.19). 
 
Figure 2.4 Arene scope for aryl amination methodology. Reactions were run in 1,2-
dichloroethane (DCE) at 0.1 M concentration with respect to the arene limiting reagent. (*) 
indicates a reaction run with 2.0 equivalents of arene, 1.0 equivalent of amine, and 1.0 
equivalent of TEMPO under an N2 atmosphere for 44 hours. Hex, hexyl group. 
 
2.2.5 Development of Conditions for Alkyl-Substituted Arenes 
While a variety of benzenoids and heterocycles worked in these reaction conditions, 
when we tried any alkyl-substituted arenes such as mesitylene or meta-xylenes, the reactions 
to produce 2.13 and 2.14 were not as clean as with other substrates. When previously 
optimized conditions were used with mesitylene, we observed the desired aryl amination 
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2.5; R = –OMOM; 52% yield; 7.8:1 p:o
2.6; R = –OTBS; 74% yield; 9.3:1 p:o
2.7; R = –Ot-Bu; 63% yield; 6:1 p:o
2.9
2.1; R = –OMe; 88% yield; 8.8:1 p:o
2.8; R = –OPh; 86% yield; 11:1 p:o










56% yield; 7.9:1 p:o




1 and 2). Bordwell predicts that the pKa of a benzylic C–H bond of an arene cation radical is 
roughly –20.11  
Table 2.3 Alkyl-substituted arene optimization. 
 
Previous groups, including Yoshida and Fukuzumi, have used this to their advantage by 
demonstrating benzylic amination and oxidation, respectively, via deprotonation of the arene 
cation radical.12,7 In fact, the aldehyde byproduct 2.21 we observed was one of the desired 
oxidation products in Fukuzumi’s work (Figure 2.5), leading us to conclude that further 
optimization for alkyl-substituted arenes would be required. To limit the amount of 
difunctionalization, we inverted the stoichiometry of the arene and amine coupling partners 
and, in fact, observed diminished difunctionalization product (Table 2.3, entries 3 and 4). 
However, this also increased the amount of oxidation byproduct observed, which proved 

















entry Atmosphere Arene:Amine TEMPO Time
1:2 None 24 hours 39%1
5 1:2 0.2 equiv. 24 hours 20%
6 1:2 1.0 equiv. 24 hours 52%









2:1 1.0 equiv. 48 hours 86%
9 1:2 None 24 hours 11%
23 °C, 
DCE [0.1M]
1:2 0.2 equiv. 24 hours 40%2
2:1 0.2 equiv. 24 hours 78%3












































Yield 2.13 Yield 2.21Yield 2.20
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Figure 2.5 Benzylic oxidation via photoredox catalysis. 
To completely retard the oxidation pathway, we examined what happened in the 
reaction without a balloon of oxygen and instead a nitrogen sparge and atmosphere. 
Interestingly, we observed roughly 20% yield of the desired aryl amine when excluding the 
terminal oxidant, oxygen (Table 2.3, entry 5). We hypothesized that TEMPO could instead 
act as a terminal oxidant which resulted in the 20% yield of product observed. After further 
optimization, it was determined that with a stoichiometric amount of TEMPO along with two 
days of irradiation, the aryl amination could be improved to 86% yield of the mono-aminated 
product (Table 2.3, entry 8). The exclusion of TEMPO and oxygen provided product in only 
11% yield, highlighting the necessity of an oxidant for the desired reactivity. Overall, we 
were able to demonstrate this aryl amination methodology with 16 different simple arene 
coupling partners with yields ranging from 30 to 88% yield. 
2.2.6 Arene Scope – Unsuccessful Substrates 
While these previous arenes all participated in the aryl amination reaction, there were 
several types of compounds that we could not functionalize (Figure 2.6). While some arenes 
gave trace amounts of products, yields could not be improved to be synthetically viable. The 
use of several anilines as the starting arene was pursued; however, in most cases, little to no 
product was observed even though the arene oxidation potentials lied within the range of the 


















result of the aniline being so electron-rich that it is in the Marcus Inverted region, where 
desired electron transfer is less favorable.13 Carbamate-protected phenols also did not 
facilitate productive amination chemistry. The use of 2-iodoanisole prevented product 
formation, which we hypothesize is due to the heavy atom effect.14 The use of 3-
fluoroanisole lead to ipso functionalization at the site of the fluorine but no desired C–H 
functionalization. Naphthalene and 1-methoxynaphthalene also did not provide the desired 
amination product. Tetrahydronaphthalene was not capable of forming the desired product 
due to the highly oxidation prone benzylic positions, and the use of anaerobic conditions did 
provide the desired adduct in low yield that could not be improved to synthetically viable 
values. 3-Bromotoluene was not electron rich enough to be oxidized by the acridinium 
catalyst. Protected indoles were used but never provided the desired adduct regardless of the 
protecting group used. Heterocycles such as 2-methoxypyrimidine were also used but were 
insufficiently electron rich to undergo SET with the catalyst.   
 
Figure 2.6 Unsuccessful arene substrates for aryl amination.  
 
 




































2.2.7 Amine Scope for Aryl Amination 
 With an arene scope in hand, we also explored the types of azole coupling partners 
we could use in this reaction methodology (Figure 2.7). Several methyl-substituted pyrazoles 
could be used in this reaction, providing product in good yields and regioselectivities (2.22 – 
2.24). 1,2,3- and 1,2,4-triazole were also shown as coupling partners, producing adducts 2.25 
and 2.26 with more modest regioselectivity. Additional five-membered nitrogen-containing 
heterocycles were competent in the reaction as nucleophiles (2.27 – 2.31). Interestingly, more 
biologically relevant nitrogen nucleophiles could be used, forming products 2.32 and 2.33. 
This ability to use histidine and adenine derivatives highlights the power of this system, in 
that more complex nucleophilic coupling partners can be used to construct C–N bonds 
rapidly, in good yield, and with relatively good regioselectivity.  
2.2.8 Application to Late-Stage Functionalization 
 Having shown that a variety of arenes and azoles could be coupled using this 
methodology, we applied it to late-stage functionalization of complex molecules (Figure 
2.8). A derivative of capsaicin underwent amination with pyrazole as the nucleophile in 66% 
yield to afford 2.34 despite the presence of a disubstituted olefin in the substrate, which could 
be problematic for other C–H functionalization strategies. Naproxen methyl ester provided 
2.35 in low yield, and the trifluoroacetate salt of a quinine derivative delivered 2.36 in 53% 
yield. In each case, single regioisomers were isolated, highlighting the excellent site 
selectivity of this methodology. The ability to utilize this chemistry to functionalize complex, 
bioactive targets in a site selective manner highlights that this strategy for C–H amination is 
amenable to a wide variety of arenes and is highly regioselective. 
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Figure 2.7 Amine scope for aryl amination methodology. Parenthetical ratios refer to 
para:ortho (p:o) selectivity for a given N-isomer. Reactions were run in 1,2-dichloroethane 
(DCE) at 0.1 M concentration with respect to the arene limiting reagent. (†) indicates a 
reaction run under N2 with 1.0 equivalent of TEMPO. 
 
 2.2.9 Aniline Construction for Aryl Amination  
 Traditionally, the construction of anilines occurs through arene nitration, requiring 
highly oxidizing and acidic conditions, followed by hydrogenation.15,16 Through the 
screening of several ammonium salts, it was found that ammonium carbamate was optimal as 
a nucleophile to directly access anilines via an arene cation radical intermediate (Table 2.4). 












































































































1.0 equiv 2.0 equiv
(20 mol % TEMPO)
catalyst C







eight different anilines (2.37 – 2.44) was demonstrated with modest regioselectivities and 
yields (Figure 2.9).   
 
Figure 2.8 Complex derivatives for late-stage functionalization. Reactions were run in 1,2-
dichloroethane (DCE) at 0.1 M concentration with respect to the arene limiting reagent.  
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1.0 equiv 2.0 equiv
(20 mol % TEMPO)
catalyst C






















B; R = Me; R' = H; E*red = +2.09 V










NH4OAc (2.0 eq.) B DCE [0.10] 15% 1:1
NH4HCO3 (2.0 eq.) B DCE [0.10] 24% 1:1.5
(NH4)2CO3 (2.0 eq.) B DCE [0.10] 35% 1:1
(NH4)2CO3 (2.0 eq.) B MeCN [0.10] 24% 2:1
(NH4)2SO3 (2.0 eq.) B DCE [0.10] 0% NA
(NH4)2CO3 (2.0 eq.) B DCE:H2O [0.10]* 43% 1.6:1
(NH4)2CO3 (4.0 eq.) C DCE:H2O [0.10]* 40% 1.2:1
NH4O2CNH2 (4.0 eq.) C DCE:H2O [0.10]* 58% 1.4:1











NH4O2CNH2 (4.0 eq.) B DCE:H2O [0.10]* 47% 1.4:1
NH4O2CNH2 (4.0 eq.) C TFE [0.10] 7% NA




Figure 2.9 Aniline substrate scope. 
2.2.10 Proposed Mechanism for Aryl Amination 
 Based on previous work by Fukuzumi,6 we propose that the acridinium photoredox 
catalyst is excited using 455 nm BLEDs (Figure 2.10). This excited state photocatalyst is 
capable of undergoing SET from the arene to generate the arene cation radical 2.45. 
Nucleophilic addition of the azole coupling partner followed by deprotonation affords 
cyclohexadienyl radical intermediate 2.47, which can then be rearomatized to afford the aryl 
amine 2.48. Based on Fukuzumi’s mechanistic work for his aryl bromination methodology, 
we believe that oxygen can oxidize acridine radical intermediate Mes-Acr•, allowing it to 
renter the catalytic cycle. Oxygen is also important for the rearomatization to afford the final 
product. While TEMPO was important to achieve optimal yields in our system, at this point 
we believe that the main role of TEMPO is to act as a radical scavenger, inhibiting 













2.38; R = –OMOM; 63% yield; 2.1:1 p:o
2.39; R = –OTBS; 44% yield; 3.9:1 p:o
2.40; R = –OPh; 62% yield; 2.9:1 p:o
2.37; R = –OMe; 59% yield; 1.6:1 p:o









1.0 equiv 4.0 equiv
(20 mol % TEMPO)











rearomatization step; however, due to the yields achieved without TEMPO, the aerobic 
reaction conditions are sufficient for this step to occur.  
 
Figure 2.10 Proposed mechanism for aryl amination. 
 Since the various azole coupling partners delivered products with differing para to 
ortho selectivities, we further examined what could cause this deviation and observed a 
strong correlation between pKa and selectivity (Figure 2.11). We believe that this supports 
that the deprotonation of intermediate 2.46 is the regioselectivity-determining step of the 
reaction. If the heterocycle is more basic, the para isomer is favored more strongly. Cole 
Cruz in the Nicewicz lab has investigated this further and has shown that the addition of acid 
can erode regioselectivity to a nearly 1:1 mixture of para and ortho isomers. Further efforts 













































































Figure 2.11 Aryl amination selectivity and basicity of nucleophile. Reactions were run in 
1,2-dichloroethane (DCE) at 0.1 M concentration with respect to the arene limiting reagent. 
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CHAPTER 3: PREDICTIVE MODEL FOR SITE-SELECTIVE 
ARYL C–H FUNCTIONALIZATION REACTIONS 
 
 Adapted from Margrey, K. A.; McManus, J. B.; Bonazzi, S.; Zerci, F.; Nicewicz, D. 
A. J. Am. Chem. Soc. 2017, 139 (32), 11288–11299. Copyright 2017 American Chemical 
Society.  
3.1 Introduction 
 The development of novel synthetic methodologies is at the forefront of research in 
organic chemistry, facilitating new routes to construct novel bonds or undergo a desired 
transformation more effectively. While this capability is required for research to advance, the 
ability to predict the outcome of a given reaction instills a deeper understanding of the 
reaction mechanism and provides insight to those wanting to apply the methodology. For this 
reason, we believed that a computational predictive model for our aryl C–H amination 
chemistry would greatly expand the scope of arenes we could functionalize and be useful as a 
tool for those wanting to apply the chemistry to substrates not disclosed in the original 
publication.1  
3.2 Previous Predictive Models 
 Predictive models for reactions such as site-selective C–H functionalizations can be 
important tools for synthetic chemists, giving them the greatest insight into where reactivity 
is most likely to occur. To this end, several other groups have developed predictive models to 
better understand the selectivity exhibited by a given reagent or catalyst. White and co-
workers have developed a catalyst-controlled aliphatic C–H oxidation methodology 
	 39 
incorporating a predictive model that correlates the physical properties of a given substrate 
with the experimental observations of oxidation site selectivity.2 Baran and Blackmond 
demonstrated a radical-based C–H functionalization of electron-deficient heteroarenes and 
systematically investigated a number of parameters that influenced regioselectivity, 
highlighting general trends as their model.3 Sigman and Davies developed a computational 
model for their rhodium-catalyzed C–H insertion chemistry based on predicted infrared 
vibrations of a diazo ester starting material and natural bond order (NBO) point charges of 
the substrate.4 These types of predictive models are important when applying the 
corresponding reactions to a broader class of substrates, when site selectivity can be more 
challenging to predict.  
3.3 Reaction Design 
 We sought to construct a predictive model for our aryl C–H amination methodology 
with azole coupling partners. This reaction, occurring via an arene cation radical 
intermediate, strongly favors functionalization at the para position of monosubstituted 
benzenoids; however, predicting site selectivity for heteroarenes and more complex 
derivatives was not as straightforward. In collaboration with Novartis Biomedical Institute of 
Research in Cambridge, MA, we were able to examine a wider variety of heterocycles to 
determine which scaffolds could be reactive under our conditions. At Novartis, we were 
given access to a 24 well plate with bottom irradiation (450 nm BLEDs), in which 1-dram 
vials were able to fit. Reactions were set up analogously to how we set up reactions at UNC; 
however, due to safety reasons, it was preferred that oxygen balloons were not used and 
instead air was used as a terminal oxidant. With this parameter being changed we knew that 
yields might not be as high as they would be with oxygen, but reactivity could still be 
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determined. Automated data processing was used so that samples could be analyzed quickly 
using an LCMS and then promising reactions were purified by prep HPLC. Arenes that 
provided the desired products were then run in setups at UNC to determine if oxygen could 
improve yields, and the specific conditions for each arene are listed in each table.  
 At the onset of this work, we wondered if precedented aromatic substitution reactivity 
patterns would accurately describe the electrophilic arene cation radical generated from 
electron rich arenes in our reactions.5 While electrophilic aromatic substitution does 
generally afford ortho and para functionalized products from electron rich arenes, the 
mechanistic pathway involves the arene as a nucleophile and not an electrophile. Conversely, 
nucleophilic aromatic substitution describes a nucleophile adding to an electron poor arene, 
usually displacing a nucleofuge such as a halogen.6 For this reason, we thought that neither 
model would be appropriate for predicting site selectivities and believed that computational 
insight regarding regioselectivity would be necessary.7 
3.3.1 Factors Influencing Site Selectivity 
 It was determined that several factors would influence the predictive model and 
required consideration, including: 1) the oxidation potential of each arene of interest, 2) the 
electrophilicity of the corresponding arene cation radical, 3) whether the intermediate after 
SET would best be described as a delocalized or localized arene cation radical, 4) if sufficient 
change in electron density between the neutral and cation radical of an arene existed, and 5) 
the impact of substituents and the electronic nature of the arene. 
 Previous work in our group by Hudson Roth and Nathan Romero detailed a 
computational method for the prediction of redox potentials (see Chapter 1.3.4).8 This 
method was used in the development of our computational model as well. Knowledge of 
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whether a given arene was electron-rich enough to undergo the desired SET process was 
critical. Several types of heterocycles, including pyrimidines, pyridazines, pyrazines, purines, 
and nucleobases, as well as unsubstituted quinoline and pyridine, were not sufficiently 
electron-rich to undergo SET with an acridinium catalyst. These data are useful for 
explaining why certain heterocycles are unreactive without needing to obtain experimental 
CV data for each compound. 
Previous work by Yoshida and Fukuzumi used computational data to describe the 
reactivity of arene cation radicals (see Chapter 1.3.3).9,10 Based on this precedent, we 
decided to use a similar strategy to predict the electron density of a given arene cation radical 
intermediate. For each compound, the geometries for the neutral and cation radical of the 
arene in 1,2-dichloroethane (DCE) were optimized at the B3LYP/6-31G+(d,p) level of 
theory, and the natural population analysis (NPA)11 values could then be determined (Figure 
3.1). Furthermore, we looked at the difference between the cation radical and neutral values 
for each arene.  
 
Figure 3.1 Natural population analysis and electrostatic potential maps of anisole. 
Generally, arene cation radicals are understood as delocalized with respect to both 
charge and spin density. The determination of spin density distribution yields insight into 

























as indole, the cation radical spin density exists primarily at the 3-position, and the positive 
charge is predominantly at the adjacent carbon atom at the 2-position.12 Based on these 
results, it can be understood that a localized iminium radical intermediate is produced by 
single electron transfer from the indole core (Figure 3.2). A careful understanding of what 
happens for a given arene after SET is critical for determining whether the system is best 
described as delocalized or localized.  
 
Figure 3.2 Iminium radical reactivity of indole.  
3.3.2 Aromatic Classes 
 Expanding on our prior work (see Chapter 2), we aimed to determine what other 
types of aromatic cores commonly used in pharmaceuticals could be functionalized. The 
aromatic cores could generally be grouped into two categories 1) six-membered aromatics 
and 2) aromatics with at least one five-membered heteroaromatic ring. The classes that 
comprise the first category that we investigated are benzenoids, pyridines, and quinolines. 
Benzenoids are ubiquitous in natural products and pharmaceuticals and are widespread in the 
development of new drugs. Pyridines and quinolines are among the most prevalent aromatic 
ring and nitrogen-containing heterocycles found in the U.S. FDA approved pharmaceuticals, 
and the latter are also present in several natural products, including the cinchona 
alkaloids.13,14 The second class includes pyrazoles, indazoles, bridging nitrogen 
polyaromatics, benzofurans, indoles, and benzazoles.15–17 Pyrazoles are found in a wide 
range of pharmaceuticals displaying antimicrobial, anti-cancer, and anti-inflammatory 















utility in antifungal, antiarrhythmic, and analgesic applications.20 Imidazo[1,2-b]pyridazines, 
imidazo[1,2-a]pyrimidines, pyrazolo[1,5-a]pyrimidines, and imidazo[1,2-a]pyridines are 
common bridging nitrogen polyaromatic heterocycles present in compounds displaying a 
wide range of biological properties including anticancer, antimalarial, antidiabetic, anti-
inflammatory, antibacterial, sedative, and anxiolytic.21–29 Benzofurans have a variety of 
biological activities including antiviral, antioxidant, and antifungal properties; additionally, 
some amino-substituted benzofurans exhibit antiarrhythmic activity.30 Indoles are found in 
numerous natural products and even in amino acids (tryptophan).31 In many pharmaceuticals, 
indole derivatives are substituted at the 3- and 5-positions and can exhibit anticancer, 
antiproliferative, antibacterial, antidiabetic, antioxidant, anti-inflammatory, and antiviral 
activities.31–33  
3.3.2.1 Six-Membered Aromatics  
 To explore the reactivity of benzenoids in our aryl C–H amination reaction, we 
examined a sterically and electronically diverse group of benzene derivatives that were 
sufficiently electron-rich to undergo functionalization. For each mono-substituted benzene, 
we observed that the para isomer was favored with minor amounts of the ortho isomer 
formed (Figure 3.3). As determined by the differences between the neutral and cation radical 
computational NPA values, the para position was predicted to be the most electrophilic site 
in all cases. Phenolic ether substrates and biphenyl underwent functionalization favoring the 
para position to afford 3.2a – 3.2f, respectively, as the model suggested. Furthermore, for all 
of the disubstituted arenes explored, the site predicted to undergo functionalization by the 
NPA values did, in fact, match the site of experimental amination (3.2g – 3.2i). While 
modified reaction conditions are required for alkyl-substituted arenes (see Chapter 2.2.5), 
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the computational predictions can still be used to predict the major isomer. Quinazolinedione 
and dihydrocoumarin substrates underwent amination para to the heteroatom to provide 3.2l 
and 3.2m, matching the site of the largest NPA difference value. 
 Other arenes not previously reported in our original paper were also highlighted in 
this predictive model. Additional functionality, including esters, O-benzyl phenols, and allyl 
substituents were tolerated in a variety of substrates under aerobic conditions to provide 3.2n 
– 3.2p. 1,3-Dimethoxybenzene and O-tosyl guaiacol also underwent amination in high yield 
to afford 3.2q and 3.2r as single regioisomers. Trisubstituted arenes were also competent in 
the C–H amination, providing 3.2s in 31% yield as a single regioisomer. For all benzenoid 
substrates studied, the experimental site of functionalization matched the predicted site of the 
largest NPA value difference.  
 The functionalization of heterocycles such as pyridine is desirable due to their 
prevalence in pharmaceuticals, yet unsubstituted pyridine is not sufficiently electron-rich to 
be oxidized by the acridinium catalyst (Ecalc,ox (pyridine•+/pyridine) = +2.64 V vs SCE).8 The 
addition of electron-donating groups lowers the oxidation potential enough that SET can 
occur with the acridinium catalyst. The previously reported substrate 2,6-dimethoxypyridine 
underwent functionalization at the 3-position, matching the site of largest NPA value 
difference (Figure 3.4).1 A similar trend was observed with 3,5-dimethoxypyridine, in which 
the computational model accurately predicts the site of functionalization. Interestingly, the 
site of the largest NPA value difference for 2,4-dimethoxypyridine did not match the 
experimental site of functionalization. We propose that this is due to the steric repulsion 
caused by the methoxy substituents, hindering functionalization at the 3-position and leading 
to predominant amination at the 5-position. Additionally, methyl-substituted pyridines 
	 45 
 
Figure 3.3 Benzenoid scope with predictions of site selectivity. Ratios refer to para:ortho 
(p:o) selectivity for the given isomer. Reactions were run in 1,2-dichloroethane (DCE) at 0.1 
M concentration with respect to the arene limiting reagent. Computational results are 
highlight using the circles indicated in the figure. All of the redox potentials were 
computationally determined and were calculated vs SCE in MeCN. (a) The reaction was run 
for 48 h. (b) The reaction was run under N2 with 1 equiv of TEMPO. 
could be functionalized, albeit in a 1:1 mixture of regioisomers (3.4e:3.4f). Overall, pyridines 
generally undergo amination at the computationally predicted site of functionalization; 
however, steric parameters could be considered for a more detailed predictive model. 
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3.2b; R = –OMOM; 52% yield; 7.8:1 p:o
       E1/2 = +1.76 V
3.2c; R = –OTBS; 74% yield; 9.3:1 p:o
       E1/2 = +1.59 V
3.2d; R = –Ot-Bu; 63% yield; 6:1 p:o
       E1/2 = +1.54 V
3.2a; R = –OMe; 88% yield; 8.8:1 p:o
       E1/2 = +1.68 V
3.2e; R = –OPh; 86% yield; 11:1 p:o






3.2j; R = Me, 82% yieldb
E1/2 = +2.02 V
3.2k; R = H, 36% yieldb























































E1/2 = +1.55 V
3.2s
= sites where the most positive radical cation charge density and largest NPA difference match
= site of most positive radical cation charge density
= the largest NPA difference site
3.2f; R = –Ph; 56% yield; 7.9:1 p:o
       E1/2 = +1.74 V
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Figure 3.4 Pyridine scope with predictions of site selectivity. Reactions were run in 1,2-
dichloroethane (DCE) at 0.1 M concentration with respect to the arene limiting reagent. 
Computational results are highlight using the circles indicated in the figure. All of the redox 
potentials were computationally determined and were calculated vs SCE in MeCN. (a) The 
reaction was run under air instead of O2, (b) The reaction was run under N2 with 1.0 equiv of 
TEMPO. 
The last six-membered heterocycle class probed was quinolines (Figure 3.5). For 
several quinoline substrates, the site of functionalization could be predicted using the largest 
NPA value difference (3.6a – 3.6d). For 4-bromo-7-methoxyquinoline (3.5e), no amination 
product was formed. For this substrate, there was no significant difference in the NPA values 
computationally, highlighting that a sufficient change in NPA values must be achieved for 
functionalization to occur. In general, when a sufficient difference is observed between NPA 
values, good yields and single regioisomers are observed. The site of functionalization on the 
quinoline core is dependent on the position of the electron-donating substituents and for 
some quinolines such as 3.6d, ipso substitution at the methoxy group was observed as a 
minor product. When large differences in NPA values are observed, quinolines generally can 
undergo the desired transformation with good site selectivity. 
N
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Figure 3.5 Quinoline scope with predictions of site selectivity. Reactions were run in 1,2-
dichloroethane (DCE) at 0.1 M concentration with respect to the arene limiting reagent. 
Computational results are highlight using the circles indicated in the figure. All of the redox 
potentials were computationally determined and were calculated vs SCE in MeCN. (a) The 
reaction was run under O2 instead of air, (b) Ipso substitution of the methoxy group was also 
observed. 
 
For six-membered aromatic compounds, selectivity can generally be predicted based 
on rules for electrophilic aromatic substitution, despite the differences between the two 
mechanisms.5 The theoretical basis of understanding for the predictive model is critical for 
understanding site selectivity, but it is also convenient to note that EAS selectivity rules can 
predict regioselectivity for benzenoids, pyridines, and quinolines.  
3.3.2.2 Aromatics Containing at Least One Five-Membered Ring 
 We predicted that aromatic systems with at least one five-membered ring would react 
differently than those with six membered rings only. Pyrazoles and indoles possess enamine 
character, which dictates the site of nucleophilicity in EAS reactions. Enamine nucleophilicity 
is not observed in five-membered heterocycles such as indazoles or benzoxazoles, which are 
incapable of adopting enamine-like resonance structures. Based on this prior knowledge of 
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five-membered heterocyclic reactivity, we wondered whether these compounds would 
undergo functionalization at a position similar to that observed during EAS reactions or if 
their reactivity would be akin to that of a distonic iminium radical (Figure 3.3). When 
enamines undergo SET, iminium radical intermediates are formed, rendering the iminium 
carbon poised for nucleophilic addition. Discerning if this type of mechanism is operative is 
critical for understanding how heterocycles with enamine character react in our system.  
N-methylpyrazole is not sufficiently electron-rich to be oxidized by the acridinium 
photocatalyst used in the reaction (Figure 3.6). The addition of a methyl substituent lowered 
the oxidation potential sufficiently to render the compounds able to undergo SET with the 
acridinium. For both 1,3- and 1,4-dimethylpyrazole, functionalization at the 5-position was 
observed to provide 3.8b and 3.8c, matching the most electrophilic site predicted by the 
model. However, 1,5-dimethylpyrazole did not undergo amination under the reaction 
conditions. From these data, aryl functionalization of N-substituted pyrazoles occurs at the 5-
position, unless this site is blocked by a substituent, in which case no functionalization 
ensues. If pyrazoles reacted similarly to six-membered heterocycles with EAS selectivity, 
functionalization at the 4-position would be predicted.34,35 However, N-substituted pyrazoles 
deviate from this trend and instead react at the most electrophilic position of the iminium 
radical generated via SET.  
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Figure 3.6 N-methylpyrazole scope with predictions of site selectivity.  Reactions were run 
in 1,2-dichloroethane (DCE) at 0.1 M concentration with respect to the arene limiting 
reagent. Computational results are highlight using the circles indicated in the figure. All of 
the redox potentials were computationally determined and were calculated vs SCE in MeCN. 
(a) The reaction was run under O2 instead of air, (b) 1H NMR yield with hexamethyldisiloxane 
as an internal standard. 
In our prior work, we disclosed that N-methylindazole underwent amination at the 3-
position to afford 3.10a, matching the predicted site of functionalization based on the largest 
NPA value difference (Figure 3.7). Indazoles are not able to adopt any enamine character as 
observed with pyrazoles and for that reason it is not a viable way to predict site selectivity. 
Functionalization at the 3-position also occurred with 7-bromo-N-methylindazole (3.10b) 
with a minor regioisomer formed at the 4-position (3.10c). This also corresponds to the 
predicted site of functionalization; however, the NPA differences between the 3- and 4-
positions were not significant, highlighting that this model could predict the minor 
regioisomer. 3-Substituted indazoles, such as 3-bromo-N-methylindazole (3.9d), did not 
produce any aryl functionalization products, potentially due to steric hindrance at the 4- and 
7-positions with the bulky pyrazole nucleophile. These few examples of indazole 
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functionalization can be described as functionalization at the same site that EAS reactivity 
predicts, which matches the site predicted by the largest NPA value difference of the model.  
 
Figure 3.7 N-methylindazole scope with predictions of site selectivity. Reactions were run in 
1,2-dichloroethane (DCE) at 0.1 M concentration with respect to the arene limiting reagent. 
Computational results are highlight using the circles indicated in the figure. All of the redox 
potentials were computationally determined and were calculated vs SCE in MeCN. (a) The 
reaction was run under O2 instead of air, (b) 1H NMR yield with hexamethyldisiloxane as an 
internal standard. 
Imidazopyrimidines, imidazopyridazines, and pyrazolopyrimidines are all 
heterocycles that are sufficiently electron-rich to undergo SET with an acridinium catalyst 
(Figure 3.8). In all cases shown, functionalization occurs selectively at one site of the 
polyaromatic core. Imidazo[1,2-b]pyridazines afforded products with functionalization at the 
3-position regardless of substitution (3.12a – 3.12d). Halogenated imidazo[1,2-b]pyridazine 
3.11d, which is more electron-poor, showed a decrease in yield, but functionalization still 
occurred at the 3-position. For imidazo[1,2-a]pyrimidine, only one regioisomer was formed 
in good yield at the 3-position (3.12e), matching the predicted site of functionalization. For 
imidazo[1,2-b]pyridazines and imidazo[1,2-a]pyrimidines, enamine character is present in 
X = sites where the most positive radical cation charge density and
= site of most positive radical cation charge density
= the largest NPA difference site
largest NPA difference match
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the ring system. As observed with N-methylpyrazoles, reactivity in these cases occurs at the 
iminium carbon of the iminium radical intermediate. Pyrazolo[1,5-a]pyrimidine produced 
adduct 3.12f in 42% yield, also undergoing functionalization at the 3-position. For this type 
of heterocycle, an iminium radical cannot be formed that is unsubstituted at the most 
electrophilic site. Substrate classes such as this highlight the necessity of a computational 
predictive model to anticipate the observed regioselectivity.  
 
Figure 3.8 Bridging nitrogen polyaromatic scope with predictions of site selectivity. 
Reactions were run in 1,2-dichloroethane (DCE) at 0.1 M concentration with respect to the 
arene limiting reagent. Computational results are highlight using the circles indicated in the 
figure. All of the redox potentials were computationally determined and were calculated vs 
SCE in MeCN. (a) The reaction was run under O2 instead of air, (b) 1H NMR yield with 
hexamethyldisiloxane as an internal standard.  
X = sites where the most positive radical cation charge density and
= site of most positive radical cation charge density
= the largest NPA difference site
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 Similarly to what we observed with 3-bromo-N-methylindazole, for 3.11g, a 
significant difference in NPA values between the neutral and cation radical did not occur 
and, accordingly, no amination product was formed. Halogen substituents were tolerated on 
the imidazo[1,2-a]pyridine core, affording adducts such as 3.12h in 37% yield, matching the 
site of greatest NPA difference. This regioselectivity for functionalization correlates to the 
site of highest electrophilicity in the iminium radical generated by SET. For most bridging 
nitrogen polyaromatic systems, enamine character dictates site selectivity, which correlates to 
the computational predictions for the most electrophilic position. However, when enamine 
character is not present, the experimental functionalization does still match that of the 
predictive model. 
 Undecorated benzofuran was an incompetent substrate under the reaction conditions, 
never affording the desired amination product (Figure 3.9). The inclusion of a methoxy 
substituent on the benzofuran core at the 5- or 7-position produced aryl amination products 
3.14b, 3.14c and 3.14d, respectively. For 5-methoxybenzofuran, functionalization afforded 
3.14b and 3.14c in a 29% combined yield and 1.2:1 ratio. Interestingly, when a 2-substituted 
benzofuran was used, such as 3.13e, only difunctionalization occurred. Unlike other classes 
of heterocycles, all benzofurans underwent functionalization at the 2-position, matching the 
site of the largest NPA value of the cation radical instead of the site of largest difference. The 
2-position does correlate to the position of a distonic oxocarbenium radical, generated by 
SET from the cyclic enol ether, to which nucleophilic addition would occur. We propose that 
following nucleophilic addition to the oxocarbenium radical, the benzylic radical 
intermediate can be oxidized to the carbocation, which is susceptible to addition by a second 
equivalent of nucleophile to form 3.14c and 3.14e. While benzofurans do not match the 
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predictive model in terms of functionalization at the site of the largest NPA difference, this 
class does undergo amination at the most electrophilic site of the oxocarbenium radical that 
has the largest NPA value. 
 
Figure 3.9 Benzofuran and indole scope with predictions of site selectivity. Reactions were 
run in 1,2-dichloroethane (DCE) at 0.1 M concentration with respect to the arene limiting 
reagent. Computational results are highlight using the circles indicated in the figure. All of 
the redox potentials were computationally determined and were calculated vs SCE in MeCN. 
(a) The reaction was run under air. 
 Similarly to benzofuran, undecorated indole did not provide any amination product 
(Figure 3.9). When a methyl group was installed at the 2-position, no functionalization was 
observed (3.14f). If the methyl group was instead located at the 5- or 6-position, amination 
did occur, albeit in very low yields. Further optimization of indole substrates would be 
required for application to a greater number of compounds. Similarly to benzofurans, indoles 
preferentially undergo functionalization at the 2-position (3.14g and 3.14h), matching the 
X = sites where the most positive radical cation charge density and
= site of most positive radical cation charge density
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largest NPA value of the cation radical and the most electrophilic position of the iminium 
radical. Nucleophilic addition to the iminium, resulting in the formation of a more stable 
benzylic radical, leads to the observed regioselectivity. 
 Overall, benzofurans and indoles possess less aromatic character compared to other 
heterocycles discussed previously.36,37 For this reason, we propose that they should not be 
treated as aromatic compounds for the purpose of the predictive model and that they instead 
should be viewed as cyclic styrenes, in which regioselectivity is dictated by the iminium or 
oxocarbenium radical intermediate. If these compounds exhibited significant aromatic 
character, rearomatization from the benzylic radical would outcompete the oxidation that 
gives rise to the difunctionalized product. Accordingly, benzofurans and indoles should be 
treated as distonic alkene cation radicals instead of delocalized arene cation radicals.  
 Several types of benzazoles were also shown as competent substrates in this 
methodology (Figure 3.10). 2-Methylbenzoxazole formed 3.16a as the major product, 
matching the site of largest NPA difference value. Benzothiazoles were also reactive, 
forming 3.16b and 3.16c in modest yields but greater than 10:1 regioselectivity, again 
corresponding to the site of the largest NPA difference. The model also accurately predicted 
the major product for 2-chloro-N-methylbenzimidazole, which formed 3.16d and 3.16e in a 
3:1 ratio and 42% yield. The site of functionalization for these benzazoles matches the site 
predicted using EAS selectivity rules, as seen previously with six-membered heterocycles.38,39 
Although the computational model was necessary for developing a theoretical underpinning 
of site selectivity, EAS regioselectivity can be used as a strategy to predict selectivity without 
requiring computational effort.  
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Figure 3.10 Benzazole scope with predictions of site selectivity. Reactions were run in 1,2-
dichloroethane (DCE) at 0.1 M concentration with respect to the arene limiting reagent. 
Computational results are highlight using the circles indicated in the figure. All of the redox 
potentials were computationally determined and were calculated vs SCE in MeCN.  
3.3.3 Nucleophile Scope and Complex Derivatives 
 To this point, only pyrazole had been used as the nucleophilic coupling partner. 
Demonstration of other nucleophiles in this work and determining whether the resultant 
products still matched the predicted site of functionalization would be critical to understand 
the generalizability of the model. The use of ammonium carbamate as the nucleophile (see 
Chapter 2.8) afforded aniline products 3.17a and 3.17b that matched the computational 
predictions for the site of functionalization. Other nitrogen heterocycles were also shown as 
competent nucleophiles experimentally, with the products arising from amination at the site 
with the largest NPA difference value (3.17c – 3.17g). In 2017, the Nicewicz lab also 
demonstrated the C–H cyanation of electron-rich arenes using a similar photoredox catalyzed 
approach and TMSCN as the nucleophile.40 For 3.17h and 3.17i, the cyanation site selectivity 
matched the position with the largest NPA difference value, as predicted by the model.  
X = sites where the most positive radical cation charge density and
= site of most positive radical cation charge density
= the largest NPA difference site
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Figure 3.11 Nucleophile scope with predictions of site selectivity. Reactions were run in 1,2-
dichloroethane (DCE) at 0.1 M concentration with respect to the arene limiting reagent. 
Computational results are highlight using the circles indicated in the figure. All of the redox 
potentials were computationally determined and were calculated vs SCE in MeCN. (a) 
NH4CO2NH2 (4.0 equiv), 5 mol % catalyst 1, 20 mol % TEMPO, 10:1 DCE/H2O, O2, 24 h, 
(b) TMSCN (1.5 equiv), 5 mol % catalyst 1, 10:1 MeCN/pH 9 Buffer, O2, 24 h.   
 The ability to utilize this C–H functionalization for late stage derivatization was 
important for the broader application of the methodology (see Chapter 2.2.7). Using more 
complex arene substrates in this chemistry, we could predict the site of functionalization 
based on which position possessed the largest difference in NPA values between the neutral 
and cation radical. This correlation held for several different complex substrates with 
pyrazole as the nitrogenous coupling partner (Figure 3.12). Additionally, using either 
pyrazole or TMSCN as the nucleophile afforded the same, predicted regioisomer for the 
X = sites where the most positive radical cation charge density and
= site of most positive radical cation charge density
= the largest NPA difference site
largest NPA difference match
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cholesterol-lowering agent gemfibrozil methyl ester as well as Boc-protected melatonin 
(3.18e – 3.18f).  
 
Figure 3.12 Complex molecule scope with predictions of site selectivity. Reactions were run 
in 1,2-dichloroethane (DCE) at 0.1 M concentration with respect to the arene limiting 
reagent. Computational results are highlight using the circles indicated in the figure. All of 
the redox potentials were computationally determined and were calculated vs SCE in MeCN. 
(a) TMSCN (1.5 equiv), 5 mol % catalyst 1, 10:1 MeCN/pH 9 Buffer, O2, 24 h.   
 Several other complex derivatives were used as substrates during the high-throughput 
screening at Novartis; however, in many instances, only starting material was recovered, 
likely due to the substrates not being oxidizable by the acridinium catalyst. Derivatives of 
both histidine and tryptophan were screened in the reaction with pyrazole as a nucleophile 
(Figure 3.13). Histidine methyl ester did couple to give product 3.20a as determined by 
LCMS and 1H NMR after isolation, but the yield was very poor and could not be improved. 
X = sites where the most positive radical cation charge density and
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Tryptophan did undergo the desired nucleophilic addition, but instead of undergoing 
rearomatization, the resultant benzylic radical was trapped by oxygen to form amino alcohol 
3.20d in 17% yield.  
Figure 3.13 Amino acid arene scope with predictions of site selectivity.  Reactions were run 
in 1,2-dichloroethane (DCE) at 0.1 M concentration with respect to the arene limiting 
reagent. 
 
Overall, several heterocyclic classes can be functionalized using this photoredox-
catalyzed aryl C–H functionalization strategy. A simple computational predictive model was 
constructed that relied on 1) the oxidation potential of the arene, 2) the most electrophilic site 
of the arene cation radical, and 3) whether sufficient change in electron density between the 
cation radical and neutral arene existed. All heterocycles explored could be grouped into one 
of two categories: i) heterocycles that follow EAS selectivity (Figure 3.14, Part A) and ii) 
heterocycles that possess enamine or enol character and react through iminium or 
oxocarbenium radical intermediates, respectively (Figure 3.14, Part B). Benzenoids, 
pyridines, quinolines, indazoles, and benzazoles constitute the first category, and pyrazoles, 
bridging nitrogen polyaromatics, benzofurans, and indoles comprise the second category. A 
flowchart for predicting site selectivity is shown in Figure 3.15. 
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3.3.4 Unsuccessful Arene Substrates 
While the heterocycle classes detailed so far generally exhibit good reactivity, several 
explored groups were not sufficiently electron rich to undergo SET to the acridinium catalyst, 
including pyrimidines, pyridazines, pyrazines, purines, and nucleobases (Figure 3.14, Part 
C). A more specific list of arenes that were tried in the high-throughput experimentation at 
Novartis is disclosed in Figures 3.16 and 3.17. Some of these substrates gave slight 
conversion to the desired amination adduct but could not be optimized or quantified at 
Novartis, and many formed no product under the reaction conditions used. Due to 
experimental limitations with the available HTE setup, air was used instead of oxygen, so the 
use of an oxygen atmosphere could prove useful for further optimization. With the 
knowledge that certain heterocycles are not reactive with this methodology, the ability to 
functionalize electron-rich arenes over electron-poor arenes selectively becomes available 
and can be broadly useful in the context of late stage complex molecule functionalization.   
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Figure 3.15 Flowchart describing general selectivities for heterocycles grouped by class 
Benzenes










Is there an 
electron-donating 






or Functionalization most likely at ortho 
position (either the 5- or 8- position)





Functionalization most likely to occur















likely para to electron-
donating group
Functionalization most















at the carbon adjacent to
the bridging nitrogen on 
the imidazole
Is the heterocycle




at the carbon adjacent to
bridging carbon on 
the pyrazole





likely at the 2-position
Difunctionalization most
likely if the 2-position is 
substituted and 2 equiv 






















likely at the position





















































Figure 3.16 Unsuccessful arenes from Novartis high-throughput screen with redox 
potentials. All measurements were computationally determined in V vs SCE in MeCN. 
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Figure 3.17 Unsuccessful arenes from Novartis high-throughput screen with redox potentials 
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CHAPTER 4: DIRECT ARYL C–H AMINATION WITH PRIMARY AMINES  
USING ORGANIC PHOTOREDOX CATALYSIS  
 
 Adapted from Margrey, K. A.; Levens, A.; Nicewicz, D. A. Angew. Chem. Int. Ed., 
2017, 56, 15644–15648. Copyright 2017 John Wiley & Sons, Inc. 
4.1 Introduction 
 Arene C–H functionalization methodologies have been developed by our lab using 
nitrogen heterocycles,1 ammonia surrogates, cyanide,2 and, in select cases, fluorine as 
coupling partners. This reactivity hinges on the use of electron-rich arenes that can undergo 
SET with an acridinium catalyst to afford an electrophilic arene cation radical, which is 
susceptible to addition by the nucleophilic partner. Several other photoredox-catalyzed 
systems have been used to generate electrophilic coupling partners different from the alkene 
and arene cation radicals commonly utilized by our lab.3 The ability to generate additional 
types of electrophilic cation radical coupling partners via an acridinium catalyst would 
facilitate the development of novel bond constructions and reactivity (Figure 4.1).  
 





-arene as limiting reagent
-expand to include aliphatic aminesacridinium
-avoid use of chloroamines and harsh reaction conditionscatalyst system
via:




4.2 Arene Functionalization with Aliphatic Amines 
 Prior work focused on the use of azoles as coupling partners for aryl C–H amination 
(see Chapter 2) and the development of a predictive model for the site selectivity of the 
transformation (see Chapter 3). At the onset of this project, we wondered whether additional 
nitrogen coupling partners, namely aliphatic amines, could be used for a similar C–H 
amination strategy. Due to the relatively low oxidation potentials associated with such 
amines (+0.40 to +1.90 V vs SCE), it was not clear if the amine or arene would be more 
likely to undergo SET with the acridinium catalyst and whether subsequent productive 
coupling could occur.4 
In 1973, Minisci reported that by exposing N-chloroamines to iron (II) sulfate in 
strongly acidic media, amine cation radicals could be generated and undergo addition to 
arenes to form substituted aniline derivatives (Figure 4.2).5,6 Minisci demonstrated that this 
was a viable mechanism mostly for secondary amines, but in some cases, primary amines 
could also be used. Anisole reacted with N-chloropiperidine, affording only para and ortho 
isomers, while toluene reacted with N-chloromethylamine to produce all regioisomers in a 
2:1:1 para:meta:ortho ratio. However, chloroamines are only stable for storage at low 
temperatures and can undergo N–Cl bond homolysis upon exposure to visible light, 
rendering them quite unstable and challenging to use. Furthermore, the necessity of strongly 
acidic conditions limits the available functional group compatibility in this type of reaction.  
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Figure 4.2 Aryl amination using N-chloroamines. 
4.3 Photoredox-Mediated Functionalization of Aliphatic Amines  
Inspired by this precedent for arene amination with aliphatic chloroamines, we 
investigated other strategies to generate amine cation radicals that avoided the use of 
prefunctionalization, including through electrochemistry, chemical oxidants, UV light-
mediated photochemistry, and visible light-mediated photochemistry. Specifically, in the 
context of visible light-mediated reactivity, photoredox catalyst excited states can often be 
quenched by amines through SET to generate the amine cation radical. Due to their 
particularly low oxidation potentials (<+1.0 V vs SCE), tertiary aliphatic amines were 
frequently used in these earlier works and have also been used more recently by Rueping, 
Stephenson, and Rovis, among others, to harness this process to generate synthetically useful 
intermediates.7,8,9 Amine cation radicals can generally undergo either H atom abstraction at 
the weakened C–H bond adjacent to nitrogen or deprotonation to generate an iminium or 
radical adjacent to nitrogen, respectively (Figure 4.3). Both of these intermediates have been 






























Figure 4.3 Previous photoredox-mediated functionalization of aliphatic amines. 
 One example of iminium generation by the Stephenson group used BrCCl3 as a 
stoichiometric oxidant to facilitate H atom abstraction adjacent to nitrogen.8 Several different 
sp3 and sp2 carbon nucleophiles were able to add into the iminium intermediate. To enable 
this type of reactivity, the amine generally must be tertiary and is often derived from aniline. 
This allows for the amine to be electron-rich enough to undergo SET with the ruthenium or 
iridium-based photoredox catalysts (E*1/2 ≈ +0.7 to +1.2 V vs SCE).  
 Primary and secondary amines have been underutilized in photoredox processes to 
this point. While these general motifs are not as electron-rich as tertiary amines, they 
generally are still sufficiently electron-rich to undergo SET with photocatalysts such as an 
acridinium (see Appendix C). We hoped to utilize an acridinium catalyst to undergo SET 
with an alkyl amine and generate a reactive electrophilic intermediate. Since aliphatic amines 
are very prevalent in synthesis and biological systems such as amino acids, we felt that the 




































 Recently, the Knowles group demonstrated that an iridium-based photocatalyst could 
be used to generate a secondary amine cation radical, which underwent anti-Markovnikov 
addition to unactivated alkenes.10 Primary amines could not be used in this reaction, but there 
was a wide scope of secondary amines and alkene coupling partners. We felt that utilizing an 
amine cation radical intermediate could be useful in arylation chemistry, accessing aniline 
derivatives from non-oxidizable arenes using an acridinium photocatalyst.  
4.4 Primary Amine Aryl Functionalization via Photoredox Catalysis 
 The ability to construct aryl C–N bonds is particularly important due to the 
prevalence of aryl amines in natural products, pharmaceuticals, and materials. This type of 
reaction mode allows for rapid functionalization and derivatization of arenes, streamlining 
synthetic routes and avoiding the preoxidation step that is required to install halides or other 
cross-coupling functional handles. Most previously developed C–H amination strategies 
relied on using electron-poor nitrogen coupling partners such as amides and imides (see 
Chapter 1). Subsequently, we developed a photoredox catalyzed strategy for C–H amination 
using nitrogen heterocycles and ammonia surrogates with a predictive model for site 
selectivity (see Chapters 2 and 3) (Figure 4.4). While these nitrogen nucleophiles were 
more electron-rich than most amides or imides, they, in most cases, were not sufficiently 
electron-rich to undergo SET with an acridinium catalyst. The cyanation chemistry 
developed in our lab uses TMSCN as a nucleophile, which is not capable of being oxidized 
by the catalyst (Ep/2 ≥ +3.0 V vs SCE).2 With the knowledge that most nucleophiles that 
could participate in our lab’s aryl C–H functionalization methodologies were not oxidizable, 
we wondered whether aryl functionalization could still occur when using electron-rich 
amines, such as primary amines, as the coupling partner.  
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Figure 4.4 Previous aryl functionalizations demonstrated by the Nicewicz lab. Redox 
potentials were determined experimentally in MeCN. 
 
4.4.1 Initial Reactivity and Optimization 
We hoped to extend our aryl amination chemistry beyond just nitrogen heterocycles 
and study amine coupling partners that can be oxidized by the acridinium photocatalyst. With 
commercial valine methyl ester hydrochloride as a non-volatile and inexpensive primary 
amine source, we began by screening solvents with anisole as the coupling partner. Initially, 
we found that the desired adduct was formed in 29% yield under aerobic conditions with 
slight excess of the amine and using DCE and 4M pH 8 phosphate buffer as the solvent, 
favoring formation of the ortho product (Table 4.1, entry 1). Replacing the pH 8 buffer with 
saturated aqueous sodium bicarbonate provided 39% yield of the desired product (Table 4.1, 
entry 2). The basic aqueous cosolvent proved necessary to deprotonate the HCl salt of the 
amine, and due to concerns with reaction reproducibility, the phosphate buffer was used for 
further optimization. Increasing the amount of amine in the reaction produced yields of up to 
55% when using three equivalents (Table 4.1, entries 3 – 4), and inversion of the 
stoichiometry proved to be inferior (Table 4.1, entry 5). An oxygen atmosphere was 
necessary for reactivity to occur, with only 2% yield of the desired adduct produced when the 
















All nucleophiles are more
electron-poor than arenes
E1/2 = +1.85 V vs. SCE
E1/2 (pyr
+•/pyr) = +2.27 V vs. SCE
E1/2 (TMSCN
+•/TMSCN) > + 3.0 V vs. SCE
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The yield of the reaction could not be increased further at this point, so we considered 
whether this was due to product instability under the reaction conditions, especially since the 
products of C–H amination are more prone to oxidation (E1/2(4.3/4.3+•) = +0.74 V vs SCE 
than the starting arenes. Unlike with azole coupling partners, the addition of TEMPO did not 
increase the yield of the reaction (Table 4.1, entry 7). However, decreasing the reaction time 
to four hours, the point at which full consumption of the starting arene was observed, 
increased the yield to 67% (Table 4.1, entry 8). Using a slightly less oxidizing catalyst B 
with the shortened reaction time provided the product in 80% yield (Table 4.1, entry 9). 
Using an additional lamp, catalyst A, or more dilute reaction concentrations significantly 
decreased the yield of the desired product (Table 4.1, entries 10 – 12). The free base of 
valine could also be used in the reaction with only slightly lower yields, so owing to 
commercial availability, the HCl salts of amino acids were used.  
Compared to the aryl C–H functionalization with azoles detailed in Chapter 2, this 
aryl C–H amination deviated significantly with respect to the regioselectivity. As seen in 
Figure 4.4, prior art from our lab was highly para selective for anisole functionalization; 
however, with valine methyl ester as the coupling partner, a statistical mixture of ortho and 
para isomers is produced. When we used TBS phenyl ether as a substrate with primary 
amines as the coupling partner, we observed that the para isomer was favored, yet never to 









Table 4.1 Initial optimization for aryl amination with primary amines. 
 
4.4.2 Amine Scope for Primary Amine Functionalization 
 Based on the divergent regioselectivity observed between anisole and TBS phenyl 
ether, we examined whether this trend would hold for a number of amine coupling partners 
(Figure 4.5). For a range of amino acids, the aryl amination favored formation of the ortho 
isomer with anisole and para isomer with TBS phenyl ether (4.1 – 4.14). Protected serine and 
threonine, N-Boc lysine, and glutamic and aspartic acid esters all reacted smoothly, affording 
4.10 – 4.14 in good yields for both arene coupling partners. Amination adducts formed when 
using isoleucine (4.6) and threonine (4.11) showed only one diastereomer by 1H NMR 

















A; R = R' = H; E*red = +2.20 V
B; R = Me; R' = H; E*red = +2.09 V
C; R = H; R' = t-Bu; E*red = +2.15 V
HN
MeO +
entry deviation from above catalyst solvent [M] yield o:p
1.5 equiv amine C 4:1 DCE: sat. Bicarb. [0.1] 39% 2.3:12
4 hours of irradition C 4:1 DCE:pH 8 Buffer [0.1] 67% 1.9:1
6
7
No O2, only sparge C 4:1 DCE:pH 8 Buffer [0.1] 2% -
8










4 hours of irradiation B 4:1 DCE:pH 8 Buffer [0.1] 80% 2.2:1
11 none A 4:1 DCE:pH 8 Buffer [0.1] 32% 2.0:1
none B 4:1 DCE:pH 8 Buffer [0.05] 50% 3.2:1
33 ºC, O2 (1 atm)
none C 4:1 DCE:pH 8 Buffer [0.1] 55% 2.3:1
3
3 equiv arene and 1 equiv amine C 4:1 DCE:pH 8 Buffer [0.1] 25% 7.3:1
4
2 equiv amine C 4:1 DCE:pH 8 Buffer [0.1] 39% 4.1:1
5









2 Lamps B 4:1 DCE:pH 8 Buffer [0.1] 25% 4.0:1
	 75 
14 different amino acid esters were shown as competent coupling partners in this reaction, 
with generally good yields.  
 Commercially available primary amines such isopropylamine and n-propylamine also 
served as effective coupling partners to produce 4.15 and 4.16, even though they are more 
prone to oxidative degradation under an aerobic atmosphere than amino acids are. When 
using such amine free bases instead of HCl salts, the pH 8 buffer could be omitted with no 
change in yield. Halogenated amines afforded the desired aryl amine (4.17), albeit in lower 
yields. Allyl- and benzylamines also provided the desired adducts (4.18 and 4.19) in 
moderate to high yields.  
 Interestingly, (S)-methylbenzylamine worked well with both anisole and TBS phenyl 
ether (4.20). HPLC analysis of the amination products revealed that, despite the presence of a 
benzylic C–H bond weakened by hyperconjugation from nitrogen, the chiral center did not 
epimerize over the course of the reaction. This coupling with anisole was amenable to scale-
up by 25-fold using a flow apparatus and short retention time in the flow cell. When this 
retention time was too long (i.e. 89 min), yields were very low; however, when retention 
times were fast (i.e. 1 min with continuous loop), the desired product could be formed in 
61% yield. Finally, tert-butylamine also participated as a coupling partner with anisole, 
although in low yield (4.21). 
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Figure 4.5 Primary amine substrate scope.  Ratios refer to ortho:para (o:p) selectivity for the 
given adduct. Reactions were run in 4:1 DCE/pH8 phosphate buffer at 0.1 M concentration 
with respect to the arene limiting reagent. (a) Reaction run in DCE in 0.1 M concentration 
with respect to the arene limiting reagent. (b) Yield of adduct determined by 1H NMR 
spectroscopy. (c) Reaction run in DCE at 0.1 M concentration, with respect to the arene 






4:1 DCE: pH 8 Buffer















4.1a; R = H; 45% yield; 1.3:1 o:p
4.1b; R = H; 49% yield; 1:1.8 o:p
4.2a; R = Me; 62% yield; 1.2:1 o:p
4.2b; R = Me; 65% yield; 1:1.9 o:p
4.3a; R = i-Pr; 80% yield; 2.2:1 o:p





4.9a; 78% yield; 2.0:1 o:p





4.13a; 72% yield; 1.3:1 o:p




4.14a; 69% yield; 1.2:1 o:p





4.15a; R = i-Pr; 53% yield;a,b 1.2:1 o:p
4.51b; R = i-Pr; 56% yield;a 1:1.8 o:p
4.16a; R = n-Pr; 56% yield;a 1.0:1 o:p
4.16b; R = n-Pr; 61% yield;a 1:1.8 o:p
4.17a; R = 3-Br-n-Pr; 58% yield;a,b 1.8:1 o:p
4.17b; R = 3-Br-n-Pr; 56% yield;a,b 1:1.4 o:p
4.18a; R = allyl; 34% yield;a 1.2:1 o:p
4.18b; R = allyl; 80% yield;a 1:2.2 o:p
MeO
NH
4.21; 34% yield;a,b 1.4:1 o:p
R'O
NH 4.19a; R = H; 90% yield;
a 1.3:1 o:p
4.19b; R = H; 70% yield;a 1:1.8 o:p
4.20a; R = Me; 74% yield;a 1.4:1 o:p
          (61% yield on 2.5 mmol scale)







4.22; R = H; 72% yield;a 
single regioisomer
memantine
4.23; R = Me; 37% yield;a 
7.0:1 o:p
rimantidine
4.24; 45% yield;a 
single regioisomer
mexiletine









4.10a; 84% yield; 1.2:1 o:p




4.11a; 68% yield; 1.4:1 o:p




4.12a; 75% yield; 1.7:1 o:p
4.12b; 62% yield; 1:2.3 o:p
Ot-Bu Ot-Bu
Me NHBoc
4.1-20a: R' = Me






4.5a; R = i-Bu; 81% yield; 1.5:1 o:p
4.5b; R = i-Bu; 89% yield; 1:2.4 o:p
4.6a; R = (S)-s-Bu; 69% yield; 2.0:1 o:p
4.6b; R = (S)-s-Bu; 82% yield; 1:1.7 o:p
4.7a; R = n-Bu; 88% yield; 1.5:1 o:p
4.7b; R = n-Bu; 89% yield; 1:2.0 o:p
4.8a; R = t-Bu; 48% yield; 5.5:1 o:p











4.4a; 77% yield; 1.5:1 o:p









 To highlight the utility of this C–H amination method for complex applications, we 
demonstrated its utility with several bioactive amines. Adamantylamine and memantine, anti-
Parkinson and anti-Alzheimer pharmaceuticals, respectively, provided 4.22 and 4.23 in 
modest to good yield.11 Rimantidine, an anti-viral agent,12 also generated the amination 
product in moderate yield (4.24). Interestingly, the three adamantyl-containing amines all 
gave excellent regioselectivity favoring the ortho isomer. Gabapentin methyl ester, a 
medication used to treat seizures,13 participated as the amine coupling partner to form 4.25, 
while anti-arrhythmic pharmaceutical, mexiletine,14 provided 4.26 in 41% yield. 
Additionally, the use of L-valyl-L-phenylalanine ethyl ester to functionalize anisole afforded 
4.27 in 58% yield and highlights the applicability of this strategy to dipeptides. Overall, a 
wide variety of amines, including amino acids and biologically active amines, could be 
shown as competent coupling partners in this methodology.  
 Several amines, however, did not participate in this reaction (Figure 4.6). Whereas 
amino acid esters worked well under the reaction conditions, no desired amination was 
observed with amino acids, likely due to competitive decarboxylative processes. Secondary 
amines were also problematic due to oxidation adjacent to nitrogen, forming amides and 
imides instead of the desired adducts. Aniline did not work as either the arene or amine 
component, similarly to our prior work (see Chapter 2.2.5). Methylamine HCl did provide 
trace quantities of amination product that could not be greatly improved through 
optimization, possibly owing to the volatility of the free base. Amines containing unprotected 
alcohols, such as serine methyl ester, or protected thiols, including trityl-protected cysteine, 
also did not participate in the reaction. 
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O-Benzyl tyrosine also did not produce any amination product under the reaction 
conditions. Ornithine methyl ester, containing two different amines, also did not provide the 
desired adduct, and returned starting material was observed. Trityl-protected histidine methyl 
ester provided 25% yield of the aryl amine, but this could not be improved further. α−Acetyl-
lysine methyl ester was able to serve as the amine coupling partner at the ε nitrogen in 30% 
yield under the previously optimized conditions, which might be further modified to improve 
the yields for both histidine and lysine derivatives. The ability to functionalize lysine at the ε 
nitrogen could lead to applications in the selective arylation of lysine in proteins. 
 
Figure 4.6 Unsuccessful aliphatic amine coupling partners.  Reactions were run in 4:1 
DCE/pH8 phosphate buffer at 0.1 M concentration with respect to the arene limiting reagent. 
 
4.4.3 Arene Scope for Primary Amine Functionalization 
 Having shown that a variety of primary amines participated in this reaction, we also 
sought to demonstrate that a range of arenes could undergo C–H functionalization under 
these conditions (Figure 4.7). A series of monosubstituted arenes underwent amination with 
valine methyl ester HCl to afford 4.3 and 4.28 – 4.34 in good yield. Regioselectivity could be 
altered based on the sterics of the substituent on the arene such that bulkier phenolic ethers 











4:1 DCE:pH 8 Buffer,
 4 h
BF4
E*red = +2.09 V


















































Figure 4.7 Arene substrate scope. Ratios refer to ortho:para (o:p) selectivity for the given 
isomer unless otherwise specified. Reactions were run using Me2-Mes-Acr+ in 4:1 DCE/pH 
8 phosphate buffer at 0.1 M concentration with respect to the arene limiting reagent. (a) Yield 
of adduct as determined by 1H NMR, (b) Reactions run with 40 mol % TEMPO and 5 mol % 
tBu2-Mes-Acr+ for 15–26 h, (c) Reaction run for 13 h, (d) Reactions were run in 4:1 
trifluorotoluene/pH 8 phosphate buffer, (e) 10 equiv of meta-xylene was used with the 
limiting amine, (f) The o:p ratio determined after isolation, (g) Reaction was run with 3 equiv 
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4.40; R = OMe; 49% yield;b  
       10.4:1 C4:C2
4.41; R = Me; 66% yield;a,b,e 
        10.1:1 C4:C5
4.43; 78% yield; 
       1:2.3 o:pf
4.44; 60% yield; 
       1:5 o:pf
4.45; 60% yield;b  







4.46; R = H; 64% yield;b  
      single regioisomer
4.47; R = Br; 66% yield;b,d  







4.35; R = F; 35% yield;b 
       single regioisomer
4.36; R = Cl; 75% yield;b  
       20:1:1 C2:C3:C1
4.37; R = Br; 57% yield;b,d 
       9.1:1 C2:C3
4.38; R = I; 33% yield;b,d  
       6.7:1 C2:C3
4.39; R = i-Pr; 43% yield;b





4.42; 63% yield;b  

































4.50; 66% yield;a,b 8.7:1 C2:C3
CO2Et
MeMe
4.3a; R = OMe; 80% yield; 2.2:1 o:p
4.28; R = OEt; 76% yield; 1.7:1 o:p
4.29; R = Ot-Bu; 82% yield; 1:1.3 o:p
4.30; R = OTES; 77% yield; 1:1.7 o:p
4.3b; R = OTBS; 72% yield; 1:1.9 o:p
4.31; R = OTBDPS; 58% yield; 1:2.3 o:p
4.32; R = OPh; 84% yield; 1:2.2 o:p
4.33; R = SPh; 37% yield;a,b 1:4.4 o:p











E*red = + 2.09 V vs SCE E*red = + 2.15 V vs SCE
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As previously discussed, optimized conditions for anisole and TBS phenyl ether 
required that the reaction only be run for 4 hours without TEMPO. When attempting to 
expand the arene scope to 1,4-disubstituted arenes, these reaction conditions were no longer 
sufficient (Table 4.2). The addition of a cocatalytic amount of TEMPO improved the 
reactivity for disubstituted arenes; however, too much TEMPO proved to be deleterious to 
the yields. Finally, the use of catalyst B gave an increased yield, affording the aniline with 
functionalization predominantly ortho to the methoxy substituent.  
Table 4.2 Optimization of 1,4-disubstitued arene substrate. 
  
With these modified reaction conditions, functionalization of halogenated anisoles 
could be demonstrated (Figure 4.7), favoring the isomer with amination ortho to the 
methoxy group (4.35 – 4.38). 4-Alkyl substituted anisole derivatives also worked with 
TEMPO as an additive, allowing access to 4.39 in 43% yield with excellent regioselectivity. 
1,3-Disubstituted benzenoids underwent amination, forming both 4.40 and 4.41 in good yield 
and regioselectivity. 2-Chloroanisole was competent as well, affording 4.42 in 63% yield. 
















B; R = Me; R' = H; E*red = +2.09 V
C; R = H; R' = t-Bu; E*red = +2.15 V
HN
MeO
entry additive catalyst solvent [M] yield







33 ºC, O2 (1 atm)
TEMPO (0.2 eq.) B 4:1 DCE:pH 8 Buffer [0.1] 52%3
TEMPO (0.8 eq.) C 4:1 DCE:pH 8 Buffer [0.1] 31%4
TEMPO (0.4 eq.) C 4:1 DCE:pH 8 Buffer [0.1] 57%5










expands the arene scope for the transformation. Substrates with more than one arene also 
underwent amination to form 4.43 and 4.44, favoring reactivity at the more electron-rich ring 
in both examples. Further, heterocycles such as pyridines and N-methyl indazoles formed 
adducts 4.45 – 4.47 as single regioisomers in good yield, highlighting applicability to 
pharmaceutically relevant scaffolds. 
Similarly to the amine scope, we applied our C–H amination strategy to complex, 
bioactive arenes (Figure 4.7). Coupling tert-leucine methyl ester with fenoprofen methyl 
ester, an anti-inflammatory drug, afforded the aniline 4.48 in 73% yield favoring reactivity 
on the more electron-rich ring. Members of the fibrate family, a class of cholesterol lowering 
drugs, including gemfibrozil methyl ester, clofibrate, and bezafibrate,15,16 underwent C–H 
amination with valine methyl ester HCl in moderate to good yields (4.49 – 4.51), even 
observing a single regioisomer in the case of 4.51. These examples highlight the ability to 
utilize primary amine coupling partners in late stage C–H functionalization reactions with 
complex substrates.  
4.4.4 Unsuccessful Arene Substrates 
Several other arenes were used as substrates but did not provide the desired product, 
or the yields could not be improved to achieve synthetic utility (Figure 4.8). 1,2- and 1,4-
disubstituted arenes with two electron-donating groups were never viable substrates; however 
1,3-dimethoxybenzene did work in the reaction. Trisubstituted arenes did not work, and we 
hypothesize that this is due to steric hindrance. Naphthalene did not provide any product, and 
aniline derivatives gave low yields of the desired product and could not be improved. We 
propose that SET with these arenes is very rapid compared to the amine coupling partner, and 
back electron transfer for these substrates is very facile (see Chapter 2.2.5 3-Fluoroanisole 
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did not provide any desired product, and, instead, ipso substitution at the 3-position was 
observed. 4-Methoxyacetophenone provided the desired product, albeit in only 25% yield, 
and that value could not be improved by modifying the reaction conditions. Heterocycles that 
previously worked for the azole aryl amination chemistry (see Chapter 2) did not work for 
this reaction. Additionally, trifluorotoluene did not undergo functionalization even when used 
as the reaction solvent, since the arene is insufficiently nucleophilic and not electron-rich 
enough to be oxidized.  
 
Figure 4.8 Arenes that could not be functionalized with aliphatic amines. Reactions were run 
in 4:1 DCE/pH8 phosphate buffer at 0.1 M concentration with respect to the arene limiting 
reagent. 
 
4.4.5 Amine Cation Radical Mechanism 
 Previously, we highlighted that an electrophilic arene cation radical could be 
generated via SET from an arene to an acridinium catalyst. Since the present system has two 
reagents that could be oxidized, the arene and the amine, we wanted to understand whether 
the amine cation radical was a pathway that would lead toward productive reactivity. To 
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SET with the acridinium (redox potential above +2.15 V vs. SCE). With modified reaction 
conditions that used solvent-level substrate, we observed that benzene and toluene could both 
undergo amination (Figure 4.9), even though SET from the arene is not plausible. The ratio 
of ortho, meta, and para products afforded when using toluene as the substrate closely 
resembles the ratio observed by Minisci (Figure 4.2).6 This lends further credence to the 
intermediacy of an amine cation radical for the functionalization of these substrates.  
Figure 4.9 Amination of benzene and toluene. Reactions were run in 4:1:1 DCE/pH8 
phosphate buffer/arene at 0.1 M concentration with respect to the amine limiting reagent. 
 
Based on Stern-Volmer fluorescence quenching studies in DCE, both the amine and 
electron-rich arenes can quench the excited state of the catalyst (Figure 4.10).  
Normalization of the ensuing fluorescence quenching constants to account for the 
stoichiometry used in the reaction leads to the quenching rates being nearly identical for the 
arene and the amine. Arenes such as toluene do not quench the excited state of the catalyst, 
as expected from the high oxidation potential. 
HN CO2Me
i-Pr
4.52; 40% yield 4.53; 50% yield; 1.2:1:2.1 o:m:p
Val-OMe•HCl (1 equiv)
t-Bu2-Mes-Acr+ (5 mol %)
TEMPO (40 mol %)
455 nm LEDs
2:2:1 DCE: arene: pH 8 Buffer
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Figure 4.10 Stern-Volmer quenching studies for aliphatic amines and arenes. Quenching 
data were determined in DCE. 
  
 Based on these results, we propose that the reaction begins with the excitation of 
Mes-Acr+ with 455 nm LEDs to Mes-Acr+* (Figure 4.11). The excited state of the catalyst 
can then remove an electron from the primary amine, generating the amine cation radical, 
4.54. Nucleophilic addition of the arene substrate followed by deprotonation affords the 
cyclohexadienyl radical, 4.55. Oxygen then facilitates the rearomatization step,17 furnishing 
the final aniline 4.56. Similarly to our prior work and consistent with precedent from 
Fukuzumi, oxygen also assists in the oxidization of the acridine radical to the acridinium to 
regenerate the active catalyst. While this is the mechanism most likely to be operative for the 
amination of insufficiently electron-rich arenes such as benzene and toluene, an arene cation 
radical mechanism cannot be excluded for more electron rich arenes (Figure 4.12, see 
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Figure 4.11 Proposed amine cation radical-mediated mechanism. 
 
Figure 4.12 Proposed arene cation radical-mediated mechanism. 
We have developed a direct aryl C–H amination reaction using primary amines via 
photoredox catalysis. This reactivity occurs under mild conditions and is compatible with a 
variety of functional groups. Extending this work to secondary amines would further expand 
the scope of anilines that can be accessed through this strategy. Furthermore, this 
methodology exhibits the ability to functionalize non-oxidizable arenes due to a reactive 
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CHAPTER 5: A GENERAL STRATEGY FOR ALIPHATIC C–H 
FUNCTIONALIZATION ENABLED BY ORGANIC PHOTOREDOX CATALYSIS  
 
Adapted from Margrey, K. A.; Czaplyski, W. L.; Nicewicz, D. A.; Alexanian, E. J. J. Am. 
Chem. Soc. 2018, 140 (12), 4213–4217. Copyright 2017 American Chemical Society. 
5.1 Introduction 
Aliphatic C–H bonds are ubiquitous in organic molecules, including natural products, 
pharmaceuticals, and materials.1–3 The ability to functionalize a particular C–H bond 
selectively in these types of complex molecules can lead to powerful tools for chemical 
synthesis, specifically in the context of late stage derivatization.4 A significant amount of 
attention has been focused on this field in recent years due to the potential impact of 
transformations accessible using bonds previously regarded as “inert.” Intramolecular, or 
substrate-directed, methods are commonly used to this end and offer opportunities in 
accessing high levels of site selectivity; however, the requirement of specific moieties to act 
as directing groups restricts the substrates that can undergo functionalization using this 
strategy. Instead, intermolecular variations that could be applied to a wider range of 
substrates are more desirable. In many instances, however, excess amounts of the alkane 
substrate are required to achieve synthetically useful yields, limiting the applicability to 





5.2 Aliphatic C–H Functionalization 
5.2.1 Unactivated Aliphatic C–H Oxidation 
Several groups have developed intermolecular C–H functionalization methodologies 
to allow access to C–H oxidation, azidation, and halogenation transformations in a site-
selective manner. In 1989, Curci developed a C–H oxidation using a strained dioxirane 
reagent (Figure 5.1).5 A moderate amount of functional groups were compatible with the 
transformation, and selectivity for monofunctionalization at tertiary C–H bonds distal from 
electron-withdrawing groups was generally observed. While the products accessed are 
synthetically valuable, the dioxirane reagents are unstable at temperatures above –20 ˚C and 
to visible light, hindering their broad application. In a related transformation disclosed in 
2009, DuBois utilized a benzoxathiazine catalyst, aqueous hydrogen peroxide, and acetic 
acid to perform a tertiary-selective C–H oxidation.6 The putative mechanism for this reaction 
involves the intermediacy of an oxaziridine that is capable of C–H hydroxylation, similarly to 
dioxiranes. 
 
Figure 5.1 Aliphatic C–H oxidation via strained heterocycles. 
White developed an aliphatic biomimetic C–H oxidation that also favored tertiary 












































5.2).7,8 A variety of functional groups were compatible with this system, but electron-rich 
arenes and compounds containing basic nitrogen functionality were not demonstrated with 
the metal-oxo catalyst. Recent modifications have enabled the oxidation of basic nitrogen-
containing compounds.9 In many cases, however, the chromatographic recycling of starting 
material was required to access synthetically useful yields. Further work by White 
demonstrated that oxidation site selectivity could be altered based on the catalyst used and 
could be controlled by non-bonding interactions instead of innate stereoelectronic factors.10 
Figure 5.2 Iron-catalyzed aliphatic C–H oxidation. 
5.2.2 Unactivated Aliphatic C–H Amination 
The site selective installation of nitrogen-containing groups via C–H functionalization 
has also been pursued by several groups. Baran reported a Ritter-type C–H amidation 
strategy using a copper catalyst and acetonitrile as the nitrogen source, favoring reactivity at 
tertiary sites (Figure 5.3).11 Additionally, Du Bois has used rhodium catalysis to generate 
nitrenoids capable of C–H insertion from aryloxysulfonamide precursors.12 Reactivity at both 
tertiary and benzylic sites was observed, and a collaboration with the Sigman group provided 






























Fe catalyst:Fe catalyst (5 mol %)















Figure 5.3 Transition metal-catalyzed aliphatic C–H amination. 
In 2015, Hartwig disclosed a tertiary selective aliphatic C–H azidation reaction using 
an iron (II) catalyst and azidoiodinane reagent (Figure 5.4).14 In this system, the substrates 
could be used as the limiting reagent and generally underwent functionalization in modest 
yields. Further extensions of this methodology to complex molecule azidation were reported 
in the following year.15 Tang also reported a metal-free tertiary-selective azidation using 
potassium persulfate as the C–H abstracting agent.16 Secondary-selective C–H azidation is 
also possible and has been reported by Groves using a manganese porphyrin catalyst.17,18 
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5.2.3 Unactivated Aliphatic C–H Halogenation and Xanthylation 
Intermolecular C–H halogenation reactions have also been developed to allow direct 
synthesis of alkyl halides from unactivated alkanes. Groves has reported chlorination of 
alkanes using a manganese porphyrin system, tetrabutylammonium chloride, and sodium 
hypochlorite (Figure 5.5).19 Excess substrate was required to achieve synthetically useful 
yields, and functionalization occurred at the most sterically accessible secondary C–H bonds. 
A similar system was used for the C–H fluorination of alkanes, again showing site selectivity 
for secondary positions.20 Several other strategies for aliphatic fluorination have been 
developed, generally involving ultraviolet irradiation or transition metal catalysis.21–24  
 
Figure 5.5 Manganese porphyrin-catalyzed aliphatic C–H halogenation. 
Recently, the Alexanian group demonstrated the C–H bromination and chlorination of 
unactivated alkanes (Figure 5.6).25,26 Both systems relied on N-haloamide reagents, in which 
light-mediated N–X homolysis forms an amidyl radical capable of abstracting a hydrogen 
atom from an alkane substrate with subsequent trapping to form the alkyl halide products. 
Selectivity for electron-rich secondary C–H bonds is observed, largely due to the electron-
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Figure 5.6 Aliphatic C–H halogenation via N-haloamides. 
This work was extended to an intermolecular C–H xanthylation (dithiocarbonation) 
using N-xanthylamide 5.1 (Figure 5.7).27 Similar selectivities to the halogenation reactions 
were observed owing to the intermediacy of the same amidyl radical, and the alkyl xanthate 
products were highly versatile, allowing the net conversion of C–H to C–C, C–N, C–D, C–O, 
and C–S bonds.		
 
Figure 5.7 Aliphatic C–H diversification via C–H xanthylation. 
 
5.2.4 Photoredox-Catalyzed Aliphatic C–H Bond Functionalization 
 C–H bonds at positions activated by hyperconjugation, including those adjacent to π 
systems or heteroatoms, are particularly poised for functionalization due to their lowered 














































































such bonds, achieving C–H alkylation and arylation at C–H bonds adjacent to heteroatoms  
(Figure 5.8).29–35  
 
Figure 5.8 Photoredox-catalyzed C–H alkylation and arylation of aliphatic amines. 
 While the functionalization of activated aliphatic C–H bonds via photoredox catalysis 
has been well-documented, there are few reports detailing similar reactivity of unactivated 
aliphatic C–H bonds. Glorius reported that an iridium-based photoredox catalyst could 
oxidatively generate benzoate radicals capable of C–H abstraction,36 and this was leveraged 
in a strategy for C–H trifluoromethylthiolation (Figure 5.9). The development of further 
strategies for unactivated C–H bond functionalization via photoredox catalysis would offer 
new opportunities for complex molecule functionalization.  
 






































































































5.3 Reaction Development 
Previously reported intermolecular C–H functionalization strategies are inherently 
limited due to the inability to access a variety of transformations using a single catalyst or 
reagent. Rather, to achieve each desired C–H functionalization, a new reaction system must 
be developed. The ability to access a variety of products from a single alkane substrate with 
common site selectivity would provide the opportunity for a C–H diversification strategy. 
While the C–H xanthylation reported by the Alexanian group accomplishes this in two 
synthetic steps, a more ideal approach would allow for single step strategy to access a variety 
of products. 
 Direct aryl C–H functionalization has been demonstrated in the Nicewicz lab with 
nitrogen, carbon, and fluorine coupling partners (see Chapters 2 – 4). In collaboration with 
the Alexanian group, we wanted to develop a photoredox-catalyzed method for unactivated 
aliphatic sp3 C–H functionalization. Whereas electron-rich arenes are poised to undergo 
functionalization via direct SET to an acridinium photoredox catalyst, unactivated alkanes do 
not possess such an ability. Inspired by Glorius’ C–H trifluoromethylthiolation strategy, we 
sought to use an acridinium catalyst to generate a reactive intermediate capable of 
intermolecular C–H bond abstraction. This would decouple the abstraction and radical 
trapping steps, raising the possibility of a modular C–H functionalization system. 
5.3.1 Reaction Optimization 
 We postulated that a highly oxidizing acridinium photoredox catalyst A 
(E1/2(cat*/cat•) = +2.08 V vs SCE)37 would be capable of oxidatively generating heteroatom-
centered radicals capable of abstracting unactivated aliphatic C–H bonds. We initially found 
that blue LED irradiation of cyclooctane in the presence of catalyst A and sulfonyl azide trap 
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5.2 in a DCE/pH 8 phosphate buffer solvent system produced cyclooctyl azide in 24% yield 
(Table 5.1, entry 1). The use of tribasic potassium phosphate (K3PO4) led to 30% yield of 
the product, but increasing the amount of K3PO4 led to a slight decrease in yield (Table 5.1, 
entries 2 – 3). Changing the solvent from DCE to a 1:1 mixture of DCE/TFE provided the 
azide in 40% yield (Table 5.1, entry 4), and using TFE as the sole solvent increased the 
yield further, to 50% (Table 5.1, entry 5). Replacing TFE with HFIP led to a further increase 
in yield to 70% (Table 5.1, entry 6), and the reaction concentration was optimal at 0.1 M 
(Table 5.1, entries 6 – 8). The pH 8 buffer proved less effective in this reaction than K3PO4 
with HFIP as the solvent, providing the azide in 60% yield (Table 5.1, entry 9). The same 
yield was observed when sulfonyl azide 5.2 was replaced with the more electron deficient 5.3 
(Table 5.1, entry 10); since this increase was more pronounced in the azidation of other 
substrates, we elected to study the substrate scope with sulfonyl azide 5.3. 
Table 5.1 Initial optimization of C–H azidation. 
 
1 equiv
catalyst A (5 mol %)
sulfonyl azide (3 equiv)
base (1.1 equiv)
455 nm LEDs,











Entry Sulfonyl Azide Solvent (concentration)
DCE (0.1 M)














































5.2; R = NHAc
5.3; R = CF3
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 To probe the site selectivity of the C–H azidation, we subjected methyl 6-
methylheptanoate to the previously optimized conditions and found that azidation occurred 
exclusively at the tertiary position in 71% yield with good mass balance (Table 5.2, entry 1).  
Table 5.2 Base optimization of C–H azidation. 
 
Wondering how critical the identity of the base was for reactivity, we varied this component 
of the reaction. Dibasic potassium phosphate provided the azide in 52% yield (Table 5.2, 
entry 2), and the monobasic version produced only 9% of the desired product (Table 5.2, 
entry 3). Due to the ability of benzoate salts to readily undergo single electron oxidation as 
reported by Glorius, we also explored their utility in our azidation. Both potassium and 
tetrabutylammonium benzoate afforded the tertiary azidation product, albeit in diminished 
yields (Table 5.2, entries 4 – 5), and similar results were observed for sodium bicarbonate 
(Table 5.2, entry 6). Use of sodium carbonate produced 61% yield of the tertiary azide but 
led to poor mass balance relative to the other bases (Table 5.2, entry 7), possibly due to 
deleterious polar processes. Changing the cation and using cesium carbonate led to 33% yield 


















































base produced only trace azidation (Table 5.2, entry 9), suggesting that the anionic character 
of the base is important for reactivity. For all bases, azidation occurred exclusively at the 
tertiary site, with no secondary products detected by 1H NMR analysis, consistent with a 
common mechanistic role of the base. 
5.3.2 C–H Azidation Substrate Scope 
With optimized conditions in hand, we explored the substrate scope for this direct 
alkane C–H azidation (Figure 5.10). Cyclic hydrocarbons provided azides 5.4 – 5.6 in good 
yields. Trans-decalin afforded only secondary azides 5.7 in 57% combined yield, and 
adamantane could also be functionalized exclusively at the tertiary C–H bond to give 5.8 in 
75% yield. Benzylic positions could also undergo azidation, as exemplified by 
propylbenzene producing 5.9 in modest yield. Tert-butylcyclohexane reacted at the tertiary 
position to provide azide 5.10, and cis-4-methylcyclohexyl pivalate produced azide 5.12 in 
52% yield. Additionally, isobutylbenzene underwent azidation favoring the tertiary position 
to give 5.11 in modest yield, serving as a precursor to the psychostimulant pharmaceutical, 
phentermine.  
In these simple systems, we observed preferential tertiary functionalization over 
secondary or primary functionalization when multiple types of C–H bonds were present in a 
compound. Accordingly, we studied the site selectivity of this system further. As discussed 
above, methyl-6-methylheptanoate produced tertiary azide 5.13 in 71% yield as a single 
regioisomer. Methyl hexanoate, which contains several electronically deactivated secondary 
C–H bonds and no tertiary sites, did not undergo functionalization with this system, 
suggesting a strong sensitivity to the BDEs of the C–H bonds in the substrate. In order to 
examine the electronic site selectivity of the C–H azidation further, several dihydrocitronellol 
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derivatives were next examined, each containing two tertiary C–H bonds. In all substrates, 
azidation was favored at the tertiary site distal to the other functionality present. Acetate and 
benzoate esters delivered 5.14 and 5.15 in 73% and 91% yield, respectively, with good levels 
of regioselectivity. Derivatives with protected primary amines or halide functionality also 
worked in this reaction, affording 5.16 and 5.17 in good yield. Dihydrocitronellol itself was a 
competent substrate, providing 5.18 in 63% yield with no observed oxidation of the free 
alcohol, highlighting the mild nature of the system.  
  
Figure 5.10 C–H azidation substrate scope. Yields refer to isolated yields. aNMR yield with 
hexamethyldisiloxane (HMDS) as an internal standard. 
1 equiv
catalyst A (5 mol %)
sulfonyl azide 5.3 (3 equiv)
K3PO4 (1.1 equiv)
455 nm LEDs,
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A phenyl ether was tolerated to deliver 5.19 in low yield and regioselectivity, even though 
oxidation of the arene is possible using the acridinium catalyst. Heterocyclic nitrogen 
functionality, commonly problematic for metal-oxo catalyzed reactions but important in the 
application to late stage functionalization of pharmaceuticals, could be tolerated in this 
system. Azidation of a pyridyl ketone substrate provided 5.20 in modest yield. 
5.3.3 Development of Modular C–H Transformations 
With azidation conditions optimized, we sought to expand our work toward 
developing a strategy for a modular C–H functionalization. Using cyclooctane as the 
substrate and limiting reagent, we examined a variety of radical traps (Figure 5.11). To 
facilitate the solubility of all reagents, we chose to use DCE as the solvent with a pH 8 
phosphate buffer instead of exogenous K3PO4 as the base. Changing the sulfonyl azide trap 
for N-fluorobenzenesulfonimide (NFSI) delivered fluorocyclooctane in moderate yield. Other 
halogens could also be installed through this strategy. Using diethyl bromomalonate as the 
radical trap afforded bromocyclooctane in good yield, and N-chlorosuccinimide functioned 
as a chlorine atom source to access chlorocyclooctane in 32% yield. We pursued the 
installation of the trifluoromethylthiol group, based on its proven use in medicinal chemistry 
due to the beneficial effects imparted upon polarity and lipophilicity.38 Using the reagent 
5.21 developed by Shen as a radical trifluoromethylthiol source,39 we accessed 
trifluoromethylthiocyclooctane, albeit in low yields owing to product instability over long 
reaction times. In all of these transformations, we could access a variety of products simply 
by switching the radical trap. No additional optimization parameters were explored for these 
reactions, so further effort to improve each reaction would be desirable. Nevertheless, this 
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highlights that a simple modification of a single reaction parameter can produce a variety of 
C–H functionalization products in a single step. 
 
Figure 5.11 Modular C–H functionalization of cyclooctane. 
 We next sought to develop a related intermolecular C–C bond formation from 
unactivated aliphatic C–H bonds. Knowles and Rovis have previously reported the use of 
iridium photoredox catalysts to generate amidyl radicals that can undergo 1,5-hydrogen atom 
abstraction on a tethered alkane, generating a carbon-centered radical.40–42 The resultant 
radical is trapped by an electron-poor alkene for a net C–H alkylation.  
We began related studies by examining the electron-poor methyl acrylate in our 
system. A mixture of DCE and 2,2,2-trifluoroethanol (TFE) as the solvent with 4M pH 8 
phosphate buffer as the base provided 10% yield of the desired C–C adduct (Table 5.3, entry 
1). Due to the reduction potential of the radical produced after addition to the olefin,43 we 
used a more reducing acridinium catalyst B that increased the yield to 23% (Table 5.3, entry 
2). TFE was essential for the desired reactivity (Table 5.3, entry 3), but TFE alone as solvent 
proved inferior (Table 5.3, entry 4). Considering whether a more basic buffer could be 
employed to increase yield, we examined the reactions with pH 9 and 10 buffers and found 
them to be inferior to pH 8 (Table 5.3, entries 5 – 6). The use of a less concentrated 2M pH 
C–H Diversification via Reagent Selection
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trap reagent (3 equiv)
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8 buffer provided the adduct in the same yield as the 4M buffer (Table 5.3, entry 7). 
Doubling the amount of 4M pH 8 buffer but keeping the amount of organic solvent constant 
led to 43% yield of the desired adduct (Table 5.3, entry 8), but a further increase in the 
amount of buffer lead to no increase in yield (Table 5.3, entry 9). Similar conditions to those 
optimized for methyl acrylate facilitated the use of methyl vinyl ketone (MVK) as the radical 
trap, affording the adduct in 76% yield. To our knowledge, this is the first report of a visible 
light-mediated unactivated C–H bond alkylation using the substrate as the limiting reagent.44  
Table 5.3 Optimization of C–H alkylation 
 
5.3.4 C–H Functionalization of Complex Targets 
We next explored the application of this modular C–H functionalization system to 
bioactive molecules possessing multiple potentially reactive sites (Figure 5.12). Benzoate 
protected (–)-menthol afforded azide 5.22 in 54% yield, favoring functionalization at the 
most electron-rich tertiary position. Since adamantyl derivatives are present in several 
pharmaceutical compounds, we sought to subject these compounds to several 
1 equiv
catalyst (5 mol %)




Entry Catalyst Solvent (concentration)
DCE/TFE/4M pH 8 phosphate buffer (7:1:2, 0.1 M)
DCE/4M pH 8 phosphate buffer (4:1, 0.1 M)
TFE/4M pH 8 phosphate buffer (4:1, 0.1 M)
DCE/TFE/4M pH 9 phosphate buffer (7:1:2, 0.1 M)
DCE/TFE/4M pH 10 phosphate buffer (7:1:2, 0.1 M)
DCE/TFE/2M pH 8 phosphate buffer (7:1:2, 0.1 M)
DCE/TFE/4M pH 8 phosphate buffer (7:1:4, 0.08 M)
DCE/TFE/4M pH 8 phosphate buffer (7:1:2, 0.1 M)











































transformations. The azidation of N-phthalimide protected memantine, an NMDA receptor 
antagonist used in the treatment Alzheimer’s disease, exclusively produced the tertiary 
product 5.23 in 55% yield. The same substrate could also be fluorinated providing 5.24 in 
86% yield with NFSI as the trap with the same tertiary selectivity. A precursor to differin, a 
topical retinoid, afforded tertiary azide 5.25 in modest yield, even in the presence of an 
oxidizable aromatic ring, highlighting the mild nature of our system. This substrate also 
underwent intermolecular alkylation using methyl vinyl ketone, forming adduct 5.26 in 45% 
yield. Ibuprofen methyl ester, possessing both tertiary and benzylic positions, underwent 
azidation that slightly favored the benzylic product 5.27 in a combined 57% yield.  
 
Figure 5.12 Modular functionalization of complex derivatives. For reaction details see the 
Supporting Information. Yields refer to NMR yields with hexamethyldisiloxane (HMDS) or 
fluorobenzene as an internal standard. 
 
Previous reports of the azidation of this substrate could produce only the benzylic azide, 
demonstrating that our system enables access to novel derivatives of common 
pharmaceuticals. Steroid 5α−cholestan-3-one, possessing 46 aliphatic C–H bonds, could be 
5.27
ibuprofen methyl ester
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functionalized at the C17 and C25 positions in a combined 39% yield of 5.28, similar to the 
selectivity observed in Curci’s hydroxylation using dioxiranes.45 
Having installed an azide directly from a C–H bond, we also wanted to highlight the utility of 
this functionalization via copper-catalyzed azide-alkyne cycloaddition (CuAAC). By 
coupling memantine azide 5.23 and ethynylestradiol, we could isolate the cycloadduct 5.29 
in 61% yield, highlighting the importance of this application in bioconjugation and late-stage 
diversification (Figure 5.13). 
 
Figure 5.13 Click reaction with C–H azidation product. 
5.3.5 Mechanistic Experiments 
 Despite the success of this system in functionalizing a variety of substrates, the active 
C–H bond abstracting species remained unclear. To this end, we sought to clarify the role of 
each component of the reaction, focusing primarily on the azidation. Stern-Volmer analysis 
determined that sulfonyl azide 5.3 did not quench the acridinium fluorescence (Figure 5.14). 
Owing to the presence of K3PO4 (pKa = 12.32 in H2O) and HFIP (pKa = 9.3 in H2O) in the 
optimized conditions, deprotonation of HFIP is thermodynamically favorable, and we 
wondered whether the resultant alkoxide could be oxidized by the acridinium catalyst to 
produce an oxygen-centered radical. Stern-Volmer with sodium 1,1,1,3,3,3-































suggesting that oxidation of this species to the corresponding oxygen-centered radical does 
not occur.  
We next turned our attention toward the base used in the reactions. While K3PO4 or 
the pH 8 phosphate buffer were used in the reactions, we could not obtain reliable Stern-
Volmer quenching with them due to insolubility or immiscibility regardless of what solvent 
was used. To circumvent this issue, we synthesized a soluble dibasic phosphate salt 5.30 
from the corresponding phosphoric acid 5.31. We found that 5.30 could, in fact, quench the 
excited state of the acridinium but the protonated acid did not, highlighting the necessity of 
the anionic phosphate (Figure 5.14).  
 
Figure 5.14 Stern-Volmer quenching of acridinium catalyst. Quenching data were 
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Addition of 5.30 also led to shifts in the 1H NMR of the catalyst A in CDCl3 (Figure 5.15), 
suggesting a possible complex between the catalyst and salt in solution. 
 
Figure 5.15 Addition of 5.30 to acridinium catalyst A 1H NMR. Top: only catalyst A, 
Middle: 1 equiv of catalyst A and 1 equiv of 5.30, Bottom: 2 equiv of catalyst A and 1 equiv 
of 5.30. 
 
We also examined the reactivity of dibasic phosphate 5.30 under the azidation conditions 
with cyclooctane as the substrate (Figure 5.16, eq 1). The use of substoichiometric 5.30 (5 or 
20 mol %) produced up to 48% yield of azide 5.6, consistent with catalytic activity of the 
base. However, employing stoichiometric 5.30 led to a diminished yield of 17%. Using 
methyl 6-methylheptanoate as the substrate with 20 mol % 5.30 produced azide 5.13 in 20% 
yield (Figure 5.16, eq 2). Importantly, only functionalization at the tertiary C–H bond 








Figure 5.16 Reactions with dibasic phosphate 5.30. 
5.3.6 Proposed Mechanism 
Based on these mechanistic data, we propose an operative mechanism for the C–H 
azidation system (Figure 5.17). Using 455 nm LEDs, the acridinium photoredox catalyst is 
excited and undergoes SET from the phosphate salt, generating oxygen centered radical 5.32. 
Abstraction of the most electron-rich C–H bond generates carbon-centered radical 5.33, 
which is subsequently trapped by the sulfonyl azide 5.3 to afford the desired product and a 
sulfonyl radical. Based on previous work in our lab, we believe that this radical is capable of 
oxidizing the acridine radical, regenerating the acridinium catalyst.46  
 








HFIP (0.1 M), 20 h
5 mol % 5.30: 20% yield 
20 mol % 5.30: 48% yield 
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5.4 Initial Studies in Polyolefin Functionalization 
5.4.1 Background 
 Polyolefins are widely prevalent in consumer products and have a range of uses, 
including plastics for automobile parts, agriculture, and food products.47 These polymers 
possess a variety of useful properties, including high tensile strength, processibility, 
resistance to chemical degradation, and low density. Traditionally, these compounds are 
synthesized via the polymerization of α-olefin monomers, particularly through transition 
metal-catalyzed chain-growth polymerizations. These processes, developed initially by 
Ziegler and Natta, give good control of the properties of the resultant materials. However, 
owing to their lack of additional functional groups, polyolefins do not interface well with 
other materials, rendering applications in which a combination of properties is desirable 
challenging. 
 Additional functionality can be incorporated into polyolefins through the 
copolymerization of the desired α-olefin with another monomer containing the preferred 
polar moiety.48 However, most polar monomers contain Lewis basic heteroatoms that can 
complex to oxophilic transition metal catalysts, inhibiting the polymerization and changing 
the properties of the resultant materials.49 An alternate strategy to accomplish the same goal 
is to perform a copolymerization of the α-olefin with a monomer containing a masked 
functionality that can be converted, following polymerization, into the desired 
functionality.50 The groups compatible with this strategy tend to be limited and include 
divinylbenzene, boranes, and p-methylstyrene, and the inclusion of the alternate monomer 
can impact the material properties of the final polyolefin material. 
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 An alternate strategy that avoids the need for copolymerization and can use existing 
polyolefins as feedstocks is post-polymerization modification (PPM), in which C–H 
functionalization can be used to install desired groups directly. This strategy has traditionally 
been used to functionalize tertiary C–H bonds of polyolefins with maleic anhydride through 
techniques such as reactive extrusion or high temperature radical initiation.51 Due to the 
vigorous conditions required for such reactivity to occur, tertiary radicals that form along the 
polymer backbone are prone to chain coupling or scission processes, both of which degrade 
the desirable physical properties of the starting material.  
 Recently, several groups have developed new C–H functionalization strategies for the 
functionalization of polyolefins. Liu and Bielawski reported the azidation of isotactic 
polypropylene (i-PP) using an azidoiodinane at elevated temperatures without an external 
radical initiator,52 presumably via an iodanyl radical as the C–H abstracting agent (Figure 
5.18). Up to 3.5% azidation could be accomplished with this system, but the material in all 
cases exhibited a significant decrease in Mn, indicative of polyolefin chain cleavage, and in 
increase in the dispersity (Đ). Hillmyer reported the C–H oxidation of polyethylene-alt-
propylene (PEP) using a manganese porphyrin catalyst with aqueous Oxone as the terminal 
oxidant and benzyldimethyltetradecylammonium chloride (BDTAC) as a phase transfer 
agent.53 Ketones and tertiary alcohols were detected via IR and 1H NMR analyses, with up to 
1.4% hydroxylation observed. Hartwig and Hillmyer collaborated to study the rhodium-
catalyzed primary-selective borylation of poly(ethylethylene) (PEE);54 after basic hydrogen 
peroxide workup, the resultant alkylboronate esters could be oxidized to afford primary 
alcohol substituents on the polyolefin. Up to 19 mol % functionalization occurred, but the 
reactions required elevated temperatures (150 – 200 ˚C). Hartwig and Lee more recently 
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disclosed the nickel-catalyzed C–H oxidation of polyethylenes with mCPBA as the oxidant.55 
Mixtures of hydroxyl, ketone, and chloride functionality were installed with up to 88% 
selectivity for hydroxylation. Alexanian and Leibfarth have also demonstrated the secondary 
selective C–H xanthylation of several polyolefins, observing up to 18 mol % xanthylation.56 
Little chain scission is observed in the radical-mediated process, and the resultant xanthate 
products could be converted into a variety of functionalized polyolefin materials. 
 
Figure 5.18 Recent methods for polyolefin C–H functionalization 
5.4.2 Photoredox-Catalyzed C–H Azidation of Polyolefins 
 Using our photoredox-catalyzed alkane functionalization strategy, we turned our 
attention toward the functionalization of polyolefins. When applying tertiary selective 
radical-mediated C–H functionalizations to polyolefin substrates, a major challenge is 
preventing chain coupling or scission of the polymer due to the usually harsh reaction 
conditions. Due to the lowered reaction temperatures associated with our system and the 
generation of a C–H abstracting species in catalytic quantities, we wondered whether we 
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 In collaboration with the Alexanian and Leibfarth groups, using poly(ethylethylene) 
(PEE) as an initial substrate, we sought to determine whether the photoredox-catalyzed 
system was competent for polyolefin azidation. We applied the conditions previously 
optimized for azidation and observed no azide stretch by IR spectroscopy and no secondary 
azidation by 1H NMR (Figure 5.19). To confirm the lack of C–H azidation, we subjected the 
isolated polyolefin to CuAAC conditions with p-tolylacetylene and detected no cycloadduct 
formation. Reasoning that the absence of azidation might be due to immiscibility of the 
polymer with HFIP, we switched to DCE as the solvent (Figure 5.20). IR spectroscopy 
revealed a characteristic azide peak at 2098 cm-1 (Figure 5.21), and 1H NMR analysis did not 
show the presence of primary or secondary alkyl azides, suggesting exclusively tertiary 
functionalization. CuAAC was successful in forming a triazole-functionalized polymer, and 
by 1H NMR analysis, up to 4 mol % triazole was incorporated into the polyolefin. Gel 
permeation chromatography (GPC) indicated a slight decrease in the Mn of the polymer and a 
negligible increase in the Đ. A new absorbance peak was observed at 252 nm by photodiode 
array (PDA) detection (Figure 5.22), indicating that the reaction sequence had, in fact, 
installed aromatic functionality onto the polyolefin. 
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Figure 5.20 C–H azidation and CuAAC of PEE.	
 
Figure 5.21 Infrared spectrum of 5.32, with azide stretch at 2100 cm–1. 
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Having observed productive azidation with PEE as the substrate, we sought to use a 
higher molecular weight polymer, hyperbranched polyethylene (HBPE),57 that would be 
useful as a larger molecular weight material. Azidation in DCE was unsuccessful, 
presumably due to immiscibility of the polymer with the solvent. Switching to a mixture of 
chlorobenzene and DCE led to effective azidation as determined by IR spectroscopy (Figure 
5.23). Based on 1H NMR analysis, no secondary or primary azidation occurred, suggestive of 
only tertiary functionalization, and GPC analysis indicated that no polymer degradation had 
occurred. CuAAC led to triazole formation, with 0.5 mol % functionalization detected. 
Correcting for the fact that the polymer possesses branching and therefore tertiary sites on 
only 13% of the monomer units, functionalization occurred on 3.8 mol % of the branch sites, 
a similar efficiency to the azidation of PEE. Further work will aim to control the amount of 
C–H azidation, and the reaction could be extended to additional polyolefin substrates to 
access a variety of useful materials. 
 
Figure 5.23 C–H azidation and CuAAC of HBPE. 
Through this work, we have developed a mild and modular functionalization of 
unactivated alkanes using a completely organic photoredox catalytic system. The ability to 
accomplish this with a number of substrates and wide variety of traps unlocks a strategy for 
the late stage derivatization of complex small molecules. Furthermore, initial results toward 
the C–H azidation of polyolefins suggest utility in the arena of post-polymerization 
modification to access functionalized materials under mild conditions. 
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APPENDIX A: SUPPORTING INFORMATION FOR CHAPTER 2 
Materials:  
Commercially available reagents were purchased from Sigma-Aldrich, Acros, Alfa Aesar, or 
TCI, Matrix Scientific, Chem Impex International, and Fisher Scientific and were used as 
received unless otherwise noted. Diethyl ether (Et2O), dichloromethane (DCM), 
tetrahydrofuran (THF), toluene, and dimethylformamide (DMF) were dried by passing 
through activated alumina under nitrogen prior to use. Other common solvents and chemical 
reagents were purified by standard published methods as noted. The following compounds 
employed as reagents in the C-H amination reactions were obtained from commercial 
vendors and used as received: 2,2,6,6- Tetramethyl-1-piperidinyloxy (TEMPO), polystyrene-
divinylbenzene-bound TEMPO, diacetoxyiodobenzene, potassium persulfate, benzoquinone, 
(diacetoxyiodo)benzene, anisole, diphenyl ether, biphenyl, 2-chloroanisole, 3-bromoanisole, 
mesitylene, m-xylene, 2,6- dimethoxypyridine, 6-methoxyquinoline, 3,4-dihydrocoumarin, 4-
methyl pyrazole, 3-methyl pyrazole, 1,2,3-triazole, 5-methyltetrazole, 1,2,4-triazole, 1,2,3-
benzotriazole, 4,5,6,7-tetrahydro- 1H-indazole, benzimidazole, and imidazole.  
General Methods:  
Proton, carbon, and fluorine nuclear magnetic resonance spectra (1H NMR, 13C NMR, 19F 
NMR) were recorded on a Bruker Avance 400 (1H NMR at 400 MHz, 13C NMR at 100 MHz, 
and 19F NMR at 376 MHz) or a Bruker Avance III 600 (1H NMR at 600 MHz and 13C NMR 
at 151 MHz) spectrometer. Chemical shifts for protons are reported in parts per million 
downfield from tetramethylsilane and are referenced to residual protium in the solvent (1H 
NMR: CHCl
3 at 7.26 ppm). Chemical shifts for carbon signals are reported in parts per 
million downfield from tetramethylsilane and are referenced to the carbon resonances of the 
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solvent peak (13C NMR: CDCl3 at 77.16 ppm). Fluorine chemical shifts are referenced to 
trichlorofluoromethane as an external standard at 0 ppm. 1H NMR data are reported as 
follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, hept = 
heptet, dd = doublet of doublets, ddd = doublet of doublet of doublets, m = multiplet, br s = 
broad singlet, app = apparent), coupling constants (Hz), and integration. Infrared (IR) spectra 
were obtained using a Jasco 260 Plus Fourier transform infrared spectrometer. High 
Resolution Mass Spectra (HRMS) were obtained using a Thermo LTqFT mass spectrometer 
with electrospray ionization in positive mode. Thin layer chromatography (TLC) was 
performed on SiliaPlate 250 µm thick silica gel plates provided by Silicycle. Visualization 
was accomplished with short wave UV light (254 nm), or development with iodine, 
ninhydrin stain, cerium ammonium molybdate or potassium permanganate solution followed 
by heating. Column chromatography was performed using SiliaFlash P60 silica gel (40- 63 
µm) purchased from Silicycle. Unless noted all reactions were run under an atmosphere of 
oxygen in flame-dried glassware with magnetic stirring. Irradiation of photochemical 
reactions was carried out using a PAR38 Royal Blue aquarium LED lamp (Model #6851) 
fabricated with high-power Cree XR-E LEDs as purchased from Ecoxotic 
(www.ecoxotic.com) with standard borosilicate glass vials purchased from Fischer Scientific. 
For all photolyses, reactions were stirred using a PTFE coated magnetic stir bar on a 
magnetic stir plate. Gas chromatography (GC) was performed on an Agilent 6850 series 
instrument equipped with a split- mode capillary injection system and Agilent 5973 network 
mass spec detector (MSD). Yield refers to isolated yield of analytically pure material unless 
otherwise noted. NMR yields were determined using hexamethyldisiloxane as an internal 
standard. All other reagents were obtained from commercial sources and used without further 
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purification unless otherwise noted.  
Photoreactor Configuration.  
Reactions were irradiated using a simple photoreactor consisting of two Par38 Royal Blue 
Aquarium LED lamps (Model #6851) is shown in which four reactions (2 dram vials) are 
irradiated simultaneously with a foil barrier preventing irradiation by two lamps. In order to 
ensure that the reactions are run near room temperature, a simple cooling fan was installed 
above the reactor to aid in dissipating the heat generated from both nonradiative decay 
pathways of the excited state catalysts and the heat generated from high power LEDs. An 
equilibrium temperature of 33 ˚C was measured with a standard alcohol thermometer. While 
a number of other blue LED sources are effective, we have found that LED emitters with 
high luminous flux and narrow viewing angle give the best results.  
Preparation of Acridinium Photocatalysts 
 
9-Mesityl-10-phenyl acridinium tetrafluoroborate (Catalyst A). 
The title compound was prepared as previously reported by our lab.1  The spectral data 
matched the values reported in the literature.  
 
















The title compound was prepared as previously reported by our lab.1 The spectral data 
matched the values reported in the literature.  
 
4-(tert-butyl)-2-((3-(tert-butyl)phenyl)amino)benzoic acid. To a flame dried 2-neck round 
bottom flask equipped with a condenser was added potassium carbonate (9.0 g, 65.3 mmol, 
1.4 equiv.), copper (594 mg, 9.34 mmol, 0.2 equiv.) and 2-bromo-4-(tert-butyl)benzoic acid 
(12 g, 46.7 mmol, 1.0 equiv.). The setup was evacuated and back filled with nitrogen gas 
three times for 15 minutes each cycle. m-Tert-butyl aniline (10.3 mL, 65.3 mmol, 1.4 equiv.) 
and 1-pentanol (72 mL) were both sparged with nitrogen for 15 minutes. Pentanol was added 
to the reaction flask followed by the aniline. The solution was heated to 140 ˚C for 16 hours. 
The solution was cooled to room temperature and diluted with water (100 mL), washed with 
3M HCl (100 mL) and extracted with dichloromethane (3x 100 mL). The organic layer was 
washed with ammonium chloride (100 mL), brine (100 mL) and dried over sodium sulfate. 
The organic solution was concentrated to afford a brown solid. The crude product was 
recrystallized from methanol to afford the desired aryl amine (10.1 g, 67% yield). 1H NMR 
(600 MHz, CDCl3): δ 11.74 (br s, 1H), 9.32 (s, 1H), 8.00 (d, J = 9 Hz, 1H), 7.36-7.35 (m, 
2H), 7.32 (t, J = 7.8 Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H), 7.07 (dd, J = 7.8 Hz, J = 0.6 Hz, 1H), 
6.83 (dd, J = 8.4 Hz, J = 1.2 Hz, 1H), 1.35 (s, 9H), 1.27 (s, 9H); 13C NMR (CDCl3, 151 
MHz): δ 173.4, 159.0, 152.5, 148.6, 140.3, 132.3, 129.0, 120.6, 119.6, 119.5, 115.1, 111.0, 







1565.92, 1416.46, 1242.90, 963.27, 700.99.; HRMS (ESI): Calculated for [M+H2O]= 
348.1940; found 348.1932. 
 
3,6-di-tert-butylacridin-9(10H)-one. To an Erlenmeyer flask equipped with a stir bar was 
added sulfuric acid (38 mL), which was heated to 100 ˚C. 4-(tert-butyl)-2-((3-(tert-
butyl)phenyl)amino)benzoic acid (5.1 g, 15.7 mmol) was added to the sulfuric acid in 
portions and stirred for 3 hours at 100 ˚C. The solution was cooled to room temperature and 
the acidic solution was then poured into water at 0 ˚C, forming a yellow precipitate. 
Ammonium hydroxide was added until an alkaline pH persisted. The yellow solid was then 
filtered over a medium fritted funnel to afford the desired product along with the undesired 
regioisomer in an 8:1 mixture. Hot filtration from methanol removed insoluble salts, 
followed by a recrystallization from methanol and dichloromethane to afford the desired 
acridone (3.6 g, 76% yield). 1H NMR (400 MHz, 3:1 CDCl3:MeOD) δ 8.12 (d, J = 8.9 Hz, 
2H), 7.26 (d, J = 1.8 Hz, 2H), 7.29-7.18 (m, 2H), 3.15 (br. s, 1H), 1.16 (d, J = 2.5 Hz, 18H).; 
13C NMR (151 MHz, CDCl3) δ 178.26, 157.33, 141.19, 125.73, 119.82, 118.44, 112.70, 
48.73, 35.02, 30.51.; IR (thin film): 3087.48, 2962.13, 2321.87, 1632.45, 1594.84, 1552.42, 








3,6-di-tert-butyl-10-phenylacridin-9(10H)-one. To a flame-dried round bottom flask was 
added 3,6-di-tert-butylacridin-9(10H)-one (3.75 g, 12.2 mmol, 1 equiv.), copper (I) iodide 
(232 mg, 1.22 mmol, 0.1 equiv.) and potassium carbonate (3.37 g, 24.4 mmol, 2.0 equiv.). 
Iodobenzene (1.48 mL, 13.3 mmol, 1.1 equiv.) and 2,2,6,6-tetramethylheptane-3,5-dione 
(0.51 mL, 2.44 mmol, 0.2 equiv.) were added in a nitrogen-filled glovebox along with 
dimethylformamide (62 mL). The solution was heated to 130 ˚C for 48 hours. The solution 
was then cooled to room temperature and quenched with 3M HCl (50 mL). The aqueous 
solution was extracted with dichloromethane (3x 100 mL). The combined organic layers 
were washed with sodium bicarbonate (150 ml), ammonium chloride (150 mL), brine, dried 
over sodium sulfate and then concentrated. The final pale yellow solid (2.95 g, 63% yield) 
was obtained after flash chromatography (20% EtOAc/Hexanes). 1H NMR (400 MHz, 
CDCl3) δ 8.50 (d, J = 8.5 Hz, 2H), 7.72 (t, J = 7.5 Hz, 2H), 7.66 (d, J = 7.3 Hz, 1H), 7.40-
7.37 (m, 2H), 7.33 (dd, J = 8.5, 1.6 Hz, 2H), 6.71 (d, J = 1.6 Hz, 2H), 1.20 (s, 18H).; 13C 
NMR (151 MHz, CDCl3) δ 177.73, 156.93, 143.38, 139.30, 131.01, 130.21, 129.59, 126.98, 
119.94, 119.77, 113.03, 35.46, 31.01.; IR (thin film): 3049.87, 2964.05, 2868.59, 1606.41, 
1452.14, 1307.50, 1197.58, 997.02, 867.81, 682.68; HRMS (ESI): Calculated for [M+H2O]= 






9-Mesityl-3,6-di-tert-butyl-10-phenylacridinium tetrafluoroborate (Catalyst C). To a 
flame dried round bottom flask equipped with a stir bar was added 3,6-di-tert-butyl-10-
phenylacridin-9(10H)-one (1.5 g, 3.91 mmol, 1.0 equiv.). The acridone was dissolved in dry 
THF (112 mL). Mesityl magnesium bromide (9.8 mL, 9.8 mmol, 1 M in Et2O, 2.5 equiv.) 
was added dropwise and the solution was stirred at room temperature for 24 hours. The 
solution was then heated to 50 ˚C for 72 hours. The red solution was cooled and quenched 
with sodium bicarbonate (100 mL). The aqueous layer was extracted with DCM (3x 100 mL) 
followed by a brine wash, drying over sodium sulfate and concentration to afford a red oil. 
The oil was dried on high vacuum for 4 hours. The oil was then dissolved in ether (67 mL) 
and tetrafluoroboric acid diethyl ether complex (0.65 mL, 4.7 mmol, 1.2 equiv.) in ether 
(12.5 mL) was added dropwise and the solution was stirred for 1 hour, during which a 
precipitate quickly appeared with the addition of acid. The yellow solid that precipitated out 
was then filtered and washed with ether (200 mL) to afford the final 3,6-di-tert-butyl-9-
mesityl-10-phenylacridin-10-ium tetrafluoroborate (2.05 g, 92% yield).1H NMR (400 MHz, 
CDCl3) δ 7.99-7.93 (m, 2H), 7.93-7.89 (m, 1H), 7.78 (q, J = 1.6 Hz, 3H), 7.77-7.70 (m, 2H), 
7.41 (d, J = 3.2 Hz, 2H), 7.26 (s, 1H), 7.16 (d, J = 2.7 Hz, 2H), 2.48 (s, 3H), 1.86 (d, J = 3.5 
Hz, 6H), 1.29 (d, J = 3.5 Hz, 9H).; 13C NMR (151 MHz, CDCl3) δ	163.72, 162.44, 142.25, 
140.31, 136.95, 136.25, 131.96, 131.75, 129.40, 129.07, 128.41, 128.12, 127.60, 124.16, 










1436.71, 1252.54, 1055.84, 915.06, 780.06, 728.96; HRMS (ESI): Calculated for [M+H2O]= 
486.3161; found 486.3158. 
Preparation of Arene Substrates 
Anisole, diphenyl ether, biphenyl, 2-chloroanisole, 3-bromoanisole, mesitylene, m-xylene, 
2,6-dimethoxypyridine, 6-methoxy quinoline, 3,4-dihydrocoumarin, 4-methyl pyrazole, 3-
methyl pyrazole, 1,2,3-triazole, 5-methyl tetrazole, 1,2,4-triazole, 1,2,3-benzotriazole, 
4,5,6,7-tetrahydro-1H-indazole, benzimidazole, and imidazole were purchased commercial 
sources and used without further purification unless otherwise noted. 
(methoxymethoxy)benzene. Prepared according to a published procedure; spectral data 
were in agreement with literature values. 2 
 
tert-butyldimethyl(phenoxy)silane. Prepared according to a published procedure; 
spectral data were in agreement with literature values. 3 
tert-butoxybenzene. Prepared according to a published procedure; spectral data were in 
agreement with literature values.4 







Tetrakis(triphenylphosphine)palladium(0) (0.15 mmol, 0.03 equiv.) was added to a 
flame-dried round bottom flask containing a magnetic stir bar, along with 938 mg (2-
chlorophenyl)boronic acid (6.0 mmol, 1.2 equiv.) and 1.38 g K2CO3 (10. mmol, 2.0 eq.). 
Separately, a 9:1 (v/v) mixture of THF/H2O was sparged with nitrogen, then added to the 
flask containing palladium, boronic acid, and carbonate. The mixture was warmed to 50 
˚C for 10 minutes while 2-bromoanisole was sparged with nitrogen in a separate vial. 2-
Bromoanisole was added, and the reaction was heated at reflux for 26 hours. After 
cooling to room temperature, 20 mL H2O was added, along with 10 mL saturated 
aqueous NH4Cl. The layers were separated, and the aqueous phase was extracted twice 
with diethyl ether. The combined extracts were washed with brine and dried with MgSO4. 
After filtration and concentration in vacuo, the crude oil was dissolved in pentanes and 
crystallization occurred when cooled in a –20 ˚C freezer. The white crystals were 
collected by vacuum filtration, washed with cold pentanes, and dried in vacuo to give 930 
mg pure material. The spectral data were in agreement with literature values. 
 
1-methyl-1H-indazole. The title compound was prepared by the published procedure. 
The material was recrystallized from a mixture of ethyl acetate and hexanes and dried in 












1,3-dihexylquinazoline-2,4(1H,3H)-dione. Benzoyleneurea (1 g, 6.2 mmol, 1.0 equiv.) 
was dissolved in dry DMF and potassium carbonate was added (2.8 g, 20.1 mmol, 3.3 
equiv.). Hexyl bromide (3.5 mL, 24.7 mmol, 4.0 equiv.) was added dropwise and the 
solution was stirred for 84 hours. The solution was concentrated and then diluted with 
dichloromethane. The organic solution was washed with water (50 mL), and the aqueous 
layer was extracted with CH2Cl2 (3x 50 mL). The combined organic layers were washed 
with brine, dried over sodium sulfate and concentrated to give a pale yellow solid. The 
crude product was purified by flash chromatography (0-20% EtOAc/Hex) to afford the 
desired pale yellow oil (1.1 g, 54% yield). 1HNMR (600 MHz, CDCl3) δ 8.24 (dd, J = 
7.9, 1.7 Hz, 1H), 7.66 (ddd, J = 8.7, 7.2, 1.7 Hz, 1H), 7.33-7.12 (m, 2H), 4.17-4.04 (m, 
4H), 1.77-1.61 (m, 4H), 1.42-1.23 (m, 11H), 0.95-0.79 (m, 7H).; 13C NMR (151 MHz, 
CDCl3) δ 161.79, 150.80, 139.89, 134.94, 129.19, 122.68, 115.88, 113.57, 43.84, 42.05, 
31.63, 31.63, 31.58, 27.88, 27.37, 26.78, 26.59, 22.69, 22.67, 14.15, 14.11;  IR (thin 
film): 2956.34, 2930.31, 2857.99, 2357.55, 1704.76, 1660.41, 1608.34, 1483.96, 
1352.82, 757.89. HRMS (ESI): Calculated for [M+H2O]= 331.2385; found 331.2379. 
 
(S)-methyl 2-(6-methoxynaphthalen-2-yl)propanoate. Prepared according to a 
published procedure; spectral data were in agreement with literature values. 5 
 
Bis-Boc-adenine. Prepared according to a published procedure; spectral data were in 












methyl (tert-butoxycarbonyl)-L-histidinate. The title compound was prepared by the 
published procedure. The material was recrystallized from a mixture of ethyl acetate and 
hexanes and dried in vacuo. The 1H NMR spectrum matches the reported data. 
 
(E)-2-methoxy-4-((8-methylnon-6-enamido)methyl)phenyl acetate. The title 
compound was synthesized from capsaicin, which was obtained from Sigma-Aldrich as a 
2:1 mixture of capsaicin ((E)-N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide) 
and dihydrocapsaicin (N-(4-hydroxy-3-methoxybenzyl)-8-methylnonanamide). The 
capsaicin was used as received and acylated by the following procedure: 750 mg 
capsaicin (2.5 mmol, 1.0 equiv.) was cooled to 0 ˚C in 11 mL DCM, and 262 µL acetyl 
chloride was added (3.7 mmol, 1.5 equiv.), followed by 693 µL trimethylamine. The 
mixture was stirred for 1 hour at 0 ˚C, then at ambient temperature for an additional 1 
hour. The mixture was diluted with 25 mL DCM and washed with brine, dilute HCl, then 
saturated aqueous NaHCO3. The organic phase was again washed with brine and dried 
with MgSO4. After concentrating in vacuo, the crude tan solid was recrystallized from a 
mixture of EtOAc and hexanes, and collected by vacuum filtration, yielding 813 mg of a 
white solid. The proton NMR spectra indicates that the ratio between O-acetyl capsaicin 
and O-acetyl dihydrocapsaicin is identical to the starting material. Note: the indicated 













for the resonances of the saturated compound. The carbon resonances listed include the 
resonances for both the unsaturated and saturated compounds in the mixture. 1HNMR 
(600 MHz, CDCl3) δ 6.98 (d, J = 8.0 Hz, 1H), 6.90 (s, 1H), 6.84 (d, J = 8.0 Hz, 1H), 5.68 
(s, 1H), 5.41 – 5.28 (m, 2H), 4.42 (d, J = 5.7 Hz, 2H), 3.82 (s, 3H), 2.31 (s, 3H), 2.21 (t, J 
= 7.4 Hz, 2H), 1.99 (q, J = 7.0 Hz, 2H), 1.67 – 1.63 (m, 2H), 1.51 (hept, J = 6.7 Hz, 1H), 
1.39 (p, J = 7.6 Hz, 2H), 0.95 (d, J = 6.7 Hz, 6H). ; 13C NMR (151 MHz, CDCl3) δ 
172.96, 169.29, 151.35, 139.21, 138.25, 137.53, 126.60, 123.01, 120.19, 112.29, 100.12, 
56.04, 43.60, 39.10, 37.00, 36.84, 32.38, 31.12, 29.45, 28.09, 27.39, 25.93, 25.40, 22.80, 
20.82. IR (thin film): 3287.07, 2928.38, 2359.48, 1766.48, 1642.09, 1511.92, 1388.25, 
1272.79, 1195.54, 1035.59. HRMS: Calculated for (M+Na)+: 370.1995 and 372.2151; 
found: 370.1987 and 370.2141.  
 
(9S)-10,11-dihydro-6’-methoxycinchonan-9-ol·2,2,2-trifluoroacetic acid. The title 
compound was prepared by stirring 1.0 g dihydroquinidine (3.1 mmol, 1.0 equiv.) in a 
15:1 (v/v) mixture of Et2O/MeOH at 0 ˚C and adding 237 µL trifluoroacetic acid (3.1 
mmol, 1.0 equiv.) slowly. The mixture was stirred for 2 hours and concentrated in vacuo. 
The crude white foam was recrystallized by dissolving in hot toluene and cooling. The 
tan solid was collected by vacuum filtration and washed with toluene. The solid was 
dried in vacuo to give quantitative yield of the salt. 1HNMR (600 MHz, CDCl3) δ 12.34 













(s, 1H), 6.98 (s, 1H), 6.37 (s, 1H), 5.66 (s, 1H), 4.16 – 3.91 (m, 1H), 3.83 (s, 3H), 3.54 – 
3.22 (m, 3H), 3.18 (s, 1H), 2.39 – 2.24 (m, 1H), 1.95 (s, 1H), 1.86 – 1.51 (m, 5H), 1.02 – 
0.88 (m, 4H). 13C NMR (151 MHz, CDCl3) δ 162.93 (q, J = 34.9 Hz), 158.20, 146.85, 
144.30, 143.27, 131.19, 125.16, 122.30, 118.36, 116.71 (q, J = 292.7 Hz), 99.36, 66.40, 
60.23, 55.79, 50.03, 49.38, 35.26, 25.16, 24.30, 23.93, 17.68, 11.50. 19F NMR (376 
MHz, CDCl3) δ –75.34. IR (thin film): 3249.47 (br), 2964.05, 2556.18, 2360.44, 
1672.95, 1509.99, 1433.82, 1242.90, 1199.51, 834.06. HRMS: Calculated for (M-
C2O2F3)+: 327.2072; found: 327.2067.  
Procedures for the Photoredox-Catalyzed Synthesis of Aryl Amines  
Notes: All isolated yields and regioisomeric ratios reported are the average of duplicate 
experiments. For inseparable mixtures of regioisomers, analytical data was collected for 
the sample as isolated from chromatography, which, in most cases, is a mixture of para- 
and ortho- isomers.  
General Method A: Synthesis of 2.1, 2.5–2.19, 2.22–2.26, 2.28–2.32, 2.34–2.36 The 
synthesis of aryl pyrazoles 2.1a and 2.1b from anisole and pyrazole is representative of 
the following general procedure:  
To a 2 dram vial containing a Teflon-coated magnetic stir bar was added 25 µmol of 
Catalyst C (0.05 equiv.), 68 mg of pyrazole (1.0 mmol, 2 equiv.), and 16 mg of (2,2,6,6- 
tetramethylpiperidin-1-yl)oxyl (0.1 mmol, 0.2 equiv.). Dichloromethane or 1,2-
Dichloroethane was added (5.0 mL), followed by the arene (0.5 mmol, 1.0 equiv.). The 
vial was sealed with a Teflon-lined septum screw cap. The septum was pierced with a 
disposable steel needle connected to an oxygen-filled balloon. A vent needle was inserted 
and the reaction medium was sparged for 5 minutes by bubbling oxygen through the 
	 130 
mixture. The vent needle was removed, and the oxygen balloon was maintained, 
providing approximately 1 atm of oxygen to the vial headspace for the course of the 
reaction. The vial was positioned on a stir plate approximately 10 cm from a Par38 LED 
lamp supplying blue light (λ = 440 – 460 nm). After irradiation for 20 hours, the reaction 
mixture was analyzed by GC-MS or concentrated in vacuo and purified by column 
chromatography on silica gel with hexanes/ethyl acetate (or with the eluent noted for 
each substrate). For reaction optimization as shown in Table 2.1 and Table 2.2, crude 
reaction mixtures were analyzed by GC-MS by the following modification to General 
Procedure A: reactions were run under concentrations given in Table 2.1 and Table 2.2 
relative to anisole on a 0.5 mmol scale. Following irradiation for 20 hours, 33 µL 1,3-
dimethoxybenzene (0.25 mmol, 0.5 equiv.) was added to the reaction mixture, which was 
passed through a short pad of silica gel and rinsed with an equal volume of 
dichloromethane. Samples were analyzed using an Agilent 5973 GC-MS system, wherein 
product yields and anisole conversions were calculated relative to the internal standard 
according to the instrument response factors, which were determined separately by 
construction of calibration curves.  
General Method B: Synthesis of Alkyl-Substituted Arenes. 
The synthesis of aryl pyrazole 2.12 from mesitylene and pyrazole is representative of the 
following general procedure:  
To a 2 dram vial containing a Teflon-coated magnetic stir bar was added 25 µmol of 
Catalyst C (0.05 equiv.), 34 mg of pyrazole (0.5 mmol, 1 equiv.), and 16 mg of (2,2,6,6- 
tetramethylpiperidin-1-yl)oxyl (0.1 mmol, 0.2 equiv.). Dichloromethane or 1,2-
Dichloroethane was added (5.0 mL), followed by addition of alkyl arene (1.0 mmol, 2 
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equiv.). The vial was sealed with a Teflon-lined septum screw cap. The septum was 
pierced with a disposable steel needle connected to a nitrogen-filled balloon. A vent 
needle was inserted and the reaction medium was sparged for 5 minutes by bubbling 
nitrogen through the mixture. The vent needle was removed, and the nitrogen line was 
maintained, providing approximately 1 atm of nitrogen to the vial headspace for the 
course of the reaction. The vial was irradiated as described in General Procedure A for 
44 hours, and the reaction mixture was analyzed by GC-MS or concentrated in vacuo and 
purified by column chromatography on silica gel with the eluent noted for each substrate. 
General Method C: Synthesis of Anilines 42-49  
To a vial containing a Teflon-coated magnetic stir bar was added Catalyst B or C (0.05 
equiv.), ammonium carbamate (4.0 equiv.), and TEMPO (0.2 equiv.). A 10:1 solvent 
mixture of 1,2- dichloroethane/water was added (0.1M), followed by the arene (1.0 
equiv.). The vial was sealed with a Teflon-lined septum screw cap, and the reaction 
mixture was sparged with O2 and irradiated in the same fashion as General Method A.  
Characterization for Aryl Amination Products. 
 
1-(4-methoxyphenyl)-1H-pyrazole, 1-(2-methoxyphenyl)-1H-pyrazole. The title 
compounds were prepared using General Method A with an irradiation time of 20 hours. 
The average para:ortho ratio of the inseparable mixture was 8.8:1 as determined by 1H 








chromatography on silica gel (10% to 20% EtOAc/Hexanes) to yield a pale yellow solid 
in 88%. Spectral data were in agreement with literature values. 7,8 
2.1a. 1H NMR (400 MHz, CDCl3) δ 7.82 (s, 1H), 7.69 (s, 1H), 7.59 (d, J = 8.9 Hz, 2H), 
6.97 (d, J = 8.9 Hz, 2H), 6.43 (s, 1H), 3.84 (s, 3H).; 13C NMR (100 MHz, CDCl3) δ 
158.25, 140.64, 134.06, 126.85, 120.91, 114.54, 107.21, 55.60. 
2.1b. 1H NMR (400 MHz, CDCl3) δ 8.03 (s, 1H), 7.72 (m, 1H), 7.69 (m, 2H), 7.30 (m, 
1H), 7.06 (m, 1H), 6.43 (s, 1H), 3.87 (s, 3H).; 13C NMR (100 MHz, CDCl3) δ 151.36, 
140.10, 131.59, 128.05, 125.31, 121.19, 112.29, 106.20, 55.97. 
 
1-(4-(methoxymethoxy)phenyl)-1H-pyrazole and 1-(2-(methoxymethoxy)phenyl)-
1H-pyrazole. The title compounds were prepared using General Method A with an 
irradiation time of 20 hours. The average para:ortho ratio of the inseparable mixture was 
7.8:1 as determined by 1H NMR of the isolated product. The title compound was purified 
by column chromatography on silica gel (10% to 20% EtOAc/Hexanes) to yield a pale 
yellow solid in 52%.  
2.5a. 1H NMR (600 MHz, CDCl3) δ 7.83 (d, J = 2.4 Hz, 1H), 7.69 (d, J = 1.7 Hz, 1H), 
7.59 (d, J = 9.0 Hz, 2H), 7.11 (d, J = 9.0 Hz, 2H), 6.43 (d, J = 2.2 Hz, 1H), 5.19 (s, 2H), 
3.49 (s, 3H).; 13C NMR (151 MHz, CDCl3) δ 155.91, 140.80, 135.03, 126.88, 120.84, 
117.08, 107.35, 94.75, 56.15. 
2.5b. 1H NMR (600 MHz, CDCl3) δ 8.03 (dd, J = 2.4, 0.8 Hz, 1H), 7.74-7.70 (m, 2H), 








MHz, CDCl3) δ  149.10, 140.24, 135.03, 131.58, 128.16, 125.55, 116.41, 106.38, 95.44, 
56.43. 
IR (thin film): 3452.67, 3124.12, 2955.38, 1597.73, 1523.49, 1396.21, 1311.36, 1237.11, 




butyldimethylsilyl) oxy)phenyl)-1H-pyrazole. The title compounds were prepared 
using General Method A with an irradiation time of 20 hours. The average para:ortho 
ratio of the inseparable mixture was 9.3:1 as determined by 1H NMR of the isolated 
product. The title compound was purified by column chromatography on silica gel (10% 
to 20% EtOAc/Hexanes) to yield a pale yellow oil in 74%.  
2.6a. 1H NMR (600 MHz, CDCl3) δ 7.83 (s, 1H), 7.70 (s, 1H), 7.56-7.54 (d, J = 8.1 Hz, 
2H), 6.93-6.92 (d, J = 8.1 Hz, 2H), 6.44 (d, J = 2.1 Hz, 1H), 1.02 (s, 9H), 0.24 (s, 6H).; 
13C NMR (151 MHz, CDCl3) δ154.11, 140.37, 134.26, 126.57, 120.56, 120.51, 106.93, 
25.45, 18.00, -4.65. 
2.6b. 1H NMR (600 MHz, CDCl3) δ 7.93 (d, J = 2.0 Hz, 1H), 7.70 (s, 1H), 7.63 (d, J = 
7.9 Hz, 1H), 7.25-7.19 (m, 1H), 7.10-7.05 (m, 1H), 6.99 (dt, J = 8.1, 1.3 Hz, 1H), 6.43 (s, 
1H), 0.90 (s, 9H), 0.05 (s, 6H).; 13C NMR (151 MHz, CDCl3) δ 147.58, 139.79, 132.08, 








IR (thin film): 2956.34, 2930.31, 2857.99, 1596.77, 1521.56, 1471.42, 1395.25, 1266.04, 
913.13, 839.84, 781.99, 747.28; HRMS (ESI): Calculated for [M+H2O]= 275.1580; 
found 275.1575. 
 
1-(4-(tert-butoxy)phenyl)-1H-pyrazole and 1-(2-(tert-butoxy)phenyl)-1H-pyrazole. 
The title compounds were prepared using General Method A with an irradiation time of 
20 hours. The average para:ortho ratio of the inseparable mixture was 6:1 as determined 
by 1H NMR of the isolated product. The title compound was purified by column 
chromatography on silica gel (10% to 20% EtOAc/Hexanes) to yield a pale yellow solid 
in 63%.  
2.7a. 1H NMR (400 MHz, CDCl3) δ 7.90 (s, 1H), 7.74 (s, 1H), 7.62 (d, J = 8.4 Hz, 2H), 
7.11 (d, J = 8.4 Hz, 2H), 6.48 (s, 1H), 1.41 (s, 9H).; 13C NMR (151 MHz, CDCl3) δ 
153.49, 140.43, 135.70, 126.47, 124.62, 119.65, 106.97, 78.58, 28.42. 
2.7b. 1H NMR (400 MHz, CDCl3) δ 8.12 (s, 1H), 7.74 (s, 1H), 7.25 (d, J = 7.8 Hz, 2H), 
7.22-7.19 (m, 2H), 6.46 (s, 1H), 1.17 (s, 9H).; 13C NMR (151 MHz, CDCl3) δ 146.78, 
139.72, 135.32, 131.47, 126.86, 125.03, 124.00, 105.73, 80.56, 27.82. 
IR (thin film): 3122.19, 2976.59, 2933.20, 2360.44, 1521.56, 1394.28, 1240.00, 1161.90, 










1-(4-phenoxyphenyl)-1H-pyrazole and 1-(2-phenoxyphenyl)-1H-pyrazole. The title 
compounds were prepared using General Method A with an irradiation time of 20 hours. 
The average para:ortho ratio of the inseparable mixture was 11:1 as determined by 1H 
NMR of the isolated product. The title compound was purified by column 
chromatography on silica gel (10% to 20% EtOAc/Hexanes) to yield a pale yellow solid 
in 86%.  
2.8a. 1H NMR (600 MHz, CDCl3) δ 7.88 (d, J = 2.4 Hz, 1H), 7.73 (d, J = 1.8 Hz, 1H), 
7.66 (d, J = 8.9 Hz, 2H), 7.37 (dd, J = 8.5, 7.3 Hz, 2H), 7.14 (td, J = 7.4, 1.1 Hz, 1H), 
7.11 (d, J = 8.8 Hz, 2H), 7.07-7.03 (m, 2H), 6.47 (t, J = 2.1 Hz, 1H).; 13C NMR (151 
MHz, CDCl3) δ 157.18, 155.80, 141.03, 136.0, 129.96, 126.92, 123.61, 120.98, 119.74, 
118.92, 107.60. 
2.8b. 1H NMR (600 MHz, CDCl3) δ 8.10 (d, J = 2.3 Hz, 1H), 7.94-7.90 (m, 1H), 7.70 (d, 
J = 1.7 Hz, 1H), 7.32 (dd, J = 8.5, 7.3 Hz, 2H), 7.27 (d, J = 3.7 Hz, 2H), 7.14 (td, J = 7.4, 
1.1 Hz, 1H), 7.11 (d, J = 8.8 Hz, 1H), 6.98 (dd, J = 7.6, 1.1 Hz, 2H), 6.38 (d, J = 2.1 Hz, 
1H).; 13C NMR (151 MHz, CDCl3) δ 156.73, 147.88, 140.55, 132.36, 131.26, 129.61, 
127.91, 125.39, 124.60, 120.98, 118.24, 115.54, 106.92. 
IR (thin film): 3056.62, 2359.48, 1589.06, 1521.56, 1488.78, 1395.25, 1236.15, 1046.19, 









1-([1,1'-biphenyl]-4-yl)-1H-pyrazole and 1-([1,1'-biphenyl]-2-yl)-1H-pyrazole. The 
title compounds were prepared using General Method A with an irradiation time of 20 
hours. The average para:ortho ratio of the inseparable mixture was 7.9:1 as determined 
by 1H NMR of the isolated product. The title compound was purified by column 
chromatography on silica gel (10% to 20% EtOAc/Hexanes) to yield a pale yellow solid 
in 56%.  
2.9a. 1H NMR (600 MHz, CDCl3) δ 7.97 (s, 1H), 7.79-7.76 (m, 3H), 7.69 (dd, J = 8.7, 
1.9 Hz, 2H), 7.64-7.62 (m, 2H), 7.48-7.45 (m, 2H), 7.39-7.36 (m, 1H), 6.50 (s, 1H).; 13C 
NMR (151 MHz, CDCl3) δ  141.29, 140.22, 139.49, 139.44, 128.99, 128.17, 127.61, 
127.08, 126.81, 119.5, 107.83. 
2.9b. 1H NMR (600 MHz, CDCl3) δ 7.65-7.60 (m, 1H), 7.50-7.44 (m, 2H), 7.32-7.28 (m, 
3H), 7.26 (m, 2H), 7.13-7.12 (dd, J = 6.7, 2.7 Hz, 2H), 7.08 (m, 1H), 6.20 (q, J = 1.9 Hz, 
1H).; 13C NMR (151 MHz, CDCl3) δ 140.36, 138.68, 136.78, 131.43, 131.13, 128.64, 
128.55, 128.47, 128.35, 127.53, 126.67, 106.48. 
IR (thin film): 3130.87, 3107.72, 2358.52, 1607.38, 1530.24, 1486.85, 1394.28, 1050.05, 
836.96, 743.42; HRMS (ESI): Calculated for [M+H2O]= 221.1079; found 221.1072. 
 
1-(3-chloro-4-methoxyphenyl)-1H-pyrazole (2.10). The title compound was prepared 










purified by column chromatography on silica gel (10% to 20% EtOAc/Hexanes) to yield 
a pale yellow solid in 70%. 1H NMR (600 MHz, CDCl3) δ 7.80 (d, J = 2.4 Hz, 1H), 7.73 
(d, J = 2.6 Hz, 1H), 7.68 (d, J = 1.8 Hz, 1H), 7.53 (dd, J = 9.0, 2.6 Hz, 1H), 6.96 (d, J = 
8.8 Hz, 1H), 6.43 (s, 1H), 3.91 (s, 3H).; 13C NMR (151 MHz, CDCl3) δ 153.67, 141.07, 
134.17, 126.84, 123.20, 121.73, 118.59, 112.40, 107.71, 56.51; IR (thin film): 3124.12, 
2965.02, 2839.67, 2359.48, 1585.20, 1504.20, 1397.17, 1278.57, 1062.59, 750.17; 
HRMS (ESI): Calculated for [M+H2O]= 231.0301; found 231.0294. 
 
1-(2-bromo-4-methoxyphenyl)-1H-pyrazole (2.11). The title compound was prepared 
using General Method A with an irradiation time of 44 hours. The title compound was 
purified by column chromatography on silica gel (10% to 20% EtOAc/Hexanes) to yield 
a white solid in 54% (two trials). 1H NMR (600 MHz, CDCl3) δ 7.71 (dd, J = 11.3, 2.1 
Hz, 2H), 7.39 (d, J = 8.9 Hz, 1H), 7.20 (d, J = 2.5 Hz, 1H), 6.93 (dd, J = 8.7, 2.5 Hz, 1H), 
6.43 (t, J = 2.3 Hz, 1H), 3.83 (s, 3H).; 13C NMR (151 MHz, CDCl3) δ  153.71, 141.10, 
134.21, 126.85, 123.24, 121.77, 118.62, 112.43, 107.73, 56.55.; IR (thin film): 3101.94, 
2965.02, 2837.74, 1602.56, 1521.56, 1396.21, 1293.04, 1232.29, 1034.62, 850.45, 
753.07; HRMS (ESI): Calculated for [M+H2O]= 252.9976; found 252.9971. 
 
1-(2'-chloro-6-methoxy-[1,1'-biphenyl]-3-yl)-1H-pyrazole (2.12). The title compound 








compound was purified by column chromatography on silica gel (5% to 10% 
EtOAc/Hexanes) to yield the desire product in 75%.  1H NMR (600 MHz, CDCl3) δ 7.86 
(d, J = 2.4 Hz, 1H), 7.72 – 7.68 (m, 1H), 7.68 (d, J = 2.8 Hz, 1H), 7.52 (d, J = 2.8 Hz, 
1H), 7.49 – 7.44 (m, 1H), 7.37 – 7.29 (m, 3H), 7.05 (d, J = 8.9 Hz, 1H), 6.45 (t, J = 2.0 
Hz, 1H), 3.83 (s, 3H);; 13C NMR (151 MHz, CDCl3) δ 155.51, 140.85, 136.88, 133.95, 
133.70, 131.69, 129.51, 129.43, 129.09, 126.97, 126.69, 122.54, 120.44, 111.64, 107.41, 
56.17. IR (thin film): 3055.66, 2934.16, 2835.81, 1593.88, 1518.67, 1400.07, 1253.50, 
1141.65, 1046.19, 750.17; HRMS (ESI): Calculated for [M+H2O]= 307.0614; found 
307.0606. 
 
1-mesityl-1H-pyrazole (2.13). The title compound was prepared using General Method 
B with an irradiation time of 44 hours. The title compound was purified by column 
chromatography on silica gel (5% to 10% EtOAc/Hexanes) to yield a yellow oil in 82%. 
1H NMR (400 MHz, CDCl3) δ 8.17 (s, 1H), 7.86 (d, J = 2.3 Hz, 1H), 7.40 (s, 2H), 6.88 
(s, 1H), 2.79 (s, 3H), 2.43 (s, 6H).; 13C NMR (151 MHz, CDCl3) δ 140.07, 138.82, 
137.05, 135.97, 130.93, 128.85, 105.83, 21.19, 17.30.; IR (thin film): 3103.87, 2921.63, 
2358.52, 1594.84, 1516.74, 1393.32, 1190.83, 1044.26, 852.38, 751.14; HRMS (ESI): 








1-(2,4-dimethylphenyl)-1H-pyrazole and1-(2,6-dimethylphenyl)-1H-pyrazole. The 
title compounds were prepared using General Method B with an irradiation time of 44 
hours. The average ratio of the inseparable mixture was >15:1 as determined by 1H NMR 
of the isolated product. The title compound was purified by column chromatography on 
silica gel (5% to 10% EtOAc/Hexanes) to yield a yellow oil in 36%. 
2.14a. 1H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.85 (s, 1H), 7.51 (d, J = 7.4 Hz, 1H), 
7.42 (s, 1H), 7.37 (d, J = 7.4 Hz, 1H), 6.72 (s, 1H), 2.68 (s, 3H), 2.50 (s, 3H).; 13C NMR 
(151 MHz, CDCl3) δ 136.07, 134.08, 133.47, 129.32, 127.74, 126.68, 123.05, 121.93, 
102.03, 17.13, 13.90. 
2.14b. 1H NMR (400 MHz, CDCl3) δ 8.04 (s, 1H), 7.74 (s, 1H), 7.25 (s, 3H), 6.75 (s, 
1H), 2.31 (s, 6H).; 13C NMR (151 MHz, CDCl3) δ 136.03, 135.21, 132.07, 126.81, 
124.91, 124.07, 101.89, 13.28. 
IR (thin film): 3103.94, 2972.73, 2936.09, 287052, 1670.05, 1507.10, 1464.67, 1395.25, 
1241.93, 1043.30; HRMS (ESI): Calculated for [M+H2O]= 195.0898; found 195.0891. 
 
2,6-dimethoxy-3-(1H-pyrazol-1-yl)pyridine (2.15). The title compound was prepared 













purified by column chromatography on silica gel (0% to 10% EtOAc/Hexanes) to yield 
the desired product in 45%. 1H NMR (600 MHz, CDCl3) δ 7.98 (d, J = 2.4 Hz, 1H), 7.93 
(d, J = 8.4 Hz, 1H), 7.68 (d, J = 1.6 Hz, 1H), 6.45 – 6.37 (m, 2H), 4.02 (s, 3H), 3.96 (s, 
3H). 13C NMR (151 MHz, CDCl3) δ 161.15, 154.17, 140.22, 136.29, 131.06, 117.65, 
106.33, 101.58, 54.02, 53.95. IR (thin film): 3103.87, 2949.59, 1592.91, 1591.63, 
1486.85, 1392.35, 1230.36, 1021.12, 812.85, 753.07; HRMS (ESI): Calculated for 
[M+H2O]= 228.0749; found 228.0741. 
 
6-methoxy-5-(1H-pyrazol-1-yl)quinoline (2.16). The title compound was prepared 
using General Method A with an irradiation time of 20 hours. The title compound was 
purified by column chromatography on silica gel (50% to 100% EtOAc/Hexanes) to yield 
a yellow oil in 60%. 1H NMR (600 MHz, CDCl3) δ 8.79 (dt, J = 4.1, 2.1 Hz, 1H), 8.21 
(d, J = 9.4 Hz, 1H), 7.85 (t, J = 2.1 Hz, 1H), 7.72-7.62 (m, 2H), 7.58 (d, J = 9.4 Hz, 1H), 
7.33 (m, 1H), 6.54 (m, 1H), 3.89 (s, 3H).; 13C NMR (151 MHz, CDCl3) δ 152.42, 
148.91, 143.37, 140.87, 133.16, 132.07, 131.01, 127.29, 116.62, 106.30, 56.92.; IR (thin 
film): 311640, 2941.88, 1618.95, 1506.13, 1398.14, 1325.82, 1267.97, 1091.51, 908.31, 















1,3-dihexyl-6-(1H-pyrazol-1-yl)quinazoline-2,4(1H,3H)-dione (2.17). The title 
compound was prepared using General Method A with an irradiation time of 20 hours. 
The average para:ortho ratio of the inseparable mixture was >15:1 as determined by 1H 
NMR of the isolated product. The title compound was purified by column 
chromatography on silica gel (10% to 20% EtOAc/Hexanes) to yield a yellow oil in 43%. 
1H NMR (600 MHz, CDCl3) δ 8.36 (d, J = 3.0 Hz, 1H), 8.18-8.17 (m, 1H), 8.00 (d, J = 
2.9 Hz, 1H), 7.73 (s, 1H), 7.27-7.26 (m, 1H), 6.49 (s, 1H), 4.14-4.07 (m, 4H), 1.73-1.68 
(m, 4H), 1.44-1.32 (m, 12H), 0.97-0.84 (m, 6H).; 13C NMR (151 MHz, CDCl3) δ 161.22, 
150.43, 141.43, 137.96, 135.49, 126.77, 126.43, 117.76, 116.27, 115.05, 108.17, 44.04, 
42.19, 31.54, 31.49, 27.78, 27.36, 26.68, 26.49, 22.60, 14.09, 14.04.; IR (thin film): 
3122.19, 2930.31, 2857.99, 1703.80, 1659.45, 1524.45, 1480.10, 1394.28, 1045.23, 
752.10; HRMS (ESI): Calculated for [M+H2O]= 419.2423; found 419.2416. 
	
1-methyl-3-(1H-pyrazol-1-yl)-1H-indazole (2.18). The title compound was prepared 
using General Method A with an irradiation time of 20 hours. The title compound was 
purified by column chromatography on silica gel (0% to 20% EtOAc/Hexanes) to yield 
the desired product in 43%. 1H NMR (600 MHz, CDCl3) δ 8.32 (dt, J = 8.3, 1.0 Hz, 1H), 
8.25 (d, J = 2.5 Hz, 1H), 7.81 (d, J = 2.0 Hz, 1H), 7.45 (ddd, J = 8.3, 6.8, 1.1 Hz, 1H), 
7.36 (d, J = 8.6 Hz, 1H), 7.24-7.16 (m, 1H), 6.49 (t, J = 2.1 Hz, 1H), 4.05 (s, 3H).; 13C 
NMR (151 MHz, CDCl3) δ 141.68, 141.42, 127.84, 127.58, 122.63, 121.37, 115.20, 






1397.17, 1256.40, 1043.30, 919.88, 743.43; HRMS (ESI): Calculated for [M+H2O]= 
221.0803; found 221.0796. 
 
6-(1H-pyrazol-1-yl)chroman-2-one (2.19). The title compound was prepared using a 
modified General Method A procedure. The reaction was run with 2 equivalences of 
3,4-dihydrocoumarin and 1 equivalent of pyrazole (2:1 ratio of arene: amine) without a 
cooling fan and with an irradiation time of 44 hours. The title compound was purified by 
column chromatography on silica gel (25% to 50% EtOAc/Hexanes) to yield a yellow 
solid in 30%. 1H NMR (600 MHz, CDCl3) δ 7.87 (d, J = 2.5 Hz, 1H), 7.71 (d, J = 1.7 
Hz, 1H), 7.60 (d, J = 2.6 Hz, 1H), 7.51 (dd, J = 8.7, 2.6 Hz, 1H), 7.11 (d, J = 8.7 Hz, 1H), 
6.47 (t, J = 2.2 Hz, 1H), 3.06 (dd, J = 8.3, 6.3 Hz, 2H), 2.81 (dd, J = 8.3, 6.2 Hz, 2H).; 
13C NMR (151 MHz, CDCl3) δ168.06, 150.33, 141.28, 136.73, 126.86,  123.94, 
119.25, 118.90, 117.85, 107.90,, 29.03, 23.93.; IR (thin film): 3127.01, 2918.73, 
1769.37, 1600.63, 1502.28, 1395.25, 1343.18, 1217.83, 1144.55, 899.63; HRMS (ESI): 
Calculated for [M+H2O]= 215.0820; found 201.0813. 
	
1-(4-methoxyphenyl)-4-methyl-1H-pyrazole, 1-(2-methoxyphenyl)-4-methyl-1H-
pyrazole. The title compounds were prepared using General Method A with an 













8:1 as determined by 1H NMR of the isolated product. The title compound was purified 
by column chromatography on silica gel (20% EtOAc/Hexanes) to yield the desired 
product in 68%.  
2.22a. 1H NMR (600 MHz, CDCl3) δ 7.59 (s, 1H), 7.54 (d, J = 9.0 Hz, 2H), 7.49 (s, 1H), 
6.94 (d, J = 9.0 Hz, 2H), 3.82 (s, 3H), 2.14 (s, 3H).; 13C NMR (151 MHz, CDCl3) δ 
157.96, 141.30, 134.23, 125.55, 120.44, 117.84, 114.52, 55.61, 9.03. 
2.22b. 1H NMR (600 MHz, CDCl3) δ = 7.80 (s, 1H), 7.68 (dd, J = 7.9, 1.5 Hz, 1H), 7.51 
(s, 1H), 7.27 – 7.24 (m, 1H), 7.06 – 7.00 (m, 2H), 3.86 (s, 3H), 2.16 (s, 3H).; 13C NMR 
(151 MHz, CDCl3) δ =  151.21, 140.89, 130.24, 130.00, 127.70, 125.05, 121.21, 116.69, 
112.27, 77.16, 55.97, 9.08. 
IR (thin film): 2966.95, 2839.67, 1519.63, 1455.03, 1261.22, 1181.19, 1041.37, 953.63, 





The title compounds were prepared using General Method A with an irradiation time of 
20 hours. The average para:ortho ratio of the inseparable mixture was 3.6:1 N1 (6:1): N2 
(8:1) as determined by 1H NMR of the isolated product. The title compound was purified 
by column chromatography on silica gel (5% to 50% EtOAc/Hexanes) to yield the 
















2.23a. 1H NMR (600 MHz, CDCl3) δ 7.70 (s, 1H), 7.54 (d, J = 8.9 Hz, 2H), 6.94 (d, J = 
8.9 Hz, 2H), 6.20 (s, 1H), 3.82 (s, 3H), 2.37 (s, 3H).; 13C NMR (151 MHz, CDCl3) δ 
157.86, 150.00, 134.09, 127.43, 120.53, 114.43, 106.99, 55.53, 13.72.;  
2.23b. 1H NMR (600 MHz, CDCl3) δ 7.92 (d, J = 2.2 Hz, 1H), 7.72 – 7.69 (m, 1H), 7.26 
– 7.22 (m, 1H), 7.07 – 6.99 (m, 2H), 6.21 – 6.20 (m, 1H), 3.85 (s, 3H), 2.38 (s, 3H).; 13C 
NMR (151 MHz, CDCl3) δ 151.16, 149.33, 132.31, 129.79, 127.54, 125.07, 121.13, 
112.16, 106.14, 55.89, 13.67. 
IR (thin film): 3459.67, 2932.23, 1646.91, 1515.77, 1456.96, 1363.43, 1247.72, 
1181.19,1045.23, 830.21 HRMS (ESI): Calculated for [M+H2O]= 211.0847; found 
211.0841. 
2.23c. 1H NMR (600 MHz, CDCl3) δ 7.54 (d, J = 1.6 Hz, 1H), 7.34 (d, J = 8.9 Hz, 2H), 
6.97 (d, J = 8.9 Hz, 2H), 6.17 (d, J = 1.3 Hz, 1H), 3.85 (s, 3H), 2.29 (s, 3H).; 13C NMR 
(151 MHz, CDCl3) δ 159.09, 139.59, 138.82, 133.17, 126.53, 114.27, 106.42, 55.66, 
12.34.  
2.23d. 1H NMR (600 MHz, CDCl3) δ 7.59 (d, J = 1.6 Hz, 1H), 7.43 – 7.39 (m, 1H), 7.33 
– 7.31 (m, 1H), 7.07 – 7.01 (m, 2H), 6.17 – 6.16 (m, 1H), 3.79 (s, 3H), 2.15 (s, 3H).; 13C 
NMR (151 MHz, CDCl3) δ 154.81, 140.75, 140.00, 130.26, 129.24,120.92, 112.12, 
105.30, 55.93, 11.41.  














The title compounds were prepared using Method A with an irradiation time of 20 hours. 
The average para:ortho ratio of the inseparable mixture was 7.5:1 as determined by 1H 
NMR of the isolated product. The title compound was purified by column 
chromatography on silica gel (0% to 20% EtOAc/Hexanes) to yield the desired product in 
85% (two trials).  
2.24a. 1H NMR (600 MHz, CDCl3) δ 7.32 (d, J = 8.9 Hz, 2H), 6.95 (d, J = 8.9 Hz, 2H), 
5.96 (s, 1H), 3.84 (s, 3H), 2.29 (s, 3H), 2.24 (s, 3H).; 13C NMR (151 MHz, CDCl3) δ 
158.87, 148.63, 139.57, 133.22, 126.49, 114.21, 106.35, 55.64, 13.64, 12.28. 
2.24b. 1H NMR (600 MHz, CDCl3) δ 7.38 (td, J = 8.0, 1.7 Hz, 1H), 7.33 – 7.32 (m, 1H), 
7.04 – 6.99 (m, 2H), 5.96 (s, 1H), 3.79 (s, 3H), 2.30 (s, 3H), 2.09 (s, 3H).; 13C NMR (151 
MHz, CDCl3) δ  154.77, 149.03, 141.56, 130.00, 129.37, 128.79, 120.90, 111.97, 105.27, 
55.88, 13.80, 11.39. 
	
1-(4-methoxyphenyl)-1H-1,2,3-triazole13, 1-(2-methoxyphenyl)-1H-1,2,3-triazole13 
The title compounds were prepared using General Method A with an irradiation time of 
20 hours. The average para:ortho ratio of the inseparable mixture was 3.5:1 as 
determined by 1H NMR of the isolated product. The title compound was purified by 
column chromatography on silica gel (0% to 20% EtOAc/Hexanes) to yield the desired 









2.25a. 1H NMR (600 MHz, CDCl3) δ 7.91 (s, 1H), 7.83 (s, 1H), 7.64 (d, J = 8.8 Hz, 2H), 
7.03 (d, J = 8.8 Hz, 2H), 3.88 (s, 3H).; 13C NMR (151 MHz, CDCl3) δ 159.95, 134.42, 
122.46, 121.98, 114.91, 112.38, 55.77.  
2.25b. 1H NMR (600 MHz, CDCl3) δ 8.12 (s, 1H), 7.81 (s, 1H), 7.78 (d, J = 7.9 Hz, 1H), 
7.43 (t, J = 7.9 Hz, 1H), 7.14 – 7.05 (m, 2H), 3.89 (s, 3H).; 13C NMR (151 MHz, CDCl3) 




The title compounds were prepared from anisole and 1,2,4-triazole according to General 
Method A with an irradiation time of 20 hours. The crude residue was purified by 
column chromatography on silica gel with an eluent of 50% EtOAc/hexanes to 5% 
MeOH/EtOAc from which were isolated two sets of fractions. The first contained a 
mixture of N1 isomers 2.26a and 2.26b in 36% yield and a 4.5:1 ratio, but which was 
separable by additional chromatography. The second contained an inseparable mixture of 
N4 isomers 2.26c and 2.26.d in 40% yield and a 4:1 ratio. The spectral data for the 
known compounds 2.26a(58) and 2.26b(58) are consistent with the literature reports. 
Although 2.26c was reportedly synthesized (59), the analytical data provided by the 
authors appeared identical to those reported for compound 2.26a. We provide a correct 
assignment for 2.26c with the corresponding spectral data.  
















7.00 (d, J = 8.9 Hz, 2H), 3.85 (s, 3H). 13C  NMR (151 MHz, CDCl3) δ 159.56, 152.48, 
140.90, 130.56, 121.98, 114.92, 55.74.  
2.26b . 1H  NMR (600 MHz, CDCl3) δ 8.74 (s, 1H), 8.07 (s, 1H), 7.77 (dd, J = 7.9, 1.3 
Hz, 1H), 7.39 – 7.32 (m, 1H), 7.10 – 7.07 (m, 2H), 3.92 (s, 3H). 13C  NMR (151 MHz, 
CDCl3) δ 151.40, 151.04, 144.71, 129.21, 126.44, 124.66, 121.45, 112.31, 56.11.  
2.26c. 1H  NMR (600 MHz, CDCl3) δ 8.38 (s, 2H), 7.29 (d, J = 8.9 Hz, 2H), 7.01 (d, J = 
8.9 Hz, 2H), 3.85 (s, 3H). 13C  NMR (151 MHz, CDCl3) δ 160.20, 142.01, 126.78, 
124.15, 115.41, 55.82.  
2.26d. 1H  NMR (600 MHz, CDCl3) δ 8.40 (s, 2H), 7.44 – 7.41 (m, 1H), 7.28 – 7.27 (m, 
1H), 7.09 – 7.05 (m, 2H), 3.85 (s, 3H). 13C  NMR (151 MHz, CDCl3) δ 152.42, 143.02, 
130.55, 125.26, 121.35, 112.58, 56.04.  
IR (thin film): 3438.46, 3139.54, 1536.99, 2836.77, 1457.92, 1269.90, 1256.40, 1097.30, 
1032.69, 831.17; HRMS: Calculated for (M+H)+: 176.0824; found: 176.0817.  
 
1-(4-methoxyphenyl)-1H-imidazole, 1-(2-methoxyphenyl)-1H-imidazole. The title 
compounds were prepared using General Method B with the following modifications: 
1.0 equiv. anisole and 2.0 equiv. imidazole were irradiated for 20 hours without nitrogen 
sparging or a balloon of nitrogen over the course of the reaction. Note: General Method 
A was incompatible with imidazole as a substrate, leading to complete suppression of 
product under the aerobic conditions. The crude residue was purified by column 








MeOH/EtOAc giving an inseparable mixture of 2.27a and 2.27b in a ratio of 4:1 in 55% 
yield, along with the product of ipso-substitution, 2.27c in 7% yield. The spectral data 
match the literature report for compounds 2.27a, 2.27b, and 2.27c (63).  
2.27a. 1H NMR (600 MHz, CDCl3) δ 7.76 (s, 1H), 7.30 (d, J = 8.9 Hz, 2H), 7.20 (s, 1H), 
7.18 (s, 1H), 6.98 (d, J = 8.8 Hz, 2H), 3.85 (s, 3H).  
2.27b . 1H NMR (600 MHz, CDCl3) δ 7.78 (s, 1H), 7.37 – 7.34 (m, 1H), 7.29 – 7.28 (m, 
1H), 7.21 (s, 1H), 7.16 (s, 1H), 7.07 – 7.02 (m, 2H), 3.85 (s, 3H).  
2.27c . 1H NMR (600 MHz, CDCl3) δ7.86 (s, 1H), 7.48 (t, J = 7.8 Hz, 2H), 7.41 – 7.36 
(m, 3H), 7.27 (s, 1H), 7.21 (s, 1H).  
13C NMR (151 MHz, CDCl3) δ 158.92, 152.58, 137.81, 137.35, 135.86, 135.58, 130.69, 
130.40, 130.03, 129.89, 128.96, 128.79, 127.49, 126.50, 125.53, 123.20, 121.47, 121.00, 





The title compounds were prepared using General Method A with an irradiation time of 
20 hours. The average para:ortho ratio of the inseparable mixture was 1.5:1 N1 (10:1): 
N2 (10:1) as determined by 1H NMR of the isolated product. The title compound was 
purified by column chromatography on silica gel (0% to 20% EtOAc/Hexanes) to yield a 






















2.28a. 1H NMR (600 MHz, CDCl3) δ 8.00 (d, J = 9.1 Hz, 2H), 7.03 (d, J = 9.1 Hz, 2H), 
3.88 (s, 3H), 2.62 (s, 3H).; 13C NMR (151 MHz, CDCl3) δ 163.11, 160.48, 130.61, 
121.40, 114.77, 77.16, 55.79, 11.13.  
2.28b . 1H NMR (600 MHz, CDCl3) δ 7.58 – 7.46 (m, 2H), 7.18 – 7.06 (m, 2H), 3.87 (s, 
3H), 2.66 (s, 3H).; 13C NMR (151 MHz, CDCl3) δ  162.96, 153.55, 132.00, 127.12, 
126.51, 120.84, 112.80, 77.16, 56.38, 11.16. 
IR (thin film): 2943.80, 2840.63, 1732.73, 1646.91, 1507.10, 1456.96, 1418.39, 1254.47, 
1023.05, 837.92; HRMS (ESI): Calculated for [M+H2O]= 191.0933; found 191.0927. 
2.28c. 1H NMR (600 MHz, CDCl3) δ 7.35 (d, J = 7.4 Hz, 2H), 7.05 (d, J = 7.3 Hz, 2H), 
3.87 (s, 3H), 2.55 (s, 3H).; 13C NMR (151 MHz, CDCl3) δ 160.93, 151.78, 126.54, 
126.16, 115.07, 55.80, 9.71. 
2.28d. 1H NMR (600 MHz, CDCl3) δ 7.54 (t, J = 8.0 Hz, 1H), 7.35 – 7.32 (m, 1H), 7.12 
– 7.09 (m, 2H), 3.81 (s, 3H), 2.42 (s, 3H).; 13C NMR (151 MHz, CDCl3) δ  153.72, 




The title compounds were prepared using General Method A with an irradiation time of 
20 hours. The average para:ortho ratio of the inseparable mixture was 3:1 as determined 









chromatography on silica gel (5% to 10% EtOAc/Hexanes) to yield the desired product in 
57%.  
2.29a. 1H NMR (600 MHz, CDCl3) δ 8.14 (d, J = 8.4 Hz, 1H), 7.68 (app d, J = 8.9 Hz, 
3H), 7.54 (t, J = 8.0 Hz, 1H), 7.43 (t, J = 7.6 Hz, 1H), 7.12 (d, J = 8.9 Hz, 2H), 3.92 (s, 
3H).; 13C NMR (151 MHz, CDCl3) δ 159.88, 146.36, 132.70, 130.04, 128.10, 124.67, 
124.32, 120.25, 115.04, 110.33, 55.75. 
2.29b . 1H NMR (600 MHz, CDCl3) δ 8.12 (d, J = 8.2 Hz, 1H), 7.55 – 7.49 (m, 2H), 7.49 
– 7.44 (m, 1H), 7.37 (app t, J = 7.4 Hz, 2H), 7.17 – 7.12 (m, 2H), 3.79 (s, 3H).; 13C NMR 
(151 MHz, CDCl3) δ 153.75, 145.74, 134.14, 131.11, 128.19, 127.62, 125.35, 123.92, 
121.16, 119.91, 112.43, 111.27, 55.88. 
IR (thin film): 3064.33, 2934.16, 2358.52, 1613.16, 1517.70, 1454.06, 1253.50, 1067.41, 




The title compounds were prepared using General Method A with an irradiation time of 
20 hours. The average para:ortho ratio of the inseparable mixture was 1:1 N1(10:1): N2 
(>20:1) as determined by 1H NMR of the isolated product. The title compound was 
purified by column chromatography on silica gel (0% to 20% EtOAc/Hexanes) to yield 











2.30a. 1H NMR (600 MHz, CDCl3) δ 7.54 – 7.49 (m, 3H), 6.93 (d, J = 9.0 Hz, 2H), 3.82 
(s, 3H), 2.77 (t, J = 6.3 Hz, 2H), 2.61 (t, J = 6.2 Hz, 2H), 1.93 – 1.81 (m, 2H), 1.81 – 1.72 
(m, 2H).; 13C NMR (151 MHz, CDCl3) δ 157.72, 150.82, 134.46, 123.93, 120.37, 
117.84, 114.50, 77.16, 55.64, 23.63, 23.61, 20.80.  
2.30b. 1H NMR (600 MHz, CDCl3) δ 7.72 (s, 1H), 7.68 (dd, J = 7.9, 1.6 Hz, 1H), 7.25 – 
7.21 (m, 1H), 7.04 – 6.99 (m, 2H), 3.87 (s, 2H), 2.80 – 2.74 (m, 2H), 2.64 – 2.58 (m, 2H), 
1.87 – 1.83 (m, 2H), 1.79 – 1.75 (m, 2H).; 13C NMR (151 MHz, CDCl3) δ 151.09, 
150.18, 130.19, 128.64, 127.27, 125.02, 121.23, 116.86, 112.15, 77.16, 55.98, 23.66, 
23.58, 20.85.  
IR (thin film): 2932.23, 2853.17, 1517.70, 1456.96, 1377.89, 1254.47, 1023.05, 837.92; 
HRMS (ESI): Calculated for [M+H2O]= 251.1160; found 251.1154. 
2.30c. 1H NMR (600 MHz, CDCl3) δ 7.43 (s, 1H), 7.38 (d, J = 8.9 Hz, 2H), 6.95 (d, J = 
8.9 Hz, 2H), 3.84 (s, 3H), 2.66 (t, J = 5.8 Hz, 2H), 2.58 (t, J = 5.7 Hz, 2H), 1.82 – 1.75 
(m, 4H).; 13C NMR (151 MHz, CDCl3) δ  158.46, 138.40, 138.29, 133.56, 124.84, 




The title compounds were prepared using Method A with an irradiation time of 20 hours. 








NMR of the isolated product. The title compound was purified by column 
chromatography on silica gel (1.5% MeOH/DCM) to yield the desired product in 72%.  
2.31a. 1H NMR (600 MHz, CDCl3) δ 8.04 (s, 1H), 7.88 – 7.86 (m, 1H), 7.45 – 7.44 (m, 
1H), 7.40 (d, J = 8.9 Hz, 2H), 7.28 – 7.33 (m, 2H), 7.06 (d, J = 8.9 Hz, 2H), 3.87 (s, 3H).; 
13C NMR (151 MHz, CDCl3) δ 159.37, 143.90, 142.62, 134.29, 129.20, 125.77, 123.57, 
122.63, 120.55, 115.17, 110.40, 55.71. 
2.31b . 1H NMR (600 MHz, CDCl3) δ 8.07 (s, 1H), 7.88 – 7.86 (m, 1H), 7.45 – 7.42 (m, 
1H), 7.41 – 7.39 (m, 1H), 7.33 – 7.27 (m, 3H), 7.13 – 7.08 (m, 2H), 3.78 (s, 3H).; 13C 
NMR (151 MHz, CDCl3) δ  154.00, 143.39, 134.50, 129.78, 127.31, 124.84, 123.29, 





methoxyphenyl)-N6,N6-bis(tert-butoxycarbonyl)-7H-purin-6-amine. The title 
compounds were prepared from anisole and Boc2-adenine S10 according to General 
Method A with an irradiation time of 20 hours and the modification that 1.25 equiv. The 
crude residue was purified by column chromatography on silica gel with an eluent of 
hexanes to 50% EtOAc/hexanes to EtOAc from which were isolated two sets of fractions. 
The first contained an inseparable mixture of N9 isomers 2.32a and 2.32b in 47% yield 
























2.32d in 52% yield and 4:1 ratio.  
2.32a. 1H NMR (600 MHz, CDCl3) δ 8.91 (s, 1H), 8.28 (s, 1H), 7.59 (d, J = 8.9 Hz, 2H), 
7.10 (d, J = 8.9 Hz, 2H), 3.89 (s, 3H), 1.49 (s, 18H). 13C NMR (151 MHz, CDCl3) δ 
159.66, 153.69, 153.49, 153.10, 152.61, 152.45, 150.64, 150.49, 150.33, 143.94, 130.52, 
129.01, 128.41, 127.47, 126.86, 125.18, 122.29, 121.08, 115.06, 112.33, 83.79, 83.68, 
55.61, 27.75, 27.74.  
2.32b. 1H NMR (600 MHz, CDCl3) δ 8.87 (s, 1H), 8.28 (s, 1H), 7.57 (d, J = 5.9 Hz, 1H), 
7.48 (t, J = 7.9 Hz, 1H), 7.18 – 7.11 (m, 2H), 3.80 (s, 3H), 1.48 (s, 18H). 13C NMR (151 
MHz, CDCl3) δ 153.69, 153.49, 152.45, 150.33, 145.86, 130.52, 128.41, 126.86, 125.12, 
122.29, 121.08, 112.33, 83.68, 55.80, 27.74.  
IR (thin film): 2979.48, 2935.13, 1790.58, 1758.76, 1595.81, 1519.63, 1455.99, 1340.28, 
1140.69; HRMS: Calculated for (M+H)+: 442.2090; found: 442.2087.  
2.32c. 1H NMR (600 MHz, CDCl3) δ 9.08 (s, 1H), 8.28 (s, 1H), 7.33 (d, J = 8.8 Hz, 2H), 
6.99 (d, J = 8.8 Hz, 2H), 3.87 (s, 3H), 1.30 (s, 18H). 13C NMR (151 MHz, CDCl3) δ 
163.68, 160.48, 153.06, 149.84, 148.71, 144.26, 127.70, 126.88, 121.51, 115.00, 84.15, 
55.83, 27.93.  
2.32d . 1H NMR (600 MHz, CDCl3) δ 9.06 (s, 1H), 8.33 (s, 1H), 7.48 (t, J = 8.0 Hz, 1H), 
7.36 – 7.33 (m, 1H), 7.10 – 7.04 (m, 2H), 3.79 (s, 3H), 1.30 (s, 18H). 13C NMR (151 
MHz, CDCl3) δ163.49, 153.79, 152.77, 150.13, 144.08, 131.04, 127.65, 125.32, 123.49, 
121.34, 121.03, 112.41, 83.94, 55.92, 27.85.  
IR (thin film): 3077.83, 2980.45, 2935.13, 2237.99, 1739.48, 1768.40, 1613.16, 1515.77, 
1369.21, 1252.54; HRMS: Calculated for (M+Na)+: 464.1910; found: 464.1910.  
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methyl Nα-(tert-butoxycarbonyl)-Nτ-(4-methoxyphenyl)-L-histidinate, methyl Nα-
(tert- butoxycarbonyl)-Nτ-(2-methoxyphenyl)-L-histidinate, methyl Nα-(tert- 
butoxycarbonyl)-Nπ-(4-methoxyphenyl)-L-histidinate, methyl Nα-(tert- 
butoxycarbonyl)-Nπ-(2-methoxyphenyl)-L-histidinate. The title compounds were 
prepared using General Method B with the following modifications: 1.0 equiv. anisole 
and 2.0 equiv. of histidine nucleophile were irradiated for 20 hours without nitrogen 
sparging or a balloon of nitrogen over the course of the reaction. Note: General Method 
A was incompatible with imidazole as a substrate, leading to complete suppression of 
product under the aerobic conditions. The crude residue was purified by column 
chromatography on silica gel with an eluent of 75% EtOAc/hexanes to EtOAc to 5% 
MeOH/EtOAc, from which were isolated 2 sets of fractions. The first set contained 2.33a 
and 2.33b in 24% yield and 8:1 ratio. The second set contained 2.33c and 2.33d in 24% 
yield and 5:1 ratio.  
2.33a. 1H NMR (600 MHz, CDCl3) δ 7.66 (s, 1H), 7.25 (d, J = 8.9 Hz, 2H), 6.96 (d, J = 





















3.15 (dd, J = 14.8, 5.6 Hz, 1H), 3.08 (dd, J = 14.7, 4.8 Hz, 1H), 1.43 (s, 9H). 13C NMR 
(151 MHz, CDCl3) δ 172.73, 159.00, 155.75, 138.41, 135.62, 130.64, 123.07, 116.42, 
115.01, 79.80, 55.73, 53.64, 52.39, 30.43, 28.48.  
2.33b. 1H NMR (600 MHz, CDCl3) δ 7.69 (s, 1H), 7.35 – 7.32 (m, 1H), 7.25 – 7.22 (m, 
1H), 7.05 – 7.00 (m, 2H), 6.97 (s, 1H), 5.56 (d, J = 8.2 Hz, 1H), 4.61 – 4.57 (m, 1H), 3.83 
(s, 3H), 3.72 (s, 3H), 3.02 (dd, J = 15.0, 5.0 Hz, 1H), 2.90 (dd, J = 15.7, 4.4 Hz, 1H), 1.44 
(s, 9H). ; 13C NMR (151 MHz, CDCl3) δ 171.59, 152.52, 137.66, 130.01, 129.00, 127.57, 
126.46, 125.41, 121.14, 117.98, 112.46, 80.52, 55.92, 53.74, 52.32, 30.39, 28.40.  
IR (thin film): 3369.07, 2976.59, 2841.60, 1746.23, 1705.73, 1517.70, 1366.32, 1251.58, 
1166.72, 1021.12; HRMS: Calculated for (M+H)+ :376.1872; found: 376.1863.  
2.33c. 1H NMR (600 MHz, CDCl3) δ 7.51 (s, 1H), 7.20 (d, J = 8.8 Hz, 2H), 6.99 (d, J = 
8.8 Hz, 2H), 6.92 (s, 1H), 4.95 (d, J = 7.9 Hz, 1H), 4.39 – 4.34 (m, 1H), 3.86 (s, 3H), 
3.62 (s, 3H), 3.06 (dd, J = 15.4, 5.2 Hz, 1H), 2.97 (dd, J = 15.5, 6.7 Hz, 1H), 1.39 (s, 9H). 
13C NMR (151 MHz, CDCl3) δ 171.98, 159.89, 155.04, 138.59, 129.01, 128.50, 127.73, 
121.10, 114.88, 80.21, 55.71, 52.72, 52.57, 28.39, 27.14.  
2.33d. 1H NMR (600 MHz, CDCl3) δ 7.46 – 7.42 (m, 2H), 7.22 – 7.18 (m, 1H), 7.07 – 
7.04 (m, 2H), 6.93 (s, 1H), 5.00 (d, J = 7.6 Hz, 1H), 4.41 – 4.33 (m, 1H), 3.81 (s, 3H), 
3.63 (s, 3H), 2.94 – 2.90 (m, 2H), 1.39 (s, 9H). 13C NMR (151 MHz, CDCl3) δ 172.13, 
160.77, 154.66, 153.68, 138.73, 130.78, 128.86, 128.08, 127.76, 127.41, 112.25, 80.11, 
55.87, 52.89, 52.50, 28.42, 26.83.  
IR (thin film): 3421.10, 2976.59, 1732.73, 1683.55, 1652.70, 1518.67, 1363.43, 1249.65, 




acetate. The title compounds were prepared from anisole and O-acetylcapsaicin 
according to General Method A with the modification that 1.25 equiv were employed 
for an irradiation time of 40 hours. The crude residue was purified by column 
chromatography on silica gel with an eluent of hexanes to 75% EtOAc/hexanes giving a 
white solid in 66% yield. Note: The product contains the same ratio of unsaturated to 
saturated capsaicin analogues as the starting material (~3:2). The provided proton NMR 
peak list below refers only to the unsaturated product 2.34; see spectrum for peaks 
corresponding to saturated product 2.34’.  
1H NMR (600 MHz, CDCl3) δ 7.70 (s, 1H), 7.64 (d, J = 2.3 Hz, 1H), 7.19 (d, J = 1.9 Hz, 
1H), 7.01 (s, 1H), 6.92 (t, J = 6.0 Hz, 1H), 6.45 (t, J = 2.1 Hz, 1H), 5.38 – 5.28 (m, 2H), 
4.23 (d, J = 6.3 Hz, 2H), 3.87 (s, 3H), 2.32 (s, 3H), 2.20 – 2.14 (m, 2H), 1.97 (q, J = 7.0 
Hz, 2H), 1.62 – 1.58 (m, 2H), 1.50 (hept, J=6.7Hz, 1H), 1.36 (p, J = 7.6 Hz, 2H), 0.94 (d, 
J = 6.7 Hz, 6H). 13C NMR (151 MHz, CDCl3) δ 172.95, 172.83, 168.87, 151.09, 140.87, 
138.84, 138.08, 133.08, 132.50, 130.75, 126.75, 119.88, 115.31, 107.11, 100.12, 56.47, 
40.00, 39.10, 37.10, 36.96, 32.41, 31.11, 29.77, 29.46, 29.42, 28.09, 27.39, 25.76, 25.27, 
22.80, 22.78, 20.75.  
IR (thin film): 3288.04. 2928.38, 2865.70, 1768.40, 1649.80, 1521.56, 1368.25, 1206.26, 
1039.44, 755.00; HRMS: Calculated for (M+Na)+: 436.2213 and 438.2369; found: 











(S)-methyl 2-(6-methoxy-5-(1H-pyrazol-1-yl)naphthalen-2-yl)propanoate (2.35). The 
title compound was prepared using a modified General Method A procedure. The 
reaction was run with 1 equivalent of naproxen methyl ester and 4 equivalences of 
pyrazole (1:4 arene: amine) with an irradiation time of 20 hours. The title compound was 
purified by column chromatography on silica gel (25% to 50% EtOAc/Hexanes) to yield 
a yellow solid in 26%. 1H NMR (600 MHz, CDCl3) δ 7.92 (d, J = 9.1 Hz, 1H), 7.86 (d, J 
= 2.0 Hz, 1H), 7.72 (d, J = 2.0 Hz, 2H), 7.65 (d, J = 2.3 Hz, 1H), 7.40-7.34 (m, 2H), 7.22 
(d, J = 8.9 Hz, 1H), 6.54 (d, J = 2.3 Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 1.56 (d, J = 7.3, 
3H).; 13C NMR (151 MHz, CDCl3) δ 174.98, 152.61, 140.70, 136.66, 133.06, 131.47, 
130.65, 128.97, 127.94, 125.97, 123.24, 122.83, 113.97, 106.10, 57.00, 52.24, 45.39, 
18.57.; IR (thin film): 2949.59, 2844.49, 1732, 1606.41, 1455.99, 1341.25, 1278.57, 
1196.61, 1071.26, 755.96; HRMS (ESI): Calculated for [M+H2O]= 333.1216; found 
333.1207. 
	
(9S)-10,11-dihydro- 6’-methoxy-5’-(1H-pyrazol-1-yl)cinchonan-9-ol · 2,2,2-





















The title compound was prepared using General Method A with an irradiation time of 
20 hours. The title compound was purified by column chromatography on silica gel (0% 
to 5% MeOH/DCM to 5% MeOH/DCM/0.05% TFA) to yield the desired product in 
53%.  
1H NMR (600 MHz, CDCl3) δ 10.85 (br s, 1H), 8.83 (d, J = 4.5 Hz, 1H), 8.34 (d, J = 9.4 
Hz, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.94 (d, J = 1.8 Hz, 1H), 7.58 (d, J = 9.4 Hz, 1H), 7.38 
(d, J = 2.2 Hz, 1H), 6.89 (br s, 1H), 6.52 (t, J = 2.0 Hz, 1H), 4.36 (s, 1H), 3.87 (s, 3H), 
3.81 (t, J = 10.5 Hz, 2H), 3.68 (t, J = 9.8 Hz, 1H), 3.16 – 3.09 (m, 1H), 2.99 (q, J = 9.3 
Hz, 1H), 1.81 – 1.59 (m, 5H), 1.52 – 1.36 (m, 2H), 0.85 (t, J = 7.4 Hz, 3H), 0.41 (dt, J = 
13.7, 7.7 Hz, 1H).; 13C NMR (151 MHz, CDCl3) δ 162.54 (q, J = 35.2 Hz), 156.32, 
148.37, 143.69, 143.37, 142.21, 134.37, 134.30, 123.76, 122.24, 121.13, 116.76 (q, J = 
292.3 Hz), 115.56, 108.15, 66.00, 60.59, 57.02, 51.03, 48.45, 35.46, 25.68, 24.20, 23.68, 
18.68, 11.56. 
IR (thin film): 3213.79, 2963.09, 2241.84, 1671.02, 1508.06, 1464.67, 1268.93, 1201.43, 
1136.83, 725.10; HRMS (ESI): Calculated for [M+H2O]= 393.2290; found 393.2282. 
 
p-anisidine (2.37a). The title compound was prepared using Method C with an 
irradiation time of 24 hours. The reaction was run through a plug of silica, concentrated 
and the reaction was purified by column chromatography on silica gel (20% 
EtOAc/Hexanes) to afford a dark-purple solid in 36% yield. The spectral data were in 




6.76 (d, J = 8.8 Hz, 1H), 6.66 (d, J = 8.8 Hz, 1H), 3.76 (s, 3H), 3.44 (br s, 2H); 13C NMR 
(151 MHz, CDCl3) δ 152.95, 140.03, 116.56, 114.94, 55.88. 
 
o-anisidine (2.37b). The title compound was prepared using Method C with an 
irradiation time of 24 hours. The reaction was run through a plug of silica, concentrated 
and the reaction was purified by column chromatography on silica gel (20% 
EtOAc/Hexanes) to afford a dark brown liquid in 22% yield. The spectral data were in 
agreement with previously reported literature values. 22 1H NMR (600 MHz, CDCl3) δ 
6.85 - 6.78 (m, 2H), 6.78 - 6.70 (m, 2H), 3.86 (s, 3H), 3.80 (br s, 2H); 13C NMR (151 
MHz, CDCl3) δ 147.45, 136.26, 121.20, 118.62, 115.16, 110.56, 55.56.		
 
4-(methoxymethyl)aniline (2.38a). The title compound was prepared using Method C 
with an irradiation time of 24 hours. The reaction was run through a plug of silica, 
concentrated and the reaction was purified by column chromatography on silica gel (20% 
to 50% EtOAc/Hexanes) to afford a brown oil in 43% yield. The spectral data were in 
agreement with previously reported literature values. 23 1H NMR (600 MHz, CDCl3) δ 
6.87 (d, J = 8.8 Hz, 2H), 6.63 (d, J = 8.8 Hz, 2H), 5.08 (s, 3H), 3.47 (s, 5H); 13C NMR 









 2-(methoxymethyl)aniline (2.38b).The title compound was prepared using Method C 
with an irradiation time of 24 hours. The reaction was run through a plug of silica, 
concentrated and the reaction was purified by column chromatography on silica gel (20% 
to 50% EtOAc/Hexanes) to afford a yellow oil in 21% yield. The spectral data were in 
agreement with previously reported literature values. 24 1H NMR (600 MHz, CDCl3) δ 
7.03 (dd, J = 8.1, 1.3 Hz, 1H), 6.85 (td, J = 7.6, 1.3 Hz, 1H), 6.77 – 6.67 (m, 2H), 5.20 (s, 
2H), 3.82 (br s, 2H), 3.51 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 144.93, 136.88, 
122.61, 118.65, 115.60, 114.89, 95.21, 56.20. 
 
4-((tert-butyldimethylsilyl)oxy)aniline (2.39a). The title compound was prepared using 
Method C with an irradiation time of 24 hours. The reaction was run through a plug of 
silica, concentrated and the reaction was purified by column chromatography on silica gel 
(10 to 20% EtOAc/Hexanes) to afford a yellow in 35% yield. The spectral data were in 
agreement with previously reported literature values. 25 1H NMR (600 MHz, CDCl3) δ 
6.67 (m, 2H), 6.59 (m, 2H), 3.41 (br s, 2H), 0.98 (s, 9H), 0.16 (s, 6H); 13C NMR (151 
MHz, CDCl3) δ 148.34, 140.39, 120.80, 116.43, 29.85, 25.89, 18.33, -4.35. 
 
2-((tert-butyldimethylsilyl)oxy)aniline (2.39b). The title compound was prepared using 
Method C with an irradiation time of 24 hours. The reaction was run through a plug of 
silica, concentrated and the reaction was purified by column chromatography on silica gel 






agreement with previously reported literature values. 26 1H NMR (600 MHz, CDCl3) δ 
6.79 (td, J = 7.5, 1.4 Hz, 1H), 6.76 – 6.71 (m, 2H), 6.63 (ddd, J = 7.9, 7.3, 1.7 Hz, 1H), 
3.70 (br s, 2H), 1.03 (s, 9H), 0.25 (s, 6H); 13C NMR (151 MHz, CDCl3) δ 143.05, 
138.27, 121.95, 118.61, 118.53, 115.78, 25.97, 18.38, -4.10. IR (thin film): 3445.17, 
2955.38, 2929.34, 2857.02, 1646.91, 1519.63, 1275.68, 1226.50, 923.74, 832.13. 
HRMS: Calculated for (M+H)+: 224.1470; found: 224.1464.  
 
4-phenoxyaniline (2.40a). The title compound was prepared using Method C with an 
irradiation time of 24 hours. The reaction was run through a plug of silica, concentrated 
and the reaction was purified by column chromatography on silica gel (20% 
EtOAc/Hexanes) to afford a light brown solid in 46% yield. The spectral data were in 
agreement with previously reported literature values. 27 1H NMR (600 MHz, CDCl3) δ 
7.32 - 7.26 (m, 2H), 7.05 - 6.99 (m, 1H), 6.97 - 6.92 (m, 2H), 6.92 - 6.85 (m, 2H), 6.72 - 
6.67 (m, 2H), 3.59 (br s, 2H); 13C NMR (151 MHz, CDCl3) δ 159.02, 148.72, 142.80, 
129.65, 122.19, 121.27, 117.34, 116.37. 
 
2-phenoxyaniline (2.40b). The title compound was prepared using Method C with an 
irradiation time of 24 hours. The reaction was run through a plug of silica, concentrated 
and the reaction was purified by column chromatography on silica gel (20% 
EtOAc/Hexanes) to afford a yellow in 16% yield. The spectral data were in agreement 






(m, 2H), 7.06 (tt, J = 7.3, 1.1 Hz, 1H), 7.01 – 6.95 (m, 3H), 6.88 (dd, J = 8.0, 1.4 Hz, 
1H), 6.83 (dd, J = 7.9, 1.6 Hz, 1H), 6.72 (td, J = 7.7, 1.6 Hz, 1H), 3.80 (br s, 2H); 13C 
NMR (151 MHz, CDCl3) δ 157.61, 143.19, 138.86, 129.84, 125.03, 122.76, 120.40, 
118.92, 117.23, 116.61. 
 
[1,1'-biphenyl]-4-amine (2.41a). The title compound was prepared using Method C with 
an irradiation time of 24 hours. The reaction was run through a plug of silica, 
concentrated and the reaction was purified by column chromatography on silica gel (20% 
EtOAc/Hexanes) to afford a brown crystalline solid in 42% yield. 22 1H NMR (600 MHz, 
CDCl3) δ 7.56 (d, J = 7.8 Hz, 2H), 7.48 - 7.35 (m, 4H), 7.33 - 7.24 (m, 1H), 6.78 (d, J = 
8.4 Hz, 2H), 3.74 (br s, 2H); 13C NMR (151 MHz, CDCl3) δ 145.93, 141.26, 131.68, 
128.76, 128.12, 126.51, 126.36, 115.49. 
 
[1,1'-biphenyl]-2-amine (2.41b): The title compound was prepared using Method C with 
an irradiation time of 24 hours. The reaction was run through a plug of silica, 
concentrated and the reaction was purified by column chromatography on silica gel (20% 
EtOAc/Hexanes) to afford a brown crystalline solid in 11% yield. The spectral data were 
in agreement with previously reported literature values. 22 1H NMR (600 MHz, CDCl3) δ 
7.49 – 7.42 (m, 4H), 7.38 – 7.33 (m, 1H), 7.20 – 7.12 (m, 2H), 6.84 (td, J = 7.4, 1.2 Hz, 
1H), 6.78 (dd, J = 8.0, 1.1 Hz, 1H), 3.76 (br s, 2H). 13C NMR (151 MHz, CDCl3) δ 







3-chloro-4-methoxyaniline (2.42). The title compound was prepared using Method C 
with an irradiation time of 48 hours. The reaction was run through a plug of silica, 
concentrated and the reaction was purified by column chromatography on silica gel (50% 
EtOAc/Hexanes) to afford a yellow oil in 33% yield. 1H NMR (600 MHz, CDCl3) δ 6.78 
(d, J = 8.7 Hz, 1H), 6.76 (d, J = 2.8 Hz, 1H), 6.56 (dd, J = 8.7, 2.8 Hz, 1H), 3.83 (s, 3H), 
3.47 (br s, 2H); 13C NMR (151 MHz, CDCl3) δ 148.31, 140.86, 123.32, 117.53, 114.39, 
114.15, 57.06. IR (thin film): 3421.10, 3361.32, 3219.58, 2931.27, 2835.81, 1634.38, 
1505.17, 1439.60, 1272.79, 1229.40. HRMS: Calculated for (M+H)+: 158.0373; found: 
158.0366. 	
 
1-methyl-1H-indazol-3-amine (2.43). The title compound was prepared using Method C 
with an irradiation time of 24 hours. The reaction was run through a plug of silica, 
concentrated and the reaction was purified by column chromatography on silica gel (50% 
to 70% EtOAc/Hexanes) to afford a pink-red crystalline solid in 33% yield. The spectral 
data were in agreement with previously reported literature values. 29 1H NMR (600 MHz, 
CDCl3) δ 7.55 (d, J = 8.1 Hz, 1H), 7.36 (dd, J = 8.1, 6.9 Hz, 1H), 7.22 (d, J = 8.6, 1H), 
7.03 (dd, J = 7.8, 6.9, 1H), 4.04 (br s, 2H), 3.86 (s, 3H); 13C NMR (151 MHz, CDCl3) δ 









6-methoxy-quinolin-5-amine (2.44). The title compound was prepared using Method C 
with an irradiation time of 32 hours. The reaction was run through a plug of silica, 
concentrated and the reaction was purified by column chromatography on silica gel (70% 
EtOAc/Hexanes) to afford a green solid in 36% yield. The spectral data were in 
agreement with previously reported literature values. 30 1H NMR (600 MHz, CDCl3) δ 
8.78 (dd, J = 4.1, 1.6 Hz, 1H), 8.14 (d, J = 8.6, 1H), 7.61 (d, J = 9.1, 1H), 7.45 (d, J = 9.1 
Hz, 1H), 7.32 (dd, J = 8.6, 4.1 Hz, 1H), 4.27 (br s, 2H), 4.00 (s, 3H); 13C NMR (151 
MHz, CDCl3) δ 148.38, 144.17, 142.72, 129.41, 129.11, 119.79, 119.72, 118.89, 116.52, 
56.76. 
Electrochemical Measurements  
Electrochemical half peak redox potentials (Ep/2) were estimated from cyclic 
voltammograms obtained by the method described previously (73). Measurements were 
performed in acetonitrile with tetrabutylammonium hexafluorophosphate (0.1 M) as the 
electrolyte, and the cyclic voltammograms were collected using a glassy carbon working 
electrode, a platinum wire counter electrode, and a Ag/AgCl reference electrode in 
saturated NaCl. The observed half peak potential was referenced to SCE by addition of 
30 mV to the value obtained vs. Ag/AgCl. For a typical measurement, the potential was 
increased from an initial potential of 0.5 V to a vertex potential of 2.8 V, then returning to 
a final potential of 0.5 V. With these parameters, all compounds listed in Table S4 
exhibited irreversible oxidation waves. Excited state reduction potentials for Catalysts A-





reduction potentials (Catalyst A: E1/2 = -0.47 V vs. SCE, Catalyst B: E1/2 = -0.58 V vs. 
SCE, Catalyst C: E1/2 = -0.52 V vs. SCE) and the excited state energy (E0,0) of the 
locally excited singlet state for 9- mesityl-10-methylacridinium tetrafluoroborate.  
Electrochemical Half Peak Potentials for (Ep/2) for the arenes and select amine 
nucleophiles employed  
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APPENDIX B: SUPPORTING INFORMATION FOR CHAPTER 3 
General Methods: 
Proton and carbon magnetic resonance spectra (1H NMR and 13C NMR) were recorded 
on a Bruker model DRX 400 (1H NMR at 400 MHz and 600 MHz and 13C NMR at 100 
and 151 MHz) spectrometer. Chemical shifts for protons are reported in parts per million 
downfield from tetramethylsilane and are referenced to residual protium in the solvent 
(1H NMR: CHCl3 at 7.27 ppm). Chemical shifts for carbons are reported in parts per 
million downfield from tetramethylsilane and are referenced to the carbon resonances of 
the solvent peak (13C NMR: CDCl3 at 77.16 ppm). 1H NMR data are reported as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, dd = doublet of doublets, 
ddt = doublet of doublet of triplets, ddd = doublet of doublet of doublets, dddd = doublet 
of doublet of doublet of doublets m = multiplet, brs = broad singlet), coupling constants 
(Hz), and integration. Infrared (IR) spectra were obtained using a Jasco 260 Plus Fourier 
transform infrared spectrometer.  High resolution mass spectra (HRMS) were obtained 
using a Thermo LTqFT mass spectrometer with electrospray ionization in positive mode. 
Thin layer chromatography (TLC) was performed on SiliaPlate 250 µm thick silica gel 
plates provided by Silicycle. Visualization was accomplished with short wave UV light 
(254 nm), cerium ammonium molybdate or potassium permanganate solution followed 
by heating. Flash chromatography was performed using SiliaFlash P60 silica gel (40-63 
µm) purchased from Silicycle. Unless noted all reactions were run under an atmosphere 
of oxygen in flame-dried glassware with magnetic stirring. Irradiation of photochemical 
reactions was carried out using a PAR38 blue aquarium LED lamp (Model #6851) 
fabricated with high-power Cree LEDs as purchased from Ecoxotic (www.ecoxotic.com) 
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with standard borosilicate glass vials purchased from Fischer Scientific. For all 
photolyses, reactions were stirred using a PTFE coated magnetic stir bar on a magnetic 
stir plate. Gas chromatography (GC) was performed on an Agilent 6850 series instrument 
equipped with a split- mode capillary injection system and Agilent 5973 network mass 
spec detector (MSD). Yield refers to isolated yield of analytically pure material unless 
otherwise noted. NMR yields were determined using hexamethyldisiloxane as an internal 
standard. All other reagents were obtained from commercial sources and used without 
further purification unless otherwise noted.  
Photoreactor Configuration. Reactions were irradiated using a simple photoreactor 
consisting of two Par38 Royal Blue Aquarium LED lamps (Model #6851) is shown in 
which reations (1 dram vials) are irradiated simultaneously. In order to ensure that the 
reactions are run near room temperature, a simple cooling fan was installed above the 
reactor to aid in dissipating the heat generated from high power LEDs. While a number of 
other blue LED sources are effective, we have found that LED emitters with high 
luminous flux and narrow viewing angles give the best results. 
Preparation of Acridinium Photocatalysts 
 










The title compound was prepared as previously reported by our lab.  The spectral data 
matched the values reported in the literature.1  
Preparation of Arene Substrates 
Arene substrates were purchased from commercial sources and used without further 
purification unless otherwise noted. 
 
1-allyl-2-(benzyloxy)benzene was prepared according to a published procedure; spectral 
data were in agreement with literature values.2 
 
1-(allyloxy)-3-methoxybenzene was prepared according to a published procedure; 
spectral data were in agreement with literature values.3 
 
2-methoxyphenyl 4-methylbenzenesulfonate was prepared according to a published 










(2,4-dimethoxyphenyl)(phenyl)methanone was prepared according to a published 
procedure; spectral data were in agreement with literature values.4 
 
1-methyl-1H-indazole was prepared according to a published procedure; spectral data 
were in agreement with literature values.1 
 
5-methoxybenzofuran was prepared according to a published procedure; spectral data 
were in agreement with literature values.5 
 
Methyl 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoate (gemfibrozil methyl ester) 
was prepared according to a published procedure; spectral data were in agreement with 
literature values.2 
Previously Synthesized Aryl Amination Products  
Arene products 3.2a-3.2m, 3.4a, 3.6a, 3.10a, 3.18a, 3.18b, 3.18h, 3.18i and 3.19a–19c 














General Procedure (Method A) for C–H amination (Air Conditions) 
To a 1 dram vial containing a Teflon-coated magnetic stir bar was added the arene (0.15 
mmol, 1 equiv.), 4.3 mg of acridinium tetrafluoroborate (0.0075 mmol, 0.05 equiv.), 20.4 
mg of pyrazole (0.3 mmol, 2 equiv.), and 4.7 mg of (2,2,6,6-tetramethylpiperidin-1-
yl)oxyl (0.03 mmol, 0.2 eq.). The solids were dissolved in 1,2-Dichloroethane (1.5 mL). 
The vial was sealed with a Teflon-lined septum screw cap. The vial was positioned on a 
stir plate approximately 10 cm from a Par38 LED lamp supplying blue light (λ = 440-460 
nm). After irradiation for 20 hours, the reaction mixture was concentrated in vacuo and 
purified by column chromatography on silica gel with hexanes/ethyl acetate with the 
eluent noted for each substrate.  
General Procedure (Method B) for C–H amination (Aerobic Conditions) 
To a 1 dram vial containing a Teflon-coated magnetic stir bar was added the arene (0.15 
mmol, 1 equiv.), 4.3 mg of acridinium tetrafluoroborate (0.0075 mmol, 0.05 equiv.), 20.4 
mg of pyrazole (0.3 mmol, 2 equiv.), and 4.7 mg of (2,2,6,6-tetramethylpiperidin-1-
yl)oxyl (0.03 mmol, 0.2 eq.). The solids were dissolved in 1,2-Dichloroethane (1.5 mL). 
The vial was sealed with a Teflon-lined septum screw cap. The septum was pierced with 
a disposable steel needle connected to an oxygen-filled balloon. A vent needle was 
inserted and the reaction medium was sparged for 5 minutes by bubbling oxygen through 
the mixture. The vent needle was removed, and the oxygen balloon was maintained, 
providing approximately 1 atm of oxygen to the vial headspace for the course of the 
reaction. The vial was positioned on a stir plate approximately 10 cm from a Par38 LED 
lamp supplying blue light (λ = 440-460 nm). After irradiation for 20 hours, the reaction 
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mixture was concentrated in vacuo and purified by column chromatography on silica gel 
with hexanes/ethyl acetate with the eluent noted for each substrate.  
General Procedure (Method C) for C–H amination (Anaerobic Conditions) 
To a 1 dram vial containing a Teflon-coated magnetic stir bar was added the arene (0.15 
mmol, 1 equiv.), 4.3 mg of acridinium tetrafluoroborate (0.0075 mmol, 0.05 equiv.), 20.4 
mg of pyrazole (0.3 mmol, 2 equiv.), and 23.4 mg of (2,2,6,6-tetramethylpiperidin-1-
yl)oxyl (0.15 mmol, 1.0 equiv.). The solids were dissolve in 1,2-Dichloroethane (1.5 
mL). The vial was sealed with a Teflon-lined septum screw cap. The septum was pierced 
with a disposable steel needle connected to a nitrogen line. A vent needle was inserted 
and the reaction medium was sparged for 5 minutes by bubbling nitrogen through the 
mixture. The vent needle was removed, and the nitrogen line was maintained, providing 
approximately 1 atm of nitrogen to the vial headspace for the course of the reaction. The 
vial was positioned on a stir plate approximately 10 cm from a Par38 LED lamp 
supplying blue light (λ = 440-460 nm). After irradiation for 20 hours, the reaction 
mixture was concentrated in vacuo and purified by column chromatography on silica gel 
with the eluent noted for each substrate.  
General Procedure (Method D) for C–H amination with heating 
To a 1 dram vial containing a Teflon-coated magnetic stir bar was added the arene (0.15 
mmol, 1 equiv.), 4.3 mg of acridinium tetrafluoroborate (0.0075 mmol, 0.05 equiv.), 20.4 
mg of pyrazole (0.3 mmol, 2 equiv.), and 4.7 mg of (2,2,6,6-tetramethylpiperidin-1-
yl)oxyl (0.03 mmol, 0.2 eq.). The solids were dissolved in 1,2-Dichloroethane (1.5 mL). 
The vial was sealed with a Teflon-lined septum screw cap and placed on a hot plate set to 
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50 ˚C. The vial was positioned on a stir plate approximately 10 cm from a Par38 LED 
lamp supplying blue light (λ = 440-460 nm). After irradiation for 20 hours, the reaction 
mixture was concentrated in vacuo and purified by column chromatography on silica gel 
with hexanes/ethyl acetate with the eluent noted for each substrate.  
Characterization for Aryl Amination Products. 
 
Methyl 2-methoxy-5-(1H-pyrazol-1-yl)benzoate (3.1n). The title compound was 
prepared using Method B with an irradiation time of 20 hours. The title compound was 
purified by column chromatography on silica gel (10% to 60% EtOAc/Hexanes) to give 
an orange solid in 64% yield. 
3.1n. 1H NMR (600 MHz, Chloroform-d) δ 8.10 (d, J = 2.9 Hz, 1H), 7.88 (d, J = 2.5 Hz, 
1H), 7.81 (dd, J = 9.0, 2.9 Hz, 1H), 7.70 (d, J = 1.8 Hz, 1H), 7.05 (d, J = 9.0 Hz, 1H), 
6.45 (t, J = 2.2 Hz, 1H), 3.93 (s, 3H), 3.91 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 
165.76, 157.60, 140.97, 133.27, 126.77, 124.43, 122.51, 120.34, 112.93, 107.61, 56.40, 
52.28. 
IR (thin film): 3442.31, 3144.37, 2951.52, 2840.63, 1729.83, 1591.95; HRMS (ESI): 









1-(3-allyl-4-(benzyloxy)phenyl)-1H-pyrazole (3.1o). The title compound was prepared 
using Method B with an irradiation time of 20 hours. The title compound was purified by 
column chromatography on silica gel (3% to 12% EtOAc/Hexanes) to give an orange oil 
in 71% yield.  
3.1o. 1H NMR (600 MHz, Chloroform-d) δ 7.86 (d, J = 2.4 Hz, 1H), 7.74 (d, J = 1.8 Hz, 
1H), 7.56 (d, J = 2.7 Hz, 1H), 7.51 – 7.47 (m, 3H), 7.44 (t, J = 7.6 Hz, 2H), 7.38 (t, J = 
7.3 Hz, 1H), 6.99 (d, J = 8.7 Hz, 1H), 6.47 (t, J = 2.1 Hz, 1H), 6.08 (ddt, J = 16.8, 10.0, 
6.7 Hz, 1H), 5.18 – 5.11 (m, 4H), 3.55 (d, J = 6.6 Hz, 2H). 13C NMR (151 MHz, CDCl3) 
δ 154.98, 140.61, 137.00, 136.20, 133.99, 130.28, 128.61, 127.96, 127.19, 126.89, 
121.55, 118.33, 116.33, 112.20, 107.16, 70.31, 34.53. 
IR (thin film): 3659.27, 3142.44, 2912.95, 2867.63, 2518.58, 2303.55, 1713.44; HRMS 
(ESI): Calculated for C19H19N2O [M+H]+= 291.1492 found 291.1487. 
 
1-(4-(allyloxy)-2-methoxyphenyl)-1H-pyrazole (3.1pi) and 1-(2-(allyloxy)-4-
methoxyphenyl)-1H-pyrazole (3.1pii). The title compound was prepared using Method 
B with an irradiation time of 20 hours. The title compound was purified by column 
chromatography on silica gel (3% to 12% EtOAc/Hexanes) to give an inseparable 
mixture as an orange oil in 95% yield (1.1:1; 3.1pi:3.1pii).  
3.1pi and 3.1pii. 1H NMR (600 MHz, Chloroform-d) δ 7.96 (d, J = 2.4 Hz, 1H), 7.89 (d, 
J = 2.4 Hz, 1H), 7.70 (d, J = 2.1 Hz, 1H), 7.63 – 7.60 (m, 1H), 7.55 (d, J = 8.7 Hz, 1H), 






1H), 5.49 – 5.44 (m, 1H), 5.39 – 5.32 (m, 2H), 5.28 (dd, J = 10.6, 1.8 Hz, 1H), 4.59 (dd, J 
= 5.0, 1.6 Hz, 2H), 4.57 (d, J = 5.1 Hz, 2H), 3.85 (s, 6H). 13C NMR (151 MHz, CDCl3) δ 
159.49, 158.71, 152.84, 151.56, 139.78, 139.69, 132.88, 132.48, 131.44, 131.39, 126.35, 
126.29, 123.94, 123.66, 118.06, 117.75, 105.86, 105.33, 105.03, 100.93, 100.30, 77.30, 
77.09, 76.88, 69.61, 69.13, 55.91, 55.60. 
IR (thin film): 3666.02, 3413.39, 3051.80, 2305.48, 2055.75, 1867.72, 1716.34; HRMS 
(ESI): Calculated for C13H15N2O2 [M+H]+= 231.1128 found 231.1126. 
 
1-(2,4-dimethoxyphenyl)-1H-pyrazole (3.1q). The title compound was prepared using 
Method B with an irradiation time of 20 hours. The title compound was purified by 
column chromatography on silica gel (10% to 40% EtOAc/Hexanes) to give an orange oil 
in 77% yield.  
3.1q. 1H NMR (600 MHz, Chloroform-d) δ 7.89 (d, J = 2.4 Hz, 1H), 7.70 (d, J = 1.8 Hz, 
1H), 7.56 (d, J = 8.6 Hz, 1H), 6.62 – 6.56 (m, 2H), 6.43 (t, J = 2.1 Hz, 1H), 3.86 (s, 3H), 
3.85 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 159.77, 152.89, 139.78, 131.42, 126.43, 
123.57, 105.86, 104.47, 55.92, 55.63. 
IR (thin film): 3396.03, 2951.52, 1610.27, 1590.99, 1503.24, 1397.17; HRMS (ESI): 







2-methoxy-5-(1H-pyrazol-1-yl)phenyl 4-methylbenzenesulfonate (3.1r). The title 
compound was prepared using Method B with an irradiation time of 20 hours. The title 
compound was purified by column chromatography on silica gel (25% to 45% 
EtOAc/Hexanes) to give yellow solid in 87% yield. 
3.1r. 1H NMR (600 MHz, Chloroform-d) δ 7.81 – 7.75 (m, 3H), 7.68 (d, J = 1.8 Hz, 1H), 
7.59 – 7.51 (m, 2H), 7.31 (d, J = 8.1 Hz, 2H), 6.90 (d, J = 8.9 Hz, 1H), 6.44 (t, J = 2.1 
Hz, 1H), 3.56 (s, 3H), 2.44 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 150.28, 145.37, 
141.03, 138.36, 133.57, 132.84, 129.46, 128.66, 126.79, 118.68, 115.69, 113.07, 107.72, 
55.88, 21.71. 
IR (thin film): 3136.65, 3053.73, 2850.27, 2305.48, 1927.50, 1595.81; HRMS (ESI) 
Calculated for C17H17N2O4S [M+H]+= 345.0904 found 345.0898. 
 
(2,4-dimethoxy-5-(1H-pyrazol-1-yl)phenyl)(phenyl)methanone (3.1s). The title 
compound was prepared using Method B with an irradiation time of 20 hours. The title 
compound was purified by column chromatography on silica gel (20% to 60% 
EtOAc/Hexanes) to give a yellow solid in 31% yield. 
3.1s. 1H NMR (600 MHz, Chloroform-d) δ 7.89 (d, J = 2.4 Hz, 1H), 7.82 (dd, J = 8.1, 
1.4 Hz, 2H), 7.75 (s, 1H), 7.68 (d, J = 1.8 Hz, 1H), 7.55 (td, J = 7.3, 1.3 Hz, 1H), 7.44 (t, 







NMR (151 MHz, CDCl3) δ 194.62, 158.39, 155.16, 140.10, 138.20, 132.75, 131.45, 
129.74, 128.21, 128.04, 122.93, 121.00, 106.20, 96.31, 56.27, 56.13. 
IR (thin film): 3054.69, 2976.59, 2847.38, 2304.52, 1961.25, 1788.65, 1723.09, 1645.95, 
1265.07. HRMS (ESI) Calculated for C18H17N2O3 [M+H]+= 309.1233; found 309.1230. 
             
2,4-dimethoxy-5-(1H-pyrazol-1-yl)pyridine (3.4b) and 2,4-dimethoxy-3-(1H-pyrazol-
1-yl)pyridine (3.4c). The title compounds were prepared using Method B with an 
irradiation time of 20 hours. The title compound was purified by column chromatography 
on silica gel (20% to 80% EtOAc/Hexanes) to give a yellow oil in a combined 67% yield. 
The minor regioisomer is contaminated with an inseparable byproduct. 
3.4b. 1H NMR (600 MHz, CDCl3) d = 8.27 (d, J = 1.4 Hz, 1H), 7.76 (d, J = 1.5 Hz, 1H), 
7.72 (d, J = 1.6 Hz, 1H), 6.44 (d, J = 1.9 Hz, 1H), 6.34 (d, J = 1.4 Hz, 1H), 4.01–3.96 (m, 
3H), 3.93–3.84 (m, 3H).; 13C NMR (151 MHz, CDCl3) d = 164.92, 160.83, 143.60, 
140.64, 131.68, 122.86, 106.58, 93.09, 56.11, 54.03. 
IR (thin film): 2943.80, 2854.13, 1614.13, 1540.85, 1397.17, 1209.15, 1046.19; HRMS 
(ESI): Calculated for C10H12N3O2 [M+H]+= 206.0929; found 206.09255. 
3.4c. 1H NMR (600 MHz, CDCl3) d = 8.17–8.08 (m, 1H), 7.78 (dt, J = 2.4, 1.5 Hz, 1H), 
7.51 (d, J = 2.5 Hz, 1H), 6.71–6.59 (m, 1H), 6.48–6.37 (m, 1H), 3.99–3.90 (m, 3H), 
3.86–3.81 (m, 3H).; 13C NMR (151 MHz, CDCl3) d = 162.96, 161.11, 148.16, 140.82, 
132.58, 112.65, 106.14, 102.40, 56.59, 54.46. 
IR (thin film): 2927.41, 2851.24, 1698.02, 1593.88, 1507.10, 1118.51; HRMS (ESI): 










3,5-dimethoxy-2-(1H-pyrazol-1-yl)pyridine (3.4d). The title compound was prepared 
using Method B with an irradiation time of 20 hours. The title compound was purified by 
column chromatography on silica gel (10% to 40% EtOAc/Hexanes) to give an orange oil 
in 60% yield.  
3.4d. 1H NMR (600 MHz, CDCl3) d = 8.03 (d, J = 2.5 Hz, 1H), 7.82 (d, J = 2.6 Hz, 1H), 
7.76 (d, J = 1.9 Hz, 1H), 6.94 (d, J = 2.4 Hz, 1H), 6.43 (t, J = 2.2 Hz, 1H), 3.92 (s, 3H), 
3.89 (s, 3H).; 13C NMR (151 MHz, CDCl3) d  = 156.21, 148.62, 140.94, 135.52, 130.64, 
124.92, 108.00, 106.43, 56.37, 56.29. 
IR (thin film): 2941.88, 1593.88, 1518.67, 1507.10, 1337.39, 1201.43, 1018.23; HRMS 
(ESI): Calculated for C10H12N3O2 [M+H]+= 206.0929; found 206.09210. 
 
6-methoxy-2-methyl-3-(1H-pyrazol-1-yl)pyridine (3.4e) and 2-methoxy-6-methyl-3-
(1H-pyrazol-1-yl)pyridine (3.4f). The title compounds were prepared using Method A 
with an irradiation time of 20 hours. The title compound was purified by column 
chromatography on silica gel (10% to 40% EtOAc/Hexanes) to give a yellow oil in a 
56% yield.  
3.4e and 3.4f. 1H NMR (600 MHz, CDCl3) d = 8.16 (d, J = 2.4 Hz, 1H), 7.96 (d, J = 7.8 
Hz, 1H), 7.72 (d, J = 1.8 Hz, 1H), 7.70 (d, J = 1.7 Hz, 1H), 7.55 (d, J = 2.3 Hz, 1H), 7.52 










1H), 6.43 (s, 1H), 4.04 (s, 3H), 3.97 (s, 3H), 2.49 (s, 3H), 2.33 (s, 3H).; 13C NMR (151 
MHz, CDCl3) d = 162.72, 154.06, 153.97, 152.04, 140.57, 140.35, 136.79, 132.22, 
131.03, 130.84, 129.97, 122.05, 116.27, 108.11, 106.50, 106.43, 53.75, 53.65, 23.73, 
20.64. 
IR (thin film): 2948.63, 1592.91, 1540.85, 1483.96, 1307.50, 1036.55, 753.01; HRMS 
(ESI): Calculated for C10H12N3O [M+H]+= 190.0980; found 190.09731. 
 
2-chloro-6-methoxy-5-(1H-pyrazol-1-yl)quinoline (3.6b). The title compounds were 
prepared using Method A with an irradiation time of 20 hours. The title compound was 
purified by column chromatography on silica gel (10% to 40% EtOAc/Hexanes) to give a 
white solid in 47% yield.  
3.6b. 1H NMR (600 MHz, CDCl3) d = 8.14 (dd, J = 9.4, 0.8 Hz, 1H), 7.88–7.82 (m, 1H), 
7.73–7.68 (m, 2H), 7.60 (s, 1H), 7.33 (s, 1H), 6.56 (s, 1H), 3.93 (s, 3H).; 13C NMR (151 
MHz, CDCl3) d = 152.64, 149.35, 142.84, 141.17, 134.44, 133.28, 131.04, 125.98, 
123.85, 122.70, 117.50, 106.61, 57.00. 
IR (thin film): 2936.09, 2846.42, 1585.20, 1499.38, 1288.22, 1111.76, 914.09; HRMS 












2-chloro-3-(chloromethyl)-7-methoxy-8-(1H-pyrazol-1-yl)quinoline (3.6c). The title 
compounds were prepared using Method A with an irradiation time of 20 hours. The title 
compound was purified by column chromatography on silica gel (10% to 40% 
EtOAc/Hexanes) to give a white solid in 52% yield.  
3.6c. 1H NMR (600 MHz, CDCl3) d = 8.25 (d, J = 2.8 Hz, 1H), 7.93 (d, J = 9.1 Hz, 1H), 
7.87 (t, J = 2.4 Hz, 1H), 7.70 (t, J = 2.8 Hz, 1H), 7.48 (d, J = 9.1 Hz, 1H), 6.64–6.54 (m, 
1H), 4.79 (s, 2H), 3.96 (d, J = 2.8 Hz, 3H).; 13C NMR (151 MHz, CDCl3) d = 156.94, 
151.91, 144.72, 140.74, 138.54, 133.42, 129.66, 127.74, 123.50, 122.12, 114.92, 105.99, 
57.09, 43.26. 
IR (thin film): 2943.80, 1617.02, 1558.20, 1519.63, 1496.49, 1265.07, 1044.26; HRMS 
(ESI): Calculated for C14H12Cl2N3O [M+H]+= 308.0357; found 308.03494. 
Based on 1H COSY, the peaks at 7.87, 7.70 and 6.64 ppm are correlated and are the 
protons on the pyrazole ring. The remaining peaks at 8.25, 7.93 and 7.48 ppm are a 
singlet, and two doublets, respectively, showing that functionalization occurred at the 4- 
or the 8-position. Based on HSQC, the protons for the benzylic position are at 4.79 ppm 
and correlate to the carbon at 43 ppm. Based on HMBC, the singlet in the proton at 8.25 
ppm correlates to the carbon at 43 ppm demonstrating that the 4-position is unsubstituted. 









4-chloro-8-methoxy-2-methyl-5-(1H-pyrazol-1-yl)quinoline (3.6d). The title 
compounds were prepared using Method A with an irradiation time of 20 hours. The title 
compound was purified to give a solid in 19% yield.  
3.6d. 1H NMR (400 MHz, DMSO-d6) δ = 7.92 (dd, J = 2.3, 0.6 Hz, 1H), 7.67 (dd, J = 
1.9, 0.6 Hz, 1H), 7.66 (s, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.30 (d, J = 8.4 Hz, 1H), 6.50 – 
6.46 (m, 1H), 4.03 (s, 3H), 2.64 (s, 3H).; 13C NMR (101 MHz, CDCl3) δ = 158.26, 
156.30, 141.05, 139.97, 138.85, 134.10, 128.86, 127.89, 126.20, 121.64, 108.32, 106.80, 
56.60, 24.66. HRMS (ESI): Calculated for C14H13ClN3O [M+Na]+= 274.014; found 
274.20. 
Based on 1H NMR, the presence of doublets at 7.53 and 7.30 ppm indicates 
functionalization occurred at either the 5- or 7-position on the quinoline. Based on 
NOESY correlations between the peaks at 7.30 and 4.03 ppm, the 7-position is 
unsubstituted. Therefore, functionalization occurred at the 5-position. 
 
2',5'-dimethyl-2'H-1,3'-bipyrazole (3.8b). The title compounds were prepared using 
Method B with an irradiation time of 20 hours. The title compound was purified by 
column chromatography on silica gel (10% to 50% EtOAc/Hexanes) to give a tan solid in 
34% yield by 1H NMR. The product was contaminated with an inseparable impurity. 
3.8b. 1H NMR (600 MHz, CDCl3) d = 7.77 (s, 1H), 7.62 (s, 1H), 6.46 (d, J = 2.2 Hz, 
1H), 6.08 (s, 1H), 3.79 (s, 3H), 2.29 (s, 3H).; 13C NMR (151 MHz, CDCl3) d = 142.00, 







IR (thin film): 2974.66, 1558.20, 1507.10, 1389.46, 1031.73, 931.45, 758.85; HRMS 
(ESI): Calculated for C10H11N3O [M+Na]+= 185.0803; found 185.07965. 
Based on 1H COSY, the peaks at 7.77, 7.62 and 6.46 ppm are correlated and are the 
pyrazole nucleophile peaks. The peak at 6.08 ppm is the unsubstituted position on the N-
methyl pyrazole and correlates to the peak at 99.90 ppm based on HSQC. Based on 
HMBC, the unsubstituted carbon correlates with the 3-methyl group on the pyrazole ring, 
meaning that the 4-position is unsubstituted. Therefore, functionalization occurred at the 
5-position. 
 
2',4'-dimethyl-2'H-1,3'-bipyrazole (3.8c). The title compounds were prepared using 
Method A with an irradiation time of 20 hours. The title compound was purified by 
column chromatography on silica gel (10% to 50% EtOAc/Hexanes) to give a tan solid in 
30% yield by 1H NMR. The product was contaminated with an inseparable impurity. 
3.8c. 1H NMR (600 MHz, CDCl3) d 7.81 (s, 1H), 7.58 (s, 1H), 7.37 (s, 1H), 6.51 (d, J = 
2.2 Hz, 1H), 3.69 (s, 3H), 1.96 (s, 3H).; 13C NMR (151 MHz, CDCl3) d =  142.16, 
138.72, 136.41, 131.98, 111.23, 107.32, 36.36, 7.97. 
IR (thin film): 3196.43, 2973.70, 1539.88, 1396.21, 1030.77, 932.41, 759.82; HRMS 
(ESI): Calculated for C8H11N4 [M+H]+= 163.0984; found 163.09767. 
Based on 1H COSY, the peaks at 7.81, 7.58 and 6.51 ppm are correlated and are the 
pyrazole nucleophile peaks. Based on HSQC, the peak at 7.37 ppm is the unsubstituted 
position on the N-methyl pyrazole and correlates to the carbon peak at 138.72 ppm. 






pyrazole ring; however, is not correlated to the N-methyl group, meaning that the 3-
position is unsubstituted. Therefore, functionalization occurred at the 5-position. 
 
7-bromo-1-methyl-3-(1H-pyrazol-1-yl)-1H-indazole (3.10b) and 7-bromo-1-methyl-
4-(1H-pyrazol-1-yl)-1H-indazole (3.10c). The title compounds were prepared using 
Method A with an irradiation time of 20 hours. The title compound was purified by 
column chromatography to afford the final product in a combined 55% yield by 1H NMR 
and 2.5:1 mixture of regioisomers, respectively.  
3.10b. 1H NMR (400 MHz, DMSO-d6) d = 8.42 (d, J = 2.5 Hz, 1H), 8.27 (dd, J = 8.2, 0.8 
Hz, 1H), 7.90 (d, J = 1.7 Hz, 1H), 7.75 (dd, J = 7.4, 0.8 Hz, 1H), 7.19–7.11 (m, 1H), 
6.74–6.49 (m, 1H), 4.36 (s, 3H).; 13C NMR (101 MHz, DMSO-d6) d = 141.64, 139.75, 
137.94, 132.05, 128.26, 122.63, 121.64, 116.67, 107.49, 102.39. 
3.10c. 1H NMR (400 MHz, DMSO-d6) d = 8.61 (dd, J = 2.6, 0.5 Hz, 1H), 8.58 (s, 1H), 
7.89 (d, J = 1.4 Hz, 1H), 7.72 (d, J = 8.1 Hz, 1H), 7.43 (d, J = 8.1 Hz, 1H), 6.63 (dd, J = 
2.5, 1.8 Hz, 1H), 4.39 (s, 3H).; 13C NMR (151 MHz, CDCl3) d = 141.69, 137.80, 132.65, 
132.28, 130.92, 129.25, 117.83, 111.01, 108.06, 99.42. 
IR (thin film): 2952.48, 2925.48, 1576.52, 1446.35, 1396.21, 1103.08, 734.74; HRMS 
(ESI): Calculated for C11H10BrN4 [M+H]+= 277.0090; found 277.4. 
For 3.10b, based on 1H NMR and HMBC the peaks at 8.27, 7.75 and 7.15 ppm are all 














For 3.10c, based on 1H NMR the peaks at 7.72 and 7.43 ppm are doublets, showing that 
functionalization occurred at the 4- or the 6-position. Based on HMBC, 8.61, 7.89 and 
6.63 ppm are correlated and are the pyrazole peaks. Based on NOESY, the peak at 8.61 
and 7.43 are correlated, showing that the 5-position at 7.43 ppm is not functionalized. 
Since a correlation is observed between the pyrazole protons and a proton on the indazole 
core, the 4-position is functionalized. 
 
3-(1H-pyrazol-1-yl)imidazo[1,2-b]pyridazine (3.12a). The title compounds were 
prepared using Method D with an irradiation time of 20 hours. The title compound was 
purified by column chromatography on silica gel (20% to 60% EtOAc/Hexanes) to give a 
light brown solid in 70% yield.  
3.12a. 1H NMR (400 MHz, DMSO-d6) d =  8.62 (dd, J = 4.4, 1.5 Hz, 1H), 8.35 (dd, J = 
2.5, 0.5 Hz, 1H), 8.27 (dd, J = 9.3, 1.5 Hz, 1H), 8.06 (s, 1H), 7.87 (d, J = 1.4 Hz, 1H), 
7.37 (dd, J = 9.3, 4.4 Hz, 1H), 6.63 (dd, J = 2.4, 1.9 Hz, 1H).; 13C NMR (101 MHz, 
DMSO-d6) d = 144.63, 141.69, 136.91, 132.79, 127.63, 126.46, 126.11, 118.27, 107.29. 
IR (thin film): 3113.51, 2928.38, 1584.24, 1523.49, 1290.14, 1093.44, 758.852; HRMS 
(ESI): Calculated for C9H8N5 [M+H]+= 186.0779; found 186.07729. 
Functionalization occurred at the 3-position based on carbon chemical shifts matching 








6-chloro-3-(1H-pyrazol-1-yl)imidazo[1,2-b]pyridazine (3.12b). The title compounds 
were prepared using Method D with an irradiation time of 20 hours. The title compound 
was purified by column chromatography on silica gel (20% to 60% EtOAc/Hexanes) to 
give a yellow solid in 50% yield.  
3.12b. 1H NMR (600 MHz, CDCl3) d = 8.31–8.28 (m, 1H), 8.05 (d, J = 1.4 Hz, 1H), 7.97 
(dd, J = 9.5, 1.5 Hz, 1H), 7.84 (d, J = 1.6 Hz, 1H), 7.13 (dd, J = 9.5, 1.5 Hz, 1H), 6.60–
6.55 (m, 1H).; 13C NMR (151 MHz, CDCl3) d = 148.03, 142.22, 135.68, 130.93, 127.91, 
127.55, 127.42, 119.04, 107.75. 
IR (thin film): 3100.01, 1698.02, 1575.56, 1519.63, 1304.61, 1113.69; HRMS (ESI): 
Calculated for C9H7ClN5 [M+H]+= 220.0390; found 220.03833. 
Functionalization occurred at the 3-position based on carbon chemical shifts matching 
with predicted values. 
 
6-chloro-2-phenyl-3-(1H-pyrazol-1-yl)imidazo[1,2-b]pyridazine (3.12c). The title 
compounds were prepared using Method B with an irradiation time of 20 hours. The title 
compound was purified by column chromatography on silica gel (10% to 40% 













3.12c. 1H NMR (400 MHz, DMSO-d6) d = 8.39 (d, J = 9.5 Hz, 1H), 8.18 (dd, J = 2.5, 0.5 
Hz, 1H), 8.01 (dd, J = 1.8, 0.5 Hz, 1H), 7.57 (d, J = 9.5 Hz, 1H), 7.48 (dd, J = 7.9, 1.9 
Hz, 2H), 7.41–7.34 (m, 3H), 6.72 (dd, J = 2.4, 1.9 Hz, 1H).; 13C NMR (101 MHz, 
CDCl3) d = 147.30, 142.98, 139.64, 135.54, 134.62, 131.34, 129.10, 128.89, 128.12, 
126.35, 121.52, 121.24, 108.40. 
IR (thin film): 3102.90, 3062.40, 2923.56, 1585.20, 1520.60, 1309.43, 1127.19; HRMS 
(ESI): Calculated for C15H11ClN5 [M+H]+= 296.0703; found 296.06949. 
 
8-bromo-6-chloro-3-(1H-pyrazol-1-yl)imidazo[1,2-b]pyridazine (3.12d). The title 
compounds were prepared using Method D with an irradiation time of 20 hours. The title 
compound was purified by column chromatography on silica gel (20% to 60% 
EtOAc/Hexanes) to give a yellow solid in 18% yield.  
3.12d. 1H NMR (600 MHz, CDCl3) d = 8.31 (d, J = 2.6 Hz, 1H), 8.11 (s, 1H), 7.85 (d, J 
= 1.8 Hz, 1H), 7.45 (s, 1H), 6.59 (t, J = 1.3 Hz, 1H).; 13C NMR (151 MHz, CDCl3) d = 
146.99, 142.47, 134.78, 130.86, 128.67, 127.66, 125.10, 121.13, 108.01. 
IR (thin film): 2951.52, 1670.05, 1567.84, 1507.10, 1445.70, 1251.58; HRMS (ESI): 
Calculated for C9H5BrClN5 [M+H]+= 297.9495; found 297.94890. 
Functionalization occurred at the 3-position based on carbon chemical shifts matching 










3-(1H-pyrazol-1-yl)imidazo[1,2-a]pyrimidine (3.12e). The title compounds were 
prepared using Method D with an irradiation time of 20 hours. The title compound was 
purified by column chromatography on silica gel to give a pale yellow solid in 37% yield 
by 1H NMR.  
3.12e. 1H NMR (600 MHz, DMSO-d6) d = 8.77 (dd, J = 6.9, 2.0 Hz, 1H), 8.65 (dd, J = 
4.1, 2.0 Hz, 1H), 8.28 (dd, J = 2.5, 0.5 Hz, 1H), 8.00 (s, 1H), 7.97 – 7.89 (m, 1H), 7.16 
(dd, J = 6.9, 4.1 Hz, 1H), 6.64 (dd, J = 2.4, 1.9 Hz, 1H).; 13C NMR (101 MHz, DMSO-
d6) d = 151.11, 145.47, 142.38, 133.04, 132.56, 126.99, 121.49, 109.79, 107.55. 
IR (thin film): 3100.97, 1716.34, 1652.70, 1568.81, 1540.85, 1520.60, 1021.12; HRMS 
(ESI): Calculated for C9H8N5 [M+H]+= 186.0779; found 186.07726. 
Based on HMBC, the peak at 8.00 ppm is on the 5-membered ring and correlates to 
carbon peaks at 145.47 and 126.99. If functionalization had occurred at the 2-position the 
peak at 8.00 ppm would have correlated to the peak at 132.56 ppm. Since this is not 
observed, functionalization occurred at the 3-position. 
 
3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine (3.12f). The title compounds were 









purified by column chromatography on silica gel (25% to 100% EtOAc/Hexanes) to give 
a yellow solid in 42% yield.  
3.12f. 1H NMR (600 MHz, CDCl3) d = 8.67 (dd, J = 7.1, 1.7 Hz, 1H), 8.56 (s, 1H), 8.55 
(dd, J = 4.0, 1.7 Hz, 1H), 8.41 (dd, J = 2.4, 0.6 Hz, 1H), 7.75 (d, J = 1.8 Hz, 1H), 6.89 
(dd, J = 7.1, 3.9 Hz, 1H), 6.50 (t, J = 2.1 Hz, 1H).; 13C NMR (151 MHz, CDCl3) d = 
149.55, 140.57, 138.85, 137.27, 135.45, 129.36, 114.78, 108.54, 106.97. 
IR (thin film): 3066.26, 1698.02, 1652.70, 1540.85, 1488.78, 775.24; HRMS (ESI): 
Calculated for C9H8N5 [M+H]+= 186.0779; found 186.07728. 
Functionalization occurred at the 3-position based on carbon chemical shifts matching 
with predicted values. 
 
8-bromo-6-chloro-3-(1H-pyrazol-1-yl)imidazo[1,2-a]pyridine (3.12h). The title 
compounds were prepared using Method D with an irradiation time of 20 hours. The title 
compound was purified by column chromatography on silica gel (20% to 50% 
EtOAc/Hexanes) to give a white solid in 37% yield.  
3.12h. 1H NMR (600 MHz, CDCl3) d = 8.36 (t, J = 1.7 Hz, 1H), 7.94–7.87 (m, 1H), 
7.78–7.71 (m, 2H), 7.58–7.50 (m, 1H), 6.60–6.51 (m, 1H).; 13C NMR (151 MHz, CDCl3) 
d = 143.16, 140.25, 132.29, 128.99, 127.48, 124.95, 121.33, 121.17, 112.51, 107.99. 
IR (thin film): 3106.97, 1698.02, 1670.05, 1558.20, 1507.10, 1395.25; HRMS (ESI): 







Based on 1H NMR, no doublet is observed meaning functionalization occurred at either 
the 2- or 3-position. Functionalization occurred at the 3-position based on carbon 
chemical shifts matching with predicted values. 
 
1-(5-methoxybenzofuran-2-yl)-1H-pyrazole (3.14b) and 1,1'-((2R,3R)-5-methoxy-2,3-
dihydrobenzofuran-2,3-diyl)bis(1H-pyrazole) (3.14c). The title compounds were 
prepared using Method B with an irradiation time of 20 hours. The title compound was 
purified by column chromatography on silica gel (10% to 40% EtOAc/Hexanes) to give 
yellow solids in a combined 29% yield.  
3.14b. 1H NMR (400 MHz, DMSO-d6) d = 8.40 (dd, J = 2.6, 0.5 Hz, 1H), 7.90–7.85 (m, 
1H), 7.53 (d, J = 9.0 Hz, 1H), 7.18 (d, J = 2.6 Hz, 1H), 6.90 (dd, J = 8.9, 2.7 Hz, 1H), 
6.86 (d, J = 0.8 Hz, 1H), 6.62 (dd, J = 2.6, 1.8 Hz, 1H), 3.80 (s, 3H).; 13C NMR (101 
MHz, DMSO-d6) d = 156.26, 149.52, 145.78, 142.66, 129.03, 128.88, 112.30, 111.62, 
108.29, 103.89, 90.80, 55.58. 
IR (thin film): 2924.52, 2850.27, 1634.38, 1507.10, 1418.39, 1197.58, 1030.77; HRMS 
(ESI): Calculated for C12H11N2O2 [M+H]+= 215.0820; found 215.08136. 
Based on NOESY, the peak at 6.86 and 7.18 ppm are correlated and the peak at 3.80 is 
correlated to both 7.18 and 6.90 ppm. The peak at 7.18 is at the 4-position, and based on 












3.14c. 1H NMR (600 MHz, CDCl3) d = 7.64 (d, J = 1.9 Hz, 1H), 7.64–7.60 (m, 2H), 7.37 
(d, J = 2.5 Hz, 1H), 6.91 (t, J = 1.9 Hz, 2H), 6.85 (dd, J = 2.3, 1.1 Hz, 1H), 6.64 (d, J = 
3.0 Hz, 1H), 6.51 (d, J = 3.0 Hz, 1H), 6.366.34 (m, 1H), 6.30 (t, J = 2.2 Hz, 1H), 3.75 (s, 
3H).; 13C NMR (151 MHz, CDCl3) d = 155.49, 153.30, 141.87, 141.27, 129.93, 128.69, 
123.51, 117.69, 111.38, 110.33, 107.08, 106.51, 95.74, 68.42, 56.04. 
IR (thin film): 2919.70, 1698.02, 1670.05, 1520.60, 1418.39, 1027.87; HRMS (ESI): 
Calculated for C15H15N4O2 [M+H]+= 283.1195; found 283.11891. 
 
1-(7-methoxybenzofuran-2-yl)-1H-pyrazole (3.14d). The title compounds were 
prepared using Method B with an irradiation time of 20 hours. The title compound was 
purified by column chromatography on silica gel (10% to 40% EtOAc/Hexanes) to give a 
yellow oil in 34% yield.  
3.14d. 1H NMR (400 MHz, DMSO-d6) d = 8.44 (dd, J = 2.6, 0.5 Hz, 1H), 7.96–7.88 (m, 
1H), 7.27 (d, J = 3.3 Hz, 1H), 7.26 (s, 1H), 7.02 (dd, J = 6.2, 2.9 Hz, 1H), 6.95 (s, 1H), 
6.66 (dd, J = 2.6, 1.8 Hz, 1H), 4.01 (s, 3H). 13C NMR (101 MHz, DMSO-d6) d = 148.91, 
144.69, 142.67, 139.93, 129.64, 129.25, 124.70, 113.17, 108.32, 107.10, 91.13, 55.84. 
IR (thin film): 3124.12, 2933.2, 1635.34, 1558.20, 1507.10, 1286.29, 743.42; HRMS 
(ESI): Calculated for C12H11N2O2 [M+H]+= 215.0820; found 215.08137. 
Based on 1H NMR, the peaks at 7.27, 7.26 and 7.02 ppm are correlated and the 6–
membered ring of the benzofuran. Based on NOESY, the peak at 7.26 correlates to the 









(3.14e). The title compounds were prepared using Method A with an irradiation time of 
20 hours. The title compound was purified by column chromatography on silica gel (10% 
to 40% EtOAc/Hexanes) to give a pale yellow solid in 36% yield.  
3.14e. 1H NMR (600 MHz, CDCl3) d = 7.71 (dd, J = 2.5, 0.7 Hz, 1H), 7.64–7.62 (m, 
1H), 7.60 (dd, J = 1.7, 0.7 Hz, 1H), 7.31 (d, J = 2.4 Hz, 1H), 6.97 (d, J = 8.9 Hz, 1H), 
6.92 (dd, J = 8.9, 2.7 Hz, 1H), 6.82 (d, J = 2.6 Hz, 1H), 6.68 (s, 1H), 6.32 (t, J = 2.1 Hz, 
1H), 6.24 (dd, J = 2.5, 1.7 Hz, 1H), 3.72 (s, 3H), 1.45 (s, 3H).; 13C NMR (151 MHz, 
CDCl3) d = 155.74, 152.87, 140.78, 140.46, 129.67, 126.83, 124.11, 117.73, 111.32, 
111.21, 106.49, 106.03, 102.83, 70.39, 55.98, 21.31. 
IR (thin film): 2996.84, 2939.95, 1489.74, 1399.28, 1219.76, 1029.80, 752.10; HRMS 
(ESI): Calculated for C16H17N4O2 [M+H]+= 297.1351; found 297.13447. 
 
5-methyl-2-(1H-pyrazol-1-yl)-1H-indole (3.14g). The title compounds were prepared 
using Method A with an irradiation time of 20 hours. The title compound was purified to 
give the final product in 10% yield.  
3.14g. 1H NMR (400 MHz, DMSO-d6) d = 11.71 (s, 1H), 8.44 (d, J = 2.4 Hz, 1H), 7.81 
(d, J = 1.4 Hz, 1H), 7.40–7.31 (m, 1H), 7.30 (d, J = 8.3 Hz, 1H), 7.03–6.84 (m, 1H), 













136.51, 132.69, 128.91, 128.67, 128.13, 122.99, 119.85, 111.69, 108.16, 87.43, 21.70. 
MS (ESI): Calculated for C12H12N3 [M+H]+= 197.10; found 198.20. 
Based on NOESY, the peaks at 7.30 and 6.52 are correlated meaning that the 3-position 
is unsubstituted. Therefore, functionalization occurred at the 2-position.  
 
6-methyl-2-(1H-pyrazol-1-yl)-1H-indole (3.14h). The title compounds were prepared 
using Method A with an irradiation time of 20 hours. The title compound was purified to 
give the final product in 12% yield.  
3.14h. 1H NMR (400 MHz, DMSO-d6) d = 11.74 (s, 1H), 8.43 (d, J = 2.4 Hz, 1H), 7.82 
(d, J = 1.5 Hz, 1H), 7.42 (d, J = 8.0 Hz, 1H), 7.22 (s, 1H), 6.90 (d, J = 8.0 Hz, 1H), 6.65–
6.58 (m, 1H), 6.55 (s, 1H), 2.43 (s, 3H); 13C NMR (151 MHz, CDCl3) d 141.15, 135.79, 
134.66, 130.64, 128.95, 125.59, 121.96, 119.96, 111.77, 108.16, 87.77, 21.90. MS (ESI): 
Calculated for C12H12N3 [M+H]+= 197.10; found 198.20. 
Based on NOESY, the peaks at 7.42 and 6.55 ppm are correlated meaning that the 3-
position is unsubstituted. Therefore, functionalization occurred at the 2-position.  
 
2-methyl-6-(1H-pyrazol-1-yl)benzo[d]oxazole (3.16a). The title compounds were 
prepared using Method D with an irradiation time of 20 hours. The title compound was 
purified by column chromatography on silica gel (20% to 50% EtOAc/Hexanes) to give a 












3.16a. 1H NMR (600 MHz, CDCl3) d = 7.95 (d, J = 2.8 Hz, 1H), 7.88 (d, J = 2.6 Hz, 1H), 
7.75 (d, J = 2.8 Hz, 1H), 7.68 (s, 1H), 7.65–7.52 (m, 1H), 6.61–6.46 (m, 1H), 2.75–2.50 
(m, 3H).; 13C NMR (151 MHz, CDCl3) d = 165.02, 151.48, 141.41, 140.11, 137.64, 
127.38, 119.80, 115.98, 108.02, 102.44, 14.80. 
IR (thin film): 2920.66, 2851.24, 1698.02, 1652.70, 1520.60, 1435.74; HRMS (ESI): 
Calculated for C11H10N3O [M+H]+= 200.0824; found 200.08176. 
Functionalization occurred at the 6-position based on carbon chemical shifts matching 
with predicted values. 
 
6-methoxy-7-(1H-pyrazol-1-yl)benzo[d]thiazole (3.16b). The title compounds were 
prepared using Method X with an irradiation time of 20 hours. The title compound was 
purified by column chromatography on silica gel (20% to 50% EtOAc/Hexanes) to give a 
yellow solid in 27% yield.  
3.16b. 1H NMR (600 MHz, CDCl3) d = 8.90 (s, 1H), 8.28 (dd, J = 2.5, 0.6 Hz, 1H), 8.03 
(d, J = 8.9 Hz, 1H), 7.84 – 7.78 (m, 1H), 7.32 (d, J = 8.9 Hz, 1H), 6.50 (dd, J = 2.5, 1.8 
Hz, 1H), 4.00 (s, 3H).; 13C NMR (151 MHz, CDCl3) d = 155.62, 149.16, 148.36, 139.89, 
132.25, 129.96, 123.84, 122.06, 112.68, 106.78, 57.20. 
IR (thin film): 2929.34, 2842.56, 1683.55, 1520.60, 1473.35, 1270.86, 1041.37; HRMS 








5-phenyl-4-(1H-pyrazol-1-yl)benzo[d]thiazole (3.16c). The title compounds were 
prepared using Method D with an irradiation time of 20 hours. The title compound was 
purified by column chromatography on silica gel (20% to 50% EtOAc/Hexanes) to give a 
yellow solid in 27% yield. The final product was inseparable from an impurity. 
3.16c. 1H NMR (600 MHz, CDCl3) d = 9.06 (s, 1H), 8.38 (d, J = 1.7 Hz, 1H), 8.04 (d, J = 
8.3 Hz, 1H), 8.00 (s, 1H), 7.84–7.81 (m, 2H), 7.81–7.76 (m, 3H), 7.73 (dd, J = 8.3, 1.8 
Hz, 1H), 6.53–6.50 (m, 1H).; 13C NMR (151 MHz, CDCl3) d = 154.94, 154.14, 141.40, 
139.71, 138.86, 138.76, 132.96, 128.49, 126.84, 124.99, 122.31, 121.84, 119.69, 107.95. 
IR (thin film): 1698.02, 1652.70, 1568.81, 1540.85, 1507.10, 1435.74; HRMS (ESI): 
Calculated for C16H12N3S [M+H]+= 278.07444; found 278.0752. 
 
2-chloro-1-methyl-6-(1H-pyrazol-1-yl)-1H-benzo[d]imidazole (3.16d) and 2-chloro-
1-methyl-5-(1H-pyrazol-1-yl)-1H-benzo[d]imidazole (3.16e). The title compounds 
were prepared using Method D with an irradiation time of 20 hours. The title compound 
was purified by column chromatography on silica gel (20% to 50% EtOAc/Hexanes) to 
give a pale yellow solid in 42% yield.  
3.16d and 3.16e. 1H NMR (600 MHz, CDCl3) d = 7.96 (d, J = 2.5 Hz, 1H), 7.93 (d, J = 

















7.71 (d, J = 8.6 Hz, 1H), 7.50 (dd, J = 8.7, 2.1 Hz, 1H), 7.34 (s, 0.3H), 6.49 (t, J = 2.1 Hz, 
1H), 6.48 (s, 0.3H), 3.81 (s, 4H).; 13C NMR (151 MHz, CDCl3) d = 142.33, 141.94, 
141.87, 141.21, 141.08, 140.23, 136.53, 136.47, 136.17, 134.40, 127.45, 127.38, 120.01, 
116.24, 114.56, 110.31, 110.00, 107.87, 107.65, 101.30, 30.90, 30.88. 
IR (thin film): 3116.40, 2930.31, 1683.55, 1507.10, 1473.35, 1418.39, 751.14; HRMS 
(ESI): Calculated for C11H10ClN4 [M+H]+= 233.0594; found 233.05864. 
3.16d. Functionalization occurred at the 6-position based on carbon chemical shifts 
matching with predicted values. 
3.16e. Functionalization occurred at the 5-position based on carbon chemical shifts 
matching with predicted values. 
 
3-(1H-imidazol-1-yl)-2,6-dimethoxypyridine (3.17c). The title compound was prepared 
using Method B with an irradiation time of 20 hours. The title compound was purified by 
column chromatography on silica gel (20% to 100% EtOAc/Hexanes to 5% 
MeOH/EtOAc) to give an orange oil in 52% yield. The spectral data matched the values 
reported in the literature.6 
 
1-(1,4-dimethyl-1H-pyrazol-5-yl)-1H-benzo[d]imidazole (3.17d). The title compounds 









was purified by column chromatography on silica gel (20% to 50% EtOAc/Hexanes) to 
give a yellow solid in 48% combined yield and a 6:1 ratio of regioisomers.  
3.17d. 1H NMR (600 MHz, CDCl3) d = 8.00–7.97 (m, 0.33H), 7.96–7.93 (m, 1H), 7.93–
7.88 (m, 1H), 7.83 (dq, J = 7.4, 1.6 Hz, 0.33H), 7.51 (d, J = 2.8 Hz, 1H), 7.37 (m, 3H), 
7.33–7.29 (m, 1H), 7.26 (s, 0.33H), 7.15 (dq, J = 7.6, 1.4 Hz, 1H), 4.63–4.41 (s, 1H), 
3.94–3.79 (s, 1H), 3.72–3.54 (s, 3H), 2.00–1.77 (s, 3H).; 13C NMR (151 MHz, CDCl3) d 
= 143.86, 143.42, 143.30, 142.82, 140.70, 139.44, 134.42, 133.38, 131.49, 124.68, 
123.57, 123.43, 122.93, 122.67, 120.95, 120.75, 113.40, 110.20, 109.25, 46.73, 42.24, 
36.02, 7.92. 
IR (thin film): 2928.38, 1558.20, 1507.10, 1456.96, 767.53, 745.35; HRMS (ESI): 
Calculated for C12H13N4 [M+H]+= 213.1140; found 213.11328. 
Functionalization occurred at the 5-position based on carbon chemical shifts matching 
with predicted values. 
 
1-methyl-3-(1H-1,2,3-triazol-1-yl)-1H-indazole (3.17ei) and 1-methyl-3-(2H-1,2,3-
triazol-2-yl)-1H-indazole (3.17eii). The title compound was prepared using Method B 
with an irradiation time of 20 hours. The title compound was purified by column 
chromatography on silica gel (5% to 30% EtOAc/Hexanes) to give an inseparable 













3.17ei and 3.17eii. 1H NMR (600 MHz, Chloroform-d) δ 8.36 (d, J = 1.0 Hz, 1H), 8.34 
(d, J = 8.3 Hz, 1H), 7.92 (s, 0.2H), 7.87 (d, J = 1.0 Hz, 1H), 7.50 – 7.45 (m, 1.1H), 7.39 
(d, J = 8.6 Hz, 1H), 7.28 (dd, J = 9.1, 5.9 Hz, 1.2H), 4.12 (s, 0.3H), 4.07 (s, 3H),. 13C 
NMR (151 MHz, CDCl3) δ 141.48, 141.34, 138.03, 135.64, 133.50, 127.91, 127.65, 
122.23, 122.07, 121.94, 121.90, 121.61, 114.95, 114.65, 109.20, 109.16, 77.33, 77.11, 
76.90, 35.84, 35.76. 
IR (thin film): 3429.79, 3144.37, 2951.52, 2840.63, 1729.83, 1591.95. HRMS (ESI) 
Calculated for C10H10N5 [M+Na]+= 222.0800; found 222.0750. 
 
5-(1H-benzo[d]imidazol-1-yl)-6-methoxyquinoline (3.17f). The title compound was 
prepared using Method B with an irradiation time of 20 hours. The title compound was 
purified by column chromatography on silica gel (0% to 100% (5% MeOH 
DCM)/Hexanes) to give a white solid in 62% yield. 
3.17f. 1H NMR (400 MHz, Chloroform-d) δ 8.87 (d, J = 4.2 Hz, 1H), 8.35 (d, J = 9.3 Hz, 
1H), 8.05 (s, 1H), 7.96 (d, J = 8.2 Hz, 1H), 7.71 (d, J = 9.4 Hz, 1H), 7.58 (d, J = 8.6 Hz, 
1H), 7.39 – 7.31 (m, 2H), 7.29 – 7.20 (m, 1H), 6.94 (d, J = 8.0 Hz, 1H), 3.90 (s, 3H). 13C 
NMR (151 MHz, CDCl3) δ 153.39, 149.08, 144.54, 143.44, 143.23, 135.11, 132.53, 
130.15, 126.72, 123.62, 122.69, 122.63, 120.44, 116.59, 116.40, 110.57, 56.58. 
IR (thin film): 3052.76, 2982.37, 2685.39, 2305.48, 1732.73, 1503.24, 1265.07. HRMS 







1-(5-methoxybenzofuran-2-yl)-1H-1,2,3-triazole (3.17g). The title compound was 
prepared using Method B with an irradiation time of 20 hours. The title compound was 
purified by column chromatography on silica gel (10% to 40% EtOAc/Hexanes) to give a 
white solid in 9% yield. 
3.17g. 1H NMR (600 MHz, Chloroform-d) δ 8.22 – 8.16 (m, 1H), 7.90 (t, J = 0.7 Hz, 
1H), 7.69 (d, J = 2.2 Hz, 1H), 7.57 (dt, J = 9.0, 0.7 Hz, 1H), 7.11 (d, J = 9.0 Hz, 1H), 
7.01 (dd, J = 2.2, 0.9 Hz, 1H), 3.91 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 150.27, 
147.45, 147.20, 133.00, 126.15, 124.70, 118.07, 112.25, 109.78, 106.15, 57.21. 
IR (thin film): 3165.58, 3134.72, 3054.69, 2966.95, 2929.34, 2847.38, 1719.23, 1624.73. 
HRMS (ESI) Calculated for C11H10N3O2 [M+Na]+= 238.0600 found 238.05886 
 
Methyl 5-(2,5-dimethyl-4-(1H-pyrazol-1-yl)phenoxy)-2,2-dimethylpentanoate 
(3.18d). The title compound was prepared using Method B with an irradiation time of 20 
hours. The title compound was purified by column chromatography on silica gel (10% to 
25% EtOAc/Hexanes) to give a colorless oil in 32% yield. 
3.18d. 1H NMR (600 MHz, Chloroform-d) δ 7.70 (d, J = 2.0 Hz, 1H), 7.55 (d, J = 2.4 Hz, 
1H), 7.12 (s, 1H), 6.69 (s, 1H), 6.42 (t, J = 2.1 Hz, 1H), 3.98 (t, J = 5.8 Hz, 2H), 3.70 (s, 
3H), 2.22 (s, 3H), 2.17 (s, 3H), 1.81 – 1.72 (m, 4H), 1.25 (s, 6H). 13C NMR (151 MHz, 
CDCl3) δ 178.30, 156.77, 139.89, 132.48, 132.09, 130.72, 128.41, 124.89, 112.83, 













IR (thin film): 3050.83, 2952.48, 2962.45, 2872.45, 1727.91, 1619.91, 1519.63, 1267.00. 
HRMS (ESI) Calculated for C19H27N2O3 [M+H]+= 331.2016 found 331.2015. 
Computational Data 
 All computations were carried out in the Gaussian 09 program suite7 at the 
B3LYP/6-31G+(d,p) level of theory. Population analyses (NPA atomic charges and 
molecular orbital populations) were performed using the NBO formalism. 
 Redox potentials were calculated as described previously by our lab.8 All redox 




!!"# !"#$%&' =  −346.6624 Hartree  
!!"# !"#$%& !"#$%"& = −346.4380 Hartree   
∆!!/!! = !!"# !"#$%&' − !!"# !"#$%& !"#$%"&
= −346.6624−−346.4380 Hartree





− !!/!!,!"# + !!/!!,!"#
=  −  −140.8110 kcal mol
!!
23.061 kcal mol!!V!! − 4.281 V − 0.141 V
=  !.!" ! !". !"# 
 
NPA values were calculated as specified below and were all calculated in DCE. 
Using gaussview, each compound of interest is drawn in the ground state.  
 






 The radical cation was also constructed by changing the charge on the molecule 




The optimized geometries and frequencies were calculated. Using the gaussview, 
each structure output was loaded and NPA values were determined using the following 





These values are the ground state and radical cation, respectively, and the 
difference was determined by subtracting the ground state values from the radical cation 





SI Table 1. Monosubstituted Benzenoids Computations 
 
Neutral Arene (DCE) Radical Cation (DCE) Difference (DCE)








































































































































SI Table 2. Disubstituted Benzenoids Computations 
 
  
Neutral Arene (DCE) Radical Cation (DCE) Difference (DCE)






























































































































































SI Table 3. New Benzenoid-Containing Compounds Computations 
 
 
Neutral Arene (DCE) Radical Cation (DCE) Difference (DCE)






























































































































SI Table 4. Pyridine Computations 
Neutral Arene (DCE) Radical Cation (DCE) Difference (DCE)
























































































































































SI Table 5. Quinoline Computations 
Neutral Arene (DCE) Radical Cation (DCE) Difference (DCE)















































































































































































































SI Table 6. Pyrazole Computations 
Neutral Arene (DCE) Radical Cation (DCE) Difference (DCE)














































































SI Table 7. Indazole Computations 
Neutral Arene (DCE) Radical Cation (DCE) Difference (DCE)















































































SI Table 8. Bridging-Nitrogen Polyaromatic Heterocycle Computations 
Neutral Arene (DCE) Radical Cation (DCE) Difference (DCE)







































































































































































































































SI Table 9. Benzofuran and Indole Computations 
 
Neutral Arene (DCE) Radical Cation (DCE) Difference (DCE)



























































































































































SI Table 10. Benzazole Computations 
 
Neutral Arene (DCE) Radical Cation (DCE) Difference (DCE)













































































































































































SI Table 11. Complex Molecule Computations 
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APPENDIX C: SUPPORTING INFORMATION FOR CHAPTER 4 
General Methods 
Proton and carbon magnetic resonance spectra (1H NMR and 13C NMR) were recorded on a 
Bruker model DRX 400 or a Bruker Avance III 600 CryoProbe(1H NMR at 400 MHz and 
600 MHz and 13C NMR at 100 and 151 MHz) spectrometer. Chemical shifts for protons are 
reported in parts per million downfield from tetramethylsilane and are referenced to residual 
protium in the solvent (1H NMR: CHCl3 at 7.26 ppm). Chemical shifts for carbons are 
reported in parts per million downfield from tetramethylsilane and are referenced to the 
carbon resonances of the solvent peak (13C NMR: CDCl3 at 77.16 ppm). Chemical shifts for 
fluorines are referenced to fluorobenzene as an internal standard (19F NMR: C6H5F at -113.15 
ppm). 1H NMR data are reported as follows: chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, sept = septet, oct = octet, dd = doublet of doublets, ddt = 
doublet of doublet of triplets, ddd = doublet of doublet of doublets, dddd = doublet of doublet 
of doublet of doublets, m = multiplet, and prefixed br = broad), coupling constants (Hz), and 
integration. Infrared (IR) spectra were obtained using a Jasco 260 Plus Fourier transform 
infrared spectrometer.  High resolution mass spectra (HRMS) were obtained using a Thermo 
LTqFT mass spectrometer with electrospray ionization in positive mode. Thin layer 
chromatography (TLC) was performed on SiliaPlate 250 µm thick silica gel plates provided 
by Silicycle. Visualization was accomplished with short wave UV light (254 nm), cerium 
ammonium molybdate or potassium permanganate solution followed by heating. Flash 
chromatography was performed using SiliaFlash P60 silica gel (40-63 µm) purchased from 
Silicycle. Unless noted all reactions were run under an atmosphere of oxygen with magnetic 
stirring. Irradiation of photochemical reactions was carried out using a PAR38 blue aquarium 
	 336 
LED lamp (Model #6851) fabricated with high-power Cree LEDs as purchased from 
Ecoxotic (www.ecoxotic.com) with standard borosilicate glass vials purchased from Fischer 
Scientific. For all photolyses, reactions were stirred using a PTFE coated magnetic stir bar on 
a magnetic stir plate. Gas chromatography (GC) was performed on an Agilent 6850 series 
instrument equipped with a split-mode capillary injection system and Agilent 5973 network 
mass spec detector (MSD). Yield refers to isolated yield of analytically pure material unless 
otherwise noted. NMR yields were determined using hexamethyldisiloxane as an internal 
standard. All other reagents were obtained from commercial sources and used without further 
purification unless otherwise noted.  
Photoreactor Configuration. Reactions were irradiated using a simple photoreactor 
consisting of two Par38 Royal Blue Aquarium LED lamps (Model #6851) in which reactions 
(1 dram vials) are irradiated simultaneously. In order to ensure that the reactions are run near 
room temperature, a simple cooling fan was installed above the reactor to aid in dissipating 
the heat generated from high power LEDs. While a number of other blue LED sources are 
effective, we have found that LED emitters with high luminous flux and narrow viewing 
angles give the best results. 
Photocatalyst Synthesis 











The title compound was prepared as previously reported by our lab. The spectral data 
matched the values reported in the literature.1  
 
9-Mesityl-3,6-di-tert-butyl-10-phenylacridinium tetrafluoroborate (Catalyst C). 
The title compound was prepared as previously reported by our lab.  The spectral data 
matched the values reported in the literature.2  
Preparation of Arene Substrates 
 
tert-Butyldimethyl(phenoxy)silane was prepared according to a published procedure; 
spectral data were in agreement with literature values.3  
 
tert-Butoxybenzene was prepared according to a published procedure; spectral data were in 














Triethyl(phenoxy)silane  was prepared according to a published procedure; spectral data 
were in agreement with literature values.5  
 
tert-Butyl(phenoxy)diphenylsilane  was prepared according to a published procedure; 
spectral data were in agreement with literature values.6  
 
Methyl 2-(3-phenoxyphenyl)propanoate (fenoprofen methyl ester) The title compound 
was prepared according to a published procedure; spectral data were in agreement with 
literature values.6 
 
Methyl 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoate (gemfibrozil methyl ester) The 
title compound was prepared according to a published procedure; spectral data were in 
agreement with literature values.6 
 
Methyl 2-(4-(2-(4-chlorobenzamido)ethyl)phenoxy)-2-methylpropanoate (bezafibrate 

















at 0 °C was added potassium carbonate (0.57 g, 4.1 mmol). Iodomethane (0.16 mL, 2.5 
mmol) was then added slowly and the reaction mixture allowed to warm to room 
temperature. After 16 hours, the reaction mixture was diluted with ethyl acetate (10 mL), 
washed with sodium hydrogen carbonate (1 x 15 mL of a saturated aqueous solution), water 
(2 x 15 mL) and brine (2 x 15 mL) and the organic layer dried (MgSO4) and concentrated in 
vacuo to give the title compound as a white solid (0.30 g, 96%).  
1H NMR (600 MHz, CDCl3) δ 7.61 (AA’BB’, J = 8.4 Hz, 2H), 7.38 (AA’BB’, J = 8.4 Hz, 
2H), 7.10 (AA’BB’, J = 8.4 Hz, 2H), 6.80 (AA’BB’, J = 8.4 Hz, 2H), 6.02 (brt, J = 6.6 Hz, 
1H), 3.77 (s, 3H), 3.67 (q, J = 6.6 Hz, 2H), 2.86 (t, J = 6.6 Hz, 2H), 1.59 (s, 6H). 13C NMR 
(151 MHz, CDCl3) δ 174.85, 166.51, 153.93, 137.54, 132.99, 132.58, 129.53, 128.73, 
128.39, 119.47, 79.12, 52.56, 41.35, 34.73, 25.36. 
IR (thin film): 3316.96, 2292.98, 2947.66, 1736.58, 1638.23, 1541.81, 1509.03, 1486.85, 
1289.18, 1235.18, 1141.65; HRMS (ESI): calculated for C20H22ClNO4 [M+H]+= 376.1310; 
found 376.1309. 
Reaction Conditions and Characterization 
General procedure (Method A) for C–H amination (monosubstituted arenes) 
To a 1 dram vial containing a Teflon-coated magnetic stir bar was added the arene (0.10 
mmol, 1 equiv.), 2.4 mg of Catalyst B (0.005 mmol, 0.05 equiv.) and amine coupling partner 
(0.3 mmol, 3 equiv.). When using amine hydrochloride salts, the reagents were dissolved in 
1,2-dichloroethane (0.8 mL) and 4M pH 8 phosphate aqueous buffer solution (0.2 mL). 
When using free amines, the reagents were dissolved in 1,2-dichloroethane (1.0 mL). The 
vial was sealed with a Teflon-lined septum screw cap. A vent needle was inserted and the 
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reaction medium was sparged for 5 minutes by bubbling oxygen through the mixture. The 
vent needle was removed, and the oxygen balloon was maintained, providing approximately 
1 atm of oxygen to the vial headspace for the course of the reaction.  The vial was positioned 
on a stir plate approximately 10 cm from a Par38 LED lamp supplying blue light (λ = 440-
460 nm). After irradiation for 4 hours, the reaction mixture was concentrated in vacuo and 
purified by column chromatography on silica gel with hexanes/ethyl acetate with the eluent 
noted for each substrate.  
General procedure (Method B) for C–H amination (complex arenes) 
To a 1 dram vial containing a Teflon-coated magnetic stir bar was added the arene (0.10 
mmol, 1 equiv.), 2.9 mg of Catalyst C (0.005 mmol, 0.05 equiv.), amine coupling partner 
(0.3 mmol, 3 equiv.), and 6.3 mg of (2,2,6,6-tetramethylpiperidin-1-yl)oxyl (0.04 mmol, 0.4 
eq.). The reagents were dissolved in 1,2-dichloroethane (0.8 mL) and 4M pH 8 phosphate 
aqueous buffer solution (0.2 mL). The vial was sealed with a Teflon-lined septum screw cap. 
The septum was pierced with a disposable steel needle connected to an oxygen-filled balloon. 
A vent needle was inserted and the reaction medium was sparged for 5 minutes by bubbling 
oxygen through the mixture. The vent needle was removed, and the oxygen balloon was 
maintained, providing approximately 1 atm of oxygen to the vial headspace for the course of 
the reaction. The vial was positioned on a stir plate approximately 10 cm from a Par38 LED 
lamp supplying blue light (λ = 440-460 nm). After irradiation overnight (15–26 hours), the 
reaction mixture was concentrated in vacuo and purified by column chromatography on silica 
gel with hexanes/ethyl acetate with the eluent noted for each substrate.  
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Characterization for aryl amination products 
        
Methyl 2-((2-methoxyphenyl)amino)acetate and methyl 2-((4-
methoxyphenyl)amino)acetate (4.1a). The title compound was prepared using Method A 
with an irradiation time of 4 hours. The title compound was purified by column 
chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.1a in 45% yield and a 
mixture of 1.3:1 ortho to para regioisomers. 
4.1a. 1H NMR (600 MHz, CDCl3) δ 6.86 (td, J = 7.6, 1.4 Hz, 1H), 6.79 (s, 2.5H), 6.72 (td, J 
= 7.7, 1.5 Hz, 1H), 6.59 (d, J = 8.9 Hz, 1.5H), 6.49 (dd, J = 7.8, 1.5 Hz, 1H), 4.82 (s, 1H), 
4.03 (s, 0.75H), 3.99–3.91 (m, 2H), 3.88 (s, 1.5H), 3.87 (s, 3H), 3.78 (s, 3H), 3.77 (s, 2.25H), 
3.75 (s, 2.25). 13C NMR (151 MHz, CDCl3) δ 172.03, 171.76, 152.77, 147.18, 141.29, 
137.09, 121.26, 117.65, 115.02, 114.50, 110.01, 109.70, 55.87, 55.57, 52.36, 46.78, 45.68. 
IR (thin film): 3420.14, 2952.48, 2836.77, 1748.16, 1508.06, 1249.65, 1225.54; HRMS 
(ESI): calculated for C10H14NO3 [M+H]+= 196.096820; found 196.09713. 
        
Methyl 2-((2-((tert-butyldimethylsilyl)oxy)phenyl)amino)acetate and methyl 2-((4-((tert-
butyldimethylsilyl)oxy)phenyl)amino)acetate (4.1b). The title compound was prepared 














column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.1b in 49% 
yield and a mixture of 1.8:1 para to ortho regioisomers.  
4.1b. 1H NMR (600 MHz, CDCl3) δ 6.86 (dd, J = 7.7, 1.4 Hz, 0.6H), 6.75 (dd, J = 7.8, 1.4 
Hz, 0.6H), 6.72 – 6.64 (m, 2H), 6.61 (dd, J = 7.7, 1.6 Hz, 0.6H), 6.55 – 6.44 (m, 2.6H), 4.76 
(s, 0.6H), 4.02 (s, 1H), 3.93 (d, J = 5.4 Hz, 1.2H), 3.87 (s, 2H), 3.79 (s, 1.8H), 3.77 (s, 3H), 
1.05 (s, 5.4H), 0.96 (s, 9H), 0.25 (s, 3.6H), 0.15 (s, 6H). 13C NMR (151 MHz, CDCl3) δ 
172.02, 171.59, 148.15, 142.83, 141.59, 139.16, 122.03, 120.88, 117.70, 117.42, 114.28, 
110.65, 52.35, 46.71, 45.74, 29.85, 25.94, 25.87, 25.84, 25.77, 18.35, 18.31, -4.17, -4.35. 
IR (thin film): 3411.46, 2955.38, 2929.34, 2857.99, 1748.16, 1601.59, 1513.85, 1253.50, 
1213.01; HRMS (ESI): calculated for C15H26NO3Si [M+H]+= 296.167651; found 296.16770. 
        
(S)-Methyl 2-((2-methoxyphenyl)amino)propanoate and (S)-methyl 2-((4-
methoxyphenyl)amino)propanoate (4.2a). The title compound was prepared using Method 
A with an irradiation time of 4 hours. The title compound was purified by column 
chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.2a in 62% yield and a 
mixture of 1.2:1 ortho to para regioisomers. 
4.2a. 1H NMR (600 MHz, CDCl3) δ 6.84 (dd, J = 7.6, 1.4 Hz, 0.5H), 6.79–6.73 (m, 2.5H), 
6.71 (dd, J = 7.7, 1.4 Hz, .5H), 6.63–6.53 (m, 2H), 6.51 (dd, J = 7.8, 1.4 Hz, .5H), 4.69 (d, J 










3H), 1.51 (dd, J = 7.0, 1.3 Hz, 1.5H), 1.46 (dd, J = 7.0, 1.2 Hz, 3H). 13C NMR (151 MHz, 
CDCl3) δ 175.56, 175.29, 152.86, 147.09, 140.78, 136.56, 121.25, 117.62, 115.15, 114.99, 
110.27, 109.78, 55.81, 55.55, 53.16, 52.36, 52.32, 51.78, 19.23, 19.09. 
IR (thin film): 3420.14, 2951.52, 2835.81, 1747.19, 1508.06, 1249.65, 1222.65; HRMS 
(ESI): calculated for C11H16NO3 [M+H]+= 210.112470; found 210.11263. 
        
(S)-Methyl 2-((2-((tert-butyldimethylsilyl)oxy)phenyl)amino)propanoate and (S)-methyl 
2-((4-((tert-butyldimethylsilyl)oxy)phenyl)amino)propanoate (4.2b). The title compound 
was prepared using Method A with an irradiation time of 4 hours. The title compound was 
purified by column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.2b 
in 65% yield and a mixture of 1.9:1 para to ortho regioisomers. 
4.2b. 1H NMR (600 MHz, CDCl3) δ 6.83 (td, J = 7.7, 1.4 Hz, 0.4H), 6.74 (dd, J = 7.8, 1.4 
Hz, 0.4H), 6.68 (d, J = 8.7 Hz, 2H), 6.60 (dd, J = 7.6, 1.5 Hz, 0.4H), 6.54 – 6.47 (m, 2.4H), 
4.64 (d, J = 8.5 Hz, 0.4H), 4.14 (dd, J = 8.4, 6.8 Hz, 0.4H), 4.06 (d, J = 7.1 Hz, 1H), 3.87 (s, 
1H), 3.72 (s, 1.2H), 3.71 (s, 3H), 1.48 (d, J = 6.9 Hz, 1.2H), 1.45 (d, J = 6.9 Hz, 3H), 1.04 (s, 
3.6H), 0.96 (s, 9H), 0.24 (d, J = 5.1 Hz, 2.4H), 0.14 (s, 6H). 13C NMR (151 MHz, CDCl3) δ 
175.56, 175.06, 148.25, 142.80, 141.09, 138.59, 122.05, 120.85, 117.93, 117.35, 114.90, 












IR (thin film): 3393.14, 2955.38, 2930.31, 2857.99, 1743.33, 1511.92, 1253.5, 1211.08, 
1160.94; HRMS (ESI): calculated for C16H28NO3Si [M+H]+= 310.183301; found 310.18307. 
        
(S)-Methyl 2-((2-methoxyphenyl)amino)-3-methylbutanoate and (S)-methyl 2-((4-
methoxyphenyl)amino)-3-methylbutanoate (4.3a). The title compound was prepared using 
Method A with an irradiation time of 4 hours. The title compound was purified by column 
chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.3a in 80% yield and a 
mixture of 2.2:1 ortho to para regioisomers. 
4.3a. 1H NMR (600 MHz, CDCl3) δ  6.82 (td, J = 7.6, 1.4 Hz, 1H), 6.76 (d, J = 8.9 Hz, 
2.4H), 6.68 (td, J = 7.7, 1.5 Hz, 1H), 6.65–6.58 (m, 1.4H), 6.54 (dd, J = 7.8, 1.5 Hz, 1H), 
4.73 (d, J = 9.2 Hz, 1H), 3.86 (s, 5.1H), 3.78 (s, 1), 3.74 (s, 2.1H), 3.70 (s, 3H), 3.69 (s, 
2.1H), 2.16 (dq, J = 13.3, 6.7 Hz, 1H), 2.12–2.05 (m, 0.7H), 1.10–0.96 (m, 10.2H). 13C NMR 
(151 MHz, CDCl3) δ 174.70, 174.37, 152.78, 147.15, 141.57, 137.26, 121.25, 117.32, 
115.31, 114.97, 110.22, 109.85, 63.88, 62.28, 55.84, 55.64, 51.97, 51.95, 31.72, 31.70, 19.32, 
19.29, 19.02, 18.85. 
IR (thin film): 3393.14, 2957.30, 2930.31, 2857.99, 1740.44, 1509.03, 1253.50; HRMS 










        
(S)-Methyl 2-((2-((tert-butyldimethylsilyl)oxy)phenyl)amino)-3-methylbutanoate and  
(S)-methyl 2-((4-((tert-butyldimethylsilyl)oxy)phenyl)amino)-3-methylbutanoate (4.3b). 
The title compound was prepared using Method A with an irradiation time of 4 hours. The 
title compound was purified by column chromatography on silica gel (10% to 30% 
EtOAc/Hexanes) to give 4.3b in 72% yield and a mixture of 2.1:1 para to ortho 
regioisomers. 
4.3b. 1H NMR (600 MHz, CDCl3) δ 6.82 (d, J = 1.4 Hz, 0.6H), 6.74 (dd, J = 7.9, 1.4 Hz, 
0.6H), 6.67 (d, J = 3.4 Hz, 2H), 6.57 (d, J = 1.5 Hz, 0.6H), 6.55 – 6.49 (m, 2.6H), 4.68 (dd, J 
= 9.7, 2.9 Hz, 0.6H), 3.89 (dd, J = 9.4, 5.6 Hz, 0.6H), 3.86 – 3.81 (m, 1H), 3.77 – 3.72 (m, 
1H), 3.69 (d, J = 3.7 Hz, 4.8H), 2.17 – 2.11 (m, 0.6H), 2.10 – 2.04 (m, 1H), 1.07 – 1.03 (m, 
5.4H), 1.03 – 0.99 (m, 9.6H), 0.96 (d, J = 3.3 Hz, 6H), 0.26 (d, J = 5.2 Hz, 3.6H), 0.14 (d, J = 
3.3 Hz, 6H). 13C NMR (151 MHz, CDCl3) δ 174.70, 174.08, 148.17, 142.81, 141.86, 139.25, 
121.98, 120.79, 117.77, 117.10, 115.12, 110.69, 63.85, 61.93, 51.90, 31.75, 31.70, 25.94, 
25.87, 19.31, 19.22, 18.87, 18.75, 18.34, 18.29, -4.14, -4.17, -4.35. 
IR (thin film): 3392.17, 2957.30, 2930.31, 2857.99, 1740.44, 1509.99, 1471.42, 1253.50; 










        
(S)-Methyl 2-((2-methoxyphenyl)amino)-4-methylpentanoate  and (S)-methyl 2-((4-
methoxyphenyl)amino)-4-methylpentanoate (4.4a). The title compound was prepared 
using Method A with an irradiation time of 4 hours. The title compound was purified by 
column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.4a in 81% 
yield and a mixture of 1.5:1 ortho to para regioisomers. 
4.4a. 1H NMR (600 MHz, CDCl3) δ 6.83 (td, J = 7.6, 1.3 Hz, 1H), 6.79–6.75 (m, 1.8H), 6.69 
(td, J = 7.7, 1.4 Hz, 1H), 6.60 (d, J = 8.8 Hz, 0.8H), 6.54 (dd, J = 7.9, 1.4 Hz, 1H), 4.56 (d, J 
= 9.1 Hz, 1H), 4.10 (dt, J = 9.0, 7.2 Hz, 1H), 4.01 (d, J = 7.8 Hz, 0.4H), 3.85 (s, 3H), 3.74 (d, 
J = 7.7 Hz, 1.2H), 3.69 (d, J = 5.6 Hz, 4.2H), 1.89–1.75 (m, 1.4H), 1.70 (t, J = 7.1 Hz, 2H), 
1.67–1.57 (m, 0.8H), 1.04–0.90 (m, 8.4H). 13C NMR (151 MHz, CDCl3) δ 175.69, 175.40, 
152.83, 147.08, 141.18, 136.95, 121.28, 117.50, 115.13, 114.98, 110.17, 109.80, 77.16, 
56.38, 55.81, 55.58, 54.84, 52.17, 52.13, 42.62, 42.41, 25.01, 22.93, 22.91, 22.32, 22.30. 
IR (thin film): 3394.10, 2955.38, 2870.52, 1747.19, 1515.77, 1456.96, 1245.79, 1227.47; 
HRMS (ESI): calculated for C14H22NO3 [M+H]+= 252.159420; found 252.15946. 



















(S)-Methyl 2-((2-((tert-butyldimethylsilyl)oxy)phenyl)amino)-4-methylpentanoate  and 
(S)-methyl 2-((4-((tert-butyldimethylsilyl)oxy)phenyl)amino)-4-methylpentanoate (4.4b). 
The title compound was prepared using Method A with an irradiation time of 4 hours. The 
title compound was purified by column chromatography on silica gel (10% to 30% 
EtOAc/Hexanes) to give 4.4b in 89% yield and a mixture of 2.4:1 para to ortho 
regioisomers. 
4.4b. 1H NMR (600 MHz, Chloroform-d) δ 6.86 – 6.80 (m, 0.5H), 6.74 (dd, J = 7.8, 1.4 Hz, 
0.5H), 6.68 – 6.63 (m, 2H), 6.58 (td, J = 7.7, 1.5 Hz, 0.5H), 6.52 (d, J = 8.8 Hz, 2.5H), 4.47 
(d, J = 9.3 Hz, 0.5H), 4.08 (ddd, J = 9.3, 7.8, 6.3 Hz, 0.5H), 4.00 (d, J = 7.3 Hz, 1H), 3.74 – 
3.69 (m, 1H), 3.68 (d, J = 3.6 Hz, 4.2H), 1.83 – 1.74 (m, 1H), 1.67 (dt, J = 7.9, 6.4 Hz, 0.5H), 
1.62 (td, J = 7.1, 1.6 Hz, 2.8H), 1.04 (s, 3.6H), 1.01 – 0.92 (m, 17.4H), 0.24 (d, J = 7.4 Hz, 
2.4H), 0.14 (s, 6H). 13C NMR (151 MHz, CDCl3) δ 175.69, 175.15, 148.25, 142.75, 141.48, 
138.97, 129.50, 122.07, 120.81, 120.24, 117.88, 117.30, 114.98, 110.71, 56.37, 54.79, 52.10, 
52.08, 42.66, 42.56, 25.95, 25.86, 25.82, 25.08, 24.99, 22.91, 22.89, 22.44, 22.37, 18.37, 
18.28, -4.14, -4.21, -4.35. 
IR (thin film): 3383.50, 2956.34, 2930.31, 2857.99, 1741.41, 1509.99, 1251.58; HRMS 
(ESI): calculated for C19H34NO3Si [M+H]+= 352.230251; found 352.23103. 










(2S,3S)-Methyl 2-((2-methoxyphenyl)amino)-3-methylpentanoateand (2S,3S)-methyl 2-
((4-methoxyphenyl)amino)-3-methylpentanoate (4.5a). The title compound was prepared 
using Method A with an irradiation time of 4 hours. The title compound was purified by 
column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.5a in 69% 
yield and a mixture of 2.0:1 ortho to para regioisomers. 
4.5a. 1H NMR (600 MHz, CDCl3) δ 6.83 (td, J = 7.6, 1.2 Hz, 1H), 6.81–6.72 (m, 2H), 6.73–
6.64 (m, 1H), 6.64–6.58 (m, 1H), 6.54 (dd, J = 7.8, 1.4 Hz, 1H), 4.74 (d, J = 9.2 Hz, 1H), 
3.95 (dd, J = 9.2, 6.2 Hz, 1H), 3.86 (s, 3H), 3.74 (d, J = 0.6 Hz, 1.5H), 3.70 (dd, J = 6.6, 0.6 
Hz, 3H), 3.69 (s, 3H), 1.91 (dtd, J = 8.9, 6.6, 4.4 Hz, 1H), 1.85–1.80 (m, 0.5H), 1.74–1.61 
(m, 1.5H), 1.38–1.27 (m, 2H), 1.06 ? 0.88 (m, 12H). 13C NMR (151 MHz, CDCl3) δ 174.61, 
174.28, 152.73, 147.13, 141.42, 137.12, 121.26, 117.26, 115.22, 114.98, 110.14, 109.82, 
62.56, 60.91, 55.83, 55.62, 51.92, 51.90, 38.20, 38.10, 25.83, 25.75, 15.68, 11.62. 
IR (thin film): 3395.07, 2963.09, 2935.13, 2876.31, 1738.51, 1602.56, 1514.81, 1456.96, 
1245.79, 1223.61; HRMS (ESI): calculated for C14H22NO3 [M+H]+= 252.159420; found 
252.15976. 
        
(2S,3S)-Methyl 2-((2-((tert-butyldimethylsilyl)oxy)phenyl)amino)-3-methylpentanoate 
and (2S,3S)-methyl 2-((4-((tert-butyldimethylsilyl)oxy)phenyl)amino)-3-











irradiation time of 4 hours. The title compound was purified by column chromatography on 
silica gel (10% to 30% EtOAc/Hexanes) to give 4.5b in 82% yield and a mixture of 1.7:1 
para to ortho regioisomers. 
4.5b. 1H NMR (600 MHz, CDCl3) δ 6.82 (td, J = 7.7, 1.4 Hz, 0.6H), 6.76 – 6.72 (m, 0.6H), 
6.70 – 6.65 (m, 2H), 6.58 (dd, J = 7.6, 1.5 Hz, 0.6H), 6.52 (d, J = 8.8 Hz, 2.6H), 4.70 (d, J = 
9.4 Hz, 0.6H), 3.96 (dd, J = 9.4, 5.8 Hz, 0.6H), 3.85 (s, 2H), 3.69 (d, J = 5.0 Hz, 4.8H), 1.88 
(m, 0.6H), 1.84 – 1.79 (m, 1H), 1.67 – 1.58 (m, 2H), 1.36 – 1.22 (m, 2H), 1.05 (s, 5.4H), 0.99 
– 0.92 (m, 21H), 0.25 (d, J = 6.0 Hz, 3.6H), 0.14 (s, 6H). 13C NMR (151 MHz, CDCl3) δ 
174.61, 173.97, 148.13, 142.77, 141.73, 139.09, 122.00, 120.80, 117.77, 117.04, 115.04, 
110.62, 62.53, 60.70, 51.85, 38.25, 25.93, 25.86, 25.76, 18.29, 15.69, 15.65, 11.77, 11.63, -
4.16, -4.18, -4.35, -4.36. 
IR (thin film): 3393.14, 2959.23, 2931.27, 2857.99, 1740.44, 1509.99, 1252.54; HRMS 
(ESI): calculated for C19H34NO3Si [M+H]+= 352.230251; found 352.23054. 
        
(S)-Methyl 2-((2-methoxyphenyl)amino)hexanoate  and (S)-methyl 2-((4-
methoxyphenyl)amino)hexanoate (4.6a). The title compound was prepared using Method 
A with an irradiation time of 4 hours. The title compound was purified by column 
chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.6a in 88% yield and a 










4.6a. 1H NMR (600 MHz, CDCl3) δ 6.83 (td, J = 7.6, 1.4 Hz, 1H), 6.77 (td, J = 7.5, 1.8 Hz, 
2.3H), 6.73–6.68 (m, 1H), 6.64–6.58 (m, 1.3H), 6.52 (dd, J = 7.8, 1.5 Hz, 1H), 4.67 (d, J = 
8.7 Hz, 1H), 4.05 (dt, J = 8.5, 6.6 Hz, 1H), 3.97 (s, 0.65H), 3.86 (s, 3H), 3.74 (s, 1.95H), 3.71 
(s, 3H), 3.70 (s, 1.95H), 1.94–1.84 (m, 0.6H), 1.84–1.78 (m, 1H), 1.38 (m, 0.6H), 1.48–1.30 
(m, 4H), 0.91 (t, J = 7.2 Hz, 4.95H). 13C NMR (151 MHz, CDCl3) δ 175.27, 174.99, 152.78, 
147.09, 141.13, 136.90, 121.25, 117.43, 115.11, 114.97, 110.19, 109.79, 57.87, 56.42, 55.81, 
55.57, 52.18, 52.15, 33.12, 32.97, 27.96, 27.94, 22.59, 14.05. 
IR (thin film): 3394.10, 2954.41, 2934.16, 2860.88, 1741.41, 1514.81, 1456.96, 1240.00; 
HRMS (ESI): calculated for C14H22NO3 [M+H]+= 252.159420; found 252.15978. 
        
(S)-Methyl 2-((2-((tert-butyldimethylsilyl)oxy)phenyl)amino)hexanoate and (S)-methyl 
2-((4-((tert-butyldimethylsilyl)oxy)phenyl)amino)hexanoate (4.6b). The title compound 
was prepared using Method A with an irradiation time of 4 hours. The title compound was 
purified by column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.6b 
in 89% yield and a mixture of 2.0:1 para to ortho regioisomers. 
4.6b. 1H NMR (600 MHz, CDCl3) δ 6.82 (td, J = 7.7, 1.4 Hz, 0.35H), 6.73 (dd, J = 7.9, 1.4 
Hz, 0.35H), 6.67 (d, J = 8.8 Hz, 2H), 6.58 (td, J = 7.7, 1.6 Hz, 0.35H), 6.51 (d, J = 8.7 Hz, 
2.35H), 4.60 (s, 0.35H), 4.06 (dt, J = 8.9, 6.3 Hz, 0.35H), 3.96 (d, J = 7.2 Hz, 1H), 3.81 (d, J 










1H), 1.43 – 1.31 (m, 5.5H), 1.04 (s, 3H), 0.96 (s, 9H), 0.92 – 0.88 (m, 4H), 0.25 (d, J = 6.2 
Hz, 2.1H), 0.14 (s, 6H). 13C NMR (151 MHz, CDCl3) δ 175.29, 174.73, 148.19, 142.77, 
141.45, 138.89, 122.04, 120.83, 117.84, 117.21, 114.94, 110.72, 57.86, 56.24, 52.13, 33.17, 
32.90, 27.94, 27.76, 25.95, 25.87, 22.60, 18.37, 18.30, 14.07, -4.14, -4.18, -4.34. 
IR (thin film): 3392.17, 2955.38, 2930.31, 2857.99, 1748.16, 1508.06, 1250.61; HRMS 
(ESI): calculated for C19H34NO3Si [M+H]+= 352.230251; found 352.23075. 
        
 
(S)-Methyl 2-((2-methoxyphenyl)amino)-3,3-dimethylbutanoate  and (S)-methyl 2-((4-
methoxyphenyl)amino)-3,3-dimethylbutanoate (4.7a). The title compound was prepared 
using Method A with an irradiation time of 4 hours. The title compound was purified by 
column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.7a in 48% 
yield and a mixture of 5.5:1 ortho to para regioisomers. 
4.7a. 1H NMR (600 MHz, CDCl3) δ 6.85 – 6.80 (m, 1H), 6.79 – 6.74 (m, 1.3H), 6.68 (td, J = 
7.7, 1.5 Hz, 1H), 6.63 (d, J = 8.9 Hz, 0.3H), 6.57 (dd, J = 7.9, 1.4 Hz, 1H), 4.82 (d, J = 10.1 
Hz, 1H), 3.86 (s, 3H), 3.82 (s, 1H), 3.67 (s, 4H), 1.08 (s, 9H), 1.05 (s, 2.7H). 13C NMR (151 
MHz, CDCl3) δ 174.42, 174.10, 152.89, 147.23, 141.82, 137.56, 130.22, 121.26, 117.30, 
115.64, 114.94, 110.24, 109.87, 103.70, 67.09, 65.09, 55.83, 55.70, 51.65, 51.61, 34.61, 













IR (thin film): 3394.10, 2955.38, 2870.52, 1734.66, 1602.56, 1514.81, 1456.96, 1249.65, 
1220.72; HRMS (ESI): calculated for C14H12NO3 [M+H]+= 252.159420; found 252.15970. 
        
(S)-Methyl 2-((2-((tert-butyldimethylsilyl)oxy)phenyl)amino)-3,3-dimethylbutanoate 
and (S)-methyl 2-((4-((tert-butyldimethylsilyl)oxy)phenyl)amino)-3,3-dimethylbutanoate 
(4.7b). The title compound was prepared using Method A with an irradiation time of 4 hours. 
The title compound was purified by column chromatography on silica gel (10% to 30% 
EtOAc/Hexanes) to give 4.7b in 33% yield and a mixture of 1.2:1 para to ortho 
regioisomers. 
4.7b. 1H NMR (600 MHz, CDCl3) δ 6.87 – 6.77 (m, 0.9H), 6.77 – 6.69 (m, 0.9H), 6.66 (dd, 
J = 5.5, 3.1 Hz, 2H), 6.59 – 6.51 (m, 3.6H), 4.84 – 4.74 (m, 1H), 3.94 – 3.84 (m, 1H), 3.84 – 
3.76 (m, 1H), 3.67 (tq, J = 6.2, 3.7, 2.8 Hz, 6.7H), 1.15 – 1.04 (m, 27H), 0.98 – 0.92 (m, 9H), 
0.26 (t, J = 4.8 Hz, 5.4H), 0.15 (s, 6H). 13C NMR (151 MHz, CDCl3) δ 174.42, 173.90, 
148.31, 142.89, 142.12, 139.52, 121.96, 120.77, 117.72, 117.11, 115.50, 110.74, 67.09, 
65.00, 51.58, 34.61, 34.42, 26.93, 26.89, 26.87, 25.96, 25.87, 25.84, 18.32, 18.29, -4.10, -
4.13, -4.35. 
IR (thin film): 3393.14, 2955.38, 2931.27, 2858.95, 1735.62, 1509.03, 1239.04; HRMS 













        
(S)-Ethyl 2-((2-methoxyphenyl)amino)-3-phenylpropanoate and (S)-ethyl 2-((4-
methoxyphenyl)amino)-3-phenylpropanoate (4.8a). The title compound was prepared 
using Method A with an irradiation time of 4 hours. The title compound was purified by 
column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.8a in 77% 
yield and a mixture of 1.5:1 ortho to para regioisomers. 
4.8a. 1H NMR (600 MHz, CDCl3) δ  7.31–7.27 (m, 2H), 7.25–7.22 (m, 1H), 7.22–7.18 (m, 
2H), 6.82 (td, J = 7.6, 1.4 Hz, 1H), 6.77 (dd, J = 8.0, 1.4 Hz, 1H), 6.70 (td, J = 7.7, 1.5 Hz, 
1H), 6.55 (dd, J = 7.8, 1.5 Hz, 1H), 4.78 (d, J = 8.8 Hz, 1H), 4.32 (dt, J = 8.9, 6.6 Hz, 1H), 
4.09 (qd, J = 7.1, 5.2 Hz, 2H), 3.83 (s, 3H), 3.19–3.11 (m, 2H), 1.14 (t, J = 7.1 Hz, 3H). 13C 
NMR (151 MHz, CDCl3) 173.41, 147.28, 136.75, 136.51, 129.42, 128.56, 127.00, 121.23, 
117.67, 110.60, 109.95, 61.12, 57.94, 55.64, 39.01, 14.24. 
IR (thin film): 3395.07, 2934.16, 2834.85, 1732.73, 1518.67, 1508.06, 1456.96; HRMS 
(ESI): calculated for C18H22NO3 [M+H]+= 300.159420; found 300.15964. 


















(S)-Ethyl 2-((2-((tert-butyldimethylsilyl)oxy)phenyl)amino)-3-phenylpropanoate and 
(S)-ethyl 2-((4-((tert-butyldimethylsilyl)oxy)phenyl)amino)-3-phenylpropanoate (4.8b). 
The title compound was prepared using Method A with an irradiation time of 4 hours. The 
title compound was purified by column chromatography on silica gel (10% to 30% 
EtOAc/Hexanes) to give 4.8b in 85% yield and a mixture of 1.4:1 para to ortho 
regioisomers. 
4.8b. 1H NMR (600 MHz, CDCl3) δ 7.33 – 7.20 (m, 5.1H), 7.18 (ddd, J = 18.0, 8.1, 1.4 Hz, 
3.4H), 6.84 (td, J = 7.7, 1.5 Hz, 0.7H), 6.75 (dd, J = 7.8, 1.4 Hz, 0.7H), 6.70 – 6.66 (m, 2H), 
6.64 – 6.52 (m, 1.4H), 6.52 (d, J = 2.3 Hz, 2H) 4.71 (s, 0.7H), 4.39 (d, J = 6.1 Hz, 0.7H), 
4.26 (t, J = 6.4 Hz, 1H), 4.17 – 4.06 (m, 3.4H), 3.15 (dd, J = 6.1, 4.2 Hz, 1.4H), 3.11 (d, J = 
6.4 Hz, 2H), 1.19 – 1.11 (m, 5.1H), 0.98 (d, J = 10.2 Hz, 15.3H), 0.25 – 0.21 (m, 4.2H), 0.15 
(s, 6H). 13C NMR (151 MHz, CDCl3) δ 173.59, 172.96, 148.25, 142.92, 140.95, 138.27, 
136.65, 136.52, 129.48, 129.43, 128.58, 128.53, 127.03, 126.94, 121.92, 120.82, 117.77, 
117.33, 115.18, 110.95, 61.10, 61.08, 59.03, 57.42, 39.01, 38.59, 25.94, 25.86, 18.31, 18.29, 
14.25, -4.13, -4.19, -4.36. 
IR (thin film): 3392.17, 3029.62, 2956.34, 2930.31, 2857.02, 1736.58, 1599.66, 1509.99, 
1253.50, 1195.65; HRMS (ESI): calculated for C23H34NO3Si [M+H]+= 300.230251; found 
400.23047. 









(S)-Methyl 2-((2-methoxyphenyl)amino)-4-phenylbutanoate   and (S)-methyl 2-((4-
methoxyphenyl)amino)-4-phenylbutanoate (4.9a). The title compound was prepared using 
Method A with an irradiation time of 4 hours. The title compound was purified by column 
chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.9a in 78% yield and a 
mixture of 2.0:1 ortho to para regioisomers. 
4.9a. 1H NMR (600 MHz, CDCl3) δ 7.29 (dd, J = 8.2, 6.9 Hz, 2H), 7.20 (ddd, J = 8.2, 7.1, 
1.6 Hz, 3H), 6.84–6.76 (m, 2H), 6.70 (td, J = 7.7, 1.5 Hz, 1H), 6.47 (dd, J = 7.8, 1.5 Hz, 1H), 
4.73 (d, J = 9.1 Hz, 1H), 4.09 (ddd, J = 9.1, 7.4, 5.7 Hz, 1H), 3.87 (s, 3H), 3.70 (s, 3H), 2.78 
(t, J = 7.8 Hz, 2H), 2.26–2.17 (m, 1H), 2.16–2.07 (m, 1H). 13C NMR (151 MHz, CDCl3) δ 
174.69, 147.19, 140.99, 136.77, 128.67, 128.59, 126.26, 121.26, 117.62, 110.38, 109.86, 
55.79, 55.62, 52.29, 34.72, 31.98.  
IR (thin film): 3394.10, 2950.55, 2834,85, 1733.69, 1508.06, 1250.61, 1223.61; HRMS 
(ESI): calculated for C18H22NO3 [M+H]+= 300.159420; found 300.15974. 
        
(S)-Methyl 2-((2-((tert-butyldimethylsilyl)oxy)phenyl)amino)-4-phenylbutanoate and 
(S)-methyl 2-((4-((tert-butyldimethylsilyl)oxy)phenyl)amino)-4-phenylbutanoate (4.9b). 
The title compound was prepared using Method A with an irradiation time of 4 hours. The 










EtOAc/Hexanes) to give 4.9b in 74% yield and a mixture of 2.0:1 para to ortho 
regioisomers. 
4.9b. 1H NMR (600 MHz, CDCl3) δ 7.32 – 7.28 (m, 3H), 7.23 – 7.15 (m, 4.5H), 6.86 – 6.81 
(m, .5H), 6.77 (dd, J = 7.8, 1.4 Hz, 0.5H), 6.69 – 6.66 (m, 2H), 6.61 (td, J = 7.7, 1.6 Hz, 
0.5H), 6.51 – 6.46 (m, 2.5H), 4.71 (d, J = 9.1 Hz, 0.5H), 4.11 (ddd, J = 8.9, 6.9, 5.5 Hz, 
0.5H), 4.00 (s, 1H), 3.90 – 3.84 (m, 1H), 3.70 (d, J = 2.1 Hz, 4.5H), 2.86 – 2.69 (m, 3H), 2.23 
– 2.12 (m, 1.5H), 2.04 (dd, J = 7.6, 6.1 Hz, 1.5H), 1.08 (s, 4.5H), 0.97 (s, 9H), 0.32 – 0.26 
(m, 3H), 0.16 (s, 6H). 13C NMR (151 MHz, CDCl3) δ 174.97, 174.38, 148.30, 142.88, 
141.28, 141.02, 138.73, 129.50, 128.64, 128.60, 126.26, 122.05, 120.82, 120.24, 117.91, 
117.41, 115.12, 110.86, 57.27, 55.61, 52.23, 52.21, 34.88, 31.96, 31.85, 25.98, 25.86, 18.39, 
18.29, -4.09, -4.16, -4.35. 
IR (thin film): 3392.17, 3027.69, 2953.45, 2929.34, 2857.02, 1741.41, 1509.03, 1252.54; 
HRMS (ESI): calculated for C23H34NO3Si [M+H]+= 400.230251; found 400.23108. 
        
(S)-tert-Butyl 3-(tert-butoxy)-2-((2-methoxyphenyl)amino)propanoate  and (S)-tert-Butyl 
3-(tert-butoxy)-2-((4-methoxyphenyl)amino)propanoate (4.10a). The title compound was 
prepared using Method A with an irradiation time of 4 hours. The title compound was 
purified by column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 










4.10a. 1H NMR (600 MHz, CDCl3) δ 6.81 (td, J = 7.6, 1.4 Hz, 1H), 6.80–6.73 (m, 2.9), 6.68 
(dd, J = 7.6, 1.5 Hz, 1H), 6.61 (d, J = 8.9 Hz, 1.9H), 6.55 (dd, J = 7.9, 1.5 Hz, 1H) 4.09 (d, J 
= 4.6 Hz, 1H), 3.99 (d, J = 4.0 Hz, 1H), 3.85 (d, J = 2.0 Hz, 3H), 3.74 (d, J = 5.9 Hz, 5H), 
3.69–3.58 (m, 2H), 1.44 (t, J = 5.4 Hz, 18H), 1.17 (t, J = 3.0 Hz, 18H).13C NMR (151 MHz, 
CDCl3) δ 171.71, 171.56, 152.61, 147.39, 141.34, 137.10, 121.09, 117.33, 115.37, 114.79, 
110.66, 109.82, 73.28, 73.24, 62.81, 62.72, 58.75, 57.45, 55.79, 55.58, 28.16, 27.51, 27.50. 
IR (thin film): 3396.03, 2974.66, 2933.20, 2874.38, 1739.48, 1514.81, 1366.32, 1244.83, 
1150.33; HRMS (ESI): calculated for C18H30NO4 [M+H]+= 324.216935; found 324.21793. 
        
(S)-tert-Butyl 3-(tert-butoxy)-2-((2-((tert-
butyldimethylsilyl)oxy)phenyl)amino)propanoate and (S)-tert-butyl 3-(tert-butoxy)-2-
((4-((tert-butyldimethylsilyl)oxy)phenyl)amino)propanoate (4.10b). The title compound 
was prepared using Method A with an irradiation time of 4 hours. The title compound was 
purified by column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 
4.10b in 83% yield and a mixture of 2.3:1 para to ortho regioisomers. 
4.10b. 1H NMR (600 MHz, CDCl3) δ 6.80 (td, J = 7.7, 1.4 Hz, 0.45H), 6.72 (dd, J = 7.8, 1.4 
Hz, 0.45H), 6.68 – 6.65 (m, 2H), 6.56 (td, J = 7.7, 1.5 Hz, 0.45H), 6.53 (d, J = 8.8 Hz, 
2.45H), 4.94 (d, J = 9.8 Hz, 0.45H), 4.19 (s, 1H), 4.05 (dd, J = 9.8, 3.9 Hz, 0.45H), 3.98 (t, J 
= 4.0 Hz, 1H), 3.78 (dd, J = 8.4, 3.7 Hz, 0.45H), 3.72 (dd, J = 8.5, 3.9 Hz, 1H), 3.62 (ddd, J = 










0.25 (d, J = 8.7 Hz, 2.7H), 0.13 (s, 6H). 13C NMR (151 MHz, CDCl3) δ 171.78, 171.38, 
148.00, 142.98, 141.72, 139.18, 121.77, 120.72, 117.74, 116.99, 115.23, 111.02, 81.39, 
73.24, 62.72, 62.70, 58.76, 57.38, 28.14, 27.51, 25.89, 18.38, 18.32, -4.10, -4.18, -4.36. 
IR (thin film): 3394.10, 2974.66, 2930.31, 2858.95, 1740.44, 1731.76, 1600.63, 1512.88, 
1473.35, 1391.39, 1365.35, 1250.61; HRMS (ESI): calculated for C23H42NO4Si [M+H]+= 
424.287766; found 424.28807. 
        
(2S,3R)-Methyl 3-(tert-butoxy)-2-((2-methoxyphenyl)amino)butanoate  and (2S,3R)-
methyl 3-(tert-butoxy)-2-((4-methoxyphenyl)amino)butanoate (4.11a). The title 
compound was prepared using Method A with an irradiation time of 4 hours. The title 
compound was purified by column chromatography on silica gel (10% to 30% 
EtOAc/Hexanes) to give 4.11a in 68% yield and a mixture of 1.4:1 ortho to para 
regioisomers. 
4.11a. 1H NMR (600 MHz, CDCl3) δ 6.84–6.73 (m, 4H), 6.68 (dd, J = 7.7, 1.5 Hz, 1H), 
6.63–6.53 (m, 2H), 6.43 (dd, J = 7.8, 1.5 Hz, 1H), 4.24–4.13 (m, 2H), 3.93 (d, J = 3.1 Hz, 
1H), 3.90–3.81 (m, 4H), 3.73 (s, 3H), 3.71–3.61 (m, 6H), 1.30 (dd, J = 8.8, 6.2 Hz, 6H), 
1.23–1.11 (m, 18H). 13C NMR (151 MHz, CDCl3) δ 173.69, 173.51, 152.51, 147.40, 141.87, 
137.60, 121.12, 117.20, 114.94, 114.92, 109.97, 109.92, 74.20, 74.14, 68.23, 68.20, 63.41, 










IR (thin film): 3395.07, 2975.62, 2951.52, 1749.12, 1732.73, 1515.77, 1242.90; HRMS 
(ESI): calculated for C16H26NO4 [M+H]+= 296.185635; found 296.18627. 
        
(2S,3R)-Methyl 3-(tert-butoxy)-2-((2-((tert-
butyldimethylsilyl)oxy)phenyl)amino)butanoate and (2S,3R)-methyl 3-(tert-butoxy)-2-
((4-((tert-butyldimethylsilyl)oxy)phenyl)amino)butanoate (4.11b). The title compound 
was prepared using Method A with an irradiation time of 4 hours. The title compound was 
purified by column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 
4.11b in 74% yield and a mixture of 2.4:1 para to ortho regioisomers. 
4.11b. 1H NMR (600 MHz, CDCl3) δ 6.82 – 6.77 (m, 0.4H), 6.74 (dd, J = 7.8, 1.4 Hz, 0.4H), 
6.66 (d, J = 8.7 Hz, 2H), 6.55 (td, J = 7.7, 1.5 Hz, 0.4H), 6.49 (d, J = 8.8 Hz, 2H), 6.38 (dd, J 
= 7.9, 1.5 Hz, 0.4H), 5.03 (d, J = 10.7 Hz, 0.4), 4.27 – 4.22 (m, 1.4H), 4.17 (dd, J = 6.2, 2.6 
Hz, 1H), 3.93 (dd, J = 10.7, 2.1 Hz, 0.4H), 3.82 (dd, J = 10.3, 2.6 Hz, 1H), 3.66 (d, J = 10.5 
Hz, 4.2H), 1.29 (dd, J = 8.2, 6.2 Hz, 4.2H), 1.15 (s, 9H), 1.13 (s, 3.6H), 1.05 (s, 3.6H), 0.95 
(s, 9H), 0.26 (d, J = 14.4 Hz, 2.4H), 0.14 (s, 6H). 13C NMR (151 MHz, CDCl3) δ 173.76, 
173.47, 147.86, 142.93, 142.15, 139.70, 121.88, 120.71, 118.01, 116.74, 114.75, 110.07, 
74.13, 68.28, 68.26, 63.39, 61.79, 52.02, 28.50, 28.45, 26.09, 25.88, 21.47, 21.39, 18.29, -
4.07, -4.19, -4.34. 
IR (thin film): 3395.07, 2974.66, 2955.38, 2930.31, 2857.99, 1749.12, 1732.73, 1509.03, 










        
 
(S)-Methyl 6-((tert-butoxycarbonyl)amino)-2-((2-methoxyphenyl)amino)hexanoate and 
(S)-methyl 6-((tert-butoxycarbonyl)amino)-2-((4-methoxyphenyl)amino)hexanoate 
(4.12a). The title compound was prepared using Method A with an irradiation time of 4 
hours. The title compound was purified by column chromatography on silica gel (10% to 
30% EtOAc/Hexanes) to give 4.12a in 75% yield and a mixture of 1.7:1 ortho to para 
regioisomers. 
4.12a. 1H NMR (600 MHz, CDCl3) δ 6.82 (td, J = 7.6, 1.4 Hz, 1H), 6.80–6.74 (m, 2.6H), 
6.70 (dd, J = 7.7, 1.5 Hz, 1H), 6.58 (d, J = 8.9 Hz, 2.6H), 6.51 (dd, J = 7.9, 1.5 Hz, 1H), 4.66 
(d, J = 8.3 Hz, 0.8H), 4.55 (s, 1H), 4.06 (d, J = 6.5 Hz, 1H), 3.99–3.94 (m, 0.8H), 3.85 (d, J = 
1.8 Hz, 4.2H), 3.73 (d, J = 2.0 Hz, 2.6H), 3.70 (d, J = 6.9 Hz, 5.4H), 3.17–3.06 (m, 4H), 1.88 
(ddd, J = 9.2, 4.7, 1.9 Hz, 1.4H), 1.82 (dd, J = 4.9, 3.1 Hz, 2H), 1.74 (dt, J = 9.2, 3.0 Hz, 
1.6H), 1.50 (t, J = 6.9 Hz, 4H), 1.47–1.38 (m, 18H). 13C NMR (151 MHz, CDCl3) δ 175.02, 
174.69, 156.07, 152.81, 147.10, 140.99, 136.72, 121.23, 117.57, 115.14, 114.97, 110.21, 
109.80, 79.24, 57.75, 56.26, 55.79, 55.55, 52.25, 52.21, 40.41, 40.33, 32.90, 32.78, 29.90, 










IR (thin film): 3366.14, 2974.66, 2935.13, 2864.74, 1733.69, 1715.37, 1698.02, 1515.77, 
1248.68, 1171.54; HRMS (ESI): calculated for C19H31N2O5 [M+H]+= 367.222749; found 
367.22371. 
        
(S)-Methyl 6-((tert-butoxycarbonyl)amino)-2-((2-((tert-
butyldimethylsilyl)oxy)phenyl)amino)hexanoate and methyl 6-((tert-
butoxycarbonyl)amino)-2-((4-((tert-butyldimethylsilyl)oxy)phenyl)amino)hexanoate 
(4.12b). The title compound was prepared using Method A with an irradiation time of 4 
hours. The title compound was purified by column chromatography on silica gel (10% to 
30% EtOAc/Hexanes) to give 4.12b in 62% yield and a mixture of 2.3:1 para to ortho 
regioisomers. 
4.12b. 1H NMR (600 MHz, CDCl3) δ 6.86 – 6.77 (m, 0.3H), 6.73 (dd, J = 7.9, 2.3 Hz, 0.3H), 
6.70 – 6.62 (m, 2H), 6.61 – 6.56 (m, 0.3H), 6.53 – 6.46 (m, 2.3H), 4.62 (d, J = 8.9 Hz, 0.3H), 
4.53 (d, J = 15.7 Hz, 1H), 4.10 – 4.04 (m, 0.3H), 3.95 (s, 1H), 3.85 (d, J = 11.3 Hz, 1H), 3.69 
(q, J = 3.6, 2.3 Hz, 4H), 3.11 (d, J = 7.0 Hz, 2.8H), 1.80 (d, J = 7.3 Hz, 1.6H), 1.74 (p, J = 
7.2 Hz, 1.2H), 1.53 – 1.47 (m, 2.9H), 1.47 – 1.37 (m, 15.8H), 1.04 (t, J = 2.3 Hz, 2.7H), 0.95 
(t, J = 2.3 Hz, 9H), 0.24 (dt, J = 4.7, 2.2 Hz, 2.4H), 0.14 (t, J = 2.3 Hz, 6H). 13C NMR (151 
MHz, CDCl3) δ 175.03, 174.41, 156.08, 148.24, 142.80, 141.31, 138.70, 122.03, 120.83, 
117.87, 117.36, 114.95, 110.76, 79.26, 57.72, 56.09, 52.22, 52.20, 40.35, 32.94, 29.93, 28.54, 










IR (thin film): 3366.14, 2952.48, 2930.31, 2857.99, 1733.69, 1716.34, 1698.02, 1509.03, 
1250.61; HRMS (ESI): calculated for C24H43N2O5Si [M+H]+= 467.293580; found 
467.29663. 
        
(S)-Dimethyl 2-((2-methoxyphenyl)amino)pentanedioate  and (S)-dimethyl 2-((4-
methoxyphenyl)amino)pentanedioate (4.13a). The title compound was prepared using 
Method A with an irradiation time of 4 hours. The title compound was purified by column 
chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.13a in 72% yield and a 
mixture of 1.3:1 ortho to para regioisomers. 
4.13a. 1H NMR (600 MHz, CDCl3) δ 6.82 (td, J = 7.6, 1.4 Hz, 1H), 6.79 – 6.73 (m, 2.8H), 
6.73 – 6.67 (m, 1H), 6.61 – 6.56 (m, 1.8H), 6.54 (dd, J = 7.9, 1.4 Hz, 1H), 4.71 (d, J = 9.1 
Hz, 1H), 4.25 – 4.09 (m, 1H), 4.04 (d, J = 6.8 Hz, 1H), 3.89 (d, J = 6.4 Hz, 1H), 3.85 (s, 3H), 
3.75 – 3.70 (m, 8.5H), 3.67 (d, J = 1.1 Hz, 5.5H), 2.58 – 2.44 (m, 4H), 2.26 – 2.19 (m, 1H), 
2.17 – 2.10 (m, 2H), 2.08 – 1.98 (m, 1H). 13C NMR (151 MHz, CDCl3) δ 174.37, 174.01, 
173.41, 173.30, 152.88, 147.11, 140.70, 136.45, 121.14, 117.66, 115.26, 114.87, 110.22, 
109.78, 57.13, 55.70, 55.48, 55.46, 52.31, 52.28, 51.80, 51.78, 30.22, 30.18, 28.04, 27.90. 
IR (thin film): 3383.50, 2999.73, 2952.48, 2835.81, 1735.62, 1602.56, 1515.77, 1456.96, 












        
(S)-Dimethyl 2-((2-((tert-butyldimethylsilyl)oxy)phenyl)amino)pentanedioate and (S)-
dimethyl 2-((4-((tert-butyldimethylsilyl)oxy)phenyl)amino)pentanedioate (4.13b). The 
title compound was prepared using Method A with an irradiation time of 4 hours. The title 
compound was purified by column chromatography on silica gel (10% to 30% 
EtOAc/Hexanes) to give 4.13b in 77% yield and a mixture of 2.8:1 para to ortho 
regioisomers. 
4.13b. 1H NMR (600 MHz, CDCl3) δ 6.83 (td, J = 7.7, 1.4 Hz, 0.4H), 6.74 (dd, J = 7.8, 1.4 
Hz, 0.4H), 6.70 – 6.65 (m, 2H), 6.60 (dd, J = 7.6, 1.5 Hz, 0.4H), 6.54 (dd, J = 8.0, 1.5 Hz, 
0.4H), 6.51 (d, J = 8.8 Hz, 2H), 4.69 (d, J = 8.9 Hz, 0.4H), 4.17 (dt, J = 8.9, 6.3 Hz, 0.4H), 
4.05 – 4.00 (m, 1H), 3.89 (d, J = 8.1 Hz, 1H), 3.71 (d, J = 7.7 Hz, 4.2H), 3.67 (d, J = 3.0 Hz, 
4.2H), 2.55 – 2.40 (m, 2.8H), 2.21 – 2.10 (m, 1.8H), 2.08 – 2.01 (m, 1H), 1.04 (s, 3.6H), 0.95 
(s, 9H), 0.25 (d, J = 5.5 Hz, 2.4H), 0.14 (s, 6H). 13C NMR (151 MHz, CDCl3) δ 174.47, 
173.81, 173.52, 173.35, 148.40, 142.92, 141.12, 138.49, 122.02, 120.83, 117.89, 117.57, 
115.13, 110.89, 57.15, 55.38, 52.38, 52.36, 51.90, 51.87, 30.30, 29.95, 28.17, 28.00, 25.93, 
25.85, 25.83, 18.36, 18.28, -4.13, -4.17, -4.36. 
IR (thin film): 3392.17, 2954.41, 2930.31, 2857.99, 1741.41, 1509.99, 1252.54; HRMS 










        
(S)-Dimethyl 2-((2-methoxyphenyl)amino)succinate  and (S)-dimethyl 2-((4-
methoxyphenyl)amino)succinate (4.14a). The title compound was prepared using Method 
A with an irradiation time of 4 hours. The title compound was purified by column 
chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.14a in 69% yield and a 
mixture of 1.2:1 ortho to para regioisomers. 
4.14a. 1H NMR (600 MHz, CDCl3) δ 6.88 (td, J = 7.6, 1.4 Hz, 1H), 6.81 – 6.78 (m, 2.6H), 
6.76 (dd, J = 7.7, 1.5 Hz, 1H), 6.70 – 6.63 (m, 2.6H), 5.00 (d, J = 9.1 Hz, 1H), 4.52 (dt, J = 
9.0, 6.0 Hz, 1H), 4.41 – 4.34 (m, 0.8H), 4.18 (d, J = 8.8 Hz, 0.8H), 3.87 (s, 3H), 3.77 (d, J = 
5.5 Hz, 7.6H), 3.73 (d, J = 1.4 Hz, 5.8H), 2.98 – 2.90 (m, 2H), 2.88 (d, J = 5.9 Hz, 1.6H). 13C 
NMR (151 MHz, CDCl3) δ 173.26, 172.99, 171.21, 171.12, 147.38, 140.38, 136.10, 121.23, 
118.09, 115.85, 114.97, 110.59, 110.01, 55.79, 55.63, 54.94, 53.12, 52.74, 52.71, 52.20, 
52.18, 37.50, 37.41. 
IR (thin film): 3393.14, 3001.66, 2953,45, 2836.77, 1733.69, 1515.77, 1223.61; HRMS 
(ESI): calculated for C13H18NO5 [M+H]+= 268.117949; found 268.11833. 


















(S)-Dimethyl 2-((2-((tert-butyldimethylsilyl)oxy)phenyl)amino)succinate and (S)-
dimethyl 2-((4-((tert-butyldimethylsilyl)oxy)phenyl)amino)succinate (4.14b). The title 
compound was prepared using Method A with an irradiation time of 4 hours. The title 
compound was purified by column chromatography on silica gel (10% to 30% 
EtOAc/Hexanes) to give 4.14b in 70% yield and a mixture of 2.0:1 para to ortho 
regioisomers. 
4.14b. 1H NMR (600 MHz, CDCl3) δ 6.88 – 6.83 (m, 0.3H), 6.78 – 6.72 (m, 0.3H), 6.69 (dt, 
J = 8.7, 2.3 Hz, 2H), 6.62 (d, J = 1.5 Hz, 0.6H), 6.59 – 6.56 (m, 2H), 4.92 (d, J = 8.9 Hz, 
0.3H), 4.46 (dt, J = 5.6, 2.5 Hz, 0.3H), 4.39 – 4.33 (m, 1H), 4.16 (d, J = 8.4 Hz, 1H), 3.74 
(ddd, J = 5.3, 3.3, 1.9 Hz, 3.9H), 3.71 – 3.66 (m, 3.9H), 2.96 – 2.87 (m, 0.6H), 2.85 (dt, J = 
5.1, 2.3 Hz, 2H), 1.03 (dd, J = 3.3, 1.9 Hz, 2.7H), 0.96 (dd, J = 3.3, 1.9 Hz, 9H), 0.27 – 0.18 
(m, 1.8H), 0.14 (dd, J = 3.4, 1.9 Hz, 6H). 13C NMR (151 MHz, CDCl3) δ 173.27, 172.78, 
171.23, 170.98, 148.68, 143.01, 140.69, 138.08, 122.02, 120.87, 118.03, 117.78, 115.56, 
110.83, 54.82, 52.69, 52.19, 37.50, 25.90, 25.86, 18.30, -4.35. 
IR (thin film): 3392.17, 2954.41, 2930.31, 2857.99, 1742.37, 1509.99, 1253.50; HRMS 
(ESI): calculated for C18H30NO5Si [M+H]+= 368.188780; found 368.19009. 
        
N-Isopropyl-2-methoxyaniline and N-isopropyl-4-methoxyaniline (4.15a). The title 
compound was prepared using Method A with an irradiation time of 4 hours. The title 










EtOAc/Hexanes) to give 4.15a in 53% yield by 1H NMR and a mixture of 1.2:1 ortho to para 
regioisomers. The spectral data were in agreement with literature values.7,8 
        
2-((tert-Butyldimethylsilyl)oxy)-N-isopropylaniline and 4-((tert-butyldimethylsilyl)oxy)-
N-isopropylaniline (4.15b). The title compound was prepared using Method A with an 
irradiation time of 4 hours. The title compound was purified by column chromatography on 
silica gel (10% to 30% EtOAc/Hexanes) to give 4.15b in 56% yield and a mixture of 1.8:1 
para to ortho regioisomers. 
4.15b. 1H NMR (600 MHz, CDCl3) δ 6.86 (td, J = 7.7, 1.5 Hz, 0.7H), 6.72 (dd, J = 7.8, 1.4 
Hz, 0.7H), 6.70 – 6.67 (m, 2H), 6.61 (dd, J = 7.9, 1.5 Hz, 0.7H), 6.53 (dd, J = 7.6, 1.6 Hz, 
0.7H), 6.51 – 6.46 (m, 2H), 3.60 (d, J = 6.3 Hz, 1H), 3.53 (p, J = 6.3 Hz, 1H), 1.21 (d, J = 6.3 
Hz, 4.2H), 1.18 (d, J = 6.3 Hz, 6H), 1.02 (s, 6.3H), 0.97 (s, 9H), 0.22 (s, 4.2H), 0.15 (s, 6H). 
13C NMR (151 MHz, CDCl3) δ 147.30, 142.44, 142.13, 139.58, 129.51, 122.13, 120.80, 
117.73, 115.84, 114.76, 111.07, 45.24, 43.98, 25.99, 25.90, 25.83, 23.26, 23.24, 18.39, 18.32, 
-4.15, -4.34. 
IR (thin film): 3395.07, 2958.27, 2929.34, 2857.99, 1508.06, 1254.47, 1239.04; HRMS 










        
2-Methoxy-N-propylaniline  and 4-methoxy-N-propylaniline (4.16a). The title compound 
was prepared using Method A with an irradiation time of 4 hours. The title compound was 
purified by column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 
4.16a in 56% yield and a mixture of 1.0:1 ortho to para regioisomers. The spectral data were 
in agreement with literature values.9,10 
        
2-((tert-Butyldimethylsilyl)oxy)-N-propylaniline and 4-((tert-butyldimethylsilyl)oxy)-N-
propylaniline (4.16b). The title compound was prepared using Method A with an irradiation 
time of 4 hours. The title compound was purified by column chromatography on silica gel 
(10% to 30% EtOAc/Hexanes) to give 4.16b in 61% yield and a mixture of 1.8:1 para to 
ortho regioisomers. 
4.16b. 1H NMR (600 MHz, CDCl3) δ 6.86 (td, J = 7.7, 1.4 Hz, 0.7H), 6.72 (dd, J = 7.8, 1.4 
Hz, 0.7H), 6.69 (d, J = 8.8 Hz, 2H), 6.60 (dd, J = 7.9, 1.6 Hz, 0.7H), 6.54 (td, J = 7.6, 1.6 Hz, 
0.7H), 6.51 (d, J = 8.8 Hz, 2H), 3.07 (d, J = 7.0 Hz, 1.4H), 3.02 (t, J = 7.1 Hz, 2H), 1.64 (dq, 
















0.15 (s, 6H). 13C NMR (151 MHz, CDCl3) δ 147.34, 143.22, 142.42, 140.64, 129.51, 122.12, 
120.79, 120.25, 117.43, 116.09, 113.92, 110.55, 46.88, 45.64, 25.98, 25.91, 25.83, 23.00, 
22.90, 18.38, 18.32, 11.86, 11.84, -4.15, -4.28, -4.34. 
IR (thin film): 3420.14, 2957.30, 2929.34, 2857.99, 1509.99, 1251.58; HRMS (ESI): 
calculated for C15H28NOSi [M+H]+= 266.193472; found 266.19358. 
        
N-(3-Bromopropyl)-2-methoxyaniline  and N-(3-bromopropyl)-4-methoxyaniline 
(4.17a). The title compound was prepared using Method A with an irradiation time of 4 
hours. The title compound was purified by column chromatography on silica gel (10% to 
30% EtOAc/Hexanes) to give 4.17a in 58% yield by 1H NMR and a mixture of 1.8:1 ortho to 
para regioisomers with an inseparable contaminant. 
4.17a. 1H NMR (600 MHz, CDCl3) δ 6.90 (ddd, J = 9.0, 6.8, 1.5 Hz, 1.5H), 6.87 – 6.82 (m, 
1.5H), 6.81 – 6.78 (m, 2H), 6.75 – 6.66 (m, 2H), 3.86 (d, J = 8.3 Hz, 3.5H), 3.85 – 3.76 (m, 
1.25H), 3.55 (t, J = 6.4 Hz, 2.5H), 3.38 (t, J = 6.6 Hz, 2.5H), 2.21 (p, J = 6.5 Hz, 2.5H). 13C 
NMR (151 MHz, CDCl3) δ 147.01, 137.55, 121.39, 121.32, 117.02, 115.66, 115.50, 115.25, 
110.20, 109.62, 55.83, 55.54, 41.97, 41.18, 32.14, 31.44, 30.32, 29.84. 
IR (thin film): 3394.10, 2931.27, 2849.31, 1615.09, 1507.10, 1261.22; HRMS (ESI): 







        
N-(3-Bromopropyl)-2-((tert-butyldimethylsilyl)oxy)aniline and N-(3-bromopropyl)-4-
((tert-butyldimethylsilyl)oxy)aniline (4.17b). The title compound was prepared using 
Method A with an irradiation time of 4 hours. The title compound was purified by column 
chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.17b in 56% yield by 
1H NMR and a mixture of 1.4:1 para to ortho regioisomers with an inseparable contaminant. 
4.17b. 1H NMR (600 MHz, CDCl3) δ 6.91 – 6.83 (m, 0.8H), 6.73 (dd, J = 7.8, 1.5 Hz, 1.1H), 
6.69 (s, 0.8H), 6.65 – 6.61 (m, 0.8H), 6.56 (dt, J = 6.4, 1.9 Hz, 1.4H), 3.56 – 3.47 (m, 1.8H), 
3.46 – 3.37 (m, 1.1H), 3.34 (t, J = 6.5 Hz, 2H), 3.28 (t, J = 6.6 Hz, 0.7H), 2.20 – 2.12 (m, 
2H), 1.01 (d, J = 3.7 Hz, 7H), 0.99 – 0.94 (m, 6.3H), 0.23 (d, J = 2.5 Hz, 4.8H), 0.19 – 0.16 
(m, 2.3H), 0.16 – 0.13 (m, 2H). 13C NMR (151 MHz, CDCl3) δ 142.61, 139.87, 122.15, 
122.12, 120.91, 117.61, 116.68, 114.50, 110.65, 43.39, 41.78, 32.20, 32.14, 31.41, 31.31, 
29.85, 26.04, 25.99, 25.88, 25.83, 25.80, 25.77, 18.39, 18.32, -4.11, -4.29, -4.34. 
IR (thin film): 3420.14, 2954.41, 2929.34, 2857.99, 1509.03, 1256.40; HRMS (ESI): 
calculated for C15H27NOBrSi [M+H]+= 344.103981; found 344.10511. 













N-Allyl-2-methoxyaniline and N-allyl-4-methoxyaniline (4.18a). The title compound was 
prepared using Method A with an irradiation time of 4 hours. The title compound was 
purified by column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 
4.18a in 34% yield and a mixture of 1.2:1 ortho to para regioisomers. The spectral data were 
in agreement with literature values.11 
        
N-Allyl-4-((tert-butyldimethylsilyl)oxy)aniline and N-allyl-2-((tert-
butyldimethylsilyl)oxy)aniline (4.18b). The title compound was prepared using Method A 
with an irradiation time of 4 hours. The title compound was purified by column 
chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.18b in 80% yield and 
a mixture of 2.2:1 para to ortho regioisomers. 
4.18b. 1H NMR (600 MHz, CDCl3) δ 6.90 – 6.82 (m, 0.7H), 6.75 – 6.72 (m, 0.7H), 6.69 (td, 
J = 5.9, 5.4, 2.1 Hz, 2H), 6.64 – 6.55 (m, 1.4H), 6.54 – 6.49 (m, 2H), 5.96 (dddd, J = 16.3, 
8.2, 4.9, 1.9 Hz, 1.7H), 5.28 (ddt, J = 15.5, 3.3, 1.7 Hz, 1.7H), 5.20 – 5.14 (m, 1.7H), 4.20 (s, 
0.7H), 3.78 (d, J = 5.9 Hz, 1.4H), 3.74 – 3.66 (m, 2.H), 3.49 (s, 0.7H), 1.03 – 0.99 (m, 6.3H), 
0.99 – 0.94 (m, 9H), 0.24 (d, J = 1.0 Hz, 4.2H), 0.20 – 0.09 (m, 6H). 13C NMR (151 MHz, 
CDCl3) δ 147.63, 142.68, 142.61, 140.14, 135.92, 135.68, 122.06, 120.76, 117.56, 116.64, 
116.31, 115.94, 114.22, 111.01, 47.64, 46.44, 26.00, 25.90, 18.40, 18.32, -4.10, -4.34. 
IR (thin film): 3419.17, 2955.38, 2929.34, 2857.99, 1509.99, 1250.61; HRMS (ESI): 







        
N-Benzyl-2-methoxyaniline and N-benzyl-4-methoxyaniline (4.19a). The title compound 
was prepared using Method A with an irradiation time of 4 hours. The title compound was 
purified by column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 
4.19a in 90% yield and a mixture of 1.3:1 ortho to para regioisomers. The spectral data were 
in agreement with literature values.12 
        
N-Benzyl-2-((tert-butyldimethylsilyl)oxy)aniline and N-benzyl-4-((tert-
butyldimethylsilyl)oxy)aniline (4.19b). The title compound was prepared using Method A 
with an irradiation time of 4 hours. The title compound was purified by column 
chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.19b in 70% yield and 
a mixture of 1.8:1 para to ortho regioisomers.  
4.19b para. 1H NMR (600 MHz, CDCl3) δ 7.40 – 7.36 (m, 2H), 7.34 (ddd, J = 7.8, 6.3, 1.8 
Hz, 2H), 7.28 (d, J = 7.3 Hz, 1H), 6.69 (d, J = 8.7 Hz, 2H), 6.54 (d, J = 8.8 Hz, 2H), 4.27 (s, 
2H), 0.96 (s, 9H), 0.15 (s, 6H). 13C NMR (151 MHz, CDCl3) δ 147.64, 142.88, 139.79, 















4.19b ortho. 1H NMR (600 MHz, CDCl3) δ 7.44 – 7.35 (m, 4H), 7.31 (m, 1H), 6.87 (s, 1H), 
6.79 (d, J = 7.8 Hz, 1H), 6.68 – 6.60 (m, 1H), 6.58 (dd, J = 8.7, 1.8 Hz, 1H), 4.38 (s, 2H), 
0.96 (s, 9H), 0.15 (s, 6H).  13C NMR (151 MHz, CDCl3) δ 162.14, 142.55, 140.28, 139.80, 
128.68, 127.18, 122.13, 117.59, 116.69, 110.92, 48.22, 25.90, 18.32, –4.33. 
IR (thin film): 3420.14, 3029.62, 2954.41, 2928.38, 2857.02, 1509.03, 1251.58; HRMS 
(ESI): calculated for C19H28NOSi [M+H]+= 314.193472; found 314.19364. 
        
(S)-2-Methoxy-N-(1-phenylethyl)aniline  and (S)-4-methoxy-N-(1-phenylethyl)aniline 
(4.20a). The title compound was prepared using Method A with an irradiation time of 4 
hours. The title compound was purified by column chromatography on silica gel (10% to 
30% EtOAc/Hexanes) to give 4.20a in 74% yield and a mixture of 1.4:1 ortho to para 
regioisomers. The spectral data were in agreement with literature values.13 
This reaction was conducted on 2.5 mmol scale using a flow apparatus previously described 
by our laboratory.14 A 50 mL RBF was charged with Me2-Mes-Acr+ (61 mg, 0.13 mmol), 
anisole (0.27 mL, 2.5 mmol), (S)-a-methylbenzylamine (0.97 mL, 7.5 mmol) and 1,2-
dichloroethane (25 mL). Oxygen was bubbled through the mixture for 10 minutes, then the 
vent needle was removed and a balloon of oxygen maintained in the headspace of the flask 
throughout the course of the reaction. The reaction mixture was stirred vigorously, with the 
Masterflex L/S Variable-Speed Drive set to 87.5 rpm, then the blue LED floodlamps were 










was removed under reduced pressure and the crude material purified by column 
chromatography to give 4.20a in 61% yield and a mixture of 1.4:1 ortho to para 
regioisomers. 
The racemic derivative has previously been characterized in the literature.15,16  
HPLC spectra were obtained using an Aglient 1200 series HPLC with detection at 210, 230, 
250 and 254 nm using a Chiralpak IC column using a flow rate of 1 mL per minute. The 
solvent system used for HPLC resolution of enantiomers was hexanes (A1) and isopropanol 
(B2). Using a method of 99A1:1B2 for 10 minutes, the racemic standard made through the 
present methodology was observed at 5.070 min and 5.636 min of equal area. With 
compound 4.20a, and the same HPLC conditions, one peak was observed at 5.586 min. No 
racemization of this product was observed in the reaction. 
 
 
Racemic alpha-methylbenzylamine coupled product trace               (S)-alpha-Methylbenzylamine coupled Product trace 
        
(S)-4-((tert-Butyldimethylsilyl)oxy)-N-(1-phenylethyl)aniline and (S)-2-((tert-










prepared using Method A with an irradiation time of 4 hours. The title compound was 
purified by column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 
4.20b in 90% yield and a mixture of 1.2:1 para to ortho regioisomers. 
4.20b. 1H NMR (600 MHz, CDCl3) δ 7.39 – 7.34 (m, 3.4H), 7.32 (td, J = 7.7, 1.5 Hz, 3.4H), 
7.23 (td, J = 7.1, 1.7 Hz, 1.7H), 6.73 (dd, J = 7.8, 1.4 Hz, 0.7H), 6.70 (td, J = 7.7, 1.4 Hz, 
0.7H), 6.61 (d, J = 8.8 Hz, 2H), 6.51 (td, J = 7.7, 1.6 Hz, 0.7H), 6.40 (d, J = 8.8 Hz, 2H), 
6.33 (dd, J = 7.9, 1.5 Hz, 0.7H), 4.53 (d, J = 5.1 Hz, 0.7H), 4.45 (dd, J = 6.7, 4.6 Hz, 0.7H), 
4.41 (q, J = 6.7 Hz, 1H), 3.76 (s, 1H), 1.53 (d, J = 6.7 Hz, 2.1H), 1.50 (d, J = 6.7 Hz, 3H), 
1.07 (s, 6.3H), 0.95 (s, 9H), 0.28 (d, J = 1.6 Hz, 4.2H), 0.12 (s, 6H). 13C NMR (151 MHz, 
CDCl3) δ 147.30, 145.68, 145.60, 142.26, 142.00, 139.43, 128.70, 128.69, 126.91, 126.89, 
126.04, 125.89, 122.02, 120.59, 117.46, 116.35, 114.47, 111.72, 54.38, 53.48, 26.01, 25.87, 
25.85, 25.45, 25.28, 18.41, 18.27, -4.07, -4.10, -4.36. 
IR (thin film): 3419.17, 3026.73, 2956.34, 2929.34, 2857.02, 1509.03, 1255.43; HRMS 
(ESI): calculated for C20H30NOSi [M+H]+= 328.209122; found 328.20957. 
        
N-(tert-Butyl)-2-methoxyaniline and N-(tert-butyl)-4-methoxyaniline (4.21). The title 
compound was prepared using Method A with an irradiation time of 4 hours. The title 
compound was purified by column chromatography on silica gel (10% to 30% 
EtOAc/Hexanes) to give 4.21 in 34% yield by 1H NMR and a mixture of 1.4:1 ortho to para 













(3s,5s,7s)-N-(2-Methoxyphenyl)adamantan-1-amine (4.22). The title compound was 
prepared using Method A with an irradiation time of 4 hours. The title compound was 
purified by column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.22 
in 72% yield as a single regioisomer. 
4.22. 1H NMR (600 MHz, CDCl3) δ 6.97 (dd, J = 7.9, 1.6 Hz, 1H), 6.81 (dd, J = 7.6, 1.5 Hz, 
1H), 6.80 – 6.75 (m, 1H), 6.70 (td, J = 7.7, 1.6 Hz, 1H), 4.14 – 4.07 (m, 1H), 3.83 (d, J = 3.0 
Hz, 3H), 2.15 – 2.09 (m, 3H), 1.94 (d, J = 3.1 Hz, 6H), 1.69 (t, J = 3.1 Hz, 6H). 13C NMR 
(151 MHz, CDCl3) δ 148.69, 136.04, 120.63, 117.57, 116.48, 109.91, 55.59, 51.89, 43.24, 
36.69, 29.88. 
IR (thin film): 3410,49, 2904.27, 2848.35, 1599.66, 1508.06, 1455.03, 1237.11; HRMS 
(ESI): calculated for C17H24NO [M+H]+= 258.185241; found 258.18554. 
 
(1r,3R,5S,7r)-N-(2-Methoxyphenyl)-3,5-dimethyladamantan-1-amine (4.23). The title 
compound was prepared using Method A with an irradiation time of 4 hours. The title 
compound was purified by column chromatography on silica gel (10% to 30% 







4.23. 1H NMR (600 MHz, CDCl3) δ 6.95 (dd, J = 7.9, 1.5 Hz, 1H), 6.86 – 6.79 (m, 1H), 6.77 
(dd, J = 8.0, 1.5 Hz, 1H), 6.70 (td, J = 7.7, 1.5 Hz, 1H), 4.12 (s, 1H), 3.82 (s, 3H), 2.21 – 2.15 
(m, 1H), 1.78 (dd, J = 3.1, 1.5 Hz, 2H), 1.60 (d, J = 11.9 Hz, 2H), 1.56 – 1.50 (m, 2H), 1.39 – 
1.35 (m, 2H), 1.31 (dt, J = 12.3, 2.6 Hz, 2H), 1.16 (s, 2H), 0.86 (s, 6H). 13C NMR (151 MHz, 
CDCl3) δ 148.65, 136.14, 120.65, 117.55, 116.37, 109.93, 55.60, 53.61, 50.95, 49.41, 42.98, 
41.74, 32.76, 30.53, 30.43. 
IR (thin film): 3335.28, 2942.84, 2899.45, 2840.63, 1519.63, 1508.06, 1233.25; HRMS 
(ESI): calculated for C19H28NO [M+H]+= 286.216541; found 286.21658. 
 
N-(1-((3r,5r,7r)-Adamantan-1-yl)ethyl)-2-methoxyaniline (4.24). The title compound was 
prepared using Method A with an irradiation time of 4 hours. The title compound was 
purified by column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.24 
in 45% yield as a single regioisomer. 
4.24. 1H NMR (600 MHz, CDCl3) δ 6.95 (dd, J = 7.9, 1.6 Hz, 1H), 6.81 (td, J = 7.6, 1.5 Hz, 
1H), 6.77 (dd, J = 8.0, 1.5 Hz, 1H), 6.70 (ddd, J = 8.0, 7.4, 1.6 Hz, 1H), 4.12 (s, 1H), 3.82 (s, 
3H), 2.17 (p, J = 3.2 Hz, 1H), 1.78 (dd, J = 3.3, 1.5 Hz, 2H), 1.60 (dt, J = 12.0, 1.2 Hz, 2H), 
1.55 – 1.51 (m, 2H), 1.39 – 1.34 (m, 2H), 1.33 – 1.27 (m, 2H), 1.16 (q, J = 1.2 Hz, 2H), 0.86 
(s, 6H). 13C NMR (151 MHz, CDCl3) δ 148.65, 136.15, 120.65, 117.55, 116.37, 109.94, 




IR (thin film): 3420.14, 2942.84, 2898.49, 2839.67, 1519.63, 1508.06, 1455.99, 1233.25; 
HRMS (ESI): calculated for C19H28NO [M+H]+= 286.216541; found 286.21642. 
 
Methyl 2-(1-(((2-methoxyphenyl)amino)methyl)cyclohexyl)acetate (4.25). The title 
compound was prepared using Method A with an irradiation time of 4 hours. The title 
compound was purified by column chromatography on silica gel (10% to 30% 
EtOAc/Hexanes) to give 4.25 in 34% yield and a mixture of 1.2:1 ortho to para 
regioisomers. 
4.25. 1H NMR (600 MHz, CDCl3) δ 6.85 (td, J = 7.7, 1.4 Hz, 1H), 6.75 (dd, J = 7.9, 1.3 Hz, 
1H), 6.69 (dd, J = 7.9, 1.5 Hz, 1H), 6.62 (td, J = 7.7, 1.5 Hz, 1H), 4.45 (s, 1H), 3.85 (s, 3H), 
3.69 – 3.61 (m, 3H), 3.16 (s, 2H), 2.45 (s, 2H), 1.53 (t, J = 7.5 Hz, 6H), 1.49 – 1.44 (m, 3H), 
1.37 (d, J = 8.1 Hz, 1H). 13C NMR (151 MHz, CDCl3) δ 173.04, 146.84, 139.14, 121.35, 
115.93, 109.91, 109.55, 55.61, 51.45, 37.98, 34.20, 26.18, 21.75. 
IR (thin film): 3421.10, 2927.41, 2854.13, 1732.73, 1698.02, 1601.59, 1521.56, 1456.96, 












N-(1-(2,6-Dimethylphenoxy)propan-2-yl)-2-methoxyaniline (4.26). The title compound 
was prepared using Method A with an irradiation time of 4 hours. The title compound was 
purified by column chromatography on silica gel (10% to 30% EtOAc/Hexanes) to give 4.26 
in 41% yield as a single regioisomer. 
4.26. 1H NMR (600 MHz, CDCl3) δ 6.99 (d, J = 7.4 Hz, 2H), 6.91 (t, J = 7.5 Hz, 1H), 6.87 
(td, J = 7.6, 1.1 Hz, 1H), 6.78 (dd, J = 7.9, 1.3 Hz, 1H), 6.74 – 6.61 (m, 1H), 6.67–6.65 (m, 
1H), 4.59 (d, J = 7.8 Hz, 1H), 3.92 – 3.87 (m, 1H), 3.87 – 3.82 (m, 4H), 3.77 (dd, J = 8.8, 5.2 
Hz, 1H), 2.26 (s, 6H), 1.50 – 1.43 (m, 3H). 13C NMR (151 MHz, CDCl3) δ 155.38, 155.32, 
152.34, 147.13, 141.42, 137.22, 131.05, 131.01, 129.04, 129.00, 128.36, 124.05, 123.99, 
121.34, 116.59, 115.26, 115.03, 110.36, 109.76, 74.36, 55.91, 55.53, 49.87, 48.48, 18.35, 
18.26, 16.40, 16.28. 
IR (thin film): 3420.14, 2923.56, 2869.56, 1508.06, 1250.61; HRMS (ESI): calculated for 
C18H24NO2 [M+H]+= 286.180155; found 286.18002. 
        
(S)-Ethyl 2-((S)-2-((2-methoxyphenyl)amino)-3-methylbutanamido)-3-
phenylpropanoate and (S)-ethyl 2-((S)-2-((4-methoxyphenyl)amino)-3-
methylbutanamido)-3-phenylpropanoate (4.27). The title compound was prepared using 
Method A with an irradiation time of 14 hours. The title compound was purified by column 
chromatography on silica gel (10% to 20% EtOAc/Hexanes) to give a pale yellow oil in 58% 



















contaminated with an inseparable impurity. The 1H/13C NMR peaks corresponding to the 
para isomer were identified using 2D NMR spectroscopy. 
4.27 ortho isomer. 1H NMR (600 MHz, CDCl3) δ 7.25 – 7.19 (m, 4H), 7.14 – 7.13 (m, 2H), 
6.82 (td, J = 7.8, 1.8 Hz, 1H), 6.79 (dd, J = 7.8, 1.8 Hz, 1H), 6.74 (td, J = 7.8, 1.8 Hz, 1H), 
6.51 (dd, J = 7.8, 1.8 Hz, 1H), 4.87 (td, J = 8.4, 6.0 Hz, 1H), 4.48 (brd, J = 4.2 Hz, 1H), 4.06 
(q, J = 7.2 Hz, 2H), 3.88 (s, 3H), 3.48 (brt, J = 4.2 Hz, 1H), 3.17 (dd, J = 14.4, 6.0 Hz, 1H), 
2.98 (dd, J = 14.4, 8.4 Hz, 1H), 2.33 – 2.25 (m, 1H), 1.11 (t, J = 7.2 Hz, 3H), 0.93 (d, J = 6.6 
Hz, 3H), 0.80 (d, J = 7.2 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 173.12, 171.28, 147.11, 
137.48, 136.37, 129.25, 128.62, 127.03, 121.40, 118.45, 112.10, 109.56, 65.49, 61.44, 55.67, 
53.12, 38.16, 31.14, 19.80, 17.40, 14.09. 
IR (thin film): 3382.53, 3310.21, 2962.13, 2936.09, 1739.48, 1654.62, 1602.56, 1509.03, 
1455.99, 1244.83, 1221.68, 1180.22; HRMS (ESI): calculated for C23H30N2O4 [M+H]+= 
399.2278; found 399.2281. 
4.27 para isomer. 1H NMR (600 MHz, CDCl3) δ 7.29 – 7.09 (m, 6H), 6.76 (AA’BB’, J = 
8.4 Hz, 2H), 6.58 (AA’BB’, J = 8.4 Hz, 2H), 4.86 (td, J = 7.8, 6.0 Hz, 1H), 4.09 (q, J = 7.2 
Hz, 2H), 3.74 (s, 3H), 3.55 (brd, J = 4.2 Hz, 1H), 3.42 (brt, J = 4.2 Hz, 1H), 3.15 (dd, J = 
14.4, 6.0 Hz, 1H), 3.00 (dd, J = 14.4, 7.8 Hz, 1H), 2.26 – 2.20 (m, 1H), 1.15 (t, J = 7.2 Hz, 
3H), 0.93 (d, J = 7.2 Hz, 3H), 0.79 (d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 
173.07, 171.33, 153.26, 141.72, 136.27, 129.26, 128.65, 127.09, 115.54, 114.86, 66.45, 
61.51, 55.83, 53.08, 38.14, 31.25, 19.76, 17.52, 14.15. 
HRMS (ESI): calculated for C23H30N2O4 [M+H]+= 399.2278; found 399.2288. 
	 380 
        
(S)-Methyl 2-((2-ethoxyphenyl)amino)-3-methylbutanoate and (S)-methyl 2-((4-
ethoxyphenyl)amino)-3-methylbutanoate (4.28). The title compound was prepared using 
Method A with an irradiation time of 4 hours. The title compound was purified by column 
chromatography on silica gel (5% EtOAc/Hexanes) to give a colorless oil in 76% yield and a 
mixture of 1.7:1 ortho to para regioisomers. 
4.28 ortho isomer. 1H NMR (600 MHz, CDCl3) δ 6.81 (td, J = 7.8, 1.8 Hz, 1H), 6.77 (dd, J 
= 7.8, 1.8 Hz, 1H), 6.66 (td, J = 7.8, 1.8 Hz, 1H), 6.54 (dd, J = 7.8, 1.8 Hz, 1H), 4.77 (brd, J 
= 9.0 Hz, 1H), 4.09 (ABX3, J = 9.0, 7.2 Hz, 1H), 4.06 (ABX3, J = 9.0, 7.2 Hz, 1H), 3.85 (dd, 
J = 9.0, 6.6 Hz, 1H), 3.71 (s, 3H), 2.17 (oct, J = 6.6 Hz, 1H), 1.45 (t, J = 7.2 Hz, 3H), 1.07 (d, 
J = 6.6 Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 174.41, 146.49, 
137.49, 121.22, 117.33, 111.10, 110.39, 64.10, 62.40, 51.95, 31.69, 19.29, 18.98, 15.13. 
IR (thin film): 3420.14, 2964.05, 2875.34, 1740.44, 1601.59, 1513.85, 1455.03; HRMS 
(ESI): calculated for C14H21NO3 [M+H]+= 252.1594; found 252.1594. 
4.28 para isomer. 1H NMR (600 MHz, CDCl3) δ 6.75 (AA’BB’, J = 9.0 Hz, 2H), 6.59 
(AA’BB’, J = 9.0 Hz, 2H), 3.94 (q, J = 7.2 Hz, 2H), 3.86 (brs, 1H), 3.76 (d, J = 6.6 Hz, 1H), 
3.69 (s, 3H), 2.08 (oct, J = 6.6 Hz, 1H), 1.36 (t, J = 7.2 Hz, 3H), 1.03 (d, J = 6.6 Hz, 3H), 
1.01 (d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 174.72, 152.09, 141.52, 115.79, 









IR (thin film): 3365.17, 2964.05, 1733.69, 1514.81, 1233.25; HRMS (ESI): calculated for 
C14H21NO3 [M+H]+= 252.1594; found 252.1592. 
        
(S)-Methyl 2-((2-(tert-butoxy)phenyl)amino)-3-methylbutanoate and (S)-methyl 2-((4-
(tert-butoxy)phenyl)amino)-3-methylbutanoate (4.29). The title compound was prepared 
using Method A with an irradiation time of 4 hours. The title compound was purified by 
column chromatography on silica gel (5% EtOAc/Hexanes) to give a colorless oil in 82% 
yield and a mixture of 1:1.3 ortho to para regioisomers. 
4.29 ortho isomer. 1H NMR (600 MHz, CDCl3) δ 6.96 (dd, J = 7.8, 1.2 Hz, 1H), 6.91 (td, J 
= 7.8, 1.2 Hz, 1H), 6.59 (td, J = 7.8, 1.2 Hz, 1H), 6.52 (dd, J = 7.8, 1.2 Hz, 1H), 4.84 (brd, J 
= 9.0 Hz, 1H), 3.87 (dd, J = 9.0, 6.0 Hz, 1H), 3.69 (s, 3H), 2.16 (broct, J = 7.2 Hz, 1H), 1.42 
(s, 9H), 1.05 (d, J = 7.2 Hz, 3H), 1.02 (d, J = 7.2 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 
174.20, 143.00, 142.01, 123.92, 122.22, 116.67, 110.56, 79.82, 61.79, 51.91, 31.70, 29.20, 
19.33, 18.76. 
IR (thin film): 3420.14, 2971.77, 2874.38, 1740.44, 1599.66, 1508.06, 1366.32, 1158.04; 
HRMS (ESI): calculated for C16H25NO3 [M+H]+= 280.1907; found 280.1906. 
4.29 para isomer. 1H NMR (600 MHz, CDCl3) δ 6.81 (AA’BB’, J = 9.0 Hz, 2H), 6.53 
(AA’BB’, J = 9.0 Hz, 2H), 3.96 (brd, J = 9.0 Hz, 1H), 3.79 (dd, J = 9.0, 6.6 Hz, 1H), 3.70 (s, 









3H). 13C NMR (151 MHz, CDCl3) δ 174.59, 147.13, 143.64, 125.58, 114.00, 77.91, 63.36, 
51.97, 31.78, 28.81, 19.30, 18.85. 
IR (thin film): 3383.50, 2973.70, 2874.38, 1734.66, 1509.03, 1364.39, 1171.54; HRMS 
(ESI): calculated for C16H25NO3 [M+H]+= 280.1907; found 280.1904. 
        
(S)-Methyl 3-methyl-2-((2-((triethylsilyl)oxy)phenyl)amino)butanoate and (S)-methyl 3-
methyl-2-((4-((triethylsilyl)oxy)phenyl)amino)butanoate (4.30). The title compound was 
prepared using Method A with an irradiation time of 4 hours. The title compound was 
purified by column chromatography on silica gel (5% EtOAc/Hexanes) to give a colorless oil 
in 77% yield and a mixture of 1:1.7 ortho to para regioisomers. 
4.30. 1H NMR (600 MHz, CDCl3) δ 6.81 (td, J = 7.8, 1.2 Hz, 0.4H), 6.73 (dd, J = 7.8, 1.2 
Hz, 0.4H), 6.68 (AA’BB’, J = 9.0 Hz, 2H), 6.56 (td, J = 7.8, 1.2 Hz, 0.4H), 6.52 (AA’BB’, J 
= 9.0 Hz, 2H), 6.53 – 6.51 (m, 0.4H), 4.69 (brd, J = 9.6 Hz, 0.4H), 3.88 – 3.85 (m, 1.4H), 
3.75 (d, J = 6.6 Hz, 1H), 3.69 (s, 4.2H), 2.16 (broct, J = 7.2 Hz, 0.4H), 2.07 (broct, J = 6.6 
Hz, 1H), 1.06 – 1.00 (m, 12H), 0.97 (t, J = 7.8 Hz, 9H), 0.79 (q, J = 7.8 Hz, 2.4H), 0.69 (q, J 
= 7.8 Hz, 6H). 13C NMR (151 MHz, CDCl3) δ 174.71, 174.16, 148.10, 142.92, 141.85, 
139.12, 121.94, 120.67, 117.53, 117.10, 115.13, 110.66, 63.86, 62.02, 51.91, 51.90, 31.76, 
31.69, 19.32, 19.24, 18.87, 18.76, 6.84, 6.80, 5.35, 5.02. 
IR (thin film): 3393.14, 2957.30, 2876.31, 1739.48, 1509.03, 1456.96, 1255.43; HRMS 









        
(S)-Methyl 2-((2-((tert-butyldiphenylsilyl)oxy)phenyl)amino)-3-methylbutanoate and 
(S)-methyl 2-((4-((tert-butyldiphenylsilyl)oxy)phenyl)amino)-3-methylbutanoate (4.31). 
The title compound was prepared using Method A with an irradiation time of 4 hours. The 
title compound was purified by column chromatography on silica gel (5% EtOAc/Hexanes) 
to give a colorless oil in 58% yield and a mixture of 1:2.3 ortho to para regioisomers. 
4.31. 1H NMR (600 MHz, CDCl3) δ 7.76 – 7.69 (m, 5.2H), 7.44 – 7.34 (m, 7.8H), 6.74 (td, J 
= 7.8, 1.8 Hz, 0.3H), 6.60 (AA’BB’, J = 9.0 Hz, 2H), 6.56 (dd, J = 7.8, 1.8 Hz, 0.3H), 6.40 
(AA’BB’, J = 9.0 Hz, 2H), 6.34 (dd, J = 7.8, 1.8 Hz, 0.3H), 6.27 (td, J = 7.8, 1.8 Hz, 0.3H), 
5.01 (brd, J = 9.6 Hz, 0.3H), 3.99 (dd, J = 9.6, 6.0 Hz, 0.3H), 3.78 (brs, 1H), 3.73 (s, 0.9H), 
3.68 (d, J = 6.6 Hz, 1H), 3.66 (s, 3H), 2.22 (broct, J = 6.6 Hz, 0.3H), 2.03 (oct, J = 6.6 Hz, 
1H), 1.14 (s, 2.7H), 1.10 – 1.06 (m, 1.8H), 1.07 (s, 9H), 1.00 (d, J = 6.6 Hz, 3H), 0.97 (d, J = 
6.6 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 174.67, 174.11, 148.33, 142.78, 141.51, 138.66, 
135.69, 135.61,135.56, 134.92, 133.46, 130.08, 129.83, 127.96, 127.78, 121.77, 120.27, 
117.95, 116.97, 114.99, 110.77, 63.79, 62.11, 51.97, 51.88, 31.71, 26.75, 26.69, 19.60, 19.56, 
19.28, 19.26, 18.83, 18.73. 
IR (thin film): 3393.14, 3048.91, 2966.20, 2857.99, 1736.58, 1509.03, 1253.50; HRMS 









        
(S)-Methyl 3-methyl-2-((2-phenoxyphenyl)amino)butanoate and (S)-methyl 3-methyl-2-
((4-phenoxyphenyl)amino)butanoate (4.32). The title compound was prepared using 
Method A with an irradiation time of 4 hours. The title compound was purified by column 
chromatography on silica gel (5% EtOAc/Hexanes) to give a colorless oil in 84% yield and a 
mixture of 1:2.2 ortho to para regioisomers. 
4.32. 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.25 (m, 2.5H), 7.12 – 6.99 (m, 3.5H), 6.94 – 
6.92 (m, 2H), 6.89 (AA’BB’, J = 8.8 Hz, 2H), 6.86 – 6.84 (m, 0.5H), 6.68 – 6.66 (m, 1H), 
6.63 (AA’BB’, J = 8.8 Hz, 2H), 4.63 (brd, J = 9.6 Hz, 0.5H), 4.04 (brd, J = 9.6 Hz, 1H), 3.88 
(dd, J = 9.6, 6.4 Hz, 0.5H), 3.82 (dd, J = 9.6, 6.0 Hz, 1H), 3.73 (s, 3H), 3.68 (s, 1.5H), 2.16 – 
2.06 (m, 1.5H), 1.06 (d, J = 6.8 Hz, 3H), 1.03 (d, J = 6.8 Hz, 3H), 0.96 (t, J = 6.8 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 174.44, 173.97, 158.97, 157.65, 148.46, 143.98, 143.73, 
139.59, 129.77, 129.63, 124.90, 122.96, 122.17, 121.28, 119.60, 117.84, 117.68, 117.36, 
114.83, 111.86, 63.25, 62.26, 52.04, 51.99, 31.74, 31.60, 19.30, 19.22, 18.83, 18.81.    
IR (thin film): 3393.14, 2963.09, 2874.38, 1737.55, 1608.34, 1589.06, 1509.03, 1488.78, 
1231.33; HRMS (ESI): calculated for C18H21NO3 [M+H]+= 300.1594; found 300.1592. 
















(S)-Methyl 3-methyl-2-((2-(phenylthio)phenyl)amino)butanoate and (S)-methyl 3-
methyl-2-((4-(phenylthio)phenyl)amino)butanoate (4.33). The title compound was 
prepared using Method B with an irradiation time of 26 hours using 2 lamps. The title 
compound was purified by column chromatography on silica gel (5% EtOAc/Hexanes) to 
give a yellow oil in 37% yield by 1H NMR and a mixture of 1:4.4 ortho to para regioisomers. 
The product was only partially separated from unreacted diphenyl sulfide. 
4.33. 1H NMR (400 MHz, CDCl3) δ 7.51 (dd, J = 7.6, 1.2 Hz, 0.1H), 7.32 (AA’BB’, J = 8.8 
Hz, 2H), 7.30 – 7.27 (m, 0.1H), 7.23 – 7.19 (m, 2.2H), 7.13 – 7.07 (m, 3.3H), 6.71 (td, J = 
7.6, 1.2 Hz, 0.1H), 6.62 (AA’BB’, J = 8.8 Hz, 2H), 6.58 (brd, J = 8.4 Hz, 0.1H), 5.35 (brd, J 
= 8.8 Hz, 0.1H), 4.30 (brd, J = 8.4 Hz, 1H), 3.88 (dd, J = 8.4, 5.6 Hz, 1H), 3.85 (dd, J = 8.8, 
6.0 Hz, 0.1H), 3.74 (s, 3H), 3.64 (s, 0.4H), 2.14 (broct, J = 6.8 Hz, 1H), 2.05 (broct, J = 6.8 
Hz, 0.1H), 1.05 (d, J = 6.8 Hz, 3H), 1.02 (d, J = 6.8 Hz, 3H), 0.85 (d, J = 6.8 Hz, 0.4H), 0.84 
(d, J = 6.8 Hz, 0.4H). 13C NMR (151 MHz, CDCl3) δ 173.95, 173.55, 148.41, 147.80, 
139.82, 137.87, 136.79, 136.30, 131.48, 129.00, 128.91, 127.31, 126.95, 125.64, 125.31, 
119.95, 117.67, 114.27, 110.60, 62.17, 61.92, 52.18, 52.02, 31.69, 31.49, 19.19, 19.14, 18.80, 
18.45. 
IR (thin film): 3390.24, 2963.09, 2932.23, 1735.62, 1596.77, 1506.13, 1477.21, 1320.04, 
1203.36, 1180.22, 1154.19; HRMS (ESI): calculated for C18H21NO2S [M+H]+= 316.1366; 
found 316.1364. 









(S)-Methyl 2-([1,1'-biphenyl]-2-ylamino)-3-methylbutanoate and (S)-methyl 2-([1,1'-
biphenyl]-4-ylamino)-3-methylbutanoate (4.34). The title compound was prepared using 
Method A with an irradiation time of 13 hours. The title compound was purified by column 
chromatography on silica gel (5% EtOAc/Hexanes) to give a pale yellow solid in 95% yield 
and a mixture of 1:2.1 ortho to para regioisomers. 
4.34. 1H NMR (400 MHz, CDCl3) δ 7.54 – 7.37 (m, 5.2H), 7.44 (AA’BB’, J = 8.8 Hz, 2H), 
7.29 – 7.24 (m, 1.3H), 7.21 (td, J = 7.6, 1.6 Hz, 0.3H), 7.12 (dd, J = 7.6, 1.6 Hz, 0.3H), 6.80 
(td, J = 7.6, 1.6 Hz, 0.3H), 6.71 (AA’BB’, J = 8.8 Hz, 2H), 6.64 (brd, J = 8.0 Hz, 0.3H), 4.40 
(brd, J = 9.2 Hz, 0.3H), 4.22 (brd, J = 9.6 Hz, 1H), 3.94 – 3.87 (m, 1.3H), 3.74 (s, 3H), 3.69 
(s, 0.9H), 2.15 (oct, J = 6.8 Hz, 1H), 2.02 (oct, J = 6.4 Hz, 0.3H), 1.07 (d, J = 6.8 Hz, 3H), 
1.04 (d, J = 6.8 Hz, 3H), 0.94 – 0.92 (m, 1.8H). 13C NMR (151 MHz, CDCl3) δ 174.26, 
174.24, 146.81, 144.15, 141.21, 139.32, 131.27, 130.63, 129.48, 129.01, 128.80, 128.77, 
128.50, 128.16, 127.43, 126.48, 126.31, 117.85, 113.84, 110.81, 62.50, 62.31, 52.09, 51.96, 
31.73, 31.54, 19.26, 18.86, 18.84. 
IR (thin film): 3393.14, 2963.09, 2873.42, 1733.69, 1614.13, 1524.45, 1298.82; HRMS 
(ESI): calculated for C18H21NO2 [M+H]+= 284.1645; found 284.1643. 
 
(S)-Methyl 2-((5-fluoro-2-methoxyphenyl)amino)-3-methylbutanoate (4.35). The title 
compound was prepared using Method B with an irradiation time of 18 hours using one 
lamp. The title compound was purified by column chromatography on silica gel (5% 








4.35. 1H NMR (600 MHz, CDCl3) δ 6.64 (dd, J = 8.4, 4.8 Hz, 1H), 6.32 (td, J = 8.4, 3.0 Hz, 
1H), 6.25 (dd, J = 10.2, 3.0 Hz, 1H), 4.83 (brd, J = 9.0 Hz, 1H), 3.83 (s, 3H), 3.78 (dd, J = 
9.0, 6.6 Hz, 1H), 3.72 (s, 3H), 2.16 (oct, J = 6.6 Hz, 1H), 1.06 (d, J = 6.6 Hz, 3H), 1.01 (d, J 
= 6.6 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 173.88, 158.20 (d, J = 235.6 Hz), 143.24 (d, J 
= 1.5 Hz), 138.46 (d, J = 10.6 Hz), 110.02 (d, J = 9.1 Hz), 101.81 (d, J = 22.7 Hz), 98.04 (d, 
J = 28.7 Hz), 62.07, 56.15, 52.10, 31.62, 19.25, 18.89. 19F NMR (376 MHz, CDCl3) δ -
122.03. 
IR (thin film): 3420.14, 2964.05, 2837.74, 1739.48, 1620.88, 1522.52, 1456.96, 1217.83; 
HRMS (ESI): calculated for C13H18FNO3 [M+H]+= 256.1343; found 256.1342. 
 
(S)-Methyl 2-((5-chloro-2-methoxyphenyl)amino)-3-methylbutanoate (4.36). The title 
compound was prepared using Method B with an irradiation time of 24 hours. The title 
compound was purified by column chromatography on silica gel (10% to 30% 
EtOAc/Hexanes) to give 4.36 in 75% yield and a mixture of 20:1:1 C2:C3:C1 adducts. 
4.36. 1H NMR (600 MHz, CDCl3) δ 7.15 (d, J = 8.7 Hz, 0.06H, ipso), 7.11 (d, J = 8.7 Hz, 
0.06H, ipso), 6.69 – 6.58 (m, 2H), 6.54 (d, J = 2.2 Hz, 0.07H, meta), 6.47 (d, J = 2.3 Hz, 1H), 
6.21 (dd, J = 8.7, 2.8 Hz, 0.06H), 6.15 (d, J = 2.7 Hz, 0.06H), 4.79 (d, J = 9.4 Hz, 1H), 3.84 
(s, 3H), 3.81 (dd, J = 9.3, 6.0 Hz, 1H), 3.76 – 3.69 (m, 3H), 2.16 (dq, J = 13.4, 6.7 Hz, 1H), 
1.05 (d, J = 6.9 Hz, 3H), 1.01 (d, J = 6.7 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 173.83, 








62.65, 62.21, 61.89, 55.86, 55.47, 52.16, 52.08, 31.61, 31.56, 19.20, 19.19, 19.16, 18.82, 
18.79, 18.77. 
IR (thin film): 3420.14, 2963.09, 2875.34, 1739.48, 1599.66, 1518.67, 1219.76; HRMS 
(ESI): calculated for C13H18ClNO3 [M+H]+= 272.104794; found 272.10523. 
 
(S)-Methyl 2-((5-bromo-2-methoxyphenyl)amino)-3-methylbutanoate (4.37). The title 
compound was prepared using Method B with an irradiation time of 24 hours using 2 lamps 
and trifluorotoluene instead of DCE as the solvent. The title compound was purified by 
column chromatography on silica gel (5% EtOAc/Hexanes) to give a colorless oil in 57% 
yield and a mixture of 9.1:1 C2:C3 regioisomers. The product was isolated with 6% of (S)-
methyl 2-((4-bromophenyl)amino)-3-methylbutanoate. The yield was calculated taking 
contamination into account. 
4.37. 1H NMR (400 MHz, CDCl3) δ 6.76 (dd, J = 8.8, 2.4 Hz, 1H), 6.61 – 6.59 (m, 2H), 4.78 
(brd, J = 9.6 Hz, 1H), 3.84 (s, 3H), 3.81 (dd, J = 9.6, 6.0 Hz, 1H), 3.73 (s, 3H), 2.16 (broct, J 
= 6.8 Hz, 1H), 1.05 (d, J = 6.8 Hz, 3H), 1.01 (d, J = 6.8 Hz, 3H). 13C NMR (151 MHz, 
CDCl3) δ 173.85, 146.21, 138.62, 119.47, 113.81, 112.83, 110.96, 61.88, 55.84, 52.12, 31.65, 
19.23, 18.84. 
IR (thin film): 3420.14, 2942.13, 2874.38, 1739.48, 1597.73, 1515.77; HRMS (ESI): 









(S)-Methyl 2-((5-iodo-2-methoxyphenyl)amino)-3-methylbutanoate (4.38). The title 
compound was prepared using Method B with an irradiation time of 19 hours using 2 lamps 
and trifluorotoluene instead of DCE as the solvent. The title compound was purified by 
column chromatography on silica gel (5% EtOAc/Hexanes) to give a colorless oil in 33% 
yield and a mixture of 6.7:1 C2:C3 regioisomers. The product was isolated with 7% of (S)-
methyl 2-((4-iodophenyl)amino)-3-methylbutanoate. The yield was calculated taking 
contamination into account. 
4.38. 1H NMR (400 MHz, CDCl3) δ 6.96 (dd, J = 8.4, 2.0 Hz, 1H), 6.76 (d, J = 2.0 Hz, 1H), 
6.49 (d, J = 8.4 Hz, 1H), 4.73 (brd, J = 9.2 Hz, 1H), 3.83 (s, 3H), 3.80 (dd, J = 9.2, 6.0 Hz, 
1H), 3.73 (s, 3H), 2.15 (broct, J = 6.8 Hz, 1H), 1.05 (d, J = 6.8 Hz, 3H), 1.01 (d, J = 6.8 Hz, 
3H). 13C NMR (151 MHz, CDCl3) δ 173.89, 147.03, 138.85, 125.91, 118.49, 111.63, 83.95, 
61.85, 55.73, 52.10, 31.66, 19.23, 18.84. 
IR (thin film): 3420.14, 2962.13, 2836.77, 1738.51, 1592.91, 1508.06, 1456.96; HRMS 
(ESI): calculated for C13H18INO3 [M+H]+= 364.0404; found 364.0401. 
 
(S)-Methyl 2-((5-isopropyl-2-methoxyphenyl)amino)-3-methylbutanoate (4.39). The title 














lamp. The title compound was purified by column chromatography on silica gel (5% 
EtOAc/Hexanes) to give a pale yellow oil in 43% yield and >10:1 regioselectivity. 
4.39. 1H NMR (400 MHz, CDCl3) δ 6.69 (d, J = 8.4 Hz, 1H), 6.53 (dd, J = 8.4, 2.4 Hz, 1H), 
6.42 (d, J = 2.4 Hz, 1H), 4.68 (brd, J = 9.2 Hz, 1H), 3.86 (dd, J = 9.2, 6.4 Hz, 1H), 3.83 (s, 
3H), 3.70 (s, 3H), 2.78 (sept, J = 6.8 Hz, 1H), 2.14 (broct, J = 6.8 Hz, 1H), 1.19 (d, J = 6.8 
Hz, 6H), 1.08 (d, J = 6.8 Hz, 3H), 1.02 (d, J = 6.8 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 
174.55, 145.37, 141.84, 137.00, 114.61, 109.68, 108.87, 62.42, 55.76, 51.91, 33.90, 31.75, 
24.47, 24.28, 19.34, 19.14. 
IR (thin film): 3421.10, 2959.23, 2872.45, 1741.41, 1598.70, 1523.49, 1463.71, 1429.96, 
1246.75, 1225.54; LRMS (EI): calculated for C16H25NO3 [M]+= 279.2; found 279.2. 
 
(S)-Methyl 2-((2,4-dimethoxyphenyl)amino)-3-methylbutanoate (4.40). The title 
compound was prepared using Method B with an irradiation time of 16 hours using 2 lamps. 
The title compound was purified by column chromatography on silica gel (10% 
EtOAc/Hexanes) to give a yellow oil in 49% yield and a mixture of 10.4:1 C4:C2 
regioisomers.  
4.40. 1H NMR (600 MHz, CDCl3) δ 6.46 – 6.44 (m, 2H), 6.35 (dd, J = 8.4, 2.4 Hz, 1H), 4.40 
(brs, 1H), 3.84 (s, 3H), 3.78 (brd, J = 6.6 Hz, 1H), 3.74 (s, 3H), 3.69 (s, 3H), 2.12 (oct, J = 






δ 174.69, 152.42, 148.35, 131.53, 110.81, 103.70, 99.46, 63.16, 55.85, 55.71, 51.90, 31.69, 
19.32, 19.07. 
IR (thin film): 3393.14, 2960.20, 2833.88, 1735.62, 1519.63, 1456.96, 1206.26; HRMS 
(ESI): calculated for C14H21NO4 [M+H]+= 268.1543; found 268.1541. 
 
(S)-Methyl 2-((2,4-dimethylphenyl)amino)-3-methylbutanoate (4.41). The title compound 
was prepared using Method B with an irradiation time of 18 hours using 2 lamps with 10 
equivalents of m-xylene. The title compound was purified by column chromatography on 
silica gel (5% EtOAc/Hexanes) to give a pale yellow oil in 66% yield by 1H NMR and a 
mixture of 10.1:1 C4:C5 regioisomers. The product was contaminated with an inseparable 
impurity. 
4.41. 1H NMR (600 MHz, CDCl3) δ 6.89 – 6.88 (m, 2H), 6.47 (d, J = 8.4 Hz, 1H), 3.90 – 
3.85 (m, 2H), 3.70 (s, 3H), 2.22 (s, 3H), 2.19 (s, 3H), 1.06 (oct, J = 7.2 Hz, 1H), 1.07 (d, J = 
7.2 Hz, 3H), 1.02 (d, J = 7.2 Hz, 3H). 13C NMR (151 MHz, CDCl3) δ 174.71, 143.07, 
131.37, 127.45, 127.09, 123.10, 110.81, 62.75, 51.97, 31.77, 20.48, 19.26, 18.96, 17.60. 
IR (thin film): 3395.07, 2963.09, 2928.38, 1737.55, 1517.70, 1464.67; HRMS (ESI): 






        
(S)-Methyl 2-((3-chloro-4-methoxyphenyl)amino)-3-methylbutanoate and (S)-methyl 2-
((4-chloro-3-methoxyphenyl)amino)-3-methylbutanoate (4.42). The title compound was 
prepared using Method B with an irradiation time of 21 hours using 2 lamps. The title 
compound was purified by column chromatography on silica gel (5% to 10% 
EtOAc/Hexanes) to give a colorless oil in 63% yield and a mixture of 3.0:1 C4:C5 
regioisomers. 
4.42. 1H NMR (600 MHz, CDCl3) δ 7.11 (d, J = 8.4 Hz, 0.2H), 6.78 (d, J = 8.4 Hz, 1H), 6.70 
(d, J = 3.0 Hz, 1H), 6.51 (dd, J = 8.4, 3.0 Hz, 1H), 6.23 (d, J = 3.0 Hz, 0.2H), 6.14 (dd, J = 
8.4, 3.0 Hz, 0.2H), 4.15 (brd, J = 9.6 Hz, 0.2H), 3.90 (brd, J = 10.2 Hz, 1H), 3.85 (s, 0.6H), 
3.83 – 3.80 (m, 0.2H), 3.81 (s, 3H), 3.74 (dd, J = 10.2, 6.0 Hz, 1H), 3.72 (s, 0.6H), 3.71 (s, 
3H), 2.14 – 2.04 (m, 1.2H), 1.05 – 1.00 (m, 7.2H). 13C NMR (151 MHz, CDCl3) δ 174.30, 
174.10, 155.65, 148.08, 147.47, 142.21, 130.58, 123.43, 116.24, 114.06, 113.03, 111.38, 
105.78, 98.65, 63.44, 62.71, 57.00, 56.03, 52.14, 52.08, 31.69, 31.67, 19.29, 19.26, 18.84, 
18.75. 
IR (thin film): 3383.50, 2963.09, 2836.77, 1732.73, 1507.16, 1456.96, 1228.43; HRMS 










(S)-Methyl 2-((4-(4-chlorophenoxy)phenyl)amino)-3-methylbutanoate (4.43). The title 
compound was prepared using Method A with an irradiation time of 4 hours. The title 
compound was purified by column chromatography on silica gel (10% to 30% 
EtOAc/Hexanes) to give 43 in 78% yield and a mixture of 1:2.3 ortho to para regioisomers. 
4.43. 1H NMR (600 MHz, CDCl3) δ 7.33 – 7.30 (m, 0.3H), 7.28 – 7.24 (m, 0.8H, 
overlapping with residual CHCl3), 7.22 (d, J = 9.0 Hz, 1.6H), 7.18 (dd, J = 8.4, 1.5 Hz, 
0.2H), 7.13 – 7.06 (m, 0.2H), 7.04 – 7.01 (m, 0.2H), 7.00 – 6.98 (m, 0.5H), 6.94 – 6.90 (m, 
0.6H), 6.85 (tt, J = 9.6, 2.3 Hz, 3.2H), 6.76 – 6.72 (m, 0.4H), 6.69 – 6.65 (m, 0.4H), 6.63 – 
6.58 (m, 2H), 4.07 (d, J = 9.7 Hz, 1H), 3.87 (dd, J = 9.5, 6.1 Hz, 0.3H), 3.83 – 3.78 (m, 1H), 
3.78 – 3.71 (m, 3H), 3.69 (d, J = 1.1 Hz, 0.8H), 2.11 (tdd, J = 9.3, 7.5, 5.1 Hz, 1.2H), 1.08 – 
1.00 (m, 6H), 0.95 (td, J = 7.2, 5.1 Hz, 2H). 13C NMR (151 MHz, CDCl3) δ 174.40, 173.94, 
173.47, 157.68, 156.35, 148.10, 144.25, 143.35, 139.60, 129.89, 129.71, 129.63, 129.61, 
129.54, 127.04, 125.36, 123.34, 121.28, 121.26, 120.23, 119.75, 118.95, 118.54, 117.86, 
117.82, 117.36, 117.13, 116.76, 114.82, 112.06, 111.65, 63.15, 62.15, 61.90, 52.15, 52.08, 
52.04, 31.73, 31.60, 31.55, 19.30, 19.22, 19.17, 18.82, 18.79, 18.64. 
IR (thin film): 3393.14, 2963.09, 2930.31, 1733.69, 1508.06, 1233.25; HRMS (ESI): 








(4.44). The title compound was prepared using Method A with an irradiation time of 4 hours. 
The title compound was purified by column chromatography on silica gel (10% to 30% 
EtOAc/Hexanes) to give 4.44 in 60% yield and a mixture of 5:1 para to ortho regioisomers. 
4.44. 1H NMR (600 MHz, CDCl3) δ 7.42 (ddd, J = 7.3, 3.9, 2.0 Hz, 1.25H), 7.30 – 7.23 (m, 
2H), 7.23 – 7.19 (m, 0.25H), 6.97 (d, J = 7.9 Hz, 0.25H), 6.82 (dd, J = 8.8, 3.6 Hz, 1H), 
a6.64 (dt, J = 8.9, 3.3 Hz, 1H), 6.52 (t, J = 3.3 Hz, 1H), 6.27 – 6.22 (m, 0.25H), 3.93 – 3.88 
(m, 1.25H), 3.81 – 3.74 (m, 1.25H), 3.73 (d, J = 5.7 Hz, 1.5H), 3.68 (dd, J = 9.1, 3.6 Hz, 6H), 
2.13 (d, J = 6.5 Hz, 0.25H), 2.09 – 2.04 (m, 1H), 1.13 (dd, J = 7.0, 4.8 Hz, 1H), 1.06 (d, J = 
6.8 Hz, 1H), 1.01 (ddq, J = 13.2, 6.5, 3.4, 2.8 Hz, 6H). 13C NMR (151 MHz, CDCl3) δ 
150.03, 148.69, 141.22, 137.93, 133.90, 132.29, 131.86, 131.73, 129.55, 129.43, 129.39, 
128.59, 128.11, 126.49, 126.44, 117.45, 114.48, 112.82, 63.72, 62.49, 56.50, 55.57, 52.51, 
52.13, 51.98, 34.33, 31.82, 31.77, 19.33, 19.15, 18.88, 18.85, 17.84. 
IR (thin film): 3393.14, 2961.16, 287342, 1732.73, 1507.10, 1262.18, 1235.18; HRMS 












(S)-Methyl 2-((2,6-dimethoxypyridin-3-yl)amino)-3-methylbutanoate (4.45). The title 
compound was prepared using Method B with an irradiation time of 16 hours using 2 lamps. 
The title compound was purified by column chromatography on silica gel (5% to 10% 
EtOAc/Hexanes) to give a pale yellow oil in 60% yield as a single regioisomer.   
4.45. 1H NMR (600 MHz, CDCl3) δ 6.77 (d, J = 8.4 Hz, 1H), 6.16 (d, J = 8.4 Hz, 1H), 4.19 
(brs, 1H), 3.97 (s, 3H), 3.83 (s, 3H), 3.73 (brd, J = 6.6 Hz, 1H), 3.69 (s, 3H), 2.11 (oct, J = 
6.6 Hz, 1H), 1.06 (d, J = 6.6 Hz, 3H), 1.01 (d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, CDCl3) 
δ 174.38, 154.77, 151.09, 125.56, 121.21, 98.77, 63.24, 53.99, 53.57, 51.99, 31.65, 19.32, 
18.98. 
IR (thin film): 3393.14, 2962.13, 2900.41, 1739.48, 1593.88, 1489.74, 1291.11, 1395.25; 
HRMS (ESI): calculated for C13H20N2O4 [M+H]+= 269.1496; found 269.1494. 
 
(S)-Methyl 3-methyl-2-((1-methyl-1H-indazol-3-yl)amino)butanoate (4.46). The title 
compound was prepared using Method B with an irradiation time of 18 hours. The title 
compound was purified by column chromatography on neutralized silica gel (20% 
EtOAc/Hexanes) to give a yellow oil in 64% yield as a single regioisomer.  
4.46. 1H NMR (600 MHz, CDCl3) δ 7.65 – 7.50 (d, J = 8.6 Hz, 1H), 7.32 (ddd, J = 8.2, 6.9, 
1.0 Hz, 1H), 7.17 (dt, J = 8.5, 0.9 Hz, 1H), 6.99 (d, J = 1.0 Hz, 1H), 4.55 – 4.24 (m, 2H), 








(151 MHz, CDCl3) δ 174.79, 148.30, 141.72, 126.92, 119.43, 118.15, 114.36, 108.57, 61.86, 
51.96, 35.01, 31.61, 19.30, 18.53. 
HRMS (ESI): calculated for C14H18N3O2 [M+H]+= 261.32; found 261.30. 
 
(S)-Methyl 2-((7-bromo-1-methyl-1H-indazol-3-yl)amino)-3-methylbutanoate (4.47). 
The title compound was prepared using Method B with an irradiation time of 18 hours using 
2 lamps and trifluorotoluene instead of DCE as the solvent. The title compound was purified 
by column chromatography on neutralized silica gel (20% EtOAc/Hexanes) to give a yellow 
oil in 66% yield as a single regioisomer.  
4.47. 1H NMR (600 MHz, CDCl3) δ 7.50 (dd, J = 7.8, 1.2 Hz, 1H), 7.47 (dd, J = 7.8, 1.2 Hz, 
1H), 6.83 (t, J = 7.8 Hz, 1H), 4.41 – 4.37 (m, 2H), 4.16 (s, 3H), 3.74 (s, 3H), 2.25 – 2.20 (m, 
1H), 1.06 (d, J = 7.2 Hz, 6H). 13C NMR (151 MHz, CDCl3) δ 174.70, 147.77, 138.83, 
131.55, 119.35, 118.76, 117.14, 102.69, 61.66, 52.07, 38.07, 31.58, 19.34, 18.49. 
IR (thin film): 3354.57, 2963.09, 2874.38, 1736.80, 1541.81, 1435.74, 1206.26; HRMS 















         
(2S)-Methyl 2-((4-(3-(1-methoxy-1-oxopropan-2-yl)phenoxy)phenyl)amino)-3,3-
dimethylbutanoate, (2S)-methyl 2-((2-(3-(1-methoxy-1-oxopropan-2-
yl)phenoxy)phenyl)amino)-3,3-dimethylbutanoate and (2S)-methyl 2-((4-(1-methoxy-1-
oxopropan-2-yl)-2-phenoxyphenyl)amino)-3,3-dimethylbutanoate (4.48). The title 
compound was prepared using Method B with an irradiation time of 17 hours using 2 lamps. 
The title compound was purified by column chromatography on silica gel (10% 
EtOAc/Hexanes) to give a pale yellow oil in 73% yield and a mixture of 1:1:1 C4:C2:C8 
regioisomers. Two additional regioisomers were observed in trace amounts. The C2 and C8 
regioisomers were inseparable by chromatography and were therefore further characterized 
by reduction to the corresponding diols SI8 and SI9 (see below). 
4.48 C4 isomer. 1H NMR (600 MHz, CDCl3) δ 7.20 (t, J = 7.8 Hz, 1H), 6.94 (brd, J = 7.2 
Hz, 1H), 6.90 – 6.89 (m, 1H), 6.88 (AA’BB’, J = 9.0 Hz, 2H), 6.77 (ddd, J = 7.8, 2.4, 1.2 Hz, 
1H), 6.64 (AA’BB’, J = 9.0 Hz, 2H), 4.09 (brs, 1H), 3.75 (brs, 1H), 3.70 (s, 3H), 3.67 – 3.65 
(m, 4H), 1.46 (d, J = 7.2 Hz, 3H), 1.07 (s, 9H). 13C NMR (151 MHz, CDCl3) δ 174.90, 
174.19, 159.10, 148.35, 144.28, 142.35, 129.75, 121.25, 121.22, 116.77, 115.77, 115.12, 
66.36, 52.24, 51.74, 45.42, 34.55, 26.88, 18.65. 
IR (thin film): 3391.21, 2954.41, 1735.62, 1509.03, 1486.85, 1238.08, 1213.97, 1161.90; 











4.48 C2 and C8 isomers. 1H NMR (600 MHz, CDCl3) δ 7.32 – 7.30 (m, 1.7H), 7.25 – 7.23 
(m, 0.7H), 7.08 – 7.05 (m, 0.7H), 7.02 – 6.97 (m, 4H), 6.95 – 6.92 (m, 1.7H), 6.86 – 6.84 (m, 
1.7H), 6.83 – 6.82 (m, 0.7H), 6.69 – 6.65 (m, 1.7H), 6.63 – 6.61 (m, 0.7H), 4.66 (d, J = 10.2 
Hz, 1H), 4.62 (d, J = 10.2 Hz, 0.7H), 3.80 (d, J = 10.2 Hz, 1H), 3.77 (d, J = 10.2 Hz, 0.7H), 
3.70 – 3.68 (m, 1H), 3.66 – 3.65 (m, 8.1H), 3.62 (s, 2.1H), 3.55 (q, J = 7.2 Hz, 0.7H), 1.48 
(d, J = 7.2 Hz, 3H), 1.40 (d, J = 7.2 Hz, 2.1H), 0.97 (s, 9H), 0.96 (s, 6.3H). 13C NMR (151 
MHz, CDCl3) δ 175.38, 175.37, 174.84, 173.60, 157.79, 157.57, 143.58, 143.38, 142.54, 
139.71, 138.84, 129.92, 129.78, 129.66, 125.05, 123.88, 122.93, 122.02, 121.98, 119.70, 
119.20, 117.65, 117.51, 117.44, 117.17, 116.29, 111.83, 111.72, 65.02, 65.00, 52.24, 52.11, 
51.71, 51.70, 45.42, 44.57, 34.51, 34.49, 26.76, 26.74, 18.71, 18.69. 
IR (thin film): 3421.10, 2953.45, 1737.55, 1608.34, 1584.24, 1518.67, 1488.78, 1434.78, 
1330.64, 1253.50, 1220.72, 1161.90; HRMS (ESI): calculated for C23H29NO5 [M+H]+= 
400.2118; found 400.2121. 
         
(2S)-2-((2-(3-(1-Hydroxypropan-2-yl)phenoxy)phenyl)amino)-3,3-dimethylbutan-1-ol 
and (2S)-2-((4-(1-hydroxypropan-2-yl)-2-phenoxyphenyl)amino)-3,3-dimethylbutan-1-ol 
(SI8 and SI9). To a solution of the C2 and C8 isomers of 4.48 (19 mg, 0.05 mmol) in diethyl 
ether (1 mL) at room temperature was added lithium aluminum hydride (4 mg, 0.1 mmol). 
After 1 hour, the reaction was quenched with water (0.1 mL) then sodium hydroxide (0.05 
mL of a 2 M aqueous solution), diethyl ether (3 mL) and MgSO4 were added sequentially. 



















reduced pressure. The title compounds were separated by column chromatography on silica 
gel (20% to 30% EtOAc/Hexanes), allowing the sites of amination to be determined using 
2D NMR spectroscopy. 
TOCSY of SI8 shows functionalization of the A ring, with multiplicities consistent with 
ortho substitution. TOCSY of SI9 shows functionalization of the B ring, with multiplicities 
consistent with either C4 or C6 substitution. Based on HMBC for SI9, a correlation exists 
between C1’ (41.62 ppm) and both H2 (6.76 ppm) and H4 (6.92 ppm), therefore amination 
occurred at C6.  
SI8. 1H NMR (600 MHz, CDCl3) δ 7.29 – 7.26 (m, 1H), 7.03 (td, J = 7.8, 1.8 Hz, 1H), 6.96 
(d, J = 7.2 Hz, 1H), 6.91 – 6.85 (m, 4H), 6.65 (td, J = 7.8, 1.8 Hz, 1H), 4.10 (brs, 1H), 3.80 
(dd, J = 10.8, 2.4 Hz, 1H), 3.69 – 3.65 (m, 2H), 3.41 – 3.34 (m, 2H), 2.96 – 2.88 (m, 1H), 
1.94 (brs, 1H), 1.24 (dd, J = 7.2, 5.4 Hz, 3H), 0.88 (s, 9H). 13C NMR (151 MHz, CDCl3) δ 
157.95, 146.22, 142.89, 141.47, 130.11, 125.26, 122.01, 120.04, 117.29, 116.24, 115.56, 
113.07, 68.62, 64.27, 62.39, 42.55, 34.99, 26.99, 17.72. 
IR (thin film): 3413.39, 2958.27, 2924.52, 2871.49, 1718.26, 1606.41, 1579.41, 1517.70, 
1485.88, 1440.56, 1333.53, 1249.65, 1189.86; HRMS (ESI): calculated for C21H29NO3 
[M+H]+= 344.2220; found 344.2232. 
SI9. 1H NMR (600 MHz, CDCl3) δ 7.34 – 7.31 (m, 2H), 7.09 – 7.07 (m, 1H), 6.99 – 6.98 (m, 
2H), 6.91 (dd, J = 8.4, 1.8 Hz, 1H), 6.87 (d, J = 8.4 Hz, 1H), 6.76 (t, J = 1.8 Hz, 1H), 4.06 
(brs, 1H), 3.82 (dd, J = 10.8, 3.6 Hz, 1H), 3.63 – 3.57 (m, 2H), 3.40 (dd, J = 10.8, 9.0 Hz, 
1H), 3.33 (dd, J = 9.0, 3.6 Hz, 1H), 2.83 – 2.78 (m, 1H), 1.98 (brs, 1H), 1.19 (dd, J = 7.2, 2.4 
Hz, 3H), 0.87 (s, 9H). 13C NMR (151 MHz, CDCl3) δ 157.57, 142.93, 140.26, 132.47, 
	 400 
130.00, 124.08, 123.07, 118.94, 117.23, 113.09, 68.93, 64.49, 62.45, 41.62, 34.94, 26.98, 
17.74. 
IR (thin film): 3391.21, 2959.23, 2924.52, 2854.13, 1716.34, 1540.85, 1520.60, 1507.10, 
1488.78, 1456.96, 1261.22, 1218.79; HRMS (ESI): calculated for C21H29NO3 [M+H]+= 
344.2220; found 344.2231. 
 
(S)-Methyl 5-(4-((1-methoxy-3-methyl-1-oxobutan-2-yl)amino)-2,5-dimethylphenoxy)-
2,2-dimethylpentanoate (4.49). The title compound was prepared using Method B with an 
irradiation time of 19 hours using 2 lamps and 5 equivalents of valine methyl ester 
hydrochloride salt. The title compound was purified by column chromatography on silica gel 
(5% to 10% EtOAc/Hexanes) to give a colorless oil in 32% yield as a single regioisomer.  
4.49. 1H NMR (600 MHz, CDCl3) δ 6.57 (s, 1H), 6.39 (s, 1H), 3.84 – 3.80 (m, 3H), 3.69 (s, 
3H), 3.66 (s, 3H), 2.18 (s, 3H), 2.15 (s, 3H), 2.10 (oct, J = 6.6 Hz, 1H), 1.69 – 1.66 (m, 4H), 
1.20 (s, 6H), 1.06 (d, J = 6.6 Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, CDCl3) 
δ 178.53, 174.98, 149.75, 139.12, 125.30, 121.52, 115.46, 114.78, 69.30, 63.62, 51.92, 51.89, 
42.24, 37.28, 31.89, 25.51, 25.33, 25.32, 19.33, 18.96, 17.60, 16.26. 
IR (thin film): 3394.1, 2955.38, 2872.45, 1732.73, 1519.63, 1456.96, 1212.04; HRMS (ESI): 











methylbutanoate (4.50). The title compound was prepared using Method B with an 
irradiation time of 24 hours using 2 lamps. The title compound was purified by column 
chromatography on silica gel (10% EtOAc/Hexanes) to give a colorless oil in 66% yield by 
1H NMR and a mixture of 8.7:1 C2:C3 regioisomers. The product was contaminated with an 
inseparable impurity. 
4.50. 1H NMR (600 MHz, CDCl3) δ 6.69 (d, J = 8.4 Hz, 1H), 6.51 (dd, J = 8.4, 2.4 Hz, 1H), 
6.47 (d, J = 2.4 Hz, 1H), 5.23 (brd, J = 9.0 Hz, 1H), 4.27 (q, J = 7.2 Hz, 2H), 3.79 (dd, J = 
9.0, 6.6 Hz, 1H), 3.71 (s, 3H), 2.18 (oct, J = 6.6 Hz, 1H), 1.57 (s, 3H), 1.56 (s, 3H), 1.30 (t, J 
= 7.2 Hz, 3H), 1.05 (d, J = 6.6 Hz, 3H), 1.01 (d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, 
CDCl3) δ 174.54, 173.72, 142.21, 140.80, 129.22, 120.43, 116.11, 110.75, 80.90, 61.80, 
61.78, 52.06, 31.59, 25.31, 24.94, 19.29, 18.68, 14.28. 
IR (thin film): 3365.17, 2965.98, 2875.34, 1736.58, 1597.73, 1516.74, 1420.32; HRMS 


















yl)oxy)phenyl)amino)-3-methylbutanoate (4.51). The title compound was prepared using 
Method B with an irradiation time of 15 hours using 2 lamps. The title compound was 
purified by column chromatography on silica gel (30% EtOAc/Hexanes) to give a colorless 
oil in 36% yield by 1H NMR and >10:1 regioselectivity. The product was contaminated with 
an inseparable impurity. 
4.51. 1H NMR (600 MHz, CDCl3) δ 7.61 (AA’BB’, J = 8.4 Hz, 2H), 7.37 (AA’BB’, J = 8.4 
Hz, 2H), 6.70 (d, J = 8.4 Hz, 1H), 6.41 (dd, J = 8.4, 1.8 Hz, 1H), 6.37 (d, J = 1.8 Hz, 1H), 
6.05 (brt, J = 5.4 Hz, 1H), 5.13 (brd, J = 9.0 Hz, 1H), 3.83 – 3.79 (m, 1H), 3.82 (s, 3H), 3.67 
– 3.63 (m, 2H), 3.65 (s, 3H), 2.79 (t, J = 7.2 Hz, 2H), 2.15 (oct, J = 6.6 Hz, 1H), 1.58 (s, 3H), 
1,57 (s, 3H), 1.04 (d, J = 6.6 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H). 13C NMR (151 MHz, CDCl3) 
δ 175.25, 174.09, 166.40, 141.28, 140.92, 137.69, 134.39, 133.12, 128.92, 128.40, 119.70, 
116.82, 111.19, 80.59, 62.01, 52.81, 51.95, 41.16, 35.44, 31.65, 25.39, 25.00, 19.33, 18.76. 
IR (thin film): 3336.25, 2959.23, 2874.38, 1734.66, 1651.73, 1595.81, 1521.56, 1289.18; 
HRMS (ESI): calculated for C26H33ClN2O6 [M+H]+= 505.2100; found 505.2097. 
 
(S)-Methyl 3-methyl-2-(phenylamino)butanoate (4.52). The title compound was prepared 
using Method B with an irradiation time of 15 hours using 0.4 mL : 0.4 mL : 0.2 mL of DCE 




silica gel (10% to 30% EtOAc/Hexanes) to give 4.52 in 40% yield. The spectral data were in 
agreement with literature values.19 
                
(S)-Methyl 3-methyl-2-(o-tolylamino)butanoate, (S)-methyl 3-methyl-2-(m-
tolylamino)butanoate and (S)-methyl 3-methyl-2-(p-tolylamino)butanoate (4.53). The 
title compound was prepared using Method B with an irradiation time of 15 hours using 0.4 
mL : 0.4 mL : 0.2 mL of DCE : toluene : pH 8 Buffer. The title compound was purified by 
column chromatography on silica gel (5% EtOAc/Hexanes) to give a colorless oil in 50% 
yield and a mixture of 1.2:1:2.1 ortho to meta to para regioisomers. The para isomer has 
previously been reported; spectral data were in agreement with literature values.20 
4.53. 1H NMR (600 MHz, CDCl3) δ 7.10 – 7.04 (m, 1.5H), 6.98 (AA’BB’, J = 8.4 Hz, 2H), 
6.68 (td, J = 7.2, 1.2 Hz, 0.5H), 6.56 – 6.54 (m, 1H), 6.55 (AA’BB’, J = 8.4 Hz, 2H), 6.47 – 
6.46 (m, 0.5H), 6.44 (dd, J = 7.8, 2.4 Hz, 0.5H), 4.06 (brd, J = 9.6 Hz, 0.5H), 4.03 (brd, J = 
9.6 Hz, 0.5H), 3.98 (brd, J = 9.6 Hz, 1H), 3.91 (dd, J = 9.6, 6.0 Hz, 0.5H), 3.86 (dd, J = 9.6, 
6.0 Hz, 0.5H), 3.83 (dd, J = 9.6, 6.0 Hz, 1H), 3.72 (s, 1.5H), 3.71 (s, 1.5H), 3.70 (s, 3H), 2.27 
(s, 1.5H), 2.23 (s, 3H), 2.22 (s, 1.5H), 2.19 – 2.05 (m, 2H), 1.08 – 1.00 (m, 12H). 13C NMR 
(151 MHz, CDCl3) δ 174.55, 174.52, 174.44, 147.43, 145.35, 145.14, 139.26, 130.49, 
129.94, 129.33, 127.64, 127.24, 122.89, 119.31, 117.85, 114.54, 113.86, 110.61, 110.47, 
62.97, 62.51, 62.39, 52.04, 52.01, 51.97, 31.77, 31.73, 31.70, 21.75, 20.54, 19.27, 19.26, 












IR (thin film): 3393.14, 2963.09, 2873.42, 1734.66, 1616.06, 1520.60, 1304.61; HRMS 
(ESI): calculated for C13H19NO2 [M+H]+= 222.1489; found 222.1488.  
  
Methyl 2-((1-methoxy-3-methyl-1-oxobutan-2-yl)imino)-3-methylbutanoate (4.54). It 
was noted that a significant byproduct in some reactions was imine 4.54, derived from 
oxidation and hydrolysis of the starting amine followed by condensation with a second 
equivalent of amine (equation 4). This observation is consistent with the presence of amine 
cation radicals under the reaction conditions. 
GC-MS: retention time 5.07 min, LRMS (EI) calculated for C12H21NO4 [M]+= 243.1; found 
243.1. 4.54 was only observed through GCMS; stability issues precluded isolation.  
Redox Potentials.  
Oxidation potentials for isopropylamine, 21  glycine ethyl ester, 22 tert-butylamine,23 and 
propylamine21 were previously reported. Anisole, TBS phenol, 2,6-dimethoxy pyridine, and 













All the other substrate redox potentials in the table were determined using CV with the 
following method. Electrochemical potentials 
were obtained with a standard set of conditions 
to maintain internal consistency. Cyclic 
voltammograms were collected with a Pine 
WaveNow Potentiostat. Samples were prepared 
with 0.05 mmol of substrate in 5 mL of 0.1 M 
tetra-n-butylammonium hexafluorophosphate in 
dry, degassed acetonitrile. Measurements 
employed a glassy carbon working electrode, 
platinum wire counter electrode, 3.5 M NaCl 
silver-silver chloride reference electrode, and a 
scan rate of 100 mV/s. Reductions were 
measured by scanning potentials in the negative 
direction and oxidations in the positive 
direction; the glassy carbon electrode was 
polished between each scan. Data was analyzed 
using MATLAB by subtracting a background 
current prior to identifying the maximum 
current (Cp) and determining the potential 
(Ep/2) at half this value (Cp/2). The obtained value was referenced to Ag|AgCl and converted 
to SCE by subtracting 0.03 V. 
Arene Oxidation Potential
































Oxidation Potentials of Amines and 
Arenes  
	 406 
 Stern-Volmer Quenching Studies 
Emission lifetime measurements were taken at ambient temperature using a Edinburgh 
FLS920 spectrometer and fit to single exponential decay according to a modification of the 
method previously described by our laboratory.24 Measurements were made by the time-
correlated single photon counting (TCSPC) capability of the instrument with pulsed 
excitation light (444.2 nm, typical pulse width = 95 ps) generated by a Edinburgh EPL-445 
ps pulsed laser diode operating at a repetition rate of 5 MHz. The maximum emission 
channel count rate was less than 5% of the laser channel count rate, and each data set 
collected greater than 10000 counts on the maximum channel. The lifetime of fluorescence 
was determined by reconvolution fit with the instrument response function using the 
Edinburgh FS900 software. In all cases, after reconvolution, fluorescence decay was 
satisfactorily fit with a monoexponential function of the form: 
!! = !!!!!/! 
where I is the intensity (counts), and t is the mean lifetime of fluorescence. 
Stern-Volmer analysis on the quenching of fluorescence lifetime was carried out in DCE 
with detection at 500 nm (15 nm bandwidth), where the concentration of acridinium was 1.6 
× 10-5 M. The quenching constant was determined with quencher concentrations in the range 
of 0 M to 2.0 × 10-2 M. Bimolecular quenching constants, kq, were determined from the 
corresponding Stern-Volmer constant.25 Quenching constants were determined for both Me2-
Mes-Acr+ and t-Bu2-Mes-Acr+ with a representative arene and amine, and were derived 
from duplicate experiments. Comparison of UV-Vis absorption spectra taken before and after 
	 407 
lifetime quenching studies verified that the acridinium was unchanged. UV-Vis spectra were 
taken on a Hewlett-Packard 8453 Chemstation spectrophotometer. 
 
 
kq = 2.79 × 109 M-1 s-1 
 









































kq = 5.54 × 108 M-1 s-1 
 
Figure S1. Stern-Volmer Quenching Studies 
Hydrogen Peroxide Detection Experiments 
Previously, an aerobic mechanism disclosed by Fukuzumi26 for benzylic oxidation indicated 
that oxygen was able to turn over the catalyst, generating hydrogen peroxide in situ. 
Fukuzumi demonstrated the formation of hydrogen peroxide in their reaction by running the 
reaction and then using 1H NMR, detected a peak for hydrogen peroxide. H2O2: 1H NMR 

















































Since the amine is usually present in 3 
equivalents, the corrected quenching rates are 
8.4 x 108 s-1 for (S)-a-methylbenzylamine and 
1.7 x 108 s-1 for valine methyl ester, 
compared to 4.75 x 108 s-1 for anisole. 
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A similar approach was taken for this reaction, in which a 1H NMR was taken before and 
after irradiation. The reaction was run in both CD3CN and CD2Cl2 in a 1-dram vial and 
transferred for acquiring NMR data. When using CD3CN, 10% yield of hydrogen peroxide 
was observed, and when using CD2Cl2, 21% yield of hydrogen peroxide was observed.  
Quantum Yield Determination 
A vial was charged with acridinium catalyst (2.5 mg, 5 mol %) and dissolved in DCE (1 mL). 
Anisole (0.1 mmol, 1 equiv) and benzyl amine (0.3 mmol, 3 equiv) were added via syringe. 
The reaction vial was sparged with oxygen for 3 minutes and then irradiated 10 cm from a 
single Par38 Royal Blue Aquarium LED lamp (Model #6851) fabricated with high-power 
Cree LEDs as purchased from Ecoxotic (www.ecoxotic.com). The sample was irradiated for 
30 minutes (1800 seconds). The reaction was concentrated and yield was determined by 1H 
NMR based on an HMDSO internal standard. The quantum yield was determined using the 
following equation where f is essentially 1 (f > 0.999) due to absorption of all incident 
light.28  
Φ =  !"#$ !" !"#$%&'!"#$ ∗ ! ∗ !  
 
The yield was determined to be 23% (0.0023 mmol) of both regioisomers after 30 minutes 
(1800 sec) of irradiation. Flux was previously disclosed in our lab using the same light 
MeO


















system and instrumentation. It was reported that flux of the Cree LED set up was 6.43 x 10-7 
mol photon s-1.24  
Φ =  2.3!10
!! !"#
6.43!10!!!"# !ℎ!"!# !!! ∗ 1800 ! ∗ 1 = 0.02 = 2% 
Fukuzumi previously reported quantum yields for several arenes involved in his aryl 
bromination chemistry. The quantum yield percentages ranged from 0.01 to 4.8%.  
	 411 
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APPENDIX D: SUPPORTING INFORMATION FOR CHAPTER 5 
General Methods and Materials 
Proton and carbon magnetic resonance spectra (1H NMR and 13C NMR) were recorded on a 
Bruker model DRX 400 or a Bruker Avance III 600 CryoProbe(1H NMR at 400 MHz and 
600 MHz and 13C NMR at 100 and 151 MHz) spectrometer. Chemical shifts for protons are 
reported in parts per million downfield from tetramethylsilane and are referenced to residual 
protium in the solvent (1H NMR: CHCl3 at 7.26 ppm). Chemical shifts for carbons are 
reported in parts per million downfield from tetramethylsilane and are referenced to the 
carbon resonances of the solvent peak (13C NMR: CDCl3 at 77.16 ppm). Chemical shifts for 
fluorines are referenced to fluorobenzene as an internal standard (19F NMR: C6H5F at –
113.15 ppm). 1H NMR data are reported as follows: chemical shift, multiplicity (s = singlet, 
d = doublet, t = triplet, q = quartet, sept = septet, oct = octet, dd = doublet of doublets, ddt = 
doublet of doublet of triplets, ddd = doublet of doublet of doublets, dddd = doublet of doublet 
of doublet of doublets, m = multiplet, and prefixed br = broad), coupling constants (Hz), and 
integration.  
High resolution mass spectra (HRMS) were obtained using a Thermo LTqFT mass 
spectrometer with electrospray ionization or atmospheric pressure chemical ionization in 
positive mode. Gas chromatography (GC) was performed on an Agilent 6850 series 
instrument equipped with a split-mode capillary injection system and Agilent 5973 network 
mass spec detector (MSD). Thin layer chromatography (TLC) was performed on SiliaPlate 
250 µm thick silica gel plates provided by Silicycle. Visualization was accomplished with 
short wave UV light (254 nm), cerium ammonium molybdate, p-anisaldehyde, or potassium 
permanganate solution followed by heating. Flash chromatography was performed using 
 489 
SiliaFlash P60 silica gel (40-63 µm) purchased from Silicycle. Irradiation of photochemical 
reactions was carried out using a PAR38 blue aquarium LED lamp (Model #6851) fabricated 
with high-power Cree LEDs as purchased from Ecoxotic (www.ecoxotic.com) or Kessil 
KSH150B Blue 36W LED Grow Lights with standard borosilicate glass vials purchased from 
Fischer Scientific. For all photolyses, reactions were stirred using a PTFE coated magnetic 
stir bar on a magnetic stir plate. Yield refers to isolated yield of analytically pure material 
unless otherwise noted. NMR yields were determined using hexamethyldisiloxane as an 
internal standard. Tetrahydrofuran, diethyl ether, and dichloromethane were dried by passage 
through a column of neutral alumina under nitrogen prior to use. All other reagents were 
obtained from commercial sources and used without further purification unless otherwise 
noted.  
Preparation of Photocatalysts and Reagents 
4-Acetamidobenzenesulfonyl azide, N-fluorobenzenesulfonimide, diethyl bromomalonate, 
and N-Chlorosuccinimide were used as purchased. Methyl acrylate and methyl vinyl ketone 
were purchased from commercial sources, deoxygenated via multiple freeze-pump-thaw 
cycles, purified by vacuum transfer, and stored at –35 ºC under in an argon-filled glovebox 












9-Mesityl-3,6-di-tert-butyl-10-phenylacridinium tetrafluoroborate (t-Bu2-Mes-Acr+) (A) 
was prepared as previously reported by the Nicewicz lab.  The spectral data matched the 




tetrafluoroborate (OMe6-Mes-Acr+) (B) was prepared as previously reported by our lab.  
The spectral data matched the values reported in the literature.2 
 
 
4-(Trifluoromethyl)benzenesulfonyl azide (5.3) was prepared as previously reported. The 
spectral data matched the values reported in the literature.3 
Preparation of Substrates 
Cyclohexane, cycloheptane, cyclooctane, trans-decalin, adamantane, n-propylbenzene, t-
butyl cyclohexane, isopropylbenzene, 3,7-dimethyl-1-octanol, 2-(1-adamantyl)-4-
bromoanisole, and 5-α-cholestan-3-one were used as purchased.  
 
 
Cis-4-methylcyclohexyl pivalate was prepared according to a published procedure; spectral 
















Methyl 6-methylheptanoate was prepared according to a published procedure; spectral data 
were in agreement with literature values.5  
 
 
3,7-Dimethyloctyl acetate was prepared according to a published procedure; spectral data 
were in agreement with literature values.6  
 
 
3,7-Dimethyloctyl benzoate was prepared according to a published procedure; spectral data 
were in agreement with literature values.7  
 
 
2-(3,7-Dimethyloctyl)isoindoline-1,3-dione was prepared according to a published 
procedure; spectral data were in agreement with literature values.8  
 
 
1-Bromo-3,7-dimethyloctane was prepared according to a published procedure; spectral 
data were in agreement with literature values.6  
 
 
((3,7-Dimethyloctyl)oxy)benzene: To a solution of phenol (1 g, 10.6 mmol) and 

























dimethyloctanol (4.47 mL, 23.4 mmol) followed by DIAD (4.6 mL, 23.4 mmol). The 
solution was warmed to rt overnight, the concentrated in vacuo. The residue was triturated 
with hexanes, and the solution was concentrated in vacuo and purified by flash column 
chromatography (0 – 5% EtOAc in hexanes) affording the product as a colorless liquid (990 
mg, 40% yield). Spectral data were in agreement with literature values.9  
 
 
4,8-Dimethyl-1-(pyridin-2-yl)nonan-1-one: To a suspension of magnesium (100 mg, 4.1 
mmol) and an iodine crystal in THF (2 mL) was added 1-bromo-3,7-dimethyloctane (995 
mg, 4.5 mmol) in THF (7 mL) dropwise. Gentle heating to facilitate initiation was 
accomplished with a heat gun. Subsequently, picolonitrile (395 mL, 4.1 mmol) was added at 
room temperature and stirred overnight. The reaction was quenched with 1M HCl, stirred for 
3 hours, and then quenched with aqueous NaHCO3. The solution was extracted three times 
with EtOAc, and the combined organic layers were washed with brine, dried with MgSO4, 
and concentrated in vacuo. The resultant oil was purified by flash column chromatography 
(10–20% EtOAc/Hex) affording the product in a 17% yield (170 mg): 
1H NMR (600 MHz, CDCl3) δ 8.63 (d, J = 5.0 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.83 – 7.66 
(m, 1H), 7.40 (dd, J = 7.6, 4.8 Hz, 1H), 3.24 – 3.05 (m, 2H), 1.84 – 1.70 (m, 1H), 1.48 (ddt, J 
= 19.7, 13.4, 6.5 Hz, 3H), 1.33 – 1.16 (m, 2H), 1.10 (h, J = 6.7, 5.4 Hz, 4H), 0.88 (d, J = 6.3 
Hz, 3H) 0.81 (d, J = 6.7 Hz, 6H).  
13C NMR (151 MHz, CDCl3) δ 202.45, 153.65, 148.94, 136.86, 126.97, 121.78, 39.36, 
37.14, 35.48, 32.69, 31.03, 28.03, 24.81, 22.78, 22.68, 19.66. 












(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl benzoate was prepared according to a 
published procedure; spectral data were in agreement with literature values.10  
 
 
2-(3,5-Dimethyladamantan-1-yl)isoindoline-1,3-dione was prepared according to a 
published procedure; spectral data were in agreement with literature values.11  
 
 
Methyl 2-(4-isobutylphenyl)propanoate was prepared according to a published procedure; 
spectral data were in agreement with literature values.12  
Products of Aliphatic C–H Functionalization 
 
General Procedure A (Azidation): In an argon-filled glovebox, a 1 dram vial with a Teflon-
coated magnetic stir bar was charged with tBu2-Mes-Acr+ A (0.05 equiv), 4-
(trifluoromethyl)benzenesulfonyl azide (3 equiv), K3PO4 (1.1 equiv), and the alkane substrate 












catalyst A (5 mol %)
sulfonyl azide 5.3 (3 equiv)
K3PO4 (1.1 equiv)
455 nm LEDs,
HFIP (0.1 M), 20 h
R–H R–N3
 494 
sealed with a Teflon-lined septum screw cap. The vial was positioned on a stir plate 
approximately 2 – 3 cm from a Par38 LED lamp supplying blue light (λ = 440-460 nm). 
After irradiation for 20 hours, the reaction mixture was passed over a short plug of silica and 
concentrated in vacuo. The residue was analyzed by 1H NMR or purified by column 
chromatography on silica gel with the eluent noted for each substrate.  
 
General Procedure B (Halogenation and Trifluoromethylthiolation): In an argon-filled 
glovebox, a 1 dram vial with a Teflon-coated magnetic stir bar was charged with tBu2-Mes-
Acr+ A (0.05 equiv), radical trap (3 equiv), and the alkane substrate (1 equiv). 1,2-
Dichloroethane (DCE) was added (0.125 M wrt alkane), and the vial was sealed with a 
Teflon-lined septum screw cap. Upon removal from the glovebox, 4 M pH 8 phosphate 
buffer was added (0.25 * amount of DCE added such that total solvent amount is 0.1 M wrt 
alkane). The vial was positioned on a stir plate approximately 2 – 3 cm from a Par38 LED 
lamp supplying blue light (λ = 440-460 nm). After irradiation for 4 – 20 hours, the reaction 
mixture was passed over a short plug of silica and concentrated in vacuo. The residue was 
analyzed by 1H NMR or purified by column chromatography on silica gel with the eluent 
noted for each substrate. 
1 equiv
catalyst A (5 mol %)
radical trap (3 equiv)
455 nm LEDs,
DCE/pH 8 phosphate buffer
(4:1, 0.1 M), 20 h
R–H R–X












General Procedure C (Alkylation): In an argon-filled glovebox, a 1 dram vial with a 
Teflon-coated magnetic stir bar was charged with OMe6-Mes-Acr+ B (0.0025 equiv), olefin 
(3 equiv), and the alkane substrate (1 equiv). A mixture of DCE and 2,2,2-trifluoroethanol 
(TFE) was added (7:1, 0.125 M wrt alkane), and the vial was sealed with a Teflon-lined 
septum screw cap. Upon removal from the glovebox, 4 M pH 8 phosphate buffer was added 
(0.5 * amount of organic solvent mixture added such that total solvent amount is 0.07 M wrt 
alkane). For methyl acrylate as the olefin, the vial was positioned on a stir plate 
approximately 2 – 3 cm from a Par38 LED lamp supplying blue light (λ = 440-460 nm). For 
methyl vinyl ketone as the olefin, the vial was positioned on a stir plate approximately 2 cm 
from two Kessil KSH150B Blue 36W LED Grow Lights supplying blue light. After 
irradiation for 20 hours, the reaction mixture was passed over a short plug of silica and 
concentrated in vacuo. The residue was analyzed by 1H NMR or purified by column 
chromatography on silica gel with the eluent noted for each substrate. 
 
 
Azidocyclohexane (5.4): Prepared according to General Procedure A (0.1 mmol scale) using 
cyclohexane, giving 58% yield by 1H NMR. The spectra matched literature values.13 
 
1 equiv
catalyst B (2.5 mol %)
olefin (3 equiv)
455 nm LEDs,









Azidocycloheptane (5.5): Prepared according to General Procedure A (0.1 mmol scale) 
using cycloheptane, giving 57% yield by 1H NMR. The spectra matched literature values.14 
 
 
Azidocyclooctane (5.6): Prepared according to General Procedure A (0.1 mmol scale) using 
cyclooctane, giving 70% yield by 1H NMR. The spectra matched literature values.6 
 
 
(2R,4aR,8aR)-2-Azidodecahydronaphthalene (5.7): Prepared according to General 
Procedure A (0.1 mmol scale) using trans-decalin, giving 57% yield by 1H NMR and a 1.4:1 
ratio of C3:C2. The spectra matched literature values.13 
 
 
1-Azidoadamantane (5.8): Prepared according to General Procedure A (0.1 mmol scale) 
using adamantane, giving 75% yield by 1H NMR. The spectra matched literature values.13 
 
(1-Azidopropyl)benzene (5.9): Prepared according to General Procedure A (0.1 mmol scale) 











1-Azido-1-(tert-butyl)cyclohexane (5.10): Prepared according to General Procedure A (0.1 
mmol scale) using tert-butylcyclohexane, giving 51% yield by 1H NMR. The spectra 
matched literature values.6 
 
 
(2-Azido-2-methylpropyl)benzene (5.11). Prepared according to General Procedure A (0.1 
mmol scale) using isopropylbenzene, giving 46% combined yield by 1H NMR (1.3:1 site 
selectivity favoring the tertiary product). The spectra matched literature values.15 
 
 
(1s,4s)-4-Azido-4-methylcyclohexyl pivalate (5.12): Prepared according to General 
Procedure A (0.1 mmol scale) using cis-4-methylcyclohexyl pivalate. 1H NMR analysis of 
the crude reaction indicated a dr of 1.4:1 with a total NMR yield of 45%. The residue was 
purified by column chromatography on silica gel (0 to 10% Et2O/Hexanes) to afford 5.12 
(6.3 mg, 24% yield). Characterization data reported for a single isolated diastereomer: 
1H NMR (600 MHz, CDCl3) δ 4.68 (tt, J = 9.8, 4.2 Hz, 1H), 1.85 – 1.71 (m, 4H), 1.68 (m, 
2H), 1.52 – 1.43 (m, 2H), 1.32 (s, 3H), 1.19 (s, 9H).  
13C NMR (151 MHz, CDCl3) δ 178.21, 71.02, 60.54, 38.86, 34.28, 27.35, 27.29, 27.23. 
HRMS (APCI): calculated for C12H21N3O2Na [M+Na]+= 262.1526; found 262.1436. 















Methyl 6-azido-6-methylheptanoate (5.13): Prepared according to General Procedure A 
(0.1 mmol scale) using methyl 6-methylheptanoate. The crude residue was purified by 
column chromatography on silica gel (0 to 10% Et2O/Hexanes) to afford 5.13 (14.2 mg, 71% 
yield): 
1H NMR (600 MHz, CDCl3) δ 3.74 – 3.63 (m, 3H), 2.36 – 2.28 (m, 2H), 1.66 – 1.59 (m, 
2H), 1.52 – 1.44 (m, 2H), 1.38 (dd, J = 7.4, 4.1 Hz, 2H), 1.24 (dd, J = 4.2, 2.4 Hz, 6H). 
13C NMR (151 MHz, CDCl3) δ 174.07, 61.59, 51.64, 41.21, 34.04, 26.09, 25.26, 23.94. 
HRMS (ESI): calculated for C9H17N3O2Na [M+Na]+= 222.1213; found 222.1218. 
IR (film) cm–1 2949.59, 2869.56, 2096.24, 1740.44, 1463.71, 1370.18, 1252.54. 
 
 
7-Azido-3,7-dimethyloctyl acetate (5.14): Prepared according to General Procedure A (0.1 
mmol scale) using 3,7-dimethyloctyl acetate. The crude residue was purified by column 
chromatography on silica gel (0 to 10% Et2O/Hexanes) to give 5.14 in 73% yield and a 4:1 
ratio of 3˚ isomers. The spectra matched literature values.6 
 
 
7-Azido-3,7-dimethyloctyl benzoate (5.15): Prepared according to General Procedure A 
(0.1 mmol scale) using 3,7-dimethyloctyl benzoate. The crude residue was purified by 
column chromatography on silica gel (0 to 10% Et2O/Hexanes) to afford 5.15 (27.7 mg, 91% 
yield, 3:1 ratio of 3˚ isomers). Characterization data reported for major isomer: 
1H NMR (600 MHz, CDCl3) δ 8.06 – 8.02 (m, 2H), 7.60 – 7.53 (m, 1H), 7.45 (d, J = 7.8 Hz, 
2H), 4.40 – 4.32 (m, 2H), 1.85 – 1.78 (m, 1H) 1.70 – 1.63 (m, 1H), 1.62 – 1.57 (m, 1H), 1.49 










13C NMR (151 MHz, CDCl3) δ 166.81, 132.97, 130.63, 129.67, 128.48, 63.57, 61.79, 41.81, 
37.27, 35.69, 30.08, 26.17, 26.14, 21.73, 19.66. 
HRMS (ESI): calculated for C17H25N3O2Na [M+H]+= 326.1839; found 326.1840. 
IR (film) cm–1 2959.23, 2131.92, 2098.17, 1719.23, 1406.82, 1275.68, 1176.36. 
 
The reaction was also performed on 1 mmol scale in a scintillation vial with irradiation from 
1 Ecoxotic lamp for 2 days and purified to afford 5.15 (182 mg, 60% yield). The decrease in 
yield is likely due to reduced light penetration through the thicker-walled scintillation vial. 
 
 
2-(7-Azido-3,7-dimethyloctyl)isoindoline-1,3-dione (5.16): Prepared according to General 
Procedure A (0.1 mmol scale) using 2-(3,7-dimethyloctyl)isoindoline-1,3-dione. The crude 
residue was purified by column chromatography on silica gel (0 to 10% Et2O/Hexanes) to 
afford 5.16 (24.7 mg, 72% yield, 3:1 ratio of 3˚ isomers). Characterization data reported for 
major isomer: 
1H NMR (600 MHz, CDCl3) δ 7.83 (dd, J = 5.4, 3.0 Hz, 2H), 7.70 (dd, J = 5.4, 3.1 Hz, 2H), 
3.70 (dq, J = 7.5, 2.9 Hz, 2H), 1.73 – 1.67 (m, 1H), 1.58 – 1.42 (m, 4H), 1.41 – 1.28 (m, 3H), 
1.24 (s, 6H), 1.21 – 1.13 (m, 1H), 0.98 (d, J = 5.9 Hz, 3H).  
13C NMR (151 MHz, CDCl3) δ 168.53, 133.97, 132.35, 123.28, 61.80, 41.67, 37.07, 36.38, 
35.61, 30.73, 26.13, 26.10, 21.63, 19.43. 
HRMS (ESI): calculated for C18H24N4O2Na [M+Na]+= 351.1792; found 351.1797. 












7-Azido-1-bromo-3,7-dimethyloctane (5.17): Prepared according to General Procedure A 
(0.1 mmol scale) using 1-bromo-3,7-dimethyloctane. The crude residue was purified by 
column chromatography on silica gel (0 to 10% Et2O/Hexanes) to afford 5.17 in 67% yield 
and a 3:1 ratio of 3˚ isomers. The spectra matched literature values.6 
 
 
7-Azido-3,7-dimethyloctan-1-ol (5.18): Prepared according to General Procedure A (0.1 
mmol scale) using 3,7-dimethyl-1-octanol to afford 5.18 in 63% yield and a 2.7:1 ratio of 3˚ 
isomers. The spectra matched literature values.6 
 
 
((7-Azido-3,7-dimethyloctyl)oxy)benzene (5.19): Prepared according to General Procedure 
A (0.1 mmol scale) using ((3,7-dimethyloctyl)oxy)benzene. The crude residue was purified 
by column chromatography on silica gel (0 to 10% Et2O/Hexanes) to afford 5.19 (8.6 mg, 
31% yield by 1H NMR, 2.1:1 ratio of 3˚ isomers). The product was characterized as an 
inseparable mixture from an impurity: 
1H NMR (600 MHz, CDCl3) δ 7.30 – 7.26 (m, 2H), 6.95 – 6.91 (m, 1H), 6.91 – 6.87 (m, 
2H), 4.04 – 3.95 (m, 2H), 2.05 – 1.94 (m, 1H), 1.83 (dtd, J = 13.8, 7.0, 5.3 Hz, 1H), 1.74 – 
1.65 (m, 1H), 1.64 – 1.55 (m, 2H), 1.50 – 1.43 (m, 2H), 1.39 – 1.32 (m, 3H), 1.29 – 1.23 (m, 
6H), 1.00 – 0.94 (m, 3H).  
13C NMR (151 MHz, CDCl3) δ 129.56, 128.86, 120.64, 114.64, 66.17, 61.84, 41.82, 37.38, 
36.33, 29.92, 26.19, 22.72, 21.75, 19.71. 
HRMS (ESI): calculated for C16H25N3ONa [M+Na]+= 298.1890; found 298.1896. 













8-Azido-4,8-dimethyl-1-(pyridin-2-yl)nonan-1-one (5.20): Prepared according to General 
Procedure A (0.1 mmol scale) using 4,8-dimethyl-1-(pyridin-2-yl)nonan-1-one. The crude 
residue was purified by column chromatography on silica gel (0 to 10% Et2O/Hexanes) to 
afford 5.20 (11.2 mg, 39% yield, 3:1 ratio of 3˚ isomers): 
1H NMR (600 MHz, CDCl3) δ 8.68 (ddd, J = 4.8, 1.7, 0.9 Hz, 1H), 8.04 (dt, J = 7.9, 1.1 Hz, 
1H), 7.83 (td, J = 7.7, 1.7 Hz, 1H), 7.50 – 7.43 (m, 1H), 3.25 – 3.18 (m, 2H), 1.83 – 1.75 (m, 
1H), 1.58 – 1.51 (m, 3H), 1.50 – 1.43 (m, 2H), 1.43 – 1.31 (m, 2H), 1.25 (s, 6H), 1.21 – 1.17 
(m, 1H), 0.95 (d, J = 6.4 Hz, 3H).  
13C NMR (151 MHz, CDCl3) δ 202.52, 153.69, 149.06, 137.01, 127.14, 121.93, 61.87, 
41.86, 37.18, 35.53, 32.67, 31.03, 26.17, 26.14, 21.84, 19.66. 
HRMS (ESI): calculated for C16H24N4ONa [M+Na]+ = 311.1843; found 311.1852.  




Fluorocyclooctane. Prepared according to General Procedure B (0.1 mmol scale) using 
cyclooctane as the substrate and NFSI as the radical trap with 4 hours of irradiation, 











Bromocyclooctane. Prepared according to General Procedure B (0.1 mmol scale) using 
cyclooctane as the substrate and diethyl bromomalonate as the radical trap with 20 hours of 
irradiation, affording 60% yield by 1H NMR. The spectra matched literature values.17  
 
 
Chlorocyclooctane. Prepared according to General Procedure B (0.1 mmol scale) using 
cyclooctane as the substrate and NCS as the radical trap with 20 hours of irradiation, 
affording 32% yield by 1H NMR. The spectra matched literature values.18  
 
 
Cyclooctyl(trifluoromethyl)sulfane. Prepared according to General Procedure B (0.1 mmol 
scale) using cyclooctane as the substrate and ((2-phenylpropan-2-
yl)oxy)(trifluoromethyl)sulfane19 as the radical trap with 4 hours of irradiation. The title 
compound cyclooctyl(trifluoromethyl)sulfane was afforded in 30% yield by 1H NMR. The 
spectra matched literature values.20  
 
 
4-Cyclooctylbutan-2-one. Prepared according to General Procedure C using cyclooctane as 
the substrate and methyl vinyl ketone as the alkene. The title compound was afforded in 76% 
yield by 1H NMR. The title compound was purified by column chromatography on silica gel 
to afford 4-cyclooctylbutan-2-one (13.8 mg, 74% yield): 
1H NMR (600 MHz, CDCl3) δ 2.45 – 2.38 (m, 2H), 2.14 (s, 3H), 1.69 – 1.61 (m, 2H), 1.60 – 






13C NMR (151 MHz, CDCl3) δ 209.79, 42.17, 37.06, 32.31, 32.08, 30.02, 27.38, 26.42, 
25.57. 
HRMS (ESI): calculated for C12H22ONa [M+Na]+= 205.1563; found 205.1563. 




Methyl 3-cyclooctylpropanoate: Prepared according to General Procedure C using 
cyclooctane as the substrate and methyl acrylate as the alkene. The residue was purified by 
column chromatography on silica gel to give methyl 3-cyclooctylpropanoate in 43% yield. 
The spectra matched literature values:21 
 
 
(1R,2S,5R)-2-(2-Azidopropan-2-yl)-5-methylcyclohexyl benzoate (5.22): Prepared 
according to General Procedure A (0.1 mmol scale) using (1R,2S,5R)-2-isopropyl-5-
methylcyclohexyl benzoate. The crude residue was purified by column chromatography on 
silica gel (0 to 10% Et2O/Hexanes) to afford 5.22 (16.3 mg, 54% yield): 
1H NMR (600 MHz, CDCl3) δ 8.07 (d, J = 7.8 Hz, 2H), 7.61 – 7.51 (m, 1H), 7.50 – 7.39 (m, 
2H), 5.10 (td, J = 11.5, 10.9, 4.4 Hz, 1H), 2.10 (d, J = 12.3 Hz, 1H), 2.07 – 1.99 (m, 1H), 
1.85 (td, J = 11.6, 10.9, 3.6 Hz, 1H), 1.78 – 1.70 (m, 1H), 1.66 – 1.52 (m, 1H), 1.29 (d, J = 








13C NMR (151 MHz, CDCl3) δ 165.84, 133.05, 130.77, 129.77, 128.53, 74.01, 63.74, 49.31, 
41.48, 34.24, 31.38, 26.70, 25.32, 24.64, 21.86. 
HRMS (ESI): calculated for C17H23N3O2Na [M+Na]+= 324.1683; found 324.1678. 




2-(3-Azido-5,7-dimethyladamantan-1-yl)isoindoline-1,3-dione (5.23): Prepared according 
to General Procedure A (0.1 mmol scale) using 2-(3,5-dimethyladamantan-1-yl)isoindoline-
1,3-dione. The crude residue was purified by column chromatography on silica gel (0 to 10% 
Et2O/Hexanes) to afford 5.23 (19.3 mg, 55% yield): 
1H NMR (600 MHz, CDCl3) δ 7.76 (dd, J = 5.4, 3.0 Hz, 2H), 7.68 (dd, J = 5.5, 3.0 Hz, 2H), 
2.45 (s, 2H), 2.14 (s, 4H), 1.61 – 1.54 (m, 2H), 1.44 (d, J = 11.9 Hz, 2H), 1.26 (dt, J = 12.7, 
2.3 Hz, 1H), 1.20 – 1.10 (m, 1H), 0.99 (s, 6H).  
13C NMR (151 MHz, CDCl3) δ 169.60, 134.04, 131.87, 122.86, 61.90, 60.79, 49.20, 46.57, 
44.99, 42.78, 34.02, 29.55. 
HRMS (ESI): calculated for C20H23N4O2 [M+H]+= 351.1833; found 351.1816. 













2-(3-Fluoro-5,7-dimethyladamantan-1-yl)isoindoline-1,3-dione (5.24). Prepared according 
to General Procedure B (0.1 mmol scale) using 2-(3,5-dimethyladamantan-1-yl)isoindoline-
1,3-dione as the substrate and NFSI as the radical trap with 4 hours of irradiation. The 
residue was purified by column chromatography on silica gel to afford 5.24 (28.2 mg, 86% 
yield). Minor amounts of secondary fluorination product are also present: 
1H NMR (600 MHz, CDCl3) δ 7.76 (dd, J = 5.4, 3.1 Hz, 2H), 7.68 (dd, J = 5.5, 3.0 Hz, 2H), 
2.60 – 2.57 (m, 2H), 2.18 – 2.13 (m, 2H), 2.08 (ddd, J = 12.4, 2.4, 1.2 Hz, 2H), 1.70 – 1.64 
(m, 2H), 1.58 – 1.53 (m, 2H), 1.23 (ddt, J = 12.8, 4.1, 2.2 Hz, 1H), 1.16 (dt, J = 12.7, 2.3 Hz, 
1H), 1.01 (s, 6H).  
13C NMR (151 MHz, CDCl3) δ 169.57, 134.03, 131.84, 122.86, 93.50 (d, J = 183.7 Hz), 
62.51 (d, J = 12.1 Hz), 49.18 (d, J = 1.5 Hz), 47.73 (d, J = 16.6 Hz), 45.01 (d, J = 1.5 Hz), 
43.95 (d, J = 21.1 Hz), 34.91 (d, J = 10.6 Hz), 29.34.  
19F NMR (400 MHz, CDCl3) δ –135.68. 
HRMS (ESI): calculated for C20H22FNO2 [M+H]+= 328.1707; found 328.1720. 




1-Azido-3-(5-bromo-2-methoxyphenyl)adamantane (5.25): Prepared according to General 
Procedure A (0.1 mmol scale) using 2-(1-adamantyl)-4-bromoanisole. The crude residue was 
purified by column chromatography on silica gel (0 to 10% Et2O/Hexanes) to give 5.25 in 





1H NMR (600 MHz, CDCl3) δ 7.34 – 7.31 (m, 1H), 7.28 (s, 1H), 6.77 (d, J = 8.7 Hz, 1H), 
3.84 (d, J = 3.8 Hz, 3H), 2.34 (dq, J = 6.5, 3.2 Hz, 2H), 2.14 (d, J = 5.9 Hz, 2H), 2.07 (dt, J = 
12.9, 2.8 Hz, 2H), 1.97 (q, J = 14.5, 12.6 Hz, 2H), 1.86 (d, J = 3.3 Hz, 3H), 1.76 – 1.65 (m, 
2H).  
13C NMR (151 MHz, CDCl3) δ 157.75, 138.48, 130.07, 129.73, 113.49, 112.42, 59.92, 
55.61, 55.40, 44.02, 43.89, 41.00, 39.72, 39.69, 39.11, 35.48, 30.31. 
HRMS (APCI): calculated for C17H20N3OBrNa [M+Na]+= 384.0682; found 384.0738. 





Prepared according to General Procedure C using 2-(1-adamantyl)-4-bromoanisole as the 
substrate and methyl vinyl ketone as the alkene. The residue was purified by column 
chromatography on silica gel to afford 5.26 (17.6 mg, 45% yield): 
1H NMR (600 MHz, CDCl3) δ 7.27 – 7.24 (m, 2H), 6.73 (d, J = 9.3 Hz, 1H), 3.80 (s, 3H), 
2.44 – 2.37 (m, 2H), 2.15 (s, 3H), 2.14 – 2.11 (m, 2H), 1.98 – 1.94 (m, 3H), 1.85 – 1.68 (m, 
4H), 1.65 – 1.57 (m, 2H), 1.47 (d, J = 2.7 Hz, 3H), 1.46 – 1.41 (m, 2H).  
13C NMR (151 MHz, CDCl3) δ 209.98, 157.96, 140.29, 129.81, 129.58, 113.49, 113.39, 
55.36, 44.98, 41.59, 39.97, 38.02, 37.81, 37.66, 36.51, 32.84, 30.08, 29.38. 
HRMS (ESI): calculated for C21H27BrO2Na [M+Na]+ = 413.1087; found 413.1082. 







The reaction was also performed on 1 mmol scale in a scintillation vial with irradiation from 
2 Kessil lamps for 2 days and purified to afford 4.26 (152 mg, 39% yield). 
 
 
Methyl 2-(4-(2-azido-2-methylpropyl)phenyl)propanoate (5.27): Prepared according to 
General Procedure A (0.1 mmol scale) using methyl 2-(4-isobutylphenyl)propanoate. 1H 
NMR analysis of the crude reaction mixture revealed a 1.1:1 ratio of benzylic to tertiary 
azide isomers. The residue was purified by column chromatography on silica gel (0 to 10% 
Et2O/Hexanes) to afford 5.27 (14.8 mg, 57% yield). Characterization data are reported for the 
previously unreported tertiary isomer; both benzylic azide diastereomers are also present as 
impurities in the product:13 
1H NMR (600 MHz, CDCl3) δ 7.30 (d, J = 8.1 Hz, 1H), 7.25 – 7.20 (m, 2H), 7.16 (d, J = 8.1 
Hz, 1H), 3.72 (m, 1H), 3.66 (s, 3H), 2.74 (s, 2H), 1.50 (dd, J = 7.2, 5.5 Hz, 3H), 1.26 (s, 6H).  
13C NMR (151 MHz, CDCl3) δ 175.17, 139.10, 135.81, 130.87, 127.34, 61.96, 52.17, 47.22, 
45.19, 26.06, 18.73. 






















Prepared according to General Procedure A (0.1 mmol scale) using 5-α-cholestan-3-one. The 
crude residue was purified by column chromatography on silica gel (0 to 10% Et2O/Hexanes) 
to afford 5.28 (13.8 mg, 37% yield), favoring functionalization at the C25 and C17 tertiary 
positions (approximately 1:1). The 13C spectrum is complicated due to the presence of minor 
secondary azidation products: 
1H NMR (600 MHz, CDCl3) δ 2.41 – 2.34 (m, 1H), 2.32 – 2.23 (m, 2H), 2.11 – 2.05 (m, 
1H), 2.04 – 1.95 (m, 2H), 1.86 – 1.60 (m, 3H), 1.60 – 1.46 (m, 5H), 1.46 – 1.29 (m, 8H), 1.28 
– 1.19 (m, 1H), 1.25 (s, 3H), 1.19 – 1.04 (m, 4H), 1.04 – 0.98 (m, 1H), 1.01 (d, J = 1.4 Hz, 
3H), 0.97 – 0.85 (m, 7.5H), 0.85 – 0.77 (m, 1H), 0.77 – 0.71 (m, 1H), 0.68 (s, 1.5H).  
13C NMR (151 MHz, CDCl3) δ 212.34, 212.31, 80.95, 61.93, 56.44, 56.42, 56.33, 53.97, 
53.95, 46.86, 44.89, 44.86, 44.80, 42.78, 42.75, 42.07, 42.02, 40.07, 40.05, 39.66, 38.72, 
38.36, 38.33, 38.28, 36.30, 35.94, 35.85, 35.80, 35.74, 35.56, 31.89, 31.87, 31.82, 29.14, 
29.13, 29.01, 28.39, 28.17, 28.13, 26.23, 26.16, 25.75, 24.39, 24.37, 23.99, 22.97, 22.92, 
22.71, 22.65, 21.60, 21.36, 20.91, 18.82, 18.75, 14.80, 14.75, 12.23, 11.63, 11.59. 
HRMS (ESI): calculated for C27H45N3ONa [M+Na]+= 450.3455; found 450.3469. 
IR (film) cm–1 2932.23, 2866.62, 2098.17, 1715.37, 1455.99, 1267.97. 
 
The singlet at δ 0.68 ppm corresponds to the methyl at C13, and this signal is underintegrated 
(1.5H instead of 3H), indicating that the methyl has been shifted for one of the azidation 
products. Since there is only trace secondary azidation, the methyl at C13 cannot be shifted 
from azidation at C12 and instead arises from tertiary azidation at C17. Additionally, the 
isopropyl methyl signals that lie between 0.85 and 0.90 ppm are underintegrated and there is 
a new signal at 1.25 ppm corresponding to azidation of the isopropyl group at C25. This 
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triazol-1-yl)-5,7-dimethyladamantan-1-yl)isoindoline-1,3-dione (5.29). In a 1-dram vial in 
the glovebox, copper (II) sulfate (1 mg, 0.006 mmol) and sodium ascorbate (13 mg, 0.066 
mmol) were dissolved in degassed DMF/H2O (0.19/0.01 mL). The solution was stirred for 30 
min, after which memantine azide 5.29 (23 mg, 0.066 mmol) and ethynylestradiol (39 mg, 
0.13 mmol) in DMF (0.4 mL) were added. The vial was sealed with a PTFE-lined screw cap 
and Teflon tape and stirred outside the glovebox for 48 h at room temperature. The reaction 
mixture was concentrated and purified by flash column chromatography on silica gel (0 – 5% 
MeOH/DCM) to give 5.29 in 61% yield. 
5.29. 1H NMR (600 MHz, CDCl3) δ 7.76 (dd, J = 5.4, 3.0 Hz, 2H), 7.69 (dd, J = 5.5, 3.0 Hz, 
2H), 7.51 (s, 1H), 7.05 (d, J = 8.4 Hz, 1H), 6.58 (dd, J = 8.4, 2.7 Hz, 1H), 6.55 (d, J = 2.6 Hz, 
1H), 5.04 (br s, 1H), 2.88 (d, J = 3.2 Hz, 2H), 2.78 (tdd, J = 14.6, 8.8, 5.2 Hz, 2H), 2.71 (s, 
1H), 2.42 (d, J = 10.2 Hz, 1H), 2.37 – 2.32 (m, 2H), 2.23 (d, J = 12.3 Hz, 2H), 2.12 (td, J = 













(qd, J = 11.0, 2.6 Hz, 1H), 1.43 – 1.36 (m, 2H), 1.36 – 1.31 (m, 2H), 1.07 (d, J = 1.4 Hz, 6H), 
1.04 (s, 3H). 13C NMR (151 MHz, CDCl3) δ 169.62, 153.52, 152.98, 138.37, 134.16, 132.74, 
131.79, 126.56, 122.94, 117.78, 115.39, 112.79, 61.88, 61.73, 49.19, 48.62, 47.94, 47.44, 
45.05, 44.00, 43.39, 39.61, 38.19, 33.92, 33.14, 29.84, 29.60, 27.39, 26.39, 23.61, 14.43. 
HRMS (APCI): calculated for C40H47N4O4 [M+H]+= 647.3592; found 647.3605. 
Robustness Screen 
Below are the results from a robustness screen surveying several different additives 
containing useful functionality or pharmaceutically relevant heterocycles. Yields of the 

















































Di(tetrabutylammonium) phenyl phosphate (5.30): To a solution of phenyl dihydrogen 
phosphate22 (1.22 g, 7 mmol) in methanol (7 mL) was added tetrabutylammonium hydroxide 
in methanol (1M, 14 mL, 14 mmol). The solution was stirred overnight and then 
concentrated in vacuo. The resultant oil was dried via high vacuum for one week to afford 
5.30 as an amorphous solid. The compound is extremely hygroscopic and unstable outside of 
an inert atmosphere:23 
1H NMR (600 MHz, CDCl3) δ 7.19 – 7.10 (m, 2H), 7.06 (t, J = 7.8 Hz, 1H), 6.97 (d, J = 8.0 
Hz, 1H), 3.31 – 3.25 (m, 16H), 1.63 – 1.55 (m, 16H), 1.39 (q, J = 7.4 Hz, 16H), 0.94 (t, J = 
7.3 Hz, 24H). 
13C NMR (151 MHz, CDCl3) δ 129.12, 128.85, 118.14, 116.11, 58.96, 24.20, 19.82, 13.79. 
As determined by cyclic voltammetry, the oxidation potential of 5.30 was Ep/2 = + 0.87 V vs 
SCE in MeCN. Phosphate esters including 5.30 are known to be unstable for prolonged 
periods in MeCN.23 
Stern-Volmer Quenching: 
Emission lifetime measurements were taken at ambient temperature using a Edinburgh 
FLS920 spectrometer and fit to single exponential decay according to a modification of the 
method previously described by our laboratory.24 Measurements were made by the time-
correlated single photon counting (TCSPC) capability of the instrument with pulsed 
excitation light (444.2 nm, typical pulse width = 95 ps) generated by a Edinburgh EPL-445 
ps pulsed laser diode operating at a repetition rate of 5 MHz. The maximum emission 
channel count rate was less than 5% of the laser channel count rate, and each data set 
collected greater than 10000 counts on the maximum channel. The lifetime of fluorescence 
was determined by reconvolution fit with the instrument response function using the 
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Edinburgh FS900 software. In all cases, after reconvolution, fluorescence decay was 
satisfactorily fit with a monoexponential function of the form: 
!! = !!!!!/! 
where I is the intensity (counts), and t is the mean lifetime of fluorescence. 
Stern-Volmer analysis on the quenching of fluorescence lifetime was carried out in DCE or 
HFIP with detection at 500 nm (15 nm bandwidth), where the concentration of acridinium 
was 1.6 × 10-5 M. The quenching constant was determined with quencher concentrations in 
the range of 0 M to 2.0 × 10-2 M. Bimolecular quenching constants, kq, were determined from 
the corresponding Stern-Volmer constant.25 Quenching constants were determined for t-Bu2-
Mes-Acr+ with sulfonyl azide 53, sodium 1,1,1,3,3,3-hexafluoroisopropoxide, and dibasic 
phosphate 5.30. Comparison of UV-Vis absorption spectra taken before and after lifetime 
quenching studies verified that the acridinium was unchanged. UV-Vis spectra were taken on 
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The methyl doublet below 1.0 ppm indicates 40% remaining starting material. The peaks at 
5.0 ppm and 4.7 ppm correspond to both diastereomers of product, but the starting material 
also has a peak at 5.0 ppm. Subtraction of 40% from the peak at 5.0 ppm gives 26% yield of 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Predominantly C25 and C17 
regioisomers 
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